

CHINA REGENERATIVE MEDICINE INTERNATIONAL LIMITED

中國再生醫學國際有限公司

Incorporated in the Cayman Islands with limited liability 於閱過群島註冊成立之有限公司

Stock Code 股份代號: 8158

2016 / 2017 ANNUAL REPORT 年報

CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

香港聯合交易所有限公司(「聯交所」) 創業板 (「創業板」) 之特點

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

創業板之定位乃為相比其他在聯交所上市之公司 帶有較高投資風險之公司提供一個上市之市場。 有意投資之人士應了解投資於該等公司之潛在 風險,並應經過審慎周詳之考慮後方作出投資決 定。創業板之較高風險及其他特點表示創業板較 適合專業及其他資深投資者。

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

鑒於在創業板上市之公司屬新興性質,在創業板 買賣之證券可能會較在主板買賣之證券承受較大 之市場波動風險,同時無法保證在創業板買賣之 證券會有高流通量之市場。

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

香港交易及結算所有限公司及聯交所對本報告之 內容概不負責,對其準確性或完整性亦不發表任 何聲明,並明確表示概不就本報告全部或任何部 份內容而產生或因依賴該等內容而引致之任何損 失承擔任何責任。

This report, for which the directors (the "Directors") of China Regenerative Medicine International Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

本報告旨在遵照聯交所創業板證券上市規則(「創業板上市規則」)之規定,提供有關中國再生醫學國際有限公司(「本公司」)之資料。本公司重事(「董事」)對此共同及個別承擔全部責任公司。董事在作出一切合理查詢後確認,就彼等所知及所信,本報告所載資料在各重要方面均屬準確完備,沒有誤導或欺詐成分,且並無遺漏任何其他事項,足以令致本報告或其所載任何陳述產生誤導。

CONTENTS 目錄



公司資料	2
Chairman's Statement 主席報告	5
Management Discussion and Analysis 管理層討論及分析	7
Biographical Details of Directors and Chief Executives 董事及最高行政人員簡介	63
Corporate Governance Report 企業管治報告	73
Environmental, Social and Governance Report 環境、社會及管治報告	97
Directors' Report 董事會報告	120
Independent Auditor's Report 獨立核數師報告	146
Consolidated Statement of Profit or Loss and Other Comprehensive Income 綜合損益及其他全面收入表	152
Consolidated Statement of Financial Position 綜合財務狀況表	153
Consolidated Statement of Changes in Equity 綜合權益變動表	154
Consolidated Statement of Cash Flows 綜合現金流量表	155
Notes to the Financial Statements 財務報表附註	157
Financial Summary 財務摘要	248

CORPORATE INFORMATION 公司資料



DIRECTORS

Executive Directors

Wong Sai Hung (Vice-chairman of the Board)
Shao Zhengkang
Chen Chunguo (Chief Executive Officer)
(appointed with effect from 25 January 2017)

Non-executive Directors

Cui Zhanfeng (Chairman of the Board)
(appointed with effect from 7 October 2016)
Ray Yip (appointed with effect from 23 February 2017)
Xiong Chengyu (appointed with effect from 20 March 2017)
Wang Hui (re-designated from independent non-executive Director to non-executive Director with effect from 1 June 2017)
Deng Shaoping (retired with effect from 9 September 2016)
Cao Fushun (resigned with effect from 18 July 2016)
Yang Zhengguo (resigned with effect from 5 August 2016)
Wang Jianjun (retired with effect from 9 September 2016)

Independent Non-executive Directors

Lui Tin Nang
Pang Chung Fai Benny
Chan Bing Woon
Wong Yiu Kit Ernest
(appointed with effect from 23 February 2017)

COMPANY SECRETARY

Cheng Chai Fu

NOMINATION COMMITTEE

Lui Tin Nang (chairman of Nomination Committee)
Wong Sai Hung (appointed with effect from 23 February 2017)
Shao Zhengkang (appointed with effect from 23 February 2017)
Chen Chunguo (appointed with effect from 23 February 2017)
Ray Yip (appointed with effect from 23 February 2017)
Wang Hui
Pang Chung Fai Benny
Chan Bing Woon
Wong Yiu Kit Ernest (appointed with effect from 23 February 2017)

董事

執行董事

黃世雄(董事會副主席) 邵政康 陳春國(行政總裁) (自二零一七年一月二十五日起獲委任)

非執行董事

崔占峰(董事會主席) (自二零一六年十月七日起獲委任) 葉雷(自二零一七年二月二十三日起獲委任) 熊澄宇(自二零一七年三月二十日起獲委任) 王輝(自二零一七年六月一日起 由獨立非執行董事調任為非執行董事) 鄧紹平(自二零一六年九月九日起退任) 曹福順(自二零一六年七月十八日起辭任) 楊正國(自二零一六年八月五日起辭任)

獨立非執行董事

呂天能 彭中輝 陳炳煥 黃耀傑 (自二零一七年二月二十三日起獲委任)

王建軍(自二零一六年九月九日起退任)

公司秘書

鄭濟富

提名委員會

呂天能(提名委員會主席) 黃世雄(自二零一七年二月二十三日起獲委任) 邵政康(自二零一七年二月二十三日起獲委任) 陳春國(自二零一七年二月二十三日起獲委任) 葉雷(自二零一七年二月二十三日起獲委任) 王輝 彭中輝 陳炳煥 黃耀傑(自二零一七年二月二十三日起獲委任)



CORPORATE INFORMATION 公司資料



REMUNERATION COMMITTEE

Pang Chung Fai Benny (chairman of Remuneration Committee)
Wong Sai Hung (appointed with effect from 23 February 2017)
Shao Zhengkang (appointed with effect from 23 February 2017)
Chen Chunguo (appointed with effect from 23 February 2017)
Ray Yip (appointed with effect from 23 February 2017)
Wang Hui

Lui Tin Nang Chan Bing Woon

Wong Yiu Kit Ernest (appointed with effect from 23 February 2017)

AUDIT COMMITTEE

Lui Tin Nang (chairman of Audit committee)
Cui Zhanfeng (appointed with effect from 23 February 2017)
Ray Yip (appointed with effect from 23 February 2017)
Xiong Chengyu (appointed with effect from 20 March 2017)
Wang Hui
Pang Chung Fai Benny
Chan Bing Woon

Wong Yiu Kit Ernest (appointed with effect from 23 February 2017)

REGISTERED OFFICE

P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

10th Floor, Everbright Centre 108 Gloucester Road Wanchai Hong Kong

COMPLIANCE OFFICER

Wong Sai Hung

AUTHORISED REPRESENTATIVES

Wong Sai Hung Shao Zhengkang

薪酬委員會

彭中輝(薪酬委員會主席)

黃世雄(自二零一七年二月二十三日起獲委任) 邵政康(自二零一七年二月二十三日起獲委任) 陳春國(自二零一七年二月二十三日起獲委任) 葉雷(自二零一七年二月二十三日起獲委任)

王輝 呂天能 陳炳煥

黃耀傑(自二零一七年二月二十三日起獲委任)

審核委員會

呂天能*(審核委員會主席)* 崔占峰(自二零一七年二月二十三日起獲委任)

葉雷(自二零一七年二月二十三日起獲委任) 熊澄宇(自二零一七年三月二十日起獲委任)

王輝 彭中輝 陳炳煥

黃耀傑(自二零一七年二月二十三日起獲委任)

註冊辦事處

P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands

總辦事處及香港主要營業地點

香港 灣仔 告士打道 108 號 光大中心 10 樓

監察主任

黃世雄

授權代表

黄世雄 邵政康

CORPORATE INFORMATION 公司資料





PRINCIPAL BANKERS

Dah Sing Bank, Limited 36th Floor, Everbright Centre 108 Gloucester Road Hong Kong

Hang Seng Bank Limited 83 Des Voeux Road Central Hong Kong

AUDITOR

BDO Limited 25th Floor, Wing On Centre 111 Connaught Road Central Hong Kong

LEGAL ADVISER ON THE CAYMAN ISLANDS LAW

Maples and Calder 53rd Floor, The Center 99 Queen's Road Central Hong Kong

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited P.O. Box 1093 Boundary Hall Cricket Square Grand Cayman KY1-1102 Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Union Registrars Limited Suites 3301-04, 33/F. Two Chinachem Exchange Square, 338 King's Road North Point Hong Kong

COMPANY WEBSITE

www.crmi.hk

STOCK CODE

主要往來銀行

大新銀行有限公司 香港 告士打道108號 光大中心36樓

恒生銀行有限公司 香港 德輔道中83號

核數師

香港立信德豪會計師事務所有限公司 香港 干諾道中111號 永安中心25樓

法律顧問 (開曼群島法律)

Maples and Calder 香港 皇后大道中 99 號 中環中心 53 樓

開曼群島股份過戶登記總處

Maples Fund Services (Cayman) Limited P.O. Box 1093 Boundary Hall Cricket Square Grand Cayman KY1-1102 Cayman Islands

香港股份過戶登記分處及 股份過戶辦事處

聯合證券登記有限公司 香港 北角 英皇道338號華懋交易廣場2期 33樓3301-04室

公司網址

www.crmi.hk

股份代號

8158



CHAIRMAN'S STATEMENT

主席報告



It has been an honour to serve our Company, China Regenerative Medicine International Limited ("CRMI"), as the Chairman of Board of Directors (the "Board"). We are presented unparalleled opportunities and moving into an important and exciting period in our corporate history.

During the last financial year, CRMI has made significant changes in the senior management team and the Board to respond the new needs for the Company development. Eminent professionals were invited to join the Board to strengthen our profile in international business, corporate strategy, as well as science and technology. A new Chief Executive Officer ("CEO") was appointed to drive the Company from the phase of research and development ("R&D") to large scale manufacture, market and sales. Under the strong leadership of our new CEO, a detailed three-year operation plan was proposed, and approved by the Board, and implemented from May 2017. It should be pointed out that this three-year operation plan focused on delivery and financial returns to shareholders.

The performance of our Company, in terms of product sales and financial figures, improved compared to previous years. The significant change in sales represented a clear indication of the Company transformation from R&D to full commercialisation. Our products and services have two important features, heavily regulated and for the unmet clinical needs, both bearing strong social responsibilities. As a public company, we recognise these social responsibilities and the responsibility of financial returns to our shareholders.

We aim at becoming a global leader in regenerative medicine. Our tissue engineered cornea product, "Acornea", has been reported by major international media including BBC, CBS etc, and attracted global attentions. Our R&D programs including those conducted in the CRMI Technology Centre at the University of Oxford resulted in cutting edge technologies to provide pipeline products for the Company. We seek opportunities for collaborations and expansion in Africa, America, Europe and Far East to enhance our international profile and to increase our market share. As the name indicates, China Regenerative Medicine International is a regenerative medicine company, mainly based in China but serving the international markets.

本人很榮幸能夠擔任本公司中國再生醫學國際有限公司(「中國再生醫學」)的董事會(「董事會」) 主席。我們正面臨前所未有的機會及邁入我們企業發展史上一個重要又激動人心的時期。

於上一財政年度,中國再生醫學在高級管理層團隊及董事會方面做出重大變動,以應對本公司邀請知名專業人士加入董事會,以增強我們在國際業務、企業戰略及科技內面的實力。本公司委任新任行政總裁(「行政總裁」),推動本公司自研發(「研發」)階段走內強裁人規模製造、營銷及銷售。在新任行政總裁的且自一發運計劃已獲量計劃自一大學運計劃自一大學運計劃自在有所建樹及給予股東財務回報。

本公司於產品銷售及財務數據方面的表現較以往 年度有所提高。銷售的顯著改善清楚體現出本公 司正自研發向完全商業化轉型。我們的產品及服 務有兩個重要特徵:嚴格監管及為滿足未被滿足 的臨床需求,兩者肩負著高度的社會責任感。作 為一間上市公司,我們深知該等社會責任及給予 股東財務回報的責任。

我們致力成為再生醫學的全球領導者。我們的組織工程角膜產品「艾欣瞳」已獲英國廣播公司主要國際媒體報道,及備受全球關注。我們的研發計劃,包括在中國再生醫學牛津司,投術研發中心進行的研發項目,已為本公司,學在研產品提供前沿技術支持。我們尋求在非洲、歐洲及遠東地區進行合作及擴張業務的。正如我們的名稱所昭示,中國再生醫學為一間再生醫學公司,雖扎根中國但服務國際市場。

CHAIRMAN'S STATEMENT

主席報告



Finally I would like to thank our friends, who helped CRMI in various ways, our collaborators and partners, who joined us to bring our new products to the patients, and our employees in CRMI and its subsidiaries, without their contributions and dedication none of the achievements was possible.

最後,本人謹此感謝曾以各種方式幫助中國再生 醫學的朋友們、加入我們並將我們的新產品帶給 患者的合作商及業務夥伴,以及中國再生醫學 及其附屬公司的員工,倘若並無彼等的貢獻及奉 獻,我們不可能取得今天的成就。

Cul

Professor Zhanfeng Cui, PhD, DSc, FREng 17 July 2017

崔占峰教授·PhD, DSc, FREng 二零一七年七月十七日

管理層討論及分析



In this fiscal year, the Company and its subsidiaries (collectively, the "Group") made new strategic adjustments and reformation on the top of continued strengthening of the four core businesses: tissue engineering, cell, cosmetic and others, and medical equipment. The Group:

本公司及其附屬公司(統稱「本集團」)在繼續加強組織工程、細胞、化妝品及其他以及醫療設備四個核心業務版塊的基礎上,本財年開啟了新的戰略調整與改革。本集團通過:

- adjusted and optimized the organizational structure, strengthened the building of operations management team, changed its operations management concept of more emphasis on sales and marketing rather than on research and development ("R&D"), and enhanced marketing development measures so as to further improve the Group's profitability;
- 調整優化組織架構、強化經營管理團隊建設、轉化重研發(「研發」)輕市場的經營管理理念,加大市場拓展力度來進一步提高集團盈利能力;
- streamlined and optimized the management process by developing four control main lines such as operations management, financial management, human resources management and technical management, defined and empowering business division management to raise the operation effectiveness and efficiency of the Group, and improving the level of management;
- 梳理及優化管理流程,建構運營管理、財務 管理、人力資源管理及技術管理四條管控 主線,明確並加大對各事業部的管理授權, 提高集團運營效率和效能,提升集團管理水平;
- upgraded its products in a comprehensive manner, introduced new business sections, reasonably enhanced and deployed the industrial layout, and strengthened its efforts on investment and merges and acquisitions ("M&A") in a bid to ensure a sustainable development in the long run.
- 全面啟動產品升級,引入新的業務版塊,合理優化和部署產業佈局,加強投資及併購 (「併購」),來構建集團長期可持續發展之路。

OPERATIONS REVIEW

業務回顧

I. Adjusting the organizational structure of the Group to optimize the management mode

I、 調整集團組織架構,優化管理模式

In this fiscal year, the Group has made comprehensive and optimized adjustments to the organizational structure by transforming the original business unit management mode to the business division management mode, which further strengthened the management control and promotion efforts on sales and marketing, and provided effective assurance for improving the profitability of the Group.

本財年集團對組織架構進行了全面的優化調整,將原有的業務單元管理模式,調整為事業部管理模式,進一步加強對市場、銷售的管控及推進力度,為提高集團盈利能力提供了有效保障。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

I. Adjusting the organizational structure of the Group to optimize the management mode (Cont'd)

The Group has established three business divisions, namely Tissue Engineering & Pharmaceutical Division, Cosmetics Division and Cell Division, to responsible for the comprehensive operations management of tissue engineering and medical equipment product lines, cosmetic product line, cell storage, preparation and cell therapy product line respectively.

As such the Group has formed a operations management hierarchy consisting of headquarters, business divisions and subsidiaries. The headquarters is a management center, a decision-making center and a capital center; the business divisions are both management centers and operation centers; and the subsidiaries are business centers and profit-making centers.

II. Strengthening the building of an operations management team to improve the team quality

In order to achieve the Group's strategic adjustments and reformation initiatives, the Board has strengthened the building of an operations management team. In October 2016, the Group set up a high-quality and experienced management team by appointed a new chief executive officer and concurrently absorbing senior management personnel in possession of a wealth of executive management experience, cross-regional and cross-cultural group management and control capabilities, better market and brand management awareness into the management teams at the Group's headquarters, business divisions and subsidiaries. Each of division and subsidiary had set up a leadership team which adheres to centrally democratic decision-making procedures, providing a talent guarantee for the strategic adjustment and reform of the Group.

業務回顧(續)

1、調整集團組織架構,優化管理模式 (續)

本集團成立了三個事業部,分別為組織工程 與藥品事業部、化妝品事業部及細胞事業 部,負責組織工程及醫療設備產品線、化妝 品產品線、細胞存儲、製備及細胞療法產品 線的全面經營管理。

至此,本集團形成了集團總部、事業部及子公司的經營管理體制,集團總部是管理中心、決策中心及資本中心;事業部既是管理中心也是經營中心;子公司是業務中心及利潤中心。

II、 強化經營管理團隊建設,提高團隊 素質

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



OPERATIONS REVIEW (Cont'd)

III. Enhancing marketing development efforts to improve business performance

The operation strategy of the Group before 2016 was focused on technical R&D. Relying on the strong scientific research capacity of the International Research Center of the Group set up at Oxford University and extensive cooperation with scientific research institutions at The University of Hong Kong and Research Institute of Tsinghua University in Shenzhen and through the unremitting endeavors made by the scientific researchers, the Group has gained a series of pioneered research achievements forerunning the industry in science and technological innovation and established its leading enterprise status in the industry of tissue engineering and regenerative medicine.

The Group's operation strategy for the second half of this fiscal year was shifted to enhance sales and marketing development measures so as to improve the Group's business performance. Effective sales distribution channel and service network system has been established gradually and noticeable improvement in sales and marketing performance of all product lines has been achieved by the adjustment of more emphasis on sales and market than on R&D, by expanding sales team of each product line, by the reformulation of marketing strategy, brand strategy and the sales incentive policy; and by the re-development and enrichment of the marketing channel, which provided assurance to achieve the operational target.

業務回顧(續)

Ⅲ、 加大市場拓展力度,提高經營業績

本集團在二零一六年之前的經營策略一直是 以技術研發為主導,經過科研人員的不懈努力,憑藉著在牛津大學設立的集團國際研究 中心強大科研力量,以及與香港大學、清華 大學深圳研究院等科研院所的廣泛合作,取 得了一系列行業內科技創新、技術領先的研 究成果,確立了本集團在組織工程與再生醫 學行業的領軍企業地位。

本財年下半年,集團的經營策略調整到加強市場銷售力度,以提高企業經營業績。藉着調整轉化重研發輕市場的經營理念,擴充各產品線市場銷售團隊;重新制定市場策略和銷售激勵政策;重新拓展、豐品時策略和銷售深道,逐步形成完善的銷售分銷渠道及服務網絡體系,各產品線的市場銷售業績都有明顯的提高,為實現經營業績目標提供保管。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

IV. Developing four management and control main lines to improve management efficiency

In order to coordinate with the management mode of the organisational structure of the business division and strengthen the management and decision-making function of the Group's headquarters, the Group developed four management and control main lines, namely the operation management line, financial management line, human resources management line and technical management line, by mobilising the management enthusiasm of Group divisions and its subsidiaries through reasonable authorization. The Group streamlined and completed the management system and flowchart of the four management and control main lines, well defined the management control point, the responsible person and management requirements of each Group division and subsidiary, specified the Group's performance appraisal system for the operating results of each division and subsidiary, which further strengthened the management fineness and promoted the market exploration efforts. Through the implementation of the four management and control main lines, the Group could have timely control on the overall picture on operations and management of each division and subsidiary; and according to the authorisations and management requirements of the Group, divisions and subsidiaries of the Group could make rapid progress in the operation management work, thus forming an effective linkage within the Group among each division and subsidiary from top to bottom. With the effective coordination among these four management and control main lines, the Group's management efficiency and working ability would be further improved.

V. Fully initiating product upgrades to optimise and improve the industrial layout

With overall streamlining the Group's existing tissue engineering product line, cosmetic product line and cell product line, the Group began to initiate the product upgrade strategy to achieve the effective combination between product and market, product and service, product and brand, single product and whole industrial chain through the innovations of products, technology and operations. Meanwhile, the Group further optimised and improved the industrial layout with the establishment of the Hospital Management Department and the Overseas Business Division of the Group as well as the arrangement of relevant business kicking off, thereby basically forming a whole industrial chain layout, enhancing investment and M&A and thus creating a long-term sustainable development path.

業務回顧(續)

IV、構建四條管控主線,提升管理效能

為了適應集團事業部制定組織架構管理模 式,強化集團總部管理決策職能,通過合理 授權調動事業部、子公司經營管理的積極 性,集團建構了運營管理、財務管理、人力 資源管理及技術管理四條管控主線,分別 梳理、完善了四條管控主線的管理制度和流 程,明確了管理節點、各事業部及子公司的 責任人和管理要求,明確了集團對各事業部 及各子公司實施經營業績考核的績效考核制 度,進一步加強管理細度,推進拓展市場力 度。通過四條管控主線的實施,集團對各事 業部及子公司的經營管理全貌有及時掌控, 事業部及子公司按照集團的授權及管理要求 快速推進各項經營管理工作,形成集團與各 事業部及子公司上下高效聯動、四條管控主 線之間有效協同的工作合力,進一步提高了 集團的管理效率和工作水平。

V、 全面啟動產品升級,優化完善產業 佈局

經過對本集團現有組織工程產品線、化妝品產品線、細胞產品線的全面梳理,本集團開始啟動了產品升級策略,通過產品創新的手段,實現產品與服務、產品與服務、產品與品牌、單一產品與是產業鏈的有效銜接。同時,集團進一步和學化完善產業佈局,增設了集團醫院管理部形成了集團全產業鏈佈局,加強投資併購,來構建集團長期可持續發展之路。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)

At present, products and operations for each business line of the Group are as follows:

1. Tissue engineering product line

The Group's tissue engineering product line is comprised of three subsidiaries in Xi'an, Shaanxi and Shenzhen. The tissue engineering products include:

(1) Tissue Engineered Skin with Living Human Cells — ActivSkin®

ActivSkin®, being the first tissue-engineered skin approved by China Food and Drug Administration, is the only tissue-engineered skin containing living cells in the PRC. It is mainly used for healing deep 2nd degree and 3rd degree burn and scald wounds. It can relieve pains, shorten healing time and reduce scars in treating burns and scalds.

(2) Acellular Corneal Stroma — Acornea

Acornea is the world's first bio-engineering cornea that has completed clinical trials and has been successfully launched to market, making China's leading position in regenerative medicine research of corneal disease in the world. The total effective rate of clinical trials of Acornea reached 94.44% with the healing effect close to donated cornea. In 2016, Acornea was reported by BBC as one of the five major scientific and technological revolutions from China, which make great contribution to the world. Its academic status makes China seize the initiative in the field of biomedical competition in the world.

(3) Calcined Bovine Bone — Gegreen

Gegreen is a protein-detracted bone substitute material for inducing natural bone regeneration, which is the independently-developed material in the PRC. It is made by extracting material from epiphysis cancellous bone of bovine femur, and then goes through the process of virus inactivation, degreasing, protein detracting and low-temperature calcination. It is extensively used for jawbone defect restoration, particularly in dental implantation and treatment of periodontal defects.

業務回顧(續)

V、 全面啟動產品升級,優化完善產業 佈局(續)

目前集團各產業鏈的產品及業務有:

1、 組織工程產品線

本集團組織工程產品線在陝西西安及 深圳共有三家子公司,組織工程產品 有:

(1) 人體活細胞組織工程皮膚 — 安 體膚®

安體膚®是國內唯一含有活細胞的組織工程皮膚,是第一個獲得國家食品藥品監督管理局批准的組織工程皮膚,主要用於深間度、間度燒燙傷創面修復。其在治療燒傷和燙傷方面可以減輕患者疼痛,縮短癒合時間,減少疤痕。

(2) 脱細胞角膜基質 — 艾欣瞳

生物工程角膜「艾欣瞳」是全球首個完成臨床試驗並成功上上角膜,使我國本工程角膜,使我國本土生醫學研究領域走產器學研究領域走達場,與4.44%,癒後效果接近重大型。二零一六年艾欣瞳世世界上,與廣播公司重點報道直擊術,其學術域的數學中國在世界生物醫藥領域的激烈競爭中搶佔了先機。

(3) 天然煅燒骨修復材料 — 骼瑞 骼瑞是一種可引導天然骨再生的 脱蛋白質骨替代材料,是中國自 主研發來自牛股骨骨骺鬆質骨, 經病毒來活、脱脂去蛋白以及低 溫鍛燒處理而成,可廣泛應用於 領骨缺損修復,特別是用於牙科 種植及牙周骨缺損的治療。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

- V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)
 - 1. Tissue engineering product line (Cont'd)
 - (4) Acellular Anal Fistula Repair Stroma Asiunin
 Asiunin is applied to simple anal fistula disease
 without going through fistulotomy operation which
 is traditionally used to cure anal fistula in western
 medicine. Fistulotomy operation has a chance to
 harm the sphincter muscle and causes relapses.
 It is believed that the relapse rate when using
 Asiunin for simple anal fistula is comparatively lower,
 bringing in revolutionary changes to anal fistula
 treatment. It can completely reshape the perianal
 tissue and protect the anal sphincter mechanism.
 Through minimally invasive operation, it can speed
 up the healing rate and shorten the hospitalization
 period.
 - (5) Oral Cavity Repair Membrane with Excellent Regeneration Capacity Megreen

 Megreen, a new product developed by Shaanxi Reshine Biotech Co. Ltd., a subsidiary of the Group, is currently applying for registration. Megreen is made from the bovine pericardium tissue with collagen as the main component through decellularization, virus inactivation and other treatments, which retains a natural three-dimensional structure. Megreen can be widely used in the repair of oral cavity tissue with its advantages of natural double-layer membrane structure, superior mechanical performance and longer degradation time.
 - (6) Cell Sheet-Autologous Chondrocyte Implantation CS-ACI CS-ACI is a cartilage repair technology based on the world's leading cell sheet preparative technology. It is used for tissue repair and functional reconstruction of damaged articular cartilage. As the first 4th generation of autologous chondrocyte treatment technology developed by China, CS-ACI is used to produce transparent cartilage as a substitute for exogenous material to avoid cell loss. In addition, since suture is not necessary and it

clinical prospect.

takes shorter time in the operation, it has a broad

業務回顧(續)

- V、 全面啟動產品升級,優化完善產業 佈局(續)
 - 1、 組織工程產品線(續)

 - (5) 卓越再生能力的口腔修復膜 一 膜瑞

膜瑞是集團陝西瑞盛公司研發的 新品,目前處於辦理註冊階段 時端是由牛心包膜組織為原報 主要成分為膠原蛋白,通製備 或,病毒滅活等處理後製備。 成,保留天然的三維空間結構和 成,保留天然的雙層膜結構和問 色的特性,可廣泛用於口腔組織 的修復。

(6) 自體軟骨細胞膜片移植技術 — 瑞骨術

> 瑞骨術是基於國際領先的細胞膜 片製備技術研發的軟骨修復 術,可以幫助損傷關節軟骨的 縮修復及功能重建。是國內首鄉 第四代自體軟骨細胞治療技, 利用瑞骨術生成透明軟骨, 外源材料,確保細胞無流失, 時, 手術無須縫合而且 手術 短, 有廣泛的臨床前景。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)

2. Cosmetics product line

(1) AMYbio Skincare series brands

By utilizing the derivatives resided during our production processes of the tissue-engineered skin, Shaanxi Aimiya Bio-Technology Company Limited, a subsidiary of the Group principally engaged in cosmetics, has successfully cultivated a pioneering human-derived active cell growth factor, which has been applied in skincare products. Series of products have been launched and an agent system has been established nationwide. Meanwhile, the products have had access to hospitals and beauty salons.

(2) Skincare cosmetics brand — Ascara

The Group imports the original skincare cosmetics brand - Ascara with a history of more than 40 years from Switzerland. Ascara has various functions, such as skin relieving, anti-aging, skin whitening, anti-freckle and so on. It is a foreign high-end skincare product line targeted at the mass market. It has built an omni-channel sales network centering DS and then radiating to CS, covering e-commerce platforms and assisted by regional distributors.

(3) CRMI PrincipleO'skin

The Group decided to launch a skincare brand "CRMI PrincipleO'skin" to be sold via e-commerce platforms. Relying on the core technology of the Group and the International Research Institute of Oxford University, the Group has designed two series of skincare products with EGF extracted from stem cell culture medium as the core raw material. At present, the project has been initiated and a team has been basically formed. The design for relevant products is under progress. It was expected that the products will be launched to market in mid-2017.

業務回顧(續)

V、 全面啟動產品升級,優化完善產業 佈局(續)

2、 化妝品產品線

(1) 艾美雅護膚系列品牌

集團子公司陝西艾美雅化妝品公司,充分利用組織工程皮膚的生產過程中產生的衍生品,成功培育出了具有開創性的人源活性細胞生長因子,並運用於護膚品中。現已形成多系列的產品,在全國已建立代理商體系,並進入醫美院線。

(2) 阿卡蘭理護化妝品品牌

本集團原裝進口瑞士具有40多年歷史的精準理護化妝品品牌阿卡蘭,該產品具有舒緩、抗老的一大,該產品與有舒緩、抗之大眾市場的國外高端護膚產品線,營銷渠道以DS為點,以CS為線,電商為面,區域經銷為輔,打造全渠道的銷售網絡。

(3) CRMI顏值定律護膚品牌

本集團確定啟動一款採用電商渠 道進行化妝品銷售的「CRMI顏 值定律」護膚品牌。該品牌依 充集團及牛津大學國際研究院 核心技術,以幹細胞培養液提取 EGF為核心原料,設計兩大系, 護膚產品。目前項目已啟動 隊已基本組建完成,正在進行相 關產品設計階段,預計二零一七 年中能夠上市。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)

3. Cell storage, preparation and therapy product line

Currently, the Group has established five cell storage, preparation and therapy centers in Tianjin, Suzhou (Jiangsu Province), Changzhou (Jiangsu Province) and Hong Kong to make a good planning layout serving the cell business globally.

(1) Tianjin Weikai

The Group's subsidiary 天津衛凱生物工程有限公司 (Tianjin Weikai Bioeng Ltd*) focuses on the R&D and applications of cell culture equipment and cell products, as well as providing cell-related outsourcing technical services. The self-developed 3DFlo cell culture instrument ensured the high-quality cell reproduction and established an in vitro model to simulate in-vivo physical condition by utilizing automated continuous perfusion cell culture technology. Meanwhile, Tianjin Weikai has established a close cooperation relationship with Institute of Chemical Physics, Chinese Academy of Sciences and other scientific research institutes at home and abroad.

(2) AK Suzhou

In 2016, the Group's subsidiary 奧凱(蘇州)生物技術有限公司 (AK (Suzhou) Biomedical Ltd#) expanded the Phase II Cell Preparation Center. It provides high standards of service and equipment for cell clinical research, testing and applications leveraging on the Oxford R&D team's unique cell processing technology and reagent formula. Its core technologies include human cell separation, purification, cultivation, amplification, storage and transportation, as well as the development and production of automated closed cell bioreactors.

業務回顧(續)

V、 全面啟動產品升級,優化完善產業 佈局(續)

3、 細胞儲存、製備及治療產品線

本集團目前在天津市、江蘇省蘇州市、江蘇省常州市和香港,分別建有 五個細胞存儲製備及治療中心,以做 好本集團服務全球細胞業務的規劃佈 局。

(1) 天津衛凱公司

(2) 奥凱(蘇州)公司

本集團所屬奧凱(蘇州)生物技術有限公司,二零一六年擴建了二期細胞製備中心,其利用中津研發團隊獨特細胞加工技術的試劑配方訣竅為細胞臨床那務及的大調配,其核心技術包括人體細胞的分離、純化、培養、擴增、細胞接續,以及自動化封閉式細胞擴增器的開發和生產。

[#] for identification only

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

- V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)
 - 3. Cell storage, preparation and therapy product line (Cont'd)
 - (3) Changzhou branch company, Jiangsu Province In October 2016, the Group started to build a Cell Storage and Preparation Center in Changzhou, Jiangsu Province. The center has been identified as the technology transformation unit of Engineering Technology Research Center for Tumor Immunotherapy of Jiangsu Province, mainly responsible for industrial transformation and clinical applications of the R&D results achieved by the center. The scope of business mainly covers cellular therapy, cell storage, genetic testing, biological agents manufacturing. The center is scheduled to be completed by the end of 2017.
 - (4) Hong Kong International Regenerative Centre
 The Hong Kong International Regenerative Centre
 ("HKIRC"), being the first large-scale comprehensive
 health care base for precision medicine in Hong
 Kong, was established by the Group at the Miramar
 Center in Tsim Sha Tsui, Hong Kong. In possession
 of precise medical technology, combining with
 precise physical examination and genetic testing,
 HKIRC aims to provide precise healthcare to meet
 the physical and mental needs from customers,
 including precise cellular therapy and precise
 medical beauty.

業務回顧(續)

- V、 全面啟動產品升級,優化完善產業 佈局(續)
 - 3、 細胞儲存、製備及治療產品線(續)
 - (3) 江蘇常州公司 本集團於二零一六年十月開工建 設位於江蘇當州的细胞有樣與制

設位於江蘇常州的細胞存儲與製備中心。該中心已被認定為江蘇常州的細胞存儲與蘇省腫瘤免疫治療工程技術可負地的技術轉化單位,主要包括一个心的研發成果進行產業轉化地度用於臨床。業務主要包括細、性物製劑製造等。該中心計劃於二零一七年底前建設完成。

(4) 香港國際再生醫學中心

本集團在香港尖沙咀美麗華中心設立的香港國際再生醫學中心(「HKIRC」)是目前香港首家大型綜合精準醫療基地。HKIRC以精準醫療技術為核心,結合精準體檢和基因檢測,為客戶身體和心理健康提供精準醫療,包括精準細胞治療和精準醫美項目。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

- V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)
 - 3. Cell storage, preparation and therapy product line (Cont'd)
 - BioCell Technology Limited ("BioCell") Our China Stem Cell Clinical Applications Centre (the "Centre"), located at Phase 3 of Hong Kong Science Park in Shatin, has started construction. Covering an area of 2,000 square meters, the Center is designed in accordance with international standards and is equipped with advanced equipment and facilities in high specifications. Stem cell clinical application facilities meet the clean room standards from EMA, FDA, CFDA, TGA and GMP PIC/S. As Asia's first international cell and gene preparation center, the Centre provides cell preparation processes for international biotechnology companies, international pharmaceutical plants, clinical application institutions and cell libraries in line with international and domestic cell preparation quality standards, as well as technology platforms for clinical application transformation for the improvement and development of the cellular therapy in the future. We will conduct pre-installation regulatory reviews in accordance with the GMP and PIC/S specifications from the Hong Kong Department of Health. The Centre has established close cooperative relationship with relevant research departments and academics, including The University of Hong Kong and The University of Oxford, laying a solid foundation for the clinical transformation and industrialization of stem cell and cellular therapy technology and for cell preparation platforms in Hong Kong and other Asian regions. Since the construction work and installation and commissioning of equipment have been completed, the Centre has been officially put into operation in June 2017.

業務回顧(續)

- V、 全面啟動產品升級,優化完善產業 佈局(續)
 - 3、 細胞儲存、製備及治療產品線(續)
 - 百奥生物科技公司(「百奧」) 本集團在位於沙田的香港科學園 三期開始建設中國幹細胞臨床應 用中心(「中心」)。該中心佔地 2,000平方米,按照國際標準及 世界先進設備及設施的高規格要 求來建造。幹細胞臨床應用設施 符合EMA、FDA、CFDA、TGA 和GMP PIC/S潔淨室的標準, 成為亞洲首家面向國際的細胞與 基因製備中心,該中心向國際生 物技術企業、國際藥廠、臨床應 用機構、細胞庫等提供符合國際 與國內的細胞製備質量標準的工 藝流程,以及臨床應用轉化的技 術平台,以用於我們日後細胞療 法的完善及發展。我們將按照香 港衛生署的GMP及PIC/S規範 進行安裝前監管審查。該中心已 與香港大學、牛津大學等有關研 究部門及學者建立緊密的合作關 係, 為幹細胞及細胞治療技術向 臨床轉化及產業化,為香港以及 整個亞洲區域的細胞製備平台中 心奠定良好的基礎。該中心已完 成建設及設備安裝調試,已於二 零一七年六月份正式投入運營。

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)

4. Medical equipment

The Group's subsidiary, 中生醫療器械有限公司 (Zhongsheng Medical Equipment Trading Company Limited#) ("Zhongsheng Medical Equipment"), is engaged in the trading of medical equipment in the PRC. During the year, Zhongsheng Medical Equipment made solid step in expanding and strengthening its sales and distribution network in the PRC, which resulted in significant increase in sales over the prior year.

5. Hospital administration division of the Group

In order to guarantee the rational layout of tissue engineering and cell business and expand channels, the hospital administration division was set up under the Group headquarters in this fiscal year, responsible for the management of future investments in hospitals and related channels of the Group. In the first half of 2016, the Group stationed in Hainan Boao Lecheng International Medical Tourism Pilot Zone and was granted 150 acres of land for the construction of a comprehensive medical institution. By leveraging on the advantages of the policy of the pilot zone, the Group will further enrich and expand its business lines and channels. At present, the Hospital Administration Division in Hainan is under planning and design.

6. Overseas business division of the Group

With the R&D transformation efforts made over the past 17 years since establishment, the Group has basically established the layout of the whole industry chain in Hong Kong and Mainland China. In order to achieve the strategic requirements of the Board, the Group set up the overseas business division in this fiscal year to further expand its overseas markets, so as to identify suitable business opportunities for overseas investment and M&A and implement the layout of overseas markets of the Group.

業務回顧(續)

V、 全面啟動產品升級,優化完善產業 佈局(續)

4、 醫療設備

本集團附屬公司中生醫療器械有限公司(「中生醫療器械」)於中國從事買賣醫療設備。於本年度,中生醫療器械於拓展及鞏固其於中國的銷售及分銷網絡方面邁出了堅實的一步,使銷售額較去年錄得大幅增長。

5、 集團醫院管理部

6、 集團海外事業部

本集團成立17年來,經過長期的研發轉化階段,目前在香港及國內已經基本規劃確定全產業鏈的佈局。為了實現董事會的戰略要求,本財年集團成立海外事業部,以進一步拓展海外市場,尋找適合商機開展海外投資併購業務,實現集團海外市場的佈局。

[#] for identification only

管理層討論及分析



OPERATIONS REVIEW (Cont'd)

- V. Fully initiating product upgrades to optimise and improve the industrial layout (Cont'd)
 - 6. Overseas business division of the Group (Cont'd)

Having completed the stationing in the United States, the United Kingdom and Japan and preliminarily established a management and operation team respectively, the Group is seeking opportunities for overseas expansion.

BUSINESS OUTLOOK

BioCell is a recognized contract manufacturer in the Asia Pacific region with GMP contract manufacturing ability for cell therapy under GMP PIC/S, FDA, CFDA, TGA, EMA, FACT and AABB standards. BioCell also provides "point-to-point" service including oversight and management of cord blood and cord collection through therapies of cell processing, cryopreservation and cell delivery. We support the entire product lifecycle from initial research to process optimisation through clinical trial manufacturing and commercial supply. Our experience spans all major cell families including stem cells and immune cells and key applications from gene and immunotherapies to cell therapies and regenerative medicine. Our partnership with The University of Hong Kong affiliated Queen Mary Hospital, The Chinese University of Hong Kong affiliated Prince of Wales Hospital, and other collaborators with cutting-edge technologies enable us to bring deep research, clinical and process expertise to all clients efficiently. Our brand new production facilities at Hong Kong Science Park Phase III comprise of 3 PIC/S Grade B cleanrooms surrounded by Grade C area, as well as 3 Grade D cleanrooms and quality control laboratories with 8 isolators to offer a gateway to transform cell manufacturing into clinical application under a coordinated quality system. It is our honor to cooperate with the world's leading stem cell companies on the most currently innovative and transformational therapies in medical field.

As a high-end anti-aging and health management service company, HKIRC provides its high-end clients with comprehensive, precise and customized anti-aging aesthetic services focusing on internationally advanced cell regeneration diagnosis and treatment, in combination with precise medical examination, gene testing, medical cosmetology, preventive medicine, functional medicine, traditional Chinese medicine, naturopathy, etc.

業務回顧(續)

- V、 全面啟動產品升級,優化完善產業 佈局(續)
 - 6、 集團海外事業部(續)

目前集團已完成美國、英國和日本的 海外布點工作,經營管理團隊已初步 搭建,正積極尋求海外拓展機會。

業務展望

百奥為亞太地區認可的合約製造商,具備符合 GMP PIC/S · FDA · CFDA · TGA · EMA · FACT 和AABB標準的細胞療法GMP合約製造能力。百 奧亦提供「點對點」服務,包括透過細胞處理、低 溫貯藏及輸送細胞的療法,監督及管理臍血和臍 帶收集。我們透過臨床試驗製造及商業供應,支 持從初步研究轉化到流程優化的整個產品生命週 期。我們的經驗涵蓋所有主要細胞家族,包括幹 细胞及免疫細胞,以及從基因及免疫療法到細胞 療法及再生醫學的主要應用。我們與香港大學附 屬瑪麗醫院、香港中文大學附屬威爾斯親王醫院 等合作夥伴合作,利用彼等的尖端技術高效地為 所有客戶提供深入的研究、臨床及流程方面的專 業知識。我們在香港科學園三期的全新生產設施 包括由C級區包圍的3個PIC/S B級潔淨室,以及 附屬的3個D級潔淨室及配備8個隔離器的質量控 制實驗室,研究將細胞製造轉化為協調質量體系 下的臨床應用。我們很榮幸能就醫學界目前最具 創新性及可轉化的療法與世界領先的幹細胞公司 展開合作。

HKIRC是一家高端的抗衰老與健康管理服務公司,以國際先進的細胞再生診療為核心,結合精準醫療體檢、基因檢測、醫療美容、預防醫學、功能醫學、傳統中醫、自然療法等,以個性化的私人訂制形式,為高端客戶提供全面、精準的抗衰老服務。

管理層討論及分析



BUSINESS OUTLOOK (Cont'd)

Boasting famous regenerative medicine scientists and anti-aging experts in Hong Kong and the world, HKIRC has established a long-term strategic partnership with several large hospitals, scientific research institutions, famous laboratories and anti-aging institutions in Europe, North America and Hong Kong, and continuously developed modern sophisticated and precise biomedical technology. It strives to provide precise and integrated medical solutions for clients by various means including traditional naturopathy.

Main services include:

- Precise biological anti-aging treatment: including cell regeneration therapy and hormone replacement therapy;
- Precise health examination: including function examination, biochemical detection of blood and urine, gene testing, and comprehensive early screening of cancers;
- Precise medical cosmetology: including customised skin care, international energy therapy for medical cosmetology, and micro-plastic surgery, etc;
- Specialized dental care: including tooth implantation, tooth whitening, etc.

FUTURE PROSPECT

The Group will further deepen and refine the management policy, and continue to enhance the level of corporate operation and management through the four management and control main lines. The Group will continue to strengthen the sales and marketing efforts in respect of tissue engineering, cell, cosmetic and others, and medical equipment for enhancing the operational results of each business chain. The Group will strive to maintain its leading position in tissue engineering, regenerative medicine and related industries by leveraging CRMI Technology Centre at the University of Oxford and the long-term cooperation with the research institutes including The University of Hong Kong and Tsinghua University, and other global well-known industry experts. Meanwhile, the Group is dedicated to the investments and M&A business in the whole industry chain by identifying suitable business opportunities from domestic and overseas markets to promote the sustainable and sound development of the Group.

業務展望(續)

香港國際再生醫學中心擁有國際及香港著名再生 醫學科學家及抗衰老專家,與歐洲,北美及香港 多家大型醫院、科研院所、著名實驗室、抗衰老 機構建立了長期戰略合作夥伴關係,不斷開發新 的現代尖端精準生物醫學技術,並結合傳統自然 療法等多種手段,為顧客提供精準的醫學綜合解 決方案。

主要業務包括:

- 精準生物抗衰老治療:包括再生細胞療法和 激素替代療法;
- 精準健康體檢:包括功能體檢,血液尿液生 化檢測,基因檢測,早期綜合癌症篩查;
- 精準醫療美容:包括個性化皮膚管理,國際 醫美能量治療,微整形醫療美容等;
- 牙科專科護理:包括牙齒種植,牙齒美白等。

未來前景

管理層討論及分析



FINANCIAL REVIEW

Result

The Group's revenue for the year ended 30 April 2017 was approximately HK\$357.0 million, representing an increase of approximately HK\$329.2 million, or 1,184.2%, compared to the Group's revenue of approximately HK\$27.8 million for last year. The overall increase in revenue was attributable to an increase in revenue across different segments, including tissue engineering, cell, cosmetics and others and medical equipment. Gross profit increased by 651.4% to approximately HK\$137.5 million by year which is in accordance with an increase in revenue.

The Group recorded a revenue of approximately HK\$126.3 million from sales of tissue engineering products for the year ended 30 April 2017, representing an increase of 2,077.6% from last year which is mainly attributable to the Group has made a significant effort to expand distribution channel to improve sales (2016: HK\$5.8 million).

The Group recorded a revenue of approximately HK\$2.7 million from provision of cell therapy service and sales of cell related medical equipment for the year ended 30 April 2017, representing an increase of 107.7% from last year (2016: HK\$1.3 million).

The Group recorded a revenue of approximately HK\$44.9 million from sales of cosmetic, healthcare and other products for the year ended 30 April 2017, representing an increase of 122.3% from last year (year ended 30 April 2016: HK\$20.2 million). 上海赫絲蒂化妝品有限公司 (Shanghai Hesidi Cosmetics Company Limited#) ("Shanghai Hesidi") and 深圳赫絲蒂生物科技有限公司 (Shenzhen Hesidi Bio-Technology Company Limited#) ("Shenzhen Hesidi", together with Shanghai Hesidi, the "Hesidi Group"), the subsidiaries of the Group, are primarily engaged in sales and distribution of cosmetics and others related products ("Products").

During the period between 30 May 2017 and 6 June 2017, the Hesidi Group received notices requesting the return of some of the Products (the "Products Return") from the customers in the aggregate value of approximately HK\$52,580,000 (with corresponding cost of sales amounted to HK\$30,556,000) claiming difficulties in selling the Products due to changes in market conditions in the PRC.

財務回顧

業績

本集團截至二零一七年四月三十日止年度之收益約357,000,000港元,較本集團上一年度收益約27,800,000港元,增加約329,200,000港元或1,184.2%。收益之整體增加歸因於不同分部(包括組織工程、細胞、化妝品及其他以及醫療設備)之收益增加。毛利於本年度增加651.4%至約137,500,000港元,與收益增加一致。

截至二零一七年四月三十日止年度,本集團銷售組織工程產品錄得約126,300,000港元收益,較去年增加2,077.6%,此乃主要由於本集團大力拓展分銷渠道以促進銷售(二零一六年:5,800,000港元)。

截至二零一七年四月三十日止年度,本集團提供細胞療法服務及銷售細胞相關醫療設備錄得約2,700,000港元收益,較去年增加107.7%(二零一六年:1,300,000港元)。

截至二零一七年四月三十日止年度,本集團銷售美容、醫療保健及其他產品錄得收益約44,900,000港元,較去年增加122.3%(截至二零一六年四月三十日止年度:20,200,000港元)。上海赫絲蒂化妝品有限公司(「上海赫絲蒂」)及深圳赫絲蒂生物科技有限公司(「深圳赫絲蒂」)為本集團附屬公司,主要從事銷售及分銷化妝品及其他相關產品(「該等產品」)。

於二零一七年五月三十日至二零一七年六月六日期間,赫絲蒂集團接獲客戶通知,聲稱由於中國市況變動導致若干該等產品難以售出,要求退回部份總值約為52,580,000港元(對應銷售成本為30,556,000港元)的該等產品(「產品退回」)。

[#] for identification only

管理層討論及分析



FINANCIAL REVIEW (Cont'd)

Result (Cont'd)

Following negotiations between the management of the Hesidi Group and the customers, it is decided to accept the Products Return from the customers for the purpose of maintaining a long-term business relationship. The management of the Hesidi Group agreed with the Supplier to arrange for the return of such Products. Details of the Products Return were contained in the Company's announcement dated 23 June 2017.

Sales of medical equipment for the year ended 30 April 2017 was approximately HK\$183.1 million, representing an increase of 458 times from last year (2016: HK\$0.4 million) because the Group has made significant effort to establish distribution channels to enhance sales.

During the year under review, the Group incurred a loss attributable to owners of the Company of approximately HK\$184.5 million, as compared to a loss of approximately HK\$190.9 million for last year. Loss for the Group slightly decreased from last year which is mainly attributable to the significant increase in gross profit from increase in sales of our owned products but being offset by a reduction of interest income from providing financial assistance to independent third parties as the Group has allocated more resources on its core business together with the increase in staff costs and advertising expenses for promoting our products to the market. The loss per share attributable to the owners of the Company for the year ended 30 April 2017 was HK1.049 cents (2016: HK1.103 cents).

The Group's total operating expenses for the year ended 30 April 2017 was approximately HK\$389.3 million, representing an increase of 28.4% as compared to last year. The expenses mainly consisted of (i) the amortisation of intangible assets of approximately HK\$41.0 million (2016: HK\$38.6 million); (ii) research and development costs of HK\$56.0 million (2016: HK\$58.7 million); (iii) staff cost of HK\$131.7 million (2016: HK\$95.1 million); and (iv) advertising, marketing and promotion expenses of HK\$38.2 million (2016: HK\$14.3 million).

財務回顧(續)

業績(續)

經赫絲蒂集團管理層與客戶磋商後,赫絲蒂集團 管理層決定接受客戶之產品退回,以維持長期業 務關係。赫絲蒂集團管理層與供應商協定安排退 回該等產品。有關產品退回之詳情載於本公司日 期為二零一七年六月二十三日之公告。

截至二零一七年四月三十日止年度,醫療設備銷售為約183,100,000港元,較去年增長458倍(二零一六年:400,000港元),此乃由於本集團致力於設立分銷渠道以增加銷量。

於回顧年度內,本集團產生本公司擁有人應佔虧損約184,500,000港元,而上一年度虧損約為190,900,000港元。本集團虧損自上一年度輕微減少,乃主要由於自有產品的銷售額增加使毛利大幅增加,但被本集團分配更多資源至其核心業務導致向獨立第三方提供財務資助所產生之利息收入下降及員工成本以及產品市場推廣的廣告開支增加所抵銷。截至二零一七年四月三十日止年度,本公司擁有人應佔每股虧損為1.049港仙(二零一六年:1.103港仙)。

本集團截至二零一七年四月三十日止年度之營運開支總額約為389,300,000港元,較去年增加28.4%。開支主要包括(i)無形資產攤銷約41,000,000港元(二零一六年:38,600,000港元):(ii)研發成本56,000,000港元(二零一六年:58,700,000港元):(iii)員工成本131,700,000港元(二零一六年:95,100,000港元):及(iv)廣告及市場推廣開支38,200,000港元(二零一六年:14,300,000港元)。

管理層討論及分析



FINANCIAL REVIEW (Cont'd)

Net Assets

Net assets of the Group amounted to approximately HK\$1,907.9 million as at 30 April 2017, as compared to approximately HK\$2,118.2 million as at 30 April 2016, representing a decrease of 9.9% which was mainly attributable to the loss incurred for the year.

Liquidity and Financial Resources

Cash and Cash Equivalents

As at 30 April 2017, the Group had cash and cash equivalents of approximately HK\$571.7 million (2016: HK\$1,300.8 million). The decrease in cash and cash equivalent of approximately HK\$729.1 million was mainly due to (i) increase in pledged bank deposits, (ii) purchase of property, plant and equipment; (iii) purchase of financial assets; and (iv) increase in prepayments and deposits in relation to operating activities.

As at 30 April 2017, the bank borrowings of approximately HK\$754.0 million (2016: HK\$542.6 million) were secured by property, plant and equipment, land use rights and pledged bank deposits.

Working Capital and Gearing Ratio

As at 30 April 2017, the Group had current assets of approximately HK\$1,017.1 million (2016: HK\$1,994.5 million), while its current liabilities stood at approximately HK\$176.3 million (2016: HK\$692.8 million), representing a net current asset position with a working capital ratio (current assets to current liabilities) of 5.77 (2016: 2.88).

The gearing ratio of the Group as at 30 April 2017, calculated as total bank borrowings to total equity was 0.40 (2016: 0.26).

As at 30 April 2017, the Group's aggregate balance of cash and cash equivalents and pledged bank deposits far exceeded its bank borrowings. Given such net cash position, the gearing ratio of the Group would not be applicable if calculated as net debt to equity.

Capital Structure

During the year ended 30 April 2017, the issued shares of the Company were reduced from 17,592,180,000 shares to 17,585,790,000 shares as a result of cancellation of repurchased share during the year.

財務回顧(續)

淨資產

本集團於二零一七年四月三十日之淨資產為約 1,907,900,000港元,較二零一六年四月三十日約 2,118,200,000港元減少9.9%,此乃主要由於年 內產生虧損。

流動資金及財務資源

現金及現金等值項目

於二零一七年四月三十日,本集團擁有現金及現金等值項目約571,700,000港元(二零一六年:1,300,800,000港元)。現金及現金等值項目減少約729,100,000港元乃主要由於(i)已抵押銀行存款增加:(ii)購買物業、廠房及設備:(iii)購買金融資產:及(iv)有關經營活動的預付款項及按金增加。

於二零一七年四月三十日,銀行借款約754,000,000港元(二零一六年:542,600,000港元)由物業、廠房及設備、土地使用權及已抵押銀行存款作抵押。

營運資金比率及資產負債比率

於二零一七年四月三十日,本集團流動資產約1,017,100,000港元(二零一六年:1,994,500,000港元),而其流動負債則約176,300,000港元(二零一六年:692,800,000港元),即處於淨流動資產狀況,而營運資金比率(流動資產比流動負債)為5.77(二零一六年:2.88)。

於二零一七年四月三十日,本集團之資產負債比率(銀行總借款相對總權益計算)為0.40(二零一六年:0.26)。

於二零一七年四月三十日,本集團現金及現金等 值項目和已抵押銀行存款之結餘總額遠高於其銀 行借款。鑒於此為淨現金狀況,倘按債務淨額相 對權益計算本集團之資產負債比率將不適用。

資本結構

於截至二零一七年四月三十日止年度,本公司之已發行股份數目由17,592,180,000股減少至17,585,790,000股,此為年內註銷已購回股份之結果。



MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



FOREIGN EXCHANGE EXPOSURE

The Group's business transactions, assets and liabilities are principally denominated in Renminbi and Hong Kong dollars. The Directors consider the risk of foreign exchange exposure of the Group is manageable. The management will continue to monitor the foreign exchange exposure of the Group and is prepared to take prudent measures such as hedging when appropriate actions are required.

MATERIAL ACQUISITIONS OR DISPOSAL OF SUBSIDIARIES AND ASSOCIATED COMPANIES

On 1 November 2016, 陝西瑞盛生物科技有限公司 (Shaanxi Reshine Biotech Co. Ltd.#) ("Shaanxi Reshine"), a wholly-owned subsidiary of the Company, entered into a sale and purchase agreement with 鼎峰醫院管理 (深圳) 有限公司 (Ding Feng Hospital Management (Shenzhen) Co., Ltd.#) in relation to the acquisition of debt receivables and the associated security package of 深圳龍珠醫院 (Shenzhen Longzhu Hospital#) at a consideration of RMB520,000,000 (the "Longzhu Acquisition"). The Group considered it to be an investment for the development of its product distribution channels in the future.

On 22 November 2016, Shaanxi Reshine entered into the sale and purchase agreement with 深圳市合正滙遠投資有限公司 (Shenzhen He Zheng Hui Yuan Investment Co. Ltd.#) ("Shenzhen He Zheng") and Shenzhen Longzhu Hospital in relation to the disposal of debt receivables and the associated security package of Shenzhen Longzhu Hospital at a consideration of RMB530,000,000. On the same date, Shaanxi Reshine and Shenzhen He Zheng also entered into the framework agreements in which, the Group has a right to occupy an area of 3,000 square meters at Shenzhen Longzhu Hospital and an area of 5,000 square meters at Luohu District, Shenzhen for a rent-free period of 8 years, to establish its product distribution channels. The Group considered it as an opportunity of asset realization and profit-taking, and at the same time, the Group still has opportunities to develop its product distribution channels by setting up a specialty hospital in the future.

Details of Longzhu Acquisition, Longzhu Disposal and Framework Agreements were disclosed in the Company's announcements dated 1 November 2016 and 22 November 2016.

外滙風險

本集團的業務交易、資產及負債主要以人民幣及 港元計值。董事認為本集團之外滙風險受控。管 理層將繼續監控本集團的外滙風險,並於情況有 需要時採取審慎措施,例如對沖。

附屬公司及聯營公司之重大收購或出 售事項

於二零一六年十一月一日,本公司的全資附屬公司陝西瑞盛生物科技有限公司(「陝西瑞盛」)與鼎峰醫院管理(深圳)有限公司訂立買賣協議,內容有關以代價人民幣520,000,000元購入其對深圳龍珠醫院的應收債務及相關抵押組合(「龍珠收購」)。本集團視此為對日後發展本集團產品分銷渠道之投資。

於二零一六年十一月二十二日,陝西瑞盛與深圳市合正滙遠投資有限公司(「深圳合正」)及深圳龍珠醫院訂立買賣協議,內容有關以代價人民幣530,000,000元出售深圳龍珠醫院的應收債務及相關抵押組合。於同日,陝西瑞盛與深圳合正亦訂立框架協議,據此,本集團可享有位於深圳配路院內3,000平方米和深圳羅湖區5,000平方米的地方之8年免租使用權,建立本集團產品分銷渠道。本集團仍擁有機會於日後成立之專科醫院發展本集團產品分銷渠道。

龍珠收購事項、龍珠出售事項及框架協議之詳情 披露於本公司日期為二零一六年十一月一日及二 零一六年十一月二十二日之公告中。

[#] for identification only



管理層討論及分析



CONTRACTUAL ARRANGEMENTS

Jiangsu Ding Xuan Contractual Arrangements

Collectively, the exclusive business cooperation agreement, the exclusive option agreement, the equity pledge agreement, the power of attorney and the consent letter of spouse, entered into among (i) 江蘇頤澤生物科技有限公司 (Jiangsu Yi Ze Biotechnology Company Limited*) ("Jiangsu Yi Ze"), a company established in the PRC, a wholly owned subsidiary of SCI Therapeutics Limited, a company incorporated in Hong Kong under limited liabilities, being owned as to (a) 80% by CRMI Medical Bio-Tech Limited, formerly known as Enlighten On Enterprise Limited, a company incorporated in the British Virgin Islands with limited liability, an indirect wholly owned subsidiary of the Company, and (b) 20% by Mr. Shi Yufang respectively as at the date of this report), (ii) 江蘇鼎鉉生物科技 有限公司 (Jiangsu Ding Xuan Biotechnology Company Limited#) ("Jiangsu Ding Xuan"), a limited liability company established in the PRC to engage in the business of providing services and equipment for human cell and stem cell related clinical applications in the PRC, including but not limited to the R&D on human stem cell technologies and equipment for human stem cell processing and for trading of its related equipment), the then (iii) registered shareholders of Jiangsu Ding Xuan and their spouses (if any).

合約安排

江蘇鼎鉉合約安排

獨家業務合作協議、獨家購股權協議、股權質押 協議、授權委託書及配偶同意函之統稱,由以下 訂約方訂立:(i)江蘇頤澤生物科技有限公司(「江 蘇頤澤」,一間於中國成立之公司,為華康生物治 療有限公司(一間於香港註冊成立之有限公司)之 全資附屬公司,於本報告日期其分別由(a)中國再 生醫學生物技術有限公司(前稱安迪企業有限公 司,一間於英屬處女群島註冊成立之有限公司, 為本公司之一間間接全資附屬公司)擁有80%及 (b) 時玉舫先生擁有20%), (ii) 江蘇鼎鉉生物科技 有限公司(「江蘇鼎鉉」,一間於中國成立之有限 公司,於中國從事為人體細胞及幹細胞相關臨床 應用提供服務及設備之業務,包括但不限於人體 幹細胞技術及人體幹細胞處理設備之研發及買賣 相關設備),(iii)江蘇鼎鉉當時登記股東及彼等的 配偶(如有)。

[#] for identification only





CONTRACTUAL ARRANGEMENTS (Cont'd)

Particulars and main business of the operating entity

At the date of this report, Jiangsu Ding Xuan is currently owned by Ms. Xu Jie as to 50% and Mr. Dai Lifeng as to 50% (hereinafter collectively referred to as the "Jiangsu Ding Xuan Shareholders"). Jiangsu Ding Xuan is controlled by the Group through Jiangsu Yi Ze by way of Jiangsu Ding Xuan Contractual Arrangements pursuant to which Jiangsu Yi Ze controls Jiangsu Ding Xuan.

Jiangsu Ding Xuan is established to engage in the business of providing services and equipment for human cell and stem cell related clinical applications in the PRC, including but not limited to the R&D on human stem cell technologies and equipment for human stem cell processing and for trading of its related equipment.

Major terms of the Jiangsu Ding Xuan Contractual **Arrangements**

Irrevocable power of attorney

Parties:

Jiangsu Ding Xuan Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the contracts under Jiangsu Ding Xuan Contractual Arrangements including their respective supplemental agreements ("Jiangsu Ding Xuan Main Obligations") have been terminated or discharged in full.

合約安排(續)

經營實體之詳情及主要業務

於本報告日期,江蘇鼎鉉現時由徐潔女十及戴立 峰先生(下文統稱「江蘇鼎鉉股東」)分別擁有 50%及50%。江蘇鼎鉉由本集團诱過江蘇頤澤藉 助江蘇鼎鉉合約安排之方式控制,據此,江蘇頤 澤控制江蘇鼎鉉。

江蘇鼎鉉之成立宗旨為於中國從事為人體細胞及 幹細胞相關臨床應用提供服務及設備之業務,包 括但不限於人體幹細胞技術及人體幹細胞處理設 備之研發及買賣相關設備。

江蘇鼎鉉合約安排之主要條款

不可撤回授權委託書 (a)

訂約方:

江蘇鼎鉉股東

年期:

於簽署後無限年期並將持續有效,直至江蘇 鼎鉉合約安排(包括其各份補充協議)(「江 蘇鼎鉉主債權」) 項下之合約均已獲全面終 止或解除。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Major terms of the Jiangsu Ding Xuan Contractual Arrangements (Cont'd)

(a) Irrevocable power of attorney (Cont'd)

Main Subject:

Jiangsu Ding Xuan Shareholders shall, among other things, irrevocably authorise Jiangsu Yi Ze and its respective successors to act on their behalf on all matters in relation to their equity interests in Jiangsu Ding Xuan, including attending shareholders' meeting, signing minutes of shareholders' meeting and shareholders' resolutions, exercising their full shareholder's rights under the articles of association of Jiangsu Ding Xuan and applicable PRC laws and regulations, including but not limited to shareholders' voting right, appointment of the legal representative, director, supervisor and senior management of Jiangsu Ding Xuan, filing documents with the relevant governmental authorities or regulatory bodies, acquisition and disposition of the equity interest of Jiangsu Ding Xuan held by Jiangsu Ding Xuan Shareholders or making decision on the liquidation of Jiangsu Ding Xuan and the formulation of the profit sharing plans of Jiangsu Ding Xuan, provided that the exercise of the power(s) of attorney shall not cause breach to the Jiangsu Ding Xuan Contractual Arrangements.

(b) Exclusive business cooperation agreement

Parties:

- (i) Jiangsu Yi Ze
- (ii) Jiangsu Ding Xuan

Terms:

The exclusive business cooperation agreement commences from 1 August 2016 and is effective perpetually, unless otherwise terminated in accordance with its terms.

Main Subject:

Jiangsu Ding Xuan should appoint Jiangsu Yi Ze as exclusive service provider for its business operations, including but not limited to, technical R&D, technical support, technical consultation, technical training and other management and corporate consultation services.

合約安排(續)

江蘇鼎鉉合約安排之主要條款(續)

(a) 不可撤回授權委託書(續)

主體事項:

江蘇鼎鉉股東將(其中包括)不可撤回授權 江蘇頤澤及其各自之繼任者代為處理有關 於江蘇鼎鉉之股權之所有事宜,包括出股東大會、簽署股東大會之大會記錄及適用中 議案、根據江蘇鼎鉉之組織章程及適用中 退法律及法規悉數行使其股東權利(包括 股東之投票權)、委任江蘇鼎域 代表人、董事、監事及高級管理人、收購 民於股東之投票權)、委任江蘇県 與東之投票權 大會之之。 關政所機關或監管機構登記備案 、收權或 置江蘇鼎鉉的清盤事宜作出決定以及制定 計算 ,惟行使授權委排 規定之權利不得違反江蘇鼎鉉合約 規定之權利不得違反江蘇鼎鉉合約

(b) 獨家業務合作協議

訂約方:

- (i) 江蘇頤澤
- (ii) 江蘇鼎鉉

年期:

獨家業務合作協議自二零一六年八月一日開始及永久有效,除非根據其條款終止。

主體事項:

江蘇鼎鉉將委聘江蘇頤澤為其業務營運之獨 家服務提供商,包括但不限於技術研發、技 術支援、技術諮詢、技術培訓及其他相關管 理及企業諮詢服務。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Major terms of the Jiangsu Ding Xuan Contractual Arrangements (Cont'd)

(c) Exclusive option agreement

Parties:

- (i) Jiangsu Yi Ze
- (ii) Jiangsu Ding Xuan Shareholders
- (iii) Jiangsu Ding Xuan

Terms:

The exclusive option agreement commences from 1 August 2016 and is effective until all the shares of Jiangsu Ding Xuan have been transferred from the Jiangsu Ding Xuan Shareholders to Jiangsu Yi Ze and/or any person(s) designated by Jiangsu Yi Ze.

Main Subject:

Jiangsu Ding Xuan Shareholders and Jiangsu Ding Xuan irrevocably agreed, to the extent permitted under the laws of the PRC, to transfer to Jiangsu Yi Ze and/or any person(s) designated by Jiangsu Yi Ze at any time and from time to time, all or part of their equity interests in Jiangsu Ding Xuan, or all or part of the assets of Jiangsu Ding Xuan.

Jiangsu Yi Ze may exercise its rights under the paragraph above at any time and in any manner at its sole discretion as permitted under the laws of the PRC. The exercise price of each of the rights under the paragraph above shall be the lowest price permitted under the laws of the PRC, subject to any other price as required by the PRC government authorities. Upon Jiangsu Ding Xuan and/or Jiangsu Ding Xuan Shareholders receive(s) the said consideration, they unconditionally transfer the said consideration to Jiangsu Yi Ze or any person(s) designated by Jiangsu Yi Ze.

合約安排(續)

江蘇鼎鉉合約安排之主要條款(續)

(c) 獨家購股權協議

訂約方:

- (i) 江蘇頤澤
- (ii) 江蘇鼎鉉股東
- (iii) 江蘇鼎鉉

年期:

獨家購股權協議自二零一六年八月一日開始 及直至江蘇鼎鉉之所有股份已自江蘇鼎鉉股 東轉讓予江蘇頤澤及/或江蘇頤澤指定之任 何人士前有效。

主體事項:

江蘇鼎鉉股東及江蘇鼎鉉不可撤回同意,於中國法律准許之範圍內,隨時及不時向江蘇頤澤及/或江蘇頤澤指定之任何人士轉讓其於江蘇鼎鉉之全部或部份股權或江蘇鼎鉉之全部或部份資產。

在中國法律准許之情況下,江蘇頤澤可全權 酌情於任何時間及以任何方式行使上段所述 權利。上段所述各項權利之行使價格將為中 國法律准許之最低價格,惟須受中國政府機 關所規定之任何其他價格規限。於江蘇鼎鉉 及/或江蘇鼎鉉股東收到上述代價後,彼等 將無條件轉讓上述代價予江蘇頤澤或江蘇頤 澤指定之任何人士。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Major terms of the Jiangsu Ding Xuan Contractual Arrangements (Cont'd)

(c) Exclusive option agreement (Cont'd)

Jiangsu Ding Xuan Shareholders and Jiangsu Ding Xuan jointly and/ or severally undertake that, among other things, without having obtained the prior written consent from Jiangsu Yi Ze, they will not (i) amend the articles of association of Jiangsu Ding Xuan; (ii) increase or decrease the registered capital of Jiangsu Ding Xuan; (iii) dispose of, transfer, mortgage, create any security interest or third party rights in its equity interests in Jiangsu Ding Xuan; (iv) appoint any director(s) or executive director(s) of Jiangsu Ding Xuan; and (v) pay dividends in any manners. Jiangsu Ding Xuan Shareholders further undertake that, without having obtained the written consent from Jiangsu Yi Ze, they and their respective related persons will not engage in any business which is in competition with the businesses of Jiangsu Ding Xuan.

(d) Equity pledge agreement

Parties:

- (i) Jiangsu Yi Ze
- (ii) Jiangsu Ding Xuan Shareholders
- (iii) Jiangsu Ding Xuan

Terms:

Effective from the registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce until all the obligations of Jiangsu Ding Xuan Shareholders and Jiangsu Ding Xuan (including but not limited to Jiangsu Ding Xuan Main Obligations) are satisfied or discharged in full. The registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce has been completed.

Main Subject:

Jiangsu Ding Xuan Shareholders pledged all equity interests in Jiangsu Ding Xuan legally held by Jiangsu Ding Xuan Shareholders (including present or future registered capital and their rights and benefits, whether through increase of capital and/or transfer of equity interest) to Jiangsu Yi Ze.

合約安排(續)

江蘇鼎鉉合約安排之主要條款(續)

(c) 獨家購股權協議(續)

(d) 股權質押協議

訂約方:

- (i) 江蘇頤澤
- (ii) 江蘇鼎鉉股東
- (iii) 江蘇鼎鉉

年期:

自於有關中國工商行政機關登記股權質押協議項下之已抵押股權起生效,直至江蘇鼎鉉股東及江蘇鼎鉉之所有債權(包括但不限於江蘇鼎鉉主債權)均已經完全被滿足或被解除。已完成於有關中國工商行政機關登記股權質押協議項下之已抵押股權。

主體事項:

江蘇鼎鉉股東向江蘇頤澤質押江蘇鼎鉉股東 合法持有之全部江蘇鼎鉉股權(包括現有或 未來註冊股本及其權利及利益,無論是透過 增加股本及/或轉讓股權之方式)。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Major terms of the Jiangsu Ding Xuan Contractual Arrangements (Cont'd)

(e) Consent letters of spouse

Parties:

The spouses of Jiangsu Ding Xuan Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the Jiangsu Ding Xuan Main Obligations are satisfied or discharged in full.

Main Subject:

The spouses of Jiangsu Ding Xuan Shareholders unconditionally agreed to the Jiangsu Ding Xuan Contractual Arrangements.

The spouses of Jiangsu Ding Xuan Shareholders undertake and declare that the equity respectively owned by Jiangsu Ding Xuan Shareholders in Jiangsu Ding Xuan contemplated on Jiangsu Ding Xuan Contractual Arrangements shall be Jiangsu Ding Xuan Shareholders' personal property respectively; and further, the said spouses undertake that they shall not take any act that causes or will cause any conflict and/or impediment to the Jiangsu Ding Xuan Contractual Arrangements.

合約安排(續)

江蘇鼎鉉合約安排之主要條款(續)

(e) 配偶同意函

訂約方:

江蘇鼎鉉股東之配偶

年期:

於簽署後無限年期並將持續有效,直至江蘇鼎鉉主債權均已經完全被滿足或被解除。

主體事項:

江蘇鼎鉉股東之配偶無條件同意江蘇鼎鉉合 約安排。

江蘇鼎鉉股東之配偶承諾及聲明,江蘇鼎鉉 合約安排中涉及的江蘇鼎鉉股東各自持有於 江蘇鼎鉉之股權分別為江蘇鼎鉉股東之個人 財產;並進一步承諾不會採取任何導致或將 導致與江蘇鼎鉉合約安排相衝突及/或阻礙 之行為。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Reason for using the Jiangsu Ding Xuan Contractual Arrangements and the significance to the Group

As advised by the legal adviser of the Company, the principal business of Jiangsu Ding Xuan involves technology for human stem cell research & development and applications which is regarded as prohibited business for foreign entity under the PRC Law. As such, the Group cannot acquire the equity interest in Jiangsu Ding Xuan at that time. Having regard to such foreign investment restrictions, the Jiangsu Ding Xuan Contractual Arrangements were designed to provide Jiangsu Yi Ze and, thus the Group, with effective control over the financial and operational policies of Jiangsu Ding Xuan and (to the extent permitted by PRC laws and regulations) the right to acquire the equity interest in Jiangsu Ding Xuan.

Revenue and assets subject to the Jiangsu Ding Xuan Contractual Arrangements

The revenue, net loss and total assets subject to the Jiangsu Ding Xuan Contractual Arrangements are set out as follows:

合約安排(續)

採用江蘇鼎鉉合約安排之理由及對本集團之重要性

據本公司法律顧問告知,江蘇鼎鉉的主要業務涉及人體幹細胞研發及應用技術,根據中國法律被視為外資企業受禁止類業務。因此,本集團當時無法收購江蘇鼎鉉之股權。經計及該等海外投資限制,設立江蘇鼎鉉合約安排之目的乃為江蘇頤澤乃至本集團提供對江蘇鼎鉉財務及經營策略之有效控制及(於中國法律及法規准許之範圍內)收購江蘇鼎鉉股權之權利。

江蘇鼎鉉合約安排之收益及資產

江蘇鼎鉉合約安排之收益、淨虧損及總資產載列 如下:

> Year ended 30 April 2017 截至二零一七年 四月三十日止年度 (HK\$'000) (千港元)

 Revenue
 收益
 —

 Net loss
 淨虧損
 2,876

 Total assets
 總資產
 9.281

For the year ended 30 April 2017, the revenue and net loss subject to Jiangsu Ding Xuan Contractual Arrangements amounted to nil and approximately 1.44% of the revenue and net loss of the Group respectively. As at 30 April 2017, the total assets subject to Jiangsu Ding Xuan Contractual Arrangements amounted to approximately 0.32% of the total assets of the Group.

截至二零一七年四月三十日止年度,江蘇鼎鉉合約安排之收益及淨虧損佔本集團收益及淨虧損為零及約1.44%。於二零一七年四月三十日,江蘇鼎鉉合約安排之總資產佔本集團總資產約0.32%。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Material changes

Save as disclosed in this report, there has not been any material changes in Jiangsu Ding Xuan Contractual Arrangements and/or the circumstances under which they were adopted.

Unwinding of Jiangsu Ding Xuan Contractual Arrangements

Up to the date of this report, there has not been any unwinding of any Jiangsu Ding Xuan Contractual Arrangements, nor has there been any failure to unwind any Jiangsu Ding Xuan Contractual Arrangements when the restrictions that led to the adoption of the Jiangsu Ding Xuan Contractual Arrangements are removed.

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks

The Group does not have any direct equity ownership in Jiangsu Ding Xuan and has relied on the Jiangsu Ding Xuan Contractual Arrangements, as the case may be, to control, operate, and be entitled to the economic benefits and risks arising from the respective businesses of Jiangsu Ding Xuan in the PRC. However, there are risks involved with the operations of Jiangsu Yi Ze under the Jiangsu Ding Xuan Contractual Arrangements, as the case may be.

合約安排(續)

重大變動

除本報告所披露者外,江蘇鼎鉉合約安排 及/或採納該等合約安排的情況並無任何重大變動。

解除江蘇鼎鉉合約安排

截至本報告日期,並無任何江蘇鼎鉉合約安排被解除,亦無於導致採納江蘇鼎鉉合約安排的限制 經移除後出現無法解除任何江蘇鼎鉉合約安排的 情況。

與江蘇鼎鉉合約安排有關之風險及本公司採取之降低風險之措施

本集團並無於江蘇鼎鉉擁有任何直接所有權權益,並已倚賴江蘇鼎鉉合約安排(視情況而定)於中國控制、運營江蘇鼎鉉各自之業務,並有權享有或承擔其經濟利益及風險。然而,江蘇鼎鉉合約安排(視情況而定)項下存有涉及江蘇頤澤經營業務之風險。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(i) There is no assurance that the Jiangsu Ding Xuan
Contractual Arrangements could comply with future
changes in the regulatory requirements in the PRC and
the PRC government may determine that the Jiangsu
Ding Xuan Contractual Arrangements do not comply with
applicable regulations

Current PRC laws and regulations prohibit foreign ownership of companies engage in the businesses concerning technology for research & development and applications of human stem cells, gene diagnose and therapy. The businesses of Jiangsu Ding Xuan are regarded as design and manufacturing of preclinical cell and stem cell related equipment which involves in technology for human stem cell research & development and applications, in addition to providing contract research services. The Company is a company incorporated under the laws of the Cayman Islands. Jiangsu Yi Ze may not engage in the businesses concerning technology for human stem cell research & development and applications in the PRC under current PRC laws. As a result, the Group will have to conduct the business of Jiangsu Ding Xuan in the PRC through the Jiangsu Ding Xuan Contractual Arrangements.

Despite the fact that there is no indication that the Jiangsu Ding Xuan Contractual Arrangements will be interfered or objected by any PRC regulatory authorities, to the best knowledge of the Directors, there is a possibility that the Ministry of Commerce and other competent authorities may have different opinions on the interpretation of the relevant regulations and would not agree that the Jiangsu Ding Xuan Contractual Arrangements comply with the current PRC laws, regulations or rules or those that may be adopted in future, and the authorities may deny the validity, effectiveness and enforceability of the Jiangsu Ding Xuan Contractual Arrangements.

If the authorities may deny the validity, effectiveness and enforceability of any of the Jiangsu Ding Xuan Contractual Arrangements, it could have a material adverse impact on the Group's businesses, financial condition and results of operations.

合約安排(續)

與江蘇鼎鉉合約安排有關之風險及本公司 採取之降低風險之措施(續)

(i) 概不能保證江蘇鼎鉉合約安排能夠遵守未來 中國監管規定之變動及中國政府可能釐定江 蘇鼎鉉合約安排並無遵守適用法規

現行中國法律及法規禁止外資公司從事有關人體幹細胞研發及應用、基因診斷及治,療技術之業務。除提供合同式研究服務外,江蘇與國主之業務為設計及生產臨床前細胞研發及無相關設備,其中涉及人體幹細胞研發及律問技術。本公司為一間根據開曼群島法蘇與用技術。本公司為一間根據開曼群島江蘇縣可於中國從事有關人體幹細胞研發過江蘇門技術之業務。因此來集團將須透過蘇縣,與該合約安排於中國進行江蘇鼎鉉之業務。

儘管並無跡象顯示江蘇鼎鉉合約安排將遭任何中國監管機構干預或反對,惟就董事所深知,商務部及其他主管機構可能對相關法規之詮釋持有異議,並將認為江蘇鼎鉉合約安排不符合現行或未來可能採納之中國法律、法規或規則,而該等機構可能否認江蘇鼎鉉合約安排之有效性、效力及可強制執行性。

倘該等機構否認任何江蘇鼎鉉合約安排之有 效性、效力及可強制執行性,其可能對本集 團之業務、財務狀況及經營業績產生重大不 利影響。

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(ii) The Jiangsu Ding Xuan Contractual Arrangements may not be as effective in providing control over and entitlement to the economic interests in the Project Company (namely "Jiangsu Ding Xuan as the case may be") as direct ownership

The Jiangsu Ding Xuan Contractual Arrangements may not be as effective in providing the Group with control over and entitlement to the economic interests in the Project Company as direct ownership. If Jiangsu Yi Ze had direct ownership of Jiangsu Ding Xuan, Jiangsu Yi Ze would be able to directly exercise its rights as a shareholder to effect changes in the board of directors of Jiangsu Ding Xuan. However, under the Jiangsu Ding Xuan Contractual Arrangements, Jiangsu Yi Ze can only look to and rely on Jiangsu Ding Xuan and the Jiangsu Ding Xuan Shareholders to perform their contractual obligations under the Jiangsu Ding Xuan Contractual Arrangements such that Jiangsu Yi Ze can exercise effective control over Jiangsu Ding Xuan. The Jiangsu Ding Xuan Shareholders may not act in the best interests of Jiangsu Ding Xuan or may not perform its/their obligations under the Jiangsu Ding Xuan Contractual Arrangements, and in that case, Jiangsu Yi Ze may replace the Jiangsu Ding Xuan Shareholders by its other nominees pursuant to the Jiangsu Ding Xuan Contractual Arrangements. However, if any dispute relating to the Jiangsu Ding Xuan Contractual Arrangements remains unresolved, Jiangsu Yi Ze will have to enforce its rights under the Jiangsu Ding Xuan Contractual Arrangements and seek to interpret the terms of the Jiangsu Ding Xuan Contractual Arrangements in accordance with the PRC laws and will be subject to uncertainties in the PRC legal system.

合約安排(續)

與江蘇鼎鉉合約安排有關之風險及本公司 採取之降低風險之措施(續)

(ii) 江蘇鼎鉉合約安排於控制項目公司(指「江蘇 鼎鉉(視情況而定)」)及享有其經濟利益方 面可能不如直接擁有權有效

> 江蘇鼎鉉合約安排於向本集團提供對項目公 司之控制權及令其享有項目公司之經濟利 益方面可能不如直接擁有權有效。倘江蘇頤 澤直接擁有江蘇鼎鉉,江蘇頤澤將可直接行 使作為股東之權利變更江蘇鼎鉉之董事會。 然而,根據江蘇鼎鉉合約安排,江蘇頤澤僅 可指望及依賴江蘇鼎鉉與江蘇鼎鉉股東履行 其於江蘇鼎鉉合約安排項下之合約義務,從 而使江蘇頤澤可行使對江蘇鼎鉉之實際控制 權。江蘇鼎鉉股東可能不會以江蘇鼎鉉之最 佳利益行事,或可能不履行彼等於江蘇鼎鉉 合約安排項下之義務,在此情況下,江蘇頤 澤可根據江蘇鼎鉉合約安排安排其他代名人 取代江蘇鼎鉉股東。然而,倘有關江蘇鼎鉉 合約安排之任何爭議未獲解決,江蘇頤澤將 強制行使其於江蘇鼎鉉合約安排項下之權利 及尋求根據中國法律詮釋江蘇鼎鉉合約安排 之條款並將面臨中國法律制度中之不明朗因 素。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(ii) (Cont'd)

Since the legal environment in the PRC is different from that in Hong Kong and other jurisdictions, the uncertainties in the PRC legal system could limit the ability of the Group to enforce the Jiangsu Ding Xuan Contractual Arrangements. There is no assurance that such arbitration result will be in favour of the Group and/or that there will not be any difficulties in enforcing any arbitral awards granted, including specific performance or injunctive relief and claiming damages by the Group. As the Group may not be able to obtain sufficient remedies in a timely manner, its ability to exert effective control over Jiangsu Ding Xuan and the conduct of the businesses concerning technology for human stem cell research & development and applications could be materially and adversely affected, and may disrupt the business of the Group and have a material adverse impact on Group's business, prospects and results of operation.

(iii) Potential conflicts of interest among Jiangsu Yi Ze, Jiangsu Ding Xuan, the Jiangsu Ding Xuan Shareholders may exist

Jiangsu Yi Ze shall rely on the Jiangsu Ding Xuan Contractual Arrangements to exercise control over and to draw the economic benefits from Jiangsu Ding Xuan. Jiangsu Yi Ze may not be able to provide sufficient incentives to the Jiangsu Ding Xuan Shareholders for the purpose of encouraging them to act in the best interests of Jiangsu Yi Ze, other than stipulating the relevant obligations in the Jiangsu Ding Xuan Contractual Arrangements. The Jiangsu Ding Xuan Shareholders may breach the Jiangsu Ding Xuan Contractual Arrangements in the event of conflicts of interest or deterioration of its/their relationship with Jiangsu Yi Ze, the results of which may have a material adverse impact on Jiangsu Yi Ze's business, prospects and results of operation.

合約安排(續)

與江蘇鼎鉉合約安排有關之風險及本公司 採取之降低風險之措施(續)

(ii) (續)

由於中國法律環境有別於香港及其他司法權區,故中國法律制度中之不明朗因素將可能限制本集團強制執行江蘇鼎鉉合約安排之能別,或強制執行所授出之任何仲裁裁決之任何困難,包括執行授予本集團之之任何困難,包括執行授予本集團可能無法及時取得足夠補救措的政策制令救濟及由本集團提出賠償。於本集團可能無法及時取得足夠補救措的及實際控制權之能力人體幹細胞技術研發及應用業務可能受對大不利影響,並可能中斷本集團之業務、前景及經營業績產生重大不利影響。

(iii) 江蘇頤澤、江蘇鼎鉉及江蘇鼎鉉股東之間可 能存在潛在利益衝突

江蘇頤澤將倚賴江蘇鼎鉉合約安排對江蘇鼎 鉉行使控制權及自其抽取經濟利益。除於 江蘇鼎鉉合約安排中訂明有關義務外,江蘇 頤澤可能無法就鼓勵江蘇鼎鉉股東以江蘇頤 澤之最佳利益行事而向江蘇鼎鉉股東提供足 夠激勵。江蘇鼎鉉股東可能於出現利益衝突 事件或其與江蘇頤澤之關係惡化時違反江蘇 鼎鉉合約安排,其結果可能對江蘇頤澤之業 務、前景及經營業績產生重大不利影響。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(iii) (Cont'd)

It is not assured that if conflicts arise, the Jiangsu Ding Xuan Shareholders will act in the best interests of Jiangsu Yi Ze or that the conflicts will be resolved in favour of Jiangsu Yi Ze. If any of the Jiangsu Ding Xuan Shareholders fails to perform its obligations under the respective Jiangsu Ding Xuan Contractual Arrangements, Jiangsu Yi Ze may have to rely on legal remedies under the PRC laws through legal proceedings, which may be expensive, time-consuming and disruptive to Jiangsu Yi Ze's operations and will be subject to uncertainties as stated above.

(iv) The Jiangsu Ding Xuan Contractual Arrangements may be subject to scrutiny of the PRC tax authorities and additional tax may be imposed

Jiangsu Ding Xuan Contractual Arrangements may be subject to scrutiny of the PRC tax authorities and additional tax may be imposed on the Jiangsu Yi Ze, as the case may be. Jiangsu Yi Ze, as the case may be, may face adverse tax consequences if the PRC tax authorities determine that the Jiangsu Ding Xuan Contractual Arrangements were not entered into based on arm's length negotiations. If the PRC tax authorities determine that the Jiangsu Ding Xuan Contractual Arrangements were not entered into on an arm's length basis, they may adjust the income and expenses of Jiangsu Yi Ze, as the case may be, for the PRC tax purposes, which could result in higher tax liabilities on Jiangsu Yi Ze, as the case may be.

The operation results of Jiangsu Yi Ze, as the case may be, may be materially and adversely affected if the tax liabilities of Jiangsu Yi Ze, Jiangsu Ding Xuan increase significantly or if they are required to pay interest on late payments.

合約安排(續)

與江蘇鼎鉉合約安排有關之風險及本公司 採取之降低風險之措施(續)

(iii) (續)

概不保證當發生衝突時,江蘇鼎鉉股東將以 江蘇頤澤之最佳利益行事或衝突將以對江蘇 頤澤有利之方式解決。倘任何江蘇鼎鉉股東 未能履行其於各份江蘇鼎鉉合約安排項下之 責任,江蘇頤澤可能須透過法律訴訟依賴中 國法律下之法律補救,此舉可能昂貴、耗時 及中斷江蘇頤澤之營運,且可能面臨上文所 述之不明朗因素。

(iv) 江蘇鼎鉉合約安排可能會受中國稅務機關審 查並徵收額外稅項

江蘇鼎鉉合約安排可能會受中國稅務機關審查,而江蘇頤澤(視情況而定)可能被徵收額外稅項。倘中國稅務機關釐定江蘇鼎鉉合約安排並非根據公平磋商訂立,則江蘇頤(視情況而定)可能面臨不利稅務後果。倘中國稅務機關釐定江蘇鼎鉉合約安排並調接公平基準訂立,其可能就中國稅務目的,其可能就中國稅務目的,,其可以入與開支之稅務負債。

倘江蘇頤澤、江蘇鼎鉉之稅務負債大幅增加 或倘彼等須就逾期付款而支付利息,江蘇頤 澤(視情況而定)之經營業績則可能受重大 不利影響。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the Jiangsu Ding Xuan Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(v) Ability to acquire the entire equity interests in or assets of the Project Company

Jiangsu Yi Ze's ability to acquire the entire equity interests in or assets of Jiangsu Ding Xuan may be subject to various limitations and substantial costs. In case Jiangsu Yi Ze exercises its options to acquire all or part of the equity interests and/or assets of Jiangsu Ding Xuan under the relevant exclusive option agreement, the acquisition of the entire equity interests in or the assets of Jiangsu Ding Xuan may only be conducted to the extent as permitted by the applicable PRC laws and will be subject to necessary approvals and relevant procedures under applicable PRC laws. In addition, the abovementioned acquisitions may be subject to a minimum price limitation (such as an appraised value for the entire equity interests in or all assets of Jiangsu Ding Xuan) or other limitations as imposed by applicable PRC laws. Further, a substantial amount of other costs (if any), expenses and time may be involved in transferring the ownership of Jiangsu Ding Xuan, which may have a material adverse impact on Jiangsu Yi Ze's businesses, prospects and results of operation.

合約安排(續)

與江蘇鼎鉉合約安排有關之風險及本公司 採取之降低風險之措施(續)

(v) 收購項目公司全部股權或資產之能力

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements

In April and August 2015, the Group completed the respective acquisitions of Tianjin Weikai and AK Suzhou through contractual arrangements. Save as disclosed in this report, there have been no changes to such Contractual Arrangements since the respective completion dates.

Collectively, the exclusive business cooperation agreement, the exclusive option agreement, the equity pledge agreement, the power of attorney and the consent letter of spouse, entered into among (i) AK Subsidiary (蘇州博凱生物技術諮詢服務有限責任公司 (Suzhou Bo Kai Biomedical Consultation Service Ltd.#)), a company established in the PRC, an indirect wholly owned subsidiary of Frame Sharp Limited (a company incorporated in the British Virgin Islands, being owned as to (a) 70% by CRMI Medical Bio-Tech Limited ("CRMI Medical"), formerly known as Enlighten On Enterprise Limited, a company incorporated in the British Virgin Islands with limited liability, an indirect wholly owned subsidiary of the Company, and (b) 30% by Remed Tiger Limited ("Remed Tiger"), a company incorporated in the Republic of Seychelles, being owned as to 100% by Mr. Zhang Xumao) respectively as at the date of this report), (ii) AK Suzhou (奥 凱(蘇州) 生物技術有限公司 (AK (Suzhou) Biomedical Ltd.#), a limited liability company established in the PRC to engage in the business of providing services and equipment for human cell and stem cell related clinical applications in the PRC, including but not limited to the R&D on human stem cell technologies and equipment for human stem cell processing and for trading of its related equipment), the then (iii) registered shareholders of AK Suzhou and their spouses (if any).

Particulars and main business of the operating entity

At the date of this report, AK Suzhou is currently owned as to 30% by Ms. Cui Keyan and as to 70% by Mr. Dai Yumin (the former executive Director of the Company, which had resigned from his directorship of the Company with effect from 30 April 2016) (hereinafter collectively referred to as the "Suzhou Biomedical Shareholders"). AK Suzhou is controlled by the Group through AK Subsidiary by way of AK Suzhou Contractual Arrangements pursuant to which AK Subsidiary controls AK Suzhou.

合約安排(續)

奧凱(蘇州)合約安排

於二零一五年四月及八月,本集團透過合約安排 分別完成收購天津衛凱及奧凱(蘇州)。除本報告 所披露者外,自各完成日期起,該等合約安排並 無任何變動。

獨家業務合作協議、獨家購股權協議、股權質押協 議、授權委託書及配偶同意函之統稱,由以下訂 約方訂立:(i)奧凱附屬公司(蘇州博凱生物技術諮 詢服務有限責任公司,一間於中國成立之公司, 為Frame Sharp Limited(一間於英屬處女群島註冊 成立之公司) 之間接全資附屬公司,於本報告日期 其分別由(a)中國再生醫學生物技術有限公司(「中 國再生醫學生物技術 | ,前稱安油企業有限公司, 一間於英屬處女群島註冊成立之有限公司,為本 公司之一間間接全資附屬公司)擁有70%,及(b) Remed Tiger Limited (「Remed Tiger」, 一間於塞 舌爾共和國註冊成立的公司,由張旭茂先生全資 擁有)擁有30%,(ii)奧凱(蘇州)(奧凱(蘇州)生 物技術有限公司,一間於中國成立之有限公司, 於中國從事為人體細胞及幹細胞相關臨床應用提 供服務及設備之業務,包括但不限於人體幹細胞 技術及人體幹細胞處理設備之研發及買賣相關設 備),(iii) 奧凱 (蘇州) 當時登記股東及彼等的配偶 (如有)。

經營實體之詳情及主要業務

於本報告日期,奧凱(蘇州)現時由崔科研女士 及戴昱敏先生(本公司之前任執行董事,自二零 一六年四月三十日起辭任本公司之董事職務)(下 文統稱「蘇州生物技術股東」)分別擁有30%及 70%。奧凱(蘇州)由本集團透過奧凱附屬公司藉 助奧凱(蘇州)合約安排之方式控制,據此,奧凱 附屬公司控制奧凱(蘇州)。

[#] for identification only



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Particulars and main business of the operating entity (Cont'd)

AK Suzhou is established to engage in the business of providing services and equipment for human cell and stem cell related clinical applications in the PRC, including but not limited to the R&D on human stem cell technologies and equipment for human stem cell processing and for trading of its related equipment.

Major terms of the AK Suzhou Contractual Arrangements

a) Irrevocable power of attorney

Parties:

Suzhou Biomedical Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the contracts under AK Suzhou Contractual Arrangements including their respective supplemental agreements ("AK Suzhou Main Obligations") have been terminated or discharged in full.

Main Subject:

Suzhou Biomedical Shareholders shall, among other things, irrevocably authorise AK Subsidiary and its respective successors to act on their behalf on all matters in relation to their equity interests in AK Suzhou, including attending shareholders' meeting, signing minutes of shareholders' meeting and shareholders' resolutions, exercising their full shareholder's rights under the articles of association of AK Suzhou and applicable PRC laws and regulations, including but not limited to shareholders' voting right, appointment of the legal representative, director, supervisor and senior management of AK Suzhou, filing documents with the relevant governmental authorities or regulatory bodies, acquisition and disposition of the equity interest of AK Suzhou held by Suzhou Biomedical Shareholders or making decision on the liquidation of AK Suzhou and the formulation of the profit sharing plans of AK Suzhou, provided that the exercise of the power(s) of attorney shall not cause breach to the AK Suzhou Contractual Arrangements.

合約安排(續)

奧凱(蘇州)合約安排(續)

經營實體之詳情及主要業務(續)

奧凱(蘇州)之成立宗旨為於中國從事為人體細胞及幹細胞相關臨床應用提供服務及設備之業務,包括但不限於人體幹細胞技術及人體幹細胞處理設備之研發及買賣相關設備。

奧凱(蘇州)合約安排之主要條款

a) 不可撤回授權委託書

訂約方:

蘇州生物技術股東

年期:

於簽署後無限年期並將持續有效,直至奧凱(蘇州)合約安排(包括其各份補充協議) (「奧凱(蘇州)主債權」)項下之合約均已 獲全面終止或解除。

主體事項:

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Major terms of the AK Suzhou Contractual Arrangements (Cont'd)

b) Exclusive business cooperation agreement

Parties:

- (i) AK Subsidiary
- (ii) AK Suzhou

Terms:

10 years commencing from 7 August 2015. The exclusive business cooperation agreement will be automatically extended for another 10 years if AK Subsidiary has no intention to terminate upon its expiry. The said automatic 10-year extension will continue until AK Subsidiary gives confirmation regarding the termination of the term.

Main Subject:

AK Suzhou should appoint AK Subsidiary as exclusive service provider for its business operations, including but not limited to, technical R&D, technical support, technical consultation, technical training and other management and corporate consultation services.

合約安排(續)

奧凱(蘇州)合約安排(續)

奧凱(蘇州)合約安排之主要條款(續)

b) 獨家業務合作協議

訂約方:

- (i) 奥凱附屬公司
- (ii) 奥凱(蘇州)

年期:

由二零一五年八月七日起為期10年。期滿後假若奧凱附屬公司沒有終止的意向表示, 則獨家業務合作協議將自動延期10年。此 自動延期10年將持續進行,直至奧凱附屬 公司作出終止年期確認。

主體事項:

奧凱(蘇州)將委聘奧凱附屬公司為其業務 營運之獨家服務提供商,包括但不限於技術 研發、技術支援、技術諮詢、技術培訓及其 他相關管理及企業諮詢服務。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Major terms of the AK Suzhou Contractual Arrangements (Cont'd)

c) Exclusive option agreements

Parties:

- (i) AK Subsidiary
- (ii) Suzhou Biomedical Shareholders
- (iii) AK Suzhou

Terms:

10 years commencing from the date of the respective exclusive option agreements. The exclusive option agreement will be automatically extended for another 10 years if AK Subsidiary has no intention to terminate upon its expiry. The said automatic 10-year extension will continue until AK Subsidiary gives confirmation regarding the termination of the term.

Main Subject:

Suzhou Biomedical Shareholders and AK Suzhou irrevocably agreed, to the extent permitted under the laws of the PRC, to transfer to AK Subsidiary or any person(s) designated by AK Subsidiary at any time and from time to time, all or part of their equity interests in AK Suzhou, or all or part of the assets of AK Suzhou.

AK Subsidiary may exercise its rights under the paragraph above at any time and in any manner at its sole discretion as permitted under the laws of the PRC. The exercise price of each of the rights under the paragraph above shall be the lowest price permitted under the laws of the PRC, subject to any other price as required by the PRC government authorities. Upon AK Suzhou and/or Suzhou Biomedical Shareholders receive(s) the said consideration, they unconditionally transfer the said consideration to AK Subsidiary or any person(s) designated by AK Subsidiary.

合約安排(續)

奧凱(蘇州)合約安排(續)

奧凱(蘇州)合約安排之主要條款(續)

c) 獨家購股權協議

訂約方:

- (i) 奥凱附屬公司
- (ii) 蘇州生物技術股東
- (iii) 奥凱(蘇州)

年期:

由各獨家購股權協議日期起為期10年。期滿後假若奧凱附屬公司沒有終止的意向表示,則獨家購股權協議將自動延期10年。此自動延期10年將持續進行,直至奧凱附屬公司作出終止年期確認。

主體事項:

蘇州生物技術股東及奧凱(蘇州)不可撤回 同意,於中國法律准許之範圍內,隨時及不 時向奧凱附屬公司或奧凱附屬公司指定之任 何人士轉讓其於奧凱(蘇州)之全部或部份 股權或奧凱(蘇州)之全部或部份資產。

在中國法律准許之情況下,奧凱附屬公司可 全權酌情於任何時間及以任何方式行使上段 所述權利。上段所述各項權利之行使價格將 為中國法律准許之最低價格,惟須受中國政 府機關所規定之任何其他價格規限。於奧凱 (蘇州)及/或蘇州生物技術股東收到上述 代價後,彼等將無條件轉讓上述代價予奧凱 附屬公司或其指定之任何人士。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Major terms of the AK Suzhou Contractual Arrangements (Cont'd)

c) Exclusive option agreements (Cont'd)

Suzhou Biomedical Shareholders and AK Suzhou jointly and/ or severally undertake that, among other things, without having obtained the prior written consent from AK Subsidiary, they will not (i) amend the articles of association of AK Suzhou; (ii) increase or decrease the registered capital of AK Suzhou; (iii) dispose of, transfer, mortgage, create any security interest or third party rights in its equity interests in AK Suzhou; (iv) appoint any director(s) or executive director(s) of AK Suzhou; and (v) pay dividends in any manners. Suzhou Biomedical Shareholders further undertake that, without having obtained the written consent from AK Subsidiary, they and their respective related persons will not engage in any business which is in competition with the businesses of AK Suzhou.

d) Equity pledge agreements

Parties:

- (i) AK Subsidiary
- (ii) Suzhou Biomedical Shareholders
- (iii) AK Suzhou

Terms:

Effective from the registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce until all the obligations of Suzhou Biomedical Shareholders and AK Suzhou (including but not limited to AK Suzhou Main Obligations) are satisfied or discharged in full. The registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce has been completed.

Main Subject:

Suzhou Biomedical Shareholders pledged all equity interests in AK Suzhou legally held by Suzhou Biomedical Shareholders (including present or future registered capital and their rights and benefits, whether through increase of capital and/or transfer of equity interest) to AK Subsidiary.

合約安排(續)

奧凱(蘇州)合約安排(續)

奧凱(蘇州)合約安排之主要條款(續)

c) 獨家購股權協議(續)

蘇州生物技術股東及奧凱(蘇州)共同及/或個別承諾,(其中包括)如未獲奧凱附屬公司事先書面同意,彼等將不會(i)修訂奧奧(蘇州)之組織章程細則;(ii)將其於奧凱(蘇州)之股權出售、轉讓、抵押、設置任與凱(蘇州)之股權益或第三方權利;(iv)委任奧凱(蘇州)之任何董事或執行董事;及(v)以任何方式,之任何董事或執行董事;改等人以任何方式,如未獲奧凱附屬公司書面同意,彼等及彼蘇如未獲奧凱附屬公司書面同意,彼等及彼蘇如未獲奧凱附屬公司書面同意,彼等及彼蘇州)業務構成競爭之業務。

d) 股權質押協議

訂約方:

- (i) 奥凱附屬公司
- (ii) 蘇州生物技術股東
- (iii) 奥凱(蘇州)

年期:

自於有關中國工商行政機關登記股權質押協議項下之已抵押股權起生效,直至蘇州生物技術股東及奧凱(蘇州)之所有債權(包括但不限於奧凱(蘇州)主債權)均已經完全被滿足或被解除。已完成於有關中國工商行政機關登記股權質押協議項下之已抵押股權。

主體事項:

蘇州生物技術股東向奧凱附屬公司質押蘇州生物技術股東合法持有之全部奧凱(蘇州)股權(包括現有或未來註冊股本及其權利及利益,無論是透過增加股本及/或轉讓股權之方式)。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Major terms of the AK Suzhou Contractual Arrangements (Cont'd)

e) Consent letter of spouse

Parties:

The spouses of Suzhou Biomedical Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the AK Suzhou Main Obligations are satisfied or discharged in full.

Main Subject:

The spouses of Suzhou Biomedical Shareholders unconditionally agreed to the AK Suzhou Contractual Arrangements.

The spouses of Suzhou Biomedical Shareholders undertake and declare that the equity respectively owned by Suzhou Biomedical Shareholders in AK Suzhou contemplated on AK Suzhou Contractual Arrangements shall be Suzhou Biomedical Shareholders' personal property respectively; and further, the said spouses undertake that they shall not take any act that causes or will cause any conflict and/or impediment to the AK Suzhou Contractual Arrangements.

Reason for using the AK Suzhou Contractual Arrangements and the significance to the Group

As advised by the legal adviser of the Company, the principal business of AK Suzhou involves technology for human stem cell research & development and applications which is regarded as prohibited business for foreign entity under the PRC Law. As such, the Group cannot acquire the equity interest in AK Suzhou at that time. Having regard to such foreign investment restrictions, the AK Suzhou Contractual Arrangements were designed to provide AK Subsidiary and, thus the Group, with effective control over the financial and operational policies of AK Suzhou and (to the extent permitted by PRC laws and regulations) the right to acquire the equity interest in AK Suzhou.

合約安排(續)

奧凱(蘇州)合約安排(續)

奧凱(蘇州)合約安排之主要條款(續)

e) 配偶同意函

訂約方:

蘇州生物技術股東之配偶

年期:

於簽署後無限年期並將持續有效,直至奧凱(蘇州)主債權均已經完全被滿足或被解除。

主體事項:

蘇州生物技術股東之配偶無條件同意奧凱(蘇州)合約安排。

蘇州生物技術股東之配偶承諾及聲明,奧凱 (蘇州)合約安排中涉及的蘇州生物技術股 東各自持有於奧凱(蘇州)之股權分別為蘇 州生物技術股東之個人財產;並進一步承諾 不會採取任何導致或將導致與奧凱(蘇州) 合約安排相衝突及/或阻礙之行為。

採用奧凱(蘇州)合約安排之理由及對本集團之重

據本公司法律顧問告知,奧凱(蘇州)的主要業務涉及人體幹細胞研發及應用技術,根據中國法律被視為外資企業受禁止類業務。因此,本集團當時無法收購奧凱(蘇州)之股權。經計及該等海外投資限制,設立奧凱(蘇州)合約安排之目的乃為奧凱附屬公司乃至本集團提供對奧凱(蘇州)財務及經營策略之有效控制及(於中國法律及法規准許之範圍內)收購奧凱(蘇州)股權之權利。

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Revenue and assets subject to the AK Suzhou Contractual Arrangements

The revenue, net loss and total assets subject to the AK Suzhou Contractual Arrangements are set out as follows:

合約安排(續)

奧凱(蘇州)合約安排(續)

奧凱(蘇州)合約安排之收益及資產

奧凱 (蘇州) 合約安排之收益、淨虧損及總資產載 列如下:

		Year ended	Year ended
		30 April 2017	30 April 2016
		截至二零一七年	截至二零一六年
		四月三十日	四月三十日
		止年度	止年度
		(HK\$'000)	(HK\$'000)
		(千港元)	(千港元)
Revenue	收益	247	55
Net loss	淨虧損	8,612	3,318
Total assets	總資產	73,901	64,707

For the year ended 30 April 2017, the revenue and net loss subject to AK Suzhou Contractual Arrangements amounted to approximately 0.07% and 4.32% of the revenue and net loss of the Group respectively. As at 30 April 2017, the total assets subject to AK Suzhou Contractual Arrangements amounted to approximately 2.56% of the total assets of the Group.

For the year ended 30 April 2016, the revenue and net loss subject to AK Suzhou Contractual Arrangements amounted to approximately 0.20% and 1.71% of the revenue and net loss of the Group respectively. As at 30 April 2017, the total assets subject to AK Suzhou Contractual Arrangements amounted to approximately 2.23% of the total assets of the Group.

Material changes

Save as disclosed in this report, there has not been any material changes in AK Suzhou Contractual Arrangements and/or the circumstances under which they were adopted.

截至二零一七年四月三十日止年度,奧凱(蘇州) 合約安排之收益及淨虧損分別佔本集團收益及淨 虧損約0.07%及4.32%。於二零一七年四月三十 日,奧凱(蘇州)合約安排之總資產佔本集團總資 產約2.56%。

截至二零一六年四月三十日止年度,奧凱(蘇州) 合約安排之收益及淨虧損分別佔本集團收益及淨虧損約0.20%及1.71%。於二零一七年四月三十日,奧凱(蘇州)合約安排之總資產佔本集團總資產約2.23%。

重大變動

除本報告所披露者外,奧凱(蘇州)合約安排及/或採納該等合約安排的情況並無任何重大變動。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

AK Suzhou Contractual Arrangements (Cont'd)

Unwinding of AK Suzhou Contractual Arrangements

Up to the date of this report, there has not been any unwinding of any AK Suzhou Contractual Arrangements, nor has there been any failure to unwind any AK Suzhou Contractual Arrangements when the restrictions that led to the adoption of the AK Suzhou Contractual Arrangements are removed.

Tianjin Weikai Contractual Arrangements

Collectively, the exclusive business cooperation agreement, the exclusive option agreement, the equity pledge agreement, the power of attorney and the consent letter of spouse, entered into among (i) Tianjin Subsidiary (Tianjin Weisheng Biotechnology Consulting Limited, a company incorporated in the PRC with Royal Noble Development Limited as its sole shareholder (a company incorporated in Hong Kong with Passion Stream Limited as its sole shareholder, a company incorporated in the British Virgin Islands, being owned as to 70% and 30% by the CRMI Medical and Remed Tiger respectively)), (ii) Tianjin Weikai (天津衛凱生物工程有限公司 (Tianjin Weikai Bioeng Ltd.#), a company incorporated in the PRC to engage in the business of designs and manufacturing of pre-clinical cell and stem cell related equipment, especially in 3D cell culture bio-reactors and their related consumables, as well as providing CRO services i.e. contract research services which mainly include drug screening, drug efficacy, toxicity assays in the drug development services to local institutions and hospitals), the then (iii) registered shareholders of Tianjin Weikai and their spouses (if any).

Particulars and main business of the operating entity

At the date of this report, Tianjin Weikai is currently owned as to 30% by Mr. Cui Zhanyong and as to 70% by Mr. Dai Yumin (hereinafter collectively referred to as the "Tianjin Weikai Shareholders"). Tianjin Weikai is controlled by the Group through Tianjin Subsidiary by way of Tianjin Weikai Contractual Arrangements pursuant to which Tianjin Subsidiary controls Tianjin Weikai.

Tianjin Weikai engages in the business of design and manufacturing of pre-clinical cell and stem cell related equipment, especially in 3D cell culture bio-reactors and their related consumables as well as providing CRO services.

合約安排(續)

奧凱(蘇州)合約安排(續)

解除奧凱(蘇州)合約安排

截至本報告日期,並無任何奧凱(蘇州)合約安排被解除,亦無於導致採納奧凱(蘇州)合約安排的限制經移除後出現無法解除任何奧凱(蘇州)合約安排的情況。

天津衛凱合約安排

獨家業務合作協議、獨家購股權協議、股權質押 協議、授權委託書及配偶同意函之統稱,由以下 訂約方訂立:(i)天津附屬公司(天津衛盛生物技 術諮詢服務有限公司,一間於中國註冊成立之公 司,凱爵發展有限公司(一間於香港註冊成立之 公司, Passion Stream Limited (一間於英屬處女 群島註冊成立之公司,由中國再生醫學生物技術 及Remed Tiger分別擁有70%及30%權益)為 其唯一股東)為其唯一股東),(ii)天津衛凱(天津 衛凱生物工程有限公司,一間於中國註冊成立之 公司,從事設計和製造臨床前的細胞和幹細胞相 關的設備業務,特別是在三維細胞灌培養物反應 器及其相關的耗材,以及提供合同式技術研究服 務,其中主要包括藥物篩選,藥物的療效,為當 地機構和醫院的藥效提供毒性檢測服務),(iii)天 津衛凱當時之登記股東及彼等之配偶(如有)。

經營實體之詳情及主要業務

於本報告日期,天津衛凱現時由崔佔永先生及戴昱敏先生(下文統稱「天津衛凱股東」)分別擁有30%及70%權益。天津衛凱由本集團透過天津附屬公司以天津衛凱合約安排之方式控制,據此,天津附屬公司控制天津衛凱。

天津衛凱從事臨床前的細胞和幹細胞相關的設備 之設計和製造(特別是在三維細胞灌培養物反應 器及其相關的耗材)業務以及提供合同式技術研 究服務。

[#] for identification only

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements

a) Irrevocable Power(s) of Attorney

Parties:

Tianjin Weikai Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the contracts under Tianjin Weikai Contractual Arrangements including their respective supplemental agreements ("Tianjin Weikai Main Obligations") are satisfied or discharged in full.

Main Subject:

Tianjin Weikai Shareholders shall, among other things, irrevocably authorise any representative and its respective successors appointed by Tianjin Subsidiary to act on their behalf all matters in relation to its equity interests in Tianjin Weikai, including attending shareholders' meeting, signing minutes of shareholders' meeting and shareholders' resolutions, exercising their full shareholder's rights under the articles of association of Tianjin Weikai and applicable PRC laws and regulations, including but not limited to shareholders' voting right, appointment of the legal representative, director, supervisor and senior management of Tianjin Weikai, filing documents with the relevant governmental authorities or regulatory bodies, acquisition and disposition of the shareholdings of Tianjin Weikai held by Tianjin Weikai Shareholders or making decision on the liquidation of Tianjin Weikai and the formulation of the profit sharing plans of Tianjin Weikai, provided that the exercise of the power(s) of attorney shall not cause to breach the Tianjin Weikai Contractual Arrangements.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款

a) 不可撤回授權委託書

訂約方:

天津衛凱股東

年期:

於簽署後無限年期並將持續有效,直至天津 衛凱合約安排(包括其各份補充協議)(「天 津衛凱主債權」)項下之合約均已獲全面達 成或解除。

主體事項:



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements (Cont'd)

b) Exclusive business cooperation agreement

Parties:

- (i) Tianjin Subsidiary
- (ii) Tianjin Weikai

Terms:

10 years commencing from 17 April 2015. The exclusive business cooperation agreement will be automatically extended for another 10 years if Tianjin Subsidiary has no intention to terminate upon its expiry. The said automatic 10-year extension will continue until Tianjin Subsidiary gives confirmation regarding the termination of the term.

Main Subject:

Tianjin Weikai should appoint Tianjin Subsidiary as service provider for its business operations, including but not limited to, technical R&D, technical support, technical consultation, technical training and other management and corporate consultation services.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款(續)

b) 獨家業務合作協議

訂約方:

- (i) 天津附屬公司
- (ii) 天津衛凱

年期:

由二零一五年四月十七日起為期10年。期滿後假若天津附屬公司沒有終止的意向表示,則獨家業務合作協議將自動延期10年。此自動延期10年將持續進行,直至天津附屬公司作出終止年期確認。

主體事項:

天津衛凱將委聘天津附屬公司為其業務營運 之服務提供商,包括但不限於技術研發、技 術支援、技術諮詢、技術培訓及其他相關管 理及企業諮詢服務。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements (Cont'd)

c) Exclusive option agreements

Parties:

- (i) Tianjin Subsidiary
- (ii) Tianjin Weikai Shareholders
- (iii) Tianjin Weikai

Terms:

10 years commencing from the date of the respective exclusive option agreements. The exclusive option agreement will be automatically extended for another 10 years if Tianjin Subsidiary has no intention to terminate upon its expiry. The said automatic 10-year extension will continue until Tianjin Subsidiary gives confirmation regarding the termination of the term.

Main Subject:

Tianjin Weikai Shareholders and Tianjin Weikai shall irrevocably agree, to the extent permitted under the laws of the PRC, to transfer to Tianjin Subsidiary or any person(s) designated by Tianjin Subsidiary at any time and from time to time, all or part of its equity interests in Tianjin Weikai, or all or part of the assets of Tianjin Weikai.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款(續)

c) 獨家購股權協議

訂約方:

- (i) 天津附屬公司
- (ii) 天津衛凱股東
- (iii) 天津衛凱

年期:

由各獨家購股權協議日期起為期10年。期滿後假若天津附屬公司沒有終止的意向表示,則獨家購股權協議將自動延期10年。此自動延期10年將持續進行,直至天津附屬公司作出終止年期確認。

主體事項:

天津衛凱股東及天津衛凱不可撤回同意,於 中國法律准許之範圍內,隨時及不時向天津 附屬公司或天津附屬公司指定之任何人士轉 讓其於天津衛凱之全部或部份股權或天津衛 凱之全部或部份資產。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements (Cont'd)

c) Exclusive option agreements (Cont'd)

Tianjin Subsidiary may exercise its rights under the paragraph above at any time and in any manner at its sole discretion as permitted under the laws of the PRC. The exercise price of each of the rights under the paragraph above shall be the lowest price permitted under the laws of the PRC, subject to any other price as required by the PRC government authorities. Upon Tianjin Weikai and/or Tianjin Weikai Shareholders receive(s) the said consideration, they unconditionally transfer the said consideration to Tianjin Subsidiary or any person(s) designated by Tianjin Subsidiary.

Tianjin Weikai Shareholders and Tianjin Weikai jointly and/or severally undertake that, among other things, without having obtained the written consent from Tianjin Subsidiary, they will not (i) amend the articles of association of Tianjin Weikai; (ii) increase or decrease the registered capital of Tianjin Weikai; (iii) dispose of, transfer, mortgage, create any security interest or third party rights in its equity interests in Tianjin Weikai; (iv) appoint any director(s) or executive director(s) of Tianjin Weikai; (v) pay dividends in any manners. Tianjin Weikai Shareholders further undertake that, without having obtained the written consent from Tianjin Subsidiary, they and their respective related persons will not engage in any business which is in competition with the businesses of Tianjin Weikai.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款(續)

c) 獨家購股權協議(續)

在中國法律准許之情況下,天津附屬公司可全權酌情於任何時間及以任何方式行使上段所述權利。上段所述各項權利之行使價格將為中國法律准許之最低價格,惟須受中國政府機關所規定之任何其他價格規限。於天津衛凱及/或天津衛凱股東收到上述代價後,彼等將無條件轉讓上述代價予天津附屬公司或其指定之任何人士。

天津衛凱股東及天津衛凱共同及/或個別承諾,(其中包括)如未獲天津附屬公司書面同意,彼等將不會()修訂天津衛凱之組織資程細則;(i)增加或減少天津衛凱之註冊資本;(ii)將其於天津衛凱之股權出售、轉讓、抵押、設置任何擔保權益或第三方權利;(iv)委任天津衛凱之任何董事或執行董事;(v)以任何方式派付股息。天津衛凱股東進一步承諾,如未獲天津附屬公司書面同意,彼等及彼等各自之關連人士將不會從事任何與天津衛凱業務構成競爭之業務。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements (Cont'd)

d) Equity pledge agreement

Parties:

- (i) Tianjin Subsidiary
- (ii) Tianjin Weikai Shareholders
- (iii) Tianjin Weikai

Terms:

Effective from the registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce until all the obligations of Tianjin Weikai Shareholders and Tianjin Weikai (including but not limited to Tianjin Weikai Main Obligations) are satisfied or discharged in full. The registration of the pledged equity interests under the equity pledge agreement at the relevant PRC administration for industry and commerce has been completed.

Main Subject:

Tianjin Weikai Shareholders pledged all equity interests in Tianjin Weikai held by Tianjin Weikai Shareholders (including present or future registered capital and their rights and benefits, whether through increase of capital and/or transfer of equity interest) to Tianjin Subsidiary.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款(續)

d) 股權質押協議

訂約方:

- (i) 天津附屬公司
- (ii) 天津衛凱股東
- (iii) 天津衛凱

年期:

自於有關中國工商行政機關登記股權質押協議項下之已抵押股權起生效,直至天津衛凱股東及天津衛凱之所有債權(包括但不限於天津衛凱主債權)均已經完全被滿足或被解除。於有關中國工商行政機關登記股權質押協議項下之已抵押股權已完成。

主體事項:

天津衛凱股東向天津附屬公司質押天津衛凱 股東持有之全部天津衛凱股權(包括現有或 未來註冊股本及其權利及利益(無論是透過 增加股本及/或轉讓股權之方式))。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Major terms of the Tianjin Weikai Contractual Arrangements (Cont'd)

e) Consent letter of spouse

Parties:

The spouses of Tianjin Weikai Shareholders

Terms:

An indefinite term upon execution and shall continue to be valid until the Tianjin Weikai Main Obligations are satisfied or discharged in full.

Main Subject:

The spouses of Tianjin Weikai Shareholders shall unconditionally agree to the Tianjin Weikai Contractual Arrangements.

The spouses of Tianjin Weikai Shareholders undertake and declare that the equity respectively owned by Tianjin Weikai Shareholders in Tianjin Weikai contemplated on the Tianjin Weikai Contractual Arrangements shall be Tianjin Weikai Shareholders' personal property respectively; and further, the said spouses undertake that they shall not take any act that causes or will cause any conflict and/or impediment to the Tianjin Weikai Contractual Arrangements.

合約安排(續)

天津衛凱合約安排(續)

天津衛凱合約安排之主要條款(續)

e) 配偶同意函

訂約方:

天津衛凱股東之配偶

年期:

於簽署後無限年期並將持續有效,直至天津衛凱主債權均已經完全被滿足或被解除。

主體事項:

天津衛凱股東之配偶無條件同意天津衛凱合 約安排。

天津衛凱股東之配偶承諾及聲明,天津衛凱 合約安排中涉及的天津衛凱股東各自持有於 天津衛凱之股權分別為天津衛凱股東之個人 財產;並且其不會採取任何與天津衛凱合約 安排相衝突及/或阻礙之行為。

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Reason for using the Tianjin Weikai Contractual Arrangements and the significance to the Group

As advised by the legal adviser of the Company, the principal business of AK Suzhou which involves technology for human stem cell research & development and applications is regarded as prohibited business for foreign entity under the PRC Law. As such, the Group cannot acquire the equity interest in Tianjin Weikai at that time. Having regard to such foreign investment restrictions, the Tianjin Weikai Contractual Arrangements were designed to provide Tianjin Subsidiary and, thus the Group, with effective control over the financial and operational policies of Tianjin Weikai and (to the extent permitted by PRC laws and regulations) the right to acquire the equity interest in Tianjin Weikai.

Revenue and assets subject to the Tianjin Weikai Contractual Arrangements

The revenue, net loss and total assets subject to the Tianjin Weikai Contractual Arrangements are set out as follows:

合約安排(續)

天津衛凱合約安排(續)

採用天津衛凱合約安排之理由及對本集團之重要性

據本公司法律顧問告知,奧凱(蘇州)的主要業務 涉及人體幹細胞研發及應用技術,根據中國法律 被視為外資企業受禁止類業務。因此,本集團當 時無法收購天津衛凱之股權。經計及該等海外投 資限制,設立天津衛凱合約安排之目的乃為天津 附屬公司乃至本集團提供對天津衛凱財務及經營 策略之有效控制及(於中國法律及法規准許之範 圍內)收購天津衛凱股權之權利。

受天津衛凱合約安排規限之收益及資產

天津衛凱合約安排之收益、淨虧損及總資產載列 如下:

		Year ended 30 April 2017 截至二零一七年	Year ended 30 April 2016 截至二零一六年
		世上一令一七十 四月三十日 止年度 (HK\$'000) (千港元)	戦主 四月三十日 止年度 (HK\$'000) (千港元)
Revenue Net loss Total assets	收益 淨虧損 總資產	2,149 5,583 107,254	1,266 6,506 114,011

For the year ended 30 April 2017, the revenue and net loss subject to Tianjin Weikai Contractual Arrangements amounted to approximately 0.60% and 2.80% of the revenue and net loss of the Group respectively. As at 30 April 2017, the total assets subject to Tianjin Weikai Contractual Arrangements amounted to approximately 3.71% of the total assets of the Group.

For the year ended 30 April 2016, the revenue and net loss subject to Tianjin Weikai Contractual Arrangements amounted to approximately 4.56% and 3.34% of the revenue and net loss of the Group respectively. As at 30 April 2016, the total assets subject to Tianjin Weikai Contractual Arrangements amounted to approximately 3.93% of the total assets of the Group.

截至二零一七年四月三十日止年度,天津衛凱合約安排之收益及淨虧損分別佔本集團收益及淨虧損之約0.60%及2.80%。於二零一七年四月三十日,天津衛凱合約安排之總資產佔本集團總資產約3.71%。

截至二零一六年四月三十日止年度,天津衛凱合約安排之收益及淨虧損分別佔本集團收益及淨虧損之約4.56%及3.34%。於二零一六年四月三十日,天津衛凱合約安排之總資產佔本集團總資產約3.93%。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Tianjin Weikai Contractual Arrangements (Cont'd)

Material changes

Save as disclosed in this report, there has not been any material changes in Tianjin Weikai Contractual Arrangements and/or the circumstances under which they were adopted.

Unwinding of Tianjin Weikai Contractual Arrangements

Up to the date of this report, there has not been any unwinding of any Tianjin Weikai Contractual Arrangements, nor has there been any failure to unwind any Tianjin Weikai Contractual Arrangements when the restrictions that led to the adoption of the Tianjin Weikai Contractual Arrangements are removed.

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks

The Group does not have any direct equity ownership in AK Suzhou and/or Tianjin Weikai and has relied on the AK Suzhou Contractual Arrangements and/or Tianjin Weikai Contractual Arrangements, as the case may be, to control, operate, and be entitled to the economic benefits and risks arising from the respective businesses of AK Suzhou and/or Tianjin Weikai in the PRC. However, there are risks involved with the operations of AK Subsidiary and/or Tianjin Subsidiary under the AK Suzhou Contractual Arrangements and/or Tianjin Weikai Contractual Arrangements, as the case may be.

合約安排(續)

天津衛凱合約安排(續)

重大變動

除於本報告披露者外,天津衛凱合約安排及/或 採納該等合約安排的情況並無任何重大變動。

解除天津衛凱合約安排

截至本報告日期,並無任何天津衛凱合約安排被解除,亦無於導致採納天津衛凱合約安排的限制 經移除後出現無法解除任何天津衛凱合約安排的 情況。

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施

本集團並無於奧凱(蘇州)及/或天津衛凱擁有任何直接所有權權益,並已倚賴奧凱(蘇州)合約安排及/或天津衛凱合約安排(視情況而定)於中國控制、運營奧凱(蘇州)及/或天津衛凱各自之業務,並有權享有或承擔其經濟利益及風險。然而,奧凱(蘇州)合約安排及/或天津衛凱合約安排(視情況而定)項下存有涉及奧凱附屬公司及/或天津附屬公司經營業務之風險。



管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with AK Suzhou Contractual Arrangements and Tianiin Weikai the Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

There is no assurance that the AK Suzhou Contractual Arrangements and Tianiin Weikai Contractual Arrangements could comply with future changes in the regulatory requirements in the PRC and the PRC government may determine that the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements do not comply with applicable regulations

Current PRC laws and regulations prohibit foreign ownership of companies engage in the businesses concerning technology for research & development and applications of human stem cells, gene diagnose and therapy. The businesses of AK Suzhou and Tianjin Weikai are regarded as design and manufacturing of preclinical cell and stem cell related equipment which involves in technology for human stem cell research & development and applications, in addition to providing contract research services. The Company is a company incorporated under the laws of the Cayman Islands. AK Subsidiary and Tianjin Subsidiary may not engage in the businesses concerning technology for human stem cell research & development and applications in the PRC under current PRC laws. As a result, the Group will have to conduct the business of AK Suzhou and Tianjin Weikai in the PRC through the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements respectively.

Despite the fact that there is no indication that the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements will be interfered or objected by any PRC regulatory authorities, to the best knowledge of the Directors, there is a possibility that the Ministry of Commerce and other competent authorities may have different opinions on the interpretation of the relevant regulations and would not agree that the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements comply with the current PRC laws, regulations or rules or those that may be adopted in future, and the authorities may deny the validity, effectiveness and enforceability of the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements.

If the authorities may deny the validity, effectiveness and enforceability of any of the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements, it could have a material adverse impact on the Group's businesses, financial condition and results of operations.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

概不能保證奧凱 (蘇州) 合約安排及天津衛凱 合約安排能夠遵守未來中國監管規定之變動 及中國政府可能釐定奧凱(蘇州)合約安排及 天津衛凱合約安排並無遵守適用法規

> 現行中國法律及法規禁止外資公司從事有關 人體幹細胞研發及應用、基因診斷及治療 技術之業務。除提供合同式研究服務外,奧 凱(蘇州)及天津衛凱之業務為設計及生產 臨床前細胞及幹細胞相關設備,其中涉及人 體幹細胞研發及應用技術。本公司為一間根 據開曼群島法律註冊成立之公司。根據現行 中國法律,奧凱附屬公司及天津附屬公司不 可於中國從事有關人體幹細胞研發及應用技 術之業務。因此,本集團將須分別透過奧凱 (蘇州) 合約安排及天津衛凱合約安排於中 國進行奧凱(蘇州)及天津衛凱之業務。

> 儘管並無跡象顯示奧凱(蘇州)合約安排及 天津衛凱合約安排將遭任何中國監管機構干 預或反對,惟就董事所深知,商務部及其他 主管機構可能對相關法規之詮釋持有異議, 並將認為奧凱(蘇州)合約安排及天津衛凱 合約安排不符合現行或未來可能採納之中國 法律、法規或規則,而該等機構可能否認奧 凱(蘇州)合約安排及天津衛凱合約安排之 有效性、效力及可強制執行性。

> 倘該等機構否認任何奧凱(蘇州)合約安排 及天津衛凱合約安排之有效性、效力及可強 制執行性,其可能對本集團之業務、財務狀 況及經營業績產生重大不利影響。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(ii) The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may not be as effective in providing control over and entitlement to the economic interests in the Project Company ("either AK Suzhou or Tianjin Weikai or both as the case may be") as direct ownership

The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may not be as effective in providing the Group with control over and entitlement to the economic interests in the Project Company as direct ownership. If AK Subsidiary had direct ownership of AK Suzhou, AK Subsidiary would be able to directly exercise its rights as a shareholder to effect changes in the board of directors of AK Suzhou. However, under the AK Suzhou Contractual Arrangements, AK Subsidiary can only look to and rely on AK Suzhou and the Suzhou Biomedical Shareholders to perform their contractual obligations under the AK Suzhou Contractual Arrangements such that AK Subsidiary can exercise effective control over AK Suzhou. The Suzhou Biomedical Shareholders may not act in the best interests of AK Suzhou or may not perform its/their obligations under the AK Suzhou Contractual Arrangements, and in that case, AK Subsidiary may replace the Suzhou Biomedical Shareholders by its other nominees pursuant to the AK Suzhou Contractual Arrangements. However, if any dispute relating to the AK Suzhou Contractual Arrangements remains unresolved, AK Subsidiary will have to enforce its rights under the AK Suzhou Contractual Arrangements and seek to interpret the terms of the AK Suzhou Contractual Arrangements in accordance with the PRC laws and will be subject to uncertainties in the PRC legal system.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

(ii) 奧凱(蘇州)合約安排及天津衛凱合約安排 於控制項目公司(「指奧凱(蘇州)或天津衛 凱,或兩者(視情況而定)」)及享有其經濟 利益方面可能不如直接擁有權有效

> 奧凱(蘇州)合約安排及天津衛凱合約安排 於向本集團提供對項目公司之控制權及令其 享有項目公司之經濟利益方面可能不如直接 擁有權有效。倘奧凱附屬公司直接擁有奧凱 (蘇州),奧凱附屬公司將可直接行使作為 股東之權利變更奧凱(蘇州)之董事會。然 而,根據奧凱(蘇州)合約安排,奧凱附屬 公司僅可指望及依賴奧凱(蘇州)與蘇州生 物技術股東履行其於奧凱(蘇州)合約安排 項下之合約義務,從而使奧凱附屬公司可行 使對奧凱(蘇州)之實際控制權。蘇州生物 技術股東可能不會以奧凱(蘇州)之最佳利 益行事,或可能不履行彼等於奧凱(蘇州) 合約安排項下之義務,在此情況下,奧凱附 屬公司可根據奧凱(蘇州)合約安排安排其 他代名人取代蘇州生物技術股東。然而,倘 有關奧凱(蘇州)合約安排之任何爭議未獲 解決,奧凱附屬公司將強制行使其於奧凱 (蘇州)合約安排項下之權利及尋求根據中 國法律詮釋奧凱(蘇州)合約安排之條款並 將面臨中國法律制度中之不明朗因素。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(ii) The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may not be as effective in providing control over and entitlement to the economic interests in the Project Company ("either AK Suzhou or Tianjin Weikai or both as the case may be") as direct ownership (Cont'd)

It will be the same situation for the Tianjin Weikai Contractual Arrangements. If Tianjin Subsidiary had direct ownership of Tianjin Weikai, Tianjin Subsidiary would be able to directly exercise its rights as a shareholder to effect changes in the board of directors of Tianjin Weikai. However, under the Tianjin Weikai Contractual Arrangements, Tianjin Subsidiary can only look to and rely on Tianjin Weikai and the Tianjin Weikai Shareholders to perform their contractual obligations under the Tianiin Weikai Contractual Arrangements such that Tianiin Subsidiary can exercise effective control over Tianjin Weikai. The Tianjin Weikai Shareholders may not act in the best interests of Tianjin Weikai or may not perform its/their obligations under the Tianjin Weikai Contractual Arrangements, and in that case, Tianjin Subsidiary may replace the Tianjin Weikai Shareholders by its other nominees pursuant to the Tianjin Weikai Contractual Arrangements. However, if any dispute relating to the Tianjin Weikai Contractual Arrangements remains unresolved, Tianjin Subsidiary will have to enforce its rights under the Tianjin Weikai Contractual Arrangements and seek to interpret the terms of the Tianjin Weikai Contractual Arrangements in accordance with the PRC laws and will be subject to uncertainties in the PRC legal system.

The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements are governed by the PRC laws. When a dispute arises under any of the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements, the relevant parties thereto shall settle the dispute through negotiation in an amicable manner. In case the dispute is not resolved, the parties to the dispute may have to rely on legal remedies under the PRC laws. The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements provided that dispute will be submitted to the China International Economic and Trade Arbitration Commission for arbitration to be conducted in Beijing. The decision of such arbitration is final and binding on the parties to the dispute.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

(ii) 奧凱(蘇州)合約安排及天津衛凱合約安排 於控制項目公司(「指奧凱(蘇州)或天津衛 凱,或兩者(視情況而定)」)及享有其經濟 利益方面可能不如直接擁有權有效(續)

> 此情況同樣適用於天津衛凱合約安排。倘天 津附屬公司直接擁有天津衛凱,天津附屬 公司將可直接行使作為股東之權利變更天津 衛凱之董事會。然而,根據天津衛凱合約安 排,天津附屬公司僅可指望及依賴天津衛凱 與天津衛凱股東履行其於天津衛凱合約安排 項下之合約義務,從而使天津附屬公司可行 使對天津衛凱之實際控制權。天津衛凱股東 可能不會以天津衛凱之最佳利益行事,或可 能不履行彼等於天津衛凱合約安排項下之義 務,在此情況下,天津附屬公司可根據天津 衛凱合約安排安排其他代名人取代天津衛凱 股東。然而,倘有關天津衛凱合約安排之任 何爭議未獲解決,天津附屬公司將強制行使 其於天津衛凱合約安排項下之權利及尋求根 據中國法律詮釋天津衛凱合約安排之條款並 將面臨中國法律制度中之不明朗因素。

> 奧凱(蘇州)合約安排及天津衛凱合約安排 受中國法律規管。倘任何一份奧凱(蘇州) 合約安排及天津衛凱合約安排出現爭議, 有關訂約方將透過磋商以友好方式解決 議。倘未能解決爭議,則爭議方可能須 賴中國法律項下之法律補救措施。奧凱(蘇 州)合約安排及天津衛凱合約安排規定 議將提交至中國國際經濟貿易仲裁委員會 於北京進行仲裁。有關仲裁裁決為最終定論 且對有關爭議方均具有約束力。

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(ii) The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may not be as effective in providing control over and entitlement to the economic interests in the Project Company ("either AK Suzhou or Tianjin Weikai or both as the case may be") as direct ownership (Cont'd)

Since the legal environment in the PRC is different from that in Hong Kong and other jurisdictions, the uncertainties in the PRC legal system could limit the ability of the Group to enforce the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements. There is no assurance that such arbitration result will be in favour of the Group and/or that there will not be any difficulties in enforcing any arbitral awards granted, including specific performance or injunctive relief and claiming damages by the Group. As the Group may not be able to obtain sufficient remedies in a timely manner, its ability to exert effective control over AK Suzhou and/or Tianjin Weikai and the conduct of the businesses concerning technology for human stem cell research & development and applications could be materially and adversely affected, and may disrupt the business of the Group and have a material adverse impact on Group's business, prospects and results of operation.

(iii) Potential conflicts of interest among the respective shareholders and the Project Company may exist

(a) Potential conflicts of interest among AK Subsidiary, AK Suzhou, the Suzhou Biomedical Shareholders may exist

AK Subsidiary shall rely on the AK Suzhou Contractual Arrangements to exercise control over and to draw the economic benefits from AK Suzhou. AK Subsidiary may not be able to provide sufficient incentives to the Suzhou Biomedical Shareholders for the purpose of encouraging them to act in the best interests of AK Subsidiary, other than stipulating the relevant obligations in the AK Suzhou Contractual Arrangements. The Suzhou Biomedical Shareholders may breach the AK Suzhou Contractual Arrangements in the event of conflicts of interest or deterioration of its/their relationship with AK Subsidiary, the results of which may have a material adverse impact on AK Subsidiary's business, prospects and results of operation.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

(ii) 奧凱(蘇州)合約安排及天津衛凱合約安排 於控制項目公司(「指奧凱(蘇州)或天津衛 凱,或兩者(視情況而定)」)及享有其經濟 利益方面可能不如直接擁有權有效(續)

(iii) 有關股東及項目公司之間可能存在潛在利益 衝突

(a) 奧凱附屬公司、奧凱(蘇州)及蘇州生物技術股東之間可能存在潛在利益衝突

MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

- (iii) Potential conflicts of interest among the respective shareholders and the Project Company may exist (Cont'd)
 - (a) Potential conflicts of interest among AK Subsidiary, AK Suzhou, the Suzhou Biomedical Shareholders may exist (Cont'd)

It is not assured that if conflicts arise, the Suzhou Biomedical Shareholders will act in the best interests of AK Subsidiary or that the conflicts will be resolved in favour of AK Subsidiary. If any of the Suzhou Biomedical Shareholders fails to perform its obligations under the respective AK Suzhou Contractual Arrangements, AK Subsidiary may have to rely on legal remedies under the PRC laws through legal proceedings, which may be expensive, time-consuming and disruptive to AK Subsidiary's operations and will be subject to uncertainties as stated above.

(b) Potential conflicts of interest among Tianjin Subsidiary, Tianjin Weikai, the Tianjin Weikai Shareholders may exist

Tianjin Subsidiary shall rely on the Tianjin Weikai Contractual Arrangements to exercise control over and to draw the economic benefits from Tianjin Weikai. Tianjin Subsidiary may not be able to provide sufficient incentives to the Tianjin Weikai Shareholders for the purpose of encouraging them to act in the best interests of Tianjin Subsidiary, other than stipulating the relevant obligations in the Tianjin Weikai Contractual Arrangements. The Tianjin Weikai Shareholders may breach the Tianjin Weikai Contractual Arrangements in the event of conflicts of interest or deterioration of its/their relationship with Tianjin Subsidiary, the results of which may have a material adverse impact on Tianjin Subsidiary's business, prospects and results of operation.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

- (iii) 有關股東及項目公司之間可能存在潛在利益 衝突(續)
 - (a) 奧凱附屬公司、奧凱(蘇州)及蘇州生物技術股東之間可能存在潛在利益衝突(續)

(b) 天津附屬公司、天津衛凱及天津衛凱 股東之間可能存在潛在利益衝突

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

- (iii) Potential conflicts of interest among the respective shareholders and the Project Company may exist (Cont'd)
 - (b) Potential conflicts of interest among Tianjin Subsidiary, Tianjin Weikai, the Tianjin Weikai Shareholders may exist (Cont'd)

It is not assured that if conflicts arise, the Tianjin Weikai Shareholders will act in the best interests of Tianjin Subsidiary or that the conflicts will be resolved in favour of Tianjin Subsidiary. If any of the Tianjin Weikai Shareholders fails to perform its obligations under the respective Tianjin Weikai Contractual Arrangements, Tianjin Subsidiary may have to rely on legal remedies under the PRC laws through legal proceedings, which may be expensive, time-consuming and disruptive to Tianjin Subsidiary's operations and will be subject to uncertainties as stated above.

(iv) The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may be subject to scrutiny of the PRC tax authorities and additional tax may be imposed

The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may be subject to scrutiny of the PRC tax authorities and additional tax may be imposed on the Tianjin Subsidiary and/or AK Subsidiary, as the case may be. Tianjin Subsidiary and/or AK Subsidiary, as the case may be, may face adverse tax consequences if the PRC tax authorities determine that the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements were not entered into based on arm's length negotiations. If the PRC tax authorities determine that the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements were not entered into on an arm's length basis, they may adjust the income and expenses of Tianjin Subsidiary and/or AK Subsidiary, as the case may be, for the PRC tax purposes, which could result in higher tax liabilities on Tianjin Subsidiary and/or AK Subsidiary, as the case may be.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

- (iii) 有關股東及項目公司之間可能存在潛在利益 衝突(續)
 - (b) 天津附屬公司、天津衛凱及天津衛凱 股東之間可能存在潛在利益衝突(續)

概不保證當發生衝突時,天津衛凱股東將以天津附屬公司之最佳利益行之最佳利益行之最佳利益行之。衛突將以對天津附屬公司有利之之,有其於各份天津衛凱合約安排項法,實任,天津附屬公司可能須透過救,國法律下之法律補數可能昂貴、耗時及中斷天津附屬公司之營運,且可能面臨上文所述之不明朗因素。

(iv) 奧凱(蘇州)合約安排及天津衛凱合約安排可能會受中國稅務機關審查並徵收額外稅項

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

(iv) The AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements may be subject to scrutiny of the PRC tax authorities and additional tax may be imposed (Cont'd)

The operation results of the Tianjin Subsidiary and/or AK Subsidiary, as the case may be, may be materially and adversely affected if the tax liabilities of AK Subsidiary, Tianjin Subsidiary, Tianjin Weikai or AK Suzhou increase significantly or if they are required to pay interest on late payments.

(v) Ability to acquire the entire equity interests in or assets of the Project Company

(a) AK Subsidiary's ability to acquire the entire equity interests in or assets of AK Suzhou may be subject to various limitations and substantial costs

In case AK Subsidiary exercises its options to acquire all or part of the equity interests and/or assets of AK Suzhou under the relevant exclusive option agreement, the acquisition of the entire equity interests in or the assets of AK Suzhou may only be conducted to the extent as permitted by the applicable PRC laws and will be subject to necessary approvals and relevant procedures under applicable PRC laws. In addition, the abovementioned acquisitions may be subject to a minimum price limitation (such as an appraised value for the entire equity interests in or all assets of AK Suzhou) or other limitations as imposed by applicable PRC laws. Further, a substantial amount of other costs (if any), expenses and time may be involved in transferring the ownership of AK Suzhou, which may have a material adverse impact on AK Subsidiary's businesses, prospects and results of operation.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

(iv) 奧凱(蘇州)合約安排及天津衛凱合約安排 可能會受中國稅務機關審查並徵收額外稅項 (續)

倘奧凱附屬公司、天津附屬公司、天津衛凱或奧凱(蘇州)之稅務負債大幅增加或倘彼等須就逾期付款而支付利息,天津附屬公司及/或奧凱附屬公司(視情況而定)之經營業績則可能受重大不利影響。

- (v) 收購項目公司全部股權或資產之能力
 - (a) 奧凱附屬公司收購奧凱(蘇州)之全部 股權或資產之能力可能面臨多項限制 及大量成本

管理層討論及分析



CONTRACTUAL ARRANGEMENTS (Cont'd)

Risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements and actions taken by the Company to mitigate the risks (Cont'd)

- (v) Ability to acquire the entire equity interests in or assets of the Project Company (Cont'd)
 - (b) Tianjin Subsidiary's ability to acquire the entire equity interests in or assets of Tianjin Weikai may be subject to various limitations and substantial costs

In case Tianjin Subsidiary exercises its options to acquire all or part of the equity interests and/or assets of Tianjin Weikai under the exclusive option agreement, the acquisition of the entire equity interests in or the assets of Tianjin Weikai may only be conducted to the extent as permitted by the applicable PRC laws and will be subject to necessary approvals and relevant procedures under applicable PRC laws. In addition, the abovementioned acquisitions may be subject to a minimum price limitation (such as an appraised value for the entire equity interests in or all assets of Tianjin Weikai) or other limitations as imposed by applicable PRC laws. Further, a substantial amount of other costs (if any), expenses and time may be involved in transferring the ownership of Tianjin Weikai, which may have a material adverse impact on Tianjin Subsidiary's businesses, prospects and results of operation.

In light of the above risks associated with the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements, the Group has adopted a set of procedures, systems and internal control measures to ensure the sound and effective operation of the Group and the implementation of the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements. Such procedures, systems and internal control measures include (i) regular discussions of matters relating to compliance and regulatory enquiries from governmental authorities, if any, by the board of directors of the Company at board meetings; and (ii) retaining legal adviser and/or other professional to assist the Group to deal with specific issues arising from the AK Suzhou Contractual Arrangements and Tianjin Weikai Contractual Arrangements, if so required.

合約安排(續)

與奧凱(蘇州)合約安排及天津衛凱合約 安排有關之風險及本公司採取之降低風險 之措施(續)

- (v) 收購項目公司全部股權或資產之能力(續)
 - (b) 天津附屬公司收購天津衛凱之全部股權或資產之能力可能面臨多項限制及 大量成本

管理層討論及分析



OTHER COMMITMENTS

The Company signed two sponsorship agreements with the University of Oxford for the researches on cell therapy and tissue engineering. The Company agreed to provide GBP9.0 million (equivalent to approximately HK\$102.6 million) to the University of Oxford by instalments over the period covered by the agreements. Up to 30 April 2017, the Company has paid GBP4.5 million (equivalent to approximately HK\$52.6 million) to the University of Oxford.

On 15 July 2017, China Regenerative Medicine Limited ("CRML"), a wholly owned subsidiary of the Company entered into the limited partnership agreement with independent third parties, pursuant to which the CRML will commit to invest US\$75 million (equivalent to approximately HK\$585 million) in Haitong International Zhong Hua Finance Acquisition Fund I, L.P. ("the Fund") as a limited partner of the Fund after receiving a drawdown notice from the general partner. It is expected that the subscription would allow the Group to participate in investing in innovative healthcare and healthcare related business which would generate a favourable return to the Group.

CHARGES IN ASSETS AND CONTINGENT LIABILITIES

As at 30 April 2017, bank loans of HK\$754.0 million were secured by the Group's property, plant and equipment, land use rights and pledged bank deposits with carrying amounts of approximately HK\$78.0 million (2016: HK\$84.5 million), HK\$4.2 million (2016: HK\$4.6 million) and HK\$794.7 million (2016: HK\$558.9 million) respectively.

As at 30 April 2017, the Group had no material contingent liabilities (2016: Nil).

其他承擔

本公司與牛津大學就細胞治療及組織工程的研究 訂立兩份贊助協議。本公司同意於協議涵蓋期間 向牛津大學分期提供9,000,000英鎊(相當於約 102,600,000港元)。截至二零一七年四月三十 日,本公司已向牛津大學支付4,500,000英鎊(相 當於約52,600,000港元)。

於二零一七年七月十五日,本公司之全資附屬公司中國再生醫學有限公司(「CRML」)已與獨立第三方訂立有限合夥協議,據此,CRML承諾將於收到普通合夥人發出的提款通知後以Haitong International Zhong Hua Finance Acquisition Fund I, L.P.(「基金」)的有限合夥人身份向基金投資75,000,000美元(相當於約585,000,000港元)。預期認購事項將令本集團得以參與投資創新醫療保健及醫療保健相關業務,為本集團產生可觀之回報。

資產抵押及或有負債

於二零一七年四月三十日,754,000,000港元銀行貸款由本集團之物業、廠房及設備、土地使用權及已抵押銀行存款(其賬面值分別約為78,000,000港元(二零一六年:84,500,000港元)、4,200,000港元(二零一六年:4,600,000港元)及794,700,000港元(二零一六年:558,900,000港元))作抵押。

於二零一七年四月三十日,本集團並無重大或有 負債(二零一六年:無)。

管理層討論及分析



DETAILS OF FUTURE PLANS FOR MATERIAL INVESTMENT OR CAPITAL ASSETS

Save as disclosed in this report, the Directors do not have any plans for material investment or capital assets at this point in time.

EMPLOYEE INFORMATION AND REMUNERATION POLICIES

As at 30 April 2017, the Group had 542 (2016: 520) employees located in Hong Kong and Mainland China. As an equal opportunity employer, the Group's remuneration and bonus policies are determined with reference to the performance and experience of individual employees. The total amount of employee remuneration (including that of the Directors and retirement benefits scheme contributions) of the Group for the year was approximately HK\$131.7 million (2016: HK\$95.1 million).

In addition, the Group may offer options to employees as a recognition of and reward for their efforts and contributions to the Group.

重大投資或資本資產未來計劃之詳情

除本報告所披露者外,董事於此時並無任何關於 重大投資或資本資產之計劃。

僱員資料及薪酬政策

於二零一七年四月三十日,本集團共有僱員542名(二零一六年:520名),分佈於香港及中國內地。本集團作為平等機會僱主,其薪酬及獎金政策均以僱員個別表現及經驗釐定。本年度本集團之僱員薪酬總額(包括董事薪金及退休福利計劃供款)約為131,700,000港元(二零一六年:95,100,000港元)。

此外,本集團可向僱員授出購股權以肯定及獎勵 彼等的努力及對本集團作出的貢獻。

董事及最高行政人員簡介



EXECUTIVE DIRECTORS

Mr. Wong Sai Hung ("Mr. Wong"), aged 62, is an executive Director and the vice-chairman of the Board ("Vice-chairman"). He is also a member of each of the nomination committee of the Board (the "Nomination Committee") and the remuneration committee of the Board (the "Remuneration Committee"). Mr. Wong joined the Group in June 2008 as a non-executive Director. He had been redesignated as an executive Director between August 2012 to April 2013 and in January 2016, as the Vice-chairman between July 2009 to August 2012 and May 2013 to July 2014 and in October 2016. He also serves as a director of some subsidiaries of the Company. Mr. Wong graduated from Hong Kong Polytechnic University with a higher diploma in business studies (marketing). Currently, he is an independent non-executive director of Ping An Insurance (Group) Company of China, Ltd. (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2318) and JP Morgan Chinese Investment Trust plc (an investment trust listed on the London Stock Exchange): a non-executive director of Credit China Holdings Limited (the shares of which are listed on the Growth Enterprise Market of the Stock Exchange, stock code: 8207) and a director of One Asset Management Limited (a company incorporated in Thailand). Mr. Wong was an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 388); an executive director of LW Asset Management Advisors Limited; a non-executive director of ARN Investment SICAV (an investment company listed on the Luxembourg Stock Exchange) and ARN Asian Enterprise Fund Limited (formerly listed on the Irish Stock Exchange); the chief executive officer and an executive director of ICBC (Asia) Investment Management Company Limited; the chief executive director of BOCI Prudential Asset Management Limited; and a regional managing director of Prudential Portfolio Managers Asia.

執行董事

黃世雄先生(「黃先生」),62歳,為執行董事兼 董事會副主席(「副主席」)。彼亦為董事會下轄 提名委員會(「提名委員會」)及董事會下轄薪酬 委員會(「薪酬委員會」)各自之成員。黃先生於 二零零八年六月加盟本集團為非執行董事。彼曾 於二零一二年八月至二零一三年四月期間及二零 一六年一月調任為執行董事,於二零零九年七月 至二零一二年八月及二零一三年五月至二零一四 年七月以及二零一六年十月為副主席。彼亦出任 本公司若干附屬公司之董事。黃先生畢業於香港 理工大學,持有商管系(市場營運)高級文憑。 彼現為中國平安保險(集團)股份有限公司(其 股份於聯交所主板上市,股份代號:2318)及 JP Morgan Chinese Investment Trust plc(於倫敦 證券交易所上市之投資信託基金)之獨立非執行 董事;中國信貸控股有限公司(其股份於聯交所 創業板上市,股份代號:8207)之非執行董事及 One Asset Management Limited(於泰國註冊成 立之公司)之董事。黃先生曾任香港交易及結算 所有限公司(其股份於聯交所主板上市,股份代 號:388)之獨立非執行董事;利達財富管理顧問 有限公司之執行董事; ARN Investment SICAV(於 盧森堡證券交易所上市之投資公司)及ARN Asian Enterprise Fund Limited (曾於愛爾蘭證券交易所 上市) 之非執行董事; 工銀亞洲投資管理有限公 司之行政總裁及執行董事;中銀國際英國保誠資 產管理有限公司之行政總裁; 及英國保誠資產管 理亞洲之區域董事總經理。



董事及最高行政人員簡介



EXECUTIVE DIRECTORS (Cont'd)

Dr. Shao Zhengkang ("Dr. Shao"), aged 64, is an executive Director. He is also a member of each of the Nomination Committee and Remuneration Committee. Dr. Shao joined the Group in May 2013 as the general manager and had been appointed as the chief executive officer of the Company ("Chief Executive Officer"/"CEO") in September 2013. He also serves as a director of some subsidiaries of the Company. Dr. Shao has 13 years' experience in bio-medical industry. Prior to joining the Company, he served as a director and the general manager of a biomedical technology company in the PRC. From 1999 to 2002, he was an executive director and the general manager of China Everbright Limited, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 165) and as a non-executive director of several companies listed on the Main Board of the Stock Exchange. Before joining the Everbright Group, he was a deputy chief of the International Department of the People's Bank of China's head office, and served as an economist of the Asia office of International Monetary Fund, Dr. Shao holds a Bachelor's degree in arts from Shanghai Institute of Foreign Languages, China. He also obtained his master's degree in business administration from the George Washington University, U.S.A. and a doctorate's degree from the International Management Centre, U.K.. Dr. Shao has over 30 years' experience in banking, corporate finance, treasury, business development and corporate management.

執行董事(續)

邵政康博士(「邵博士」),64歲,為執行董事。 彼亦為提名委員會及薪酬委員會各自之成員。邵 博士於二零一三年五月加盟本集團為總經理,並 於二零一三年九月被委任為本公司行政總裁(「行 政總裁1)。彼亦出任本公司若干附屬公司之董 事。邵博士於生物醫藥行業有十三年的經驗。彼 於加入本公司前曾出任一間中國生物醫藥科技公 司之董事兼總經理。於一九九九年至二零零二年 間,彼為中國光大控股有限公司(其股份於聯交 所主板上市,股份代號:165)之執行董事兼總 經理及擔任數家聯交所主板上市公司的非執行董 事。加入光大集團前,彼曾任職中國人民銀行總 行國際司副處長及國際貨幣基金組織亞洲部經濟 師。邵博士持有中國上海外國語學院學士學位。 彼亦獲美國喬治華盛頓大學工商管理碩士學位及 英國國際管理學院管理學博士銜。邵博士擁有超 過三十年的銀行、企業融資、財務、業務發展及 企業管理經驗。

董事及最高行政人員簡介



EXECUTIVE DIRECTORS (Cont'd)

Mr. Chen Chunguo ("Mr. Chen"), aged 44, is an executive Director and the CEO. He is also a member of each of the Nomination Committee and Remuneration committee. Mr. Chen joined the Company in October 2016 as the president and re-designated as the CEO in February 2017. Mr. Chen has 20 years of relevant experience and has accumulated abundant experience in investment and M&A as well as corporation management. He also serves as a director of some subsidiaries of the Company. He graduated from Dongbei University of Finance and Economics and obtained a master's degree. From 1996 to 2012, Mr. Chen served as the president of \pm 連實德集團 (Dalian Shide Group Co., Ltd.#) ("Dalian Shide") who was responsible for the overall management of this 3000-employee group. Under his management, he established 8 production bases across the country for new construction materials, all of which were put into operation successfully, and developed over 100 distribution channels, making "Shide Profiles" one of the well-known brands in the People's Republic of China (the "PRC"). During his tenure with Dalian Shide. he led the investment in and acquisition of 河北凌雲股份有限公司 (Lingvun Industrial Corporation Limited# (SSE code: 600480)) and 寧 夏大元股份有限公司 (Ningxia Dayuan Chemical Co., Ltd.# (SSE code: 600146)), and invested in a number of financial institutions such as \pm 連銀行股份有限公司 (Bank of Dailian Co., Ltd.#), 太平洋保險股份有 限公司 (China Pacific Insurance Co., Ltd.#), 生命人壽保險股份有限公 司 (Sino Life Insurance Co., Ltd.#), 華匯人壽保險股份有限公司 (Sino-Conflux Insurance Company Ltd.#), 鐵嶺銀行股份有限 公司(Bank of Tieling Co., Ltd.#) and 景順長城基金管理有限公司 (Invesco Great Wall Fund Management Company Limited#), etc. During such period, he also formed 大連實德石化有限公司 (Dalian Shide Petrochemical Co., Ltd.#), 實德集團控股有限公司(港資)(Shide Group (Hongkong) Holdings Co., Ltd.#), 大連實德足球俱樂部 (Dalian Shide Football Club#), 大連實德投資有限公司 (Dalian Shide Investment Co., Ltd.#) and other dozens of companies. In total, Mr. Chen managed nearly a hundred of parents and subsidiaries and a billion-dollar group during his tenure with in Dalian Shide. From 2012 to 2016, as president of 大連海潤來集團 (Hairunlai Group Co., Ltd.#), Mr. Chen has led the investment in and acquisition of 盛銀互聯網金融株式會 社 (Shengyin Internet Financial Services Co., Ltd.#, based in Korea) and the investment in 百斯頓環球食品有限公司 (Beston Global Food Company Ltd#.), based in Australia, 河北唐宋互聯網大數據有 限公司 (Chinatsi Big Data Inc.#) and 國金金融租賃有限公司 (Guojin Financial Leasing Co., Ltd.#), etc. In addition, Mr. Chen has integrated the group's resources and implemented an overall transition in the group. Mr. Chen is also the chairman of 上海湧涵股權投資有限公司 (Shanghai Yonghan Equity Investment Co., Ltd.#).

執行董事(續)

陳春國先生(「陳先生」),44歳,為執行董事兼 行政總裁。彼亦為提名委員會及薪酬委員會各自 之成員。陳先生於二零一六年十月加盟本公司擔 任總裁,並於二零一七年二月調任為行政總裁。 陳先生擁有20年相關經驗,於投資併購及企業 管理方面擁有豐富的經驗。彼亦出任本公司若干 附屬公司之董事。彼畢業於東北財經大學,持有 碩士學位。於一九九六年至二零一二年,陳先生 在大連實德集團(「大連實德」)就職總裁,期間 負責整體管理僱員達3000人之集團。在彼之管 理下,彼組建了全國八個新型建材生產基地,並 全部順利投入生產運營,成功搭建了100多家銷 售網路,「實德型材」成為中華人民共和國(「中 國」) 知名品牌之一。於彼在大連實德之期間,彼 投資及收購了河北凌雲股份有限公司(上海證券 交易所代號:600480)及寧夏大元股份有限公司 () 海證券交易所代號:600146),並已投資大連 銀行股份有限公司、太平洋保險股份有限公司、 生命人壽保險股份有限公司、華匯人壽保險股份 有限公司、鐵嶺銀行股份有限公司及景順長城基 金管理有限公司等眾多金融機構。於此期間,彼 亦組建了大連實德石化有限公司、實德集團控股 有限公司(港資)、大連實德足球俱樂部、大連 實德投資有限公司等幾十家實體公司。陳先生於 大連實德任職期間共管理了近百家母子公司,及 數十億資產的集團公司。二零一二年至二零一六 年,陳先生在大連海潤來集團就職總裁職務,投 資及收購了韓國盛銀互聯網金融株式會社,亦投 資了澳洲的百斯頓環球食品有限公司、河北唐宋 互聯網大數據有限公司及國金金融租賃有限公司 等公司 。此外,陳先生已整合了集團資源,並對 集團實施了全面轉型工作。陳先生亦為上海湧涵 股權投資有限公司董事長。

[#] for identification only



董事及最高行政人員簡介



NON-EXECUTIVE DIRECTORS

Professor Cui Zhanfeng ("Prof. Cui"), aged 54, is a non-executive Director and the chairman of the Board ("Chairman"). He is also a member of the audit committee of the Board (the "Audit Committee"). Prof. Cui joined the Group in November 2013 as a consultant. He currently serves as a director of a subsidiary of the Company. Prof. Cui obtained his bachelor's degree of in science from Inner Mongolia Polytechnic University, the PRC in 1982, and a master's degree in science in 1984 and a doctorate's degree in philosophy in 1987 from Dalian University of Technology, the PRC. Prof. Cui was a postdoctoral fellow in the Bioengineering Unit, Strathclyde University, the United Kingdom from 1988 to 1991 and a lecturer in Edinburgh University from 1991 to 1994. He moved to the Oxford University as a lecturer from 1994 to 1999 and was promoted to a reader in 1999. In 2000, he was elected to the Donald Pollock Chair of Chemical Engineering in the Oxford University at the age of 37. He is a professorial fellow of Hertford College, the Oxford University. He was a visiting professor to Georgia Institute of Technology, the United States of America ("USA") in 1999 and University of Minnesota, USA in 2004, and to several universities in the PRC. He is a chartered scientist, a chartered engineer, and a fellow of the Institution of Chemical Engineers. Prof. Cui was awarded the Doctor of Science (DSc) by the Oxford University in 2009. In 2013, Prof. Cui was elected to a fellow of the Royal Academy of Engineering (FREng).

Prof. Cui was the first Chinese who was elected to a Statutory Chair in the Oxford University. He has a wide range of collaborative activities with universities and Chinese Academy of Sciences in the PRC. He was a Chang Jiang Scholar of the Ministry of Education of the PRC and has acted as an adviser to several governmental organisations, including the Overseas Chinese Affair Office of the State Council.

Dr. Ray Yip ("Dr. Yip"), aged 66, is a non-executive Director. Dr. Yip joined the Group in February 2017. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in the PRC in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the "CDC") in 2013, and the China program director of the Bill and Melinda Gates Foundation (the "Foundation") in 2017. Dr. Yip is known as a specialist for health and medical issues in the PRC.

非執行董事

崔占峰教授(「崔教授」),54歳,為非執行董事 兼董事會主席(「主席」)。彼亦為董事會下轄審 核委員會(「審核委員會」)之成員。崔教授於二 零一三年十一月加盟本集團擔任顧問。彼現出任 本公司一間附屬公司之董事。崔教授於一九八二 年在中國內蒙古工學院獲取其理學學士學位, 其後分別於一九八四年和一九八十年在中國大 連理工大學獲取理學碩士及哲學博士學位。於 一九八八年至一九九一年,崔教授為英國斯特拉 斯大學生物工程研究所資深博士及於一九九一年 至一九九四年,曾為愛丁堡大學的講師。其後, 於一九九四年至一九九九年,履職英國牛津大學 大學講師一職,並於一九九九年晉升為副教授。 彼更於二零零零年,即年僅37歲之時,被推選為 牛津大學化學工程學Donald Pollock終身教授。 彼亦為牛津大學赫特福德 (Herford) 學院院士。 彼於一九九九年曾擔任美利堅合眾國(「美國」) 佐治亞理工學院和於二零零四年美國密尼蘇達 大學及中國幾所大學的客座教授。彼為化學工程 師學會英國特許科學家、特許工程師及理事。於 二零零九年,崔教授獲牛津大學授予科學博士學 位。於二零一三年,崔教授當選為英國皇家工程 院院士。

崔教授是第一位在牛津大學被選為終身教授的中國人。彼與中國之大學及中國科學院均有廣泛的合作。彼曾為中國教育部長江學者講座教授,並擔任若干中國政府機構之顧問(包括國務院僑辦諮詢專家)。

葉雷博士(「葉博士」),66歲,為非執行董事。 葉博士於二零一七年二月加入本集團。彼亦為會 會、提名委員會及薪酬委員會、提名委員會及薪酬委員會 自之成員。彼為國際公共健康先鋒,已在全至 養、母嬰健康、艾滋病及控煙等健康領域作出 要貢獻。葉博士近年一直在中國參與戰爭及飢 應急救援、長遠計劃及政策制定。葉博士於二零一 一三年成為美國疾病控制與預防中心(「「疾控中 心」)中國辦事處的創始主任,及於二零一七中國 為比爾及梅琳達◆蓋茨基金會(「基金會」)內國 項目主任。葉博士於中國為公認的健康及醫療專 家。

董事及最高行政人員簡介



NON-EXECUTIVE DIRECTORS (Cont'd)

Dr. Yip's major contributions to the global health include: refining the international criteria for screening for malnutrition and anemia and increasing the awareness of diarrhea as a major contributor to acute malnutrition. His work in the PRC has resulted in the mainstreaming of hepatitis B vaccine for routine immunization, the adoption of hospital-based delivery as a strategy which significantly reduced maternal mortality, transformation of the national AIDS response to one targeting those high-risk groups by accepting the role of civil society and assisting in engineering the policy support for tobacco control at the top level.

Dr. Yip established the Foundation's mission in China by assisting the government in addressing the key public health issues such as HIV and tobacco. He also transformed the Foundation's strategy in giving it a new focus "China-for-Africa" which includes identifying successful Chinese experience and technology to assist in the development of Africa. Since 2017, Dr. Yip has served as a special advisor focusing on health and clean energy for bgC3, a think-tank headed by Bill Gates.

Dr. Yip served at the faculty of the University of California-San Francisco between 1990 and 1994 and was an adjunct professor at the Friedman School and Nutrition Science and Policy of Tufts University between 2006 and 2010. Currently, Dr. Yip is an adjunct professor at the Research Centre for Public Health of Tsinghua University.

Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric haematologist-oncologist.

Professor Xiong Chengyu ("Prof. Xiong"), aged 63, is a nonexecutive Director. He is also a member of the Audit Committee. Prof. Xiong joined the Group in March 2017. Prof. Xiong is currently a professor and a doctoral supervisor of the School of Journalism and Communication of Tsinghua University in the PRC. Professor Xiong has extensive experience in new media studies, media development and journalism. He was a member of each of 國家信息化專家諮詢委 員會委員 (the Advisory Committee for State Informatisation#) and 國 家互聯網發展與管理專家諮詢委員會委員 (the Advisory Committee for Internet Development and Management#), and served as a vice dean of the School of Journalism and Communication of Tsinghua University in the PRC. Professor Xiong currently serves as a member of the University Academic Committee and the chairman of the National Research Center of Cultural Industries in Tsinghua University in the PRC. Professor Xiong was an independent director of each of 湖南電廣傳媒股份有限公司 (Hunan TV & Broadcast Intermediary Co., Ltd.#) (Shenzhen Stock Exchange: 000917) and 中南出版傳 媒集團股份有限公司 (China South Publishing & Media Group Co., Ltd.#) (Shanghai Stock Exchange: 601098). He currently serves as an independent director of 江蘇省廣電有線信息網絡股份有限公 司 (Jiangsu Broadcasting Cable Information Network Corporation Limited#) (Shanghai Stock Exchange: 600959).

葉博士對全球健康的主要貢獻包括:完善營養不良和貧血篩查的國際標準及宣傳腹瀉是急性營養不良的主要原因。其於中國的工作已產生以下;輕極影響:常規免疫接種乙肝炎疫苗成為主流;採用醫院分娩策略,顯著降低孕產婦死亡率;借助民間力量將全國性的艾滋病應對轉化為集中關注高風險人群;及協助推動控煙獲得政府高層的政策支持。

葉博士為基金會設立的中國任務為協助政府解決 艾滋病及吸煙等主要公共健康問題。彼亦轉變基 金會的策略,賦予其新的焦點「中-非」(Chinafor-Africa),其中包括發現中國的成功經驗及技 術,為非洲發展提供幫助。自二零一七年起,葉 博士一直擔任bgC3(由比爾蓋茨領導的智囊團) 的特別顧問,專注於健康及清潔能源領域。

葉博士曾於一九九零年至一九九四年間在加州大學三藩市分校任教,並曾於二零零六年至二零一零年間擔任塔夫茨大學弗裡曼營養學與政策學院的副教授。葉博士現為清華大學公共健康研究中心副教授。

葉博士畢業於明尼蘇達大學醫學院及公共衛生學院,隨後獲得小兒血液腫瘤科的行醫執照。

非執行董事(續)

[#] for identification only



董事及最高行政人員簡介



NON-EXECUTIVE DIRECTORS (Cont'd)

Mr. Wang Hui ("Mr. Wang"), aged 59, is a non-executive Director. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. Wang joined the Group in June 2015. He was re-designated as a non-executive director in June 2017. Mr. Wang has been serving as the chief executive officer of First China Capital, Inc. ("FCC") since 1995, which provides financial advisory services in M&A and strategic alliance including corporations in the PRC and oversea. Over the past two decades, FCC served as financial advisor to Morgan Stanley, UBS, Sumitomo Mitsui Banking Corporation, financial institutions in the PRC, and other public and private businesses. Some of the transactions that Mr. Wang advised, such as UBS establishing UBS Securities through acquiring Beijing Securities, were considered as landmark in the industry.

In addition, Mr. Wang is a governor of Pardee RAND Graduate School of US RAND Corporation ("RAND"). For much of the time since 1988, he has been associated with RAND as a policy analyst and an adjunct researcher. Mr. Wang is also a committee member of China Society of Economics Reform. During the period between 1986 and 1988, Mr. Wang was assistant to president of China Institute for Economic Reform ("CIER") and the director of department of quantitative studies of CIER. Mr. Wang has published more than 20 books and academic publications over the years.

Mr. Wang obtained a master's degree in economics from China Academy of Social Sciences and a Ph.D. in policy analysis from Pardee BAND Graduate School.

非執行董事(續)

王輝先生(「王先生」),59歲,為非執行董事。彼亦為審核委員會、提名委員會及薪酬委員會各自之成員。王先生於二零一五年六月加加事。王先生自一九九五年起一直擔任First China Capital, Inc.(「FCC」)行政總裁,專門為中外企業提供併購和戰略合作的財務顧問服務。過去二十年之間,FCC曾擔任摩根士丹利、瑞士銀行、中國金融機構以及其他上市公司的財務顧問。王先生提供顧問服務可諾。王先生提供顧問服務可諾。

此外,王先生為美國蘭德公司(「蘭德公司」)研究生院董事會董事。於一九八八年後的大部份時間,彼於蘭德公司擔任政策分析師及顧問研究員。王先生亦為中國經濟體制改革研究會理事。於一九八六年至一九八八年期間,王先生為中國經濟體制改革研究所(「中國經濟體制改革研究所))所長助理及中國經濟體制改革研究所數量經濟研究室主任。王先生歷年曾公開發表的書籍及學術著作超過二十餘本。

王先生持有中國社會科學院經濟學碩士學位,並 為美國蘭德公司研究生院政策分析博士。







INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Lui Tin Nang ("Mr. Lui"), aged 59, is an independent nonexecutive Director. He is also the chairman of each of the Audit Committee and Nomination Committee, and a member of the Remuneration Committee, Mr. Lui joined the Group in September 2004. He obtained a bachelor's degree in science from the University of Leeds and a master's degree in business administration from the University of Bradford in United Kingdom, and a postgraduate diploma in insolvency from Hong Kong Institute of Certified Public Accountants ("HKICPA"). Mr. Lui is a fellow member of the HKICPA (Practising), the Institute of Chartered Accountants in England & Wales, the Taxation Institute of Hong Kong and The Society of Chinese Accountants and Auditors. He is also a member of the Chartered Institute of Management Accountant, Institute of Certified Public Accountants in Australia and the Certified Tax Adviser. Mr. Lui has years of experience in accounting, auditing, taxation, corporate finance and business advisory. Mr. Lui is currently an independent non-executive director of Brilliant Circle Holdings International Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 1008) and Northern New Energy Holdings Limited (the shares of which are listed on the GEM of the Stock Exchange, stock code: 8246).

獨立非執行董事

呂天能先生(「呂先生」),59歲,為獨立非執行 董事。彼亦為審核委員會及提名委員會各自之主 席,以及薪酬委員會成員。呂先生於二零零四年 九月加入本集團。彼取得英國 University of Leeds 理學士學位、英國University of Bradford工商管 理碩士學位及香港會計師公會(「香港會計師公 會|)破產管理研究生文憑。呂先生為香港會計師 公會(執業)、英格蘭及威爾斯特許會計師公會、 香港稅務學會及香港華人會計師公會等之資深會 員。彼亦為英國特許管理會計師協會會員、澳洲 會計師公會會員及香港註冊税務師。呂先生於會 計、審核、税務、企業融資及業務諮詢等方面累 積多年經驗。呂先生目前為貴聯控股國際有限公 司(其股份於聯交所主板上市,股份代號:1008) 及北方新能源控股有限公司(其股份於聯交所創 業板上市,股份代號:8246)之獨立非執行董事。



董事及最高行政人員簡介



INDEPENDENT NON-EXECUTIVE DIRECTORS (Cont'd)

Mr. Pang Chung Fai Benny ("Mr. Pang"), aged 44, is an independent non-executive Director. He is also the chairman of the Remuneration Committee, and a member of each of the Audit Committee and Nomination Committee. Mr. Pang joined the Group in September 2012. He is the managing partner of Benny Pang & Co which specializes in capital markets and general corporate and commercial work. Mr. Pang is also an executive director and a vice chairman of Huabang Financial Holdings Limited (previously known as Goldenmars Technology Holdings Limited) ("Huabang"), the shares of which are listed on the Stock Exchange, stock code: 3638). since January 2017. He was an independent non-executive director of Huabang since June 2012. Between 1997 and 2017, Mr. Pang practiced as a lawyer with several international law firms in Hong Kong and Sydney. He received his bachelor's degree in laws with honours from Bond University, Australia, in 1996. In 1997, Mr. Pang obtained his graduate diploma in legal practice and master's degree in laws from The College of Law, Sydney and the University of New South Wales, Australia, respectively. He has been admitted as a legal practitioner of the Supreme Court of New South Wales, Australia since 1997 and as a solicitor of the High Court of Hong Kong since 2009. Mr. Pang is a member of both the Law Society of New South Wales, Australia and the Law Society of Hong Kong. He is currently an independent non-executive director of Yuanda China Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 2789).

獨立非執行董事(續)

彭中輝先生(「彭先生」),44歲,為獨立非執行 董事。彼亦為薪酬委員會主席,以及審核委員會 及提名委員會各自之成員。彭先生於二零一二年 九月加入本集團。彼為Benny Pang & Co的主理 合夥人, Benny Pang & Co專門從事資本市場以 及一般企業及商業工作。彭先生亦自二零一七年 一月起為華邦金融控股有限公司(前稱晶芯科技 控股有限公司)(「華邦」,其股份於聯交所上市, 股份代號:3638)之執行董事及副主席。彼自 二零一二年六月起為華邦之獨立非執行董事。自 一九九七年至二零一七年,彭先生於香港及悉尼 多家國際律師事務所執業為律師。彼於一九九六 年畢業於澳大利亞邦德大學,獲得法學榮譽學士 學位。於一九九十年,彭先生於悉尼法律學院及 澳大利亞新南威爾斯大學分別獲得法律執業研究 課程文憑及法律碩士學位。彼於一九九七年獲澳 大利亞新南威爾斯最高法院認可為執業律師,並 於二零零九年獲香港高等法院認可為律師。彭先 生是澳大利亞新南威爾斯律師公會及香港律師會 的成員。彼現任遠大中國控股有限公司(其股份 於聯交所主板上市,股份代號:2789)獨立非執 行董事。

BIOGRAPHICAL DETAILS OF DIRECTORS AND CHIEF EXECUTIVES

董事及最高行政人員簡介



INDEPENDENT NON-EXECUTIVE DIRECTORS (Cont'd)

Mr. Chan Bing Woon, SBS, JP, ("Mr. Chan"), aged 72, is an independent non-executive Director. He is also a member of each of the Audit Committee. Nomination Committee and Remuneration Committee. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has over 40 years' experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong, and the chairman of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital. Mr. Chan was a member of the Hospital Authority and a past chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).

Mr. Wong Yiu Kit Ernest ("Mr. E Wong"), aged 49, is an independent non-executive Director. He is also the member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. E Wong joined the Group in February 2017. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. E Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited ("KVB") since November 2011 and as the chief financial officer and the company secretary of KVB's group company, KVB Kunlun Financial Group Limited (the shares of which are listed on the Stock Exchange, HKEx stock code: 8077) since October 2014. Mr. E Wong has also served as an independent nonexecutive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code: 1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016.

Mr. E Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.

獨立非執行董事(續)

黃耀傑先生(「黃耀傑先生」),49歲,為獨立非 執行董事。彼亦為審核委員會、提名委員會及薪 酬委員會各自之成員。黃耀傑先生於二零一七年 二月加入本集團。彼於創業投資、企業財務、業 務發展及一般管理方面擁有逾25年經驗。黃耀 傑先生自二零一一年十一月起擔任KVB Kunlun Holdings Limited(「KVB」) 之總裁及集團財務 總監,及自二零一四年十月起擔任KVB集團公司 昆侖國際金融集團有限公司(其股份於聯交所上 市,香港聯交所股份代號:8077)之財務總監及 公司秘書。黃耀傑先生亦自二零一一年十月起、 自二零一四年七月起、自二零一六年十一月起及 自二零一六年十一月起分別擔任仁恒實業控股有 限公司(香港聯交所股份代號:3628)、弘達金融 控股有限公司(香港聯交所股份代號:1822)、朸 濬國際集團控股有限公司(香港聯交所股份代號: 1355) 及進昇集團控股有限公司(香港聯交所股 份代號:1581)之獨立非執行董事。

黃耀傑先生亦於 Adamas Finance Asia Limited (倫敦證券交易所股份編號:ADAM) 擔任數職,包括自二零零八年五月至二零一四年二月期間擔任執行董事、自二零零八年五月至二零一一年十月期間擔任財務總監及自二零一四年二月起擔任非執行董事。



BIOGRAPHICAL DETAILS OF DIRECTORS AND CHIEF EXECUTIVES

董事及最高行政人員簡介



INDEPENDENT NON-EXECUTIVE DIRECTORS (Cont'd)

Mr. E Wong obtained a bachelor's degree in business administration from The University of Hong Kong in 1991, a master's degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master's degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.

Mr. E Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.

獨立非執行董事(續)

黃耀傑先生於一九九一年獲得香港大學工商管理 學學士學位,於一九九八年獲得香港科技大學投 資管理學理學碩士學位,及於二零零八年獲得香 港中文大學電子工程理學碩士學位。

黃耀傑先生分別於一九九九年十一月及二零零二年十月獲准成為英國特許公認會計師公會及會養會計師公會資深會員。彼於一九九八年九月獲准成為特許財務分析師學會之特許財務分析師及於二零零八年一月成為英格蘭和威爾士特許會會長、哲學學畢業生議會副主席、香港大學畢業生議會副主席、香港大學校董、特許公認會計師公會香港分會理事會委員及香港財經分析師協會執行董事。



企業管治報告



CORPORATE GOVERNANCE PRACTICES

The Board is committed to maintaining a high standard of corporate governance practices. The Group believes that high standard of corporate governance provides a framework and solid foundation for achieving, attracting and retaining the high standard and quality of the Group's management, promoting high standards of sound internal control, accountability and transparency to all shareholders of the Company ("Shareholders") and also meeting the expectations of the Group's various stakeholders.

The Company has complied with all the code provisions as set out in the Corporate Governance Code and Corporate Governance Report contained in the Appendix 15 of the GEM Listing Rules (the "CG Code") throughout the year ended 30 April 2017, with the exception of code provision A.6.7 of the CG Code.

Under code provision A.6.7 of the CG Code, independent non-executive Directors and other non-executive Directors, as equal board members, should attend general meetings and develop a balanced understanding of the views of Shareholders. Two non-executive Directors, Professor Deng Shaoping and Mr. Wang Jianjun and one independent non-executive Director, Mr. Wang Hui, did not attend the Company's annual general meeting held on 9 September 2016 (the "AGM") due to their engagements in other business commitments. Other Board members, including members of the Audit, Remuneration and Nomination Committees, attended the AGM and made themselves available to answer questions to ensure effective communication with the Shareholders.

CORPORATE GOVERNANCE STRUCTURE

The Board is charged with the duty to put in place a proper corporate governance structure of the Company. It is primarily responsible for setting directions, formulating strategies, monitoring performance and managing risks of the Group. Under the Board, there are currently 3 subcommittees, namely the Audit Committee, the Remuneration Committee and the Nomination Committee. All these committees perform their distinct roles in accordance with their respective terms of reference and assist the Board in supervising certain functions of the senior management.

企業管治常規

董事會致力維持高水平之企業管治常規。本集團認為,高水平之企業管治有助建立完善機制及鞏固根基,提升本集團管理層之水平、吸引並挽留良才、加強內部監控、提高本公司的全體股東(「股東」)問責性及透明度,亦能滿足本集團各持份者之期望。

本公司於截至二零一七年四月三十日止年度已遵守創業板上市規則附錄十五所載之企業管治守則及企業管治報告(「企業管治守則」)之所有守則條文,惟企業管治守則之守則條文第A.6.7條除外。

根據企業管治守則之守則條文第A.6.7條,獨立非執行董事及其他非執行董事作為與其他董事會成員,應出席股東大會,司股東的意見有公正的了解。兩名非執行董事出席股東大會之至。 紹平教授及王建軍先生及一名獨立非執行董事事的 超平教授及王建軍先生及一名獨立非執行董事事所 大生因彼等須參與其他業務,因而未能出年大會上 工零一六年九月九日舉行之本公司股東週年大會 「股東週年大會」)。其他董事會成員,包括審 委員會、薪酬委員會及提名委員會之成員,的有 來對東週年大會解答疑問,以確保與股東的有 效溝通。

企業管治架構

董事會有責任為本公司建立一套良好之企業管治架構。董事會主要負責為本集團訂立指引、制定策略、監管表現及管理風險。董事會轄下現有三個委員會,即審核委員會、薪酬委員會及提名委員會。各委員會根據其職權範圍履行本身獨特之職責,並協助董事會監管高級管理人員之特定工作。

企業管治報告



BOARD OF DIRECTORS

Board Composition and Board Practices

The Board is responsible to the Shareholders for leadership and control of the Company and is collectively responsible for promoting the success of the Company and its businesses by directing and supervising the Company's affairs. Details of the membership of the Board together with their roles and functions are posted on the Stock Exchange and the Company's website and such information shall be updated as soon as practicable whenever there are changes.

The composition of the Board reflects a balance of skills and experience desirable for an effective leadership of the Company.

As at 30 April 2017, the Board had eleven Directors, including three executive Directors; three non-executive Directors, and five independent non-executive Directors.

Given below are names of the Directors as at the date of this report:

董事會

董事會之組成及董事會常規

董事會須就領導及監管本公司之事宜向股東負 責,並須共同負責指導及監管本公司事務,務求 令本公司及其業務再創佳績。董事會成員之詳 情, 連同彼等之角色及職責, 載於聯交所及本公 司網站,而當有關資料有所變動時,在切實可行 的範圍內將作更新。

董事會之組成體現本公司於有效領導所需之技能 及經驗方面取得之平衡。

於二零一七年四月三十日,董事會有十一名董 事,包括三名執行董事、三名非執行董事及五名 獨立非執行董事。

於本報告日期,董事姓名如下:

Executive Directors		<i>執行董事</i>	
Mr. Wong Sai Hung	(Vice-chairman of the Board, member of the Nomination and Remuneration Committee)	黄世雄先生	(董事會副主席、提名委 員會及薪酬委員會成員)
Dr. Shao Zhengkang	(Member of the Nomination and Remuneration Committee)	邵政康博士	(提名委員會及薪酬委員會 成員)
Mr. Chen Chunguo	(Chief Executive Officer and member of the Nomination and Remuneration Committee)	陳春國先生	(行政總裁、提名委員會及 薪酬委員會成員)
Non-executive Directors		非執行董事	
Professor Cui Zhanfeng	(Chairman of the Board and member of the Audit Committee)	崔占峰教授	(董事會主席及審核委員會 成員)
Dr. Ray Yip	(member of the Nomination, Remuneration and Audit Committee)	葉雷博士	(提名委員會、薪酬委員會 及審核委員會成員)
Professor Xiong Chengyu	(member of the Audit Committee)	熊澄宇教授	(審核委員會成員)
Mr. Wang Hui	(member of the Nomination, Remuneration and Audit Committee)	王輝先生	(提名委員會、薪酬委員會 及審核委員會成員)
Independent non-executive	Directors	獨立非執行董事	
Mr. Lui Tin Nang	(chairman of the Audit and Nomination Committee and member of the Remuneration Committee)	呂天能先生	(審核委員會及提名委員會 主席及薪酬委員會成員)
Mr. Pang Chung Fai Benny	(chairman of Remuneration Committee and member of the Nomination and Audit Committee)	彭中輝先生	(薪酬委員會主席及提名委 員會及審核委員會成員)
Mr. Chan Bing Woon	(member of the Nomination, Remuneration and Audit Committee)	陳炳煥先生	(提名委員會、薪酬委員會 及審核委員會成員)
Mr. Wong Yiu Kit Ernest	(member of the Nomination, Remuneration and Audit Committee)	黃耀傑先生	(提名委員會、薪酬委員會 及審核委員會成員)

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Board Composition and Board Practices (Cont'd)

Biographical details of each director are set out in the section "Biographical Details of Directors and Chief Executives" on pages 63 to 72 of this annual report.

There is no financial, business, family or other material/relevant relationship amongst the Directors.

The Board focuses on overall strategies and policies with particular attention paid to the growth and financial performance of the Group. The principle functions of the Board are to:

- establish the strategic direction and development of the Group;
- determine the broad policies, strategies and objectives of the Group;
- approve annual budgets, major funding proposals, investment and divestment proposals;
- oversee the processes for evaluating the adequacy and integrity of internal controls, risk management, financial reporting and compliance;
- approve the nominations of Directors by Nomination Committee and appointment of external auditors;
- ensure accurate, adequate and timely reporting to, and communication with Shareholders;
- monitor and manage potential conflicts of interest of management, Board members and Shareholders, including misuse of corporate assets and abuse in related party transactions; and assume responsibility for corporate governance.

董事會(續)

董事會之組成及董事會常規(續)

各董事的簡介詳情載於本年報第63至第72頁「董事及最高行政人員簡介」一節。

董事之間並無財務、業務、家族或其他重大/有 關關係。

董事會專注於整體策略及政策,特別重視本集團之增長及財務表現。董事會之主要職責為:

- 訂立本集團之策略指引及發展;
- 審批年度預算、主要融資建議、投資及撤資 建議;
- 監管衡量內部監控、風險管理、財務呈報及 遵守法規方面是否充足及完善之程序;
- 批准提名委員會之董事提名以及委任外聘核 數師;
- 確保向股東作出準確、充足和及時之呈報及 溝通;
- 監管及管理管理層、董事會成員及股東之間 之潛在利益衝突,包括不當使用公司資產及 在關連人士交易中濫用職權;及承擔企業管 治之責任。

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Board Composition and Board Practices (Cont'd)

The Board delegates day-to-day management, administration and operations of the Group to the executive Directors and senior management, while reserving certain key matters for its approval. The management is responsible for the implementation of the Company's strategies and policies, while the progress and development are periodically reviewed by Directors. During this financial year, the management provided all members of the Board with monthly management updates ("Monthly Management Updates") in accordance with the code provision C.1.2 of the CG Code. The Monthly Management Updates contained latest financials with summaries of key events of the Group, giving a balanced and understandable assessment of the Company's performance, position and prospects.

The Company recognises and embraces the benefits of diversity in the boardroom and has adopted the board diversity policy ("Board Diversity Policy"). The Board Diversity Policy sets out the approach to achieve diversity on the Board.

The Board has set measurable objectives to implement the Board Diversity Policy. The Nomination Committee has primary responsibility for identifying and giving recommendation suitably qualified candidates to become members of the Board. Selection of candidates will be based on a range of diversity perspectives, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service. The ultimate Board decision will be based on merit and contribution that the selected candidates will bring to the Board.

The Board has also regularly reviewed the contribution of each Director as to whether the Director is spending sufficient time to perform his/her responsibilities to the Board.

The Board considers that the current composition of the Board, with core competencies in areas such as accounting and finance, business and management, medical science, legal profession, marketing management, media development and M&A, is appropriate for the businesses of the Company. The Board will review its composition from time to time taking into consideration of the specific needs for the overall Company and its subsidiaries' businesses.

董事會(續)

董事會之組成及董事會常規(續)

董事會將本集團之日常管理、行政及運作授權執 行董事及高級管理人員處理,但若干主要事宜仍 須獲董事會審批。管理層負責實施本公司之策 及政策,進展及發展由董事定期檢討。於本財政 年度,根據企業管治守則之守則條文第C.1.2條, 管理層已向董事會全體成員提供月度更新資料 (「月度更新資料」)。月度更新資料包含最新的財 務數據與本集團主要事件的摘要,其就本公司之 表現、狀況及前景作出一個平衡及易於理解的 估。

本公司認定並確信董事會成員多元化的好處及已 採納董事會成員多元化政策(「董事會成員多元化 政策」)。董事會成員多元化政策列載董事會為達 致成員多元化而採取的方針。

董事會已訂立可衡量的目標以實行董事會成員多元化政策。提名委員會主要負責物色及推薦合適的合資格董事會成員候選人。甄選候選人將按一系列多元化範疇為基準,包括但不限性別、年齡、文化及教育背景、種族、專業經驗、技能、知識及服務任期。最終將按候選人的長處及可為董事會提供的貢獻而作決定。

董事會亦就董事是否付出足夠時間履行其對董事 會之職責定期檢討各董事之貢獻。

董事會認為目前董事會之組成,在會計及財務、 商業及管理、醫療科學、法律專業、營銷管理、 媒體發展及併購等領域各具專長,符合本公司業 務需要。董事會將考慮本公司及其附屬公司整體 業務之特定需求,不時檢討其組成。

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Board Composition and Board Practices (Cont'd)

During this financial year, there were five independent non-executive Directors so that there is a strong element of independence in the Board to exercise independent judgment and of sufficient caliber and number for their views to carry weight. Amongst them, at least two of the independent non-executive Directors have professional qualifications, or accounting or related financial management expertise.

The independent non-executive Directors have the same duties of care and skill and fiduciary duties as the executive Directors. Their functions include, but not limited to:

- participating in Board meetings to bring in independent judgment to bear on issues of corporate strategy, corporate performance, accountability, resources, key appointments and standard of conducts;
- taking the lead when potential conflicts of interests arise;
- serving on Audit Committee, Remuneration Committee and Nomination Committee, if invited; and
- scrutinising the Group's performance in achieving agreed corporate goals and objectives, and monitoring the reporting of performance.

The Company has received an annual written confirmation from each of the independent non-executive Directors of their independence to the Company. The Company considers that all of the independent non-executive Directors are independent.

董事會(續)

董事會之組成及董事會常規(續)

於本財政年度,董事會擁有五名獨立非執行董事,此舉足以確保董事會內有足夠獨立人士,行使獨立判斷,以及在資歷及人數上均足以作出具影響力之建議。其中,最少兩名獨立非執行董事具備專業資格或會計或相關財務管理專業知識。

獨立非執行董事與執行董事同具有審慎行事之責任及技能以及誠信責任。彼等之職能包括但不限於:

- 參與董事會會議,於企業策略、企業表現、 問責性、資源、重要任命及操守準則等事宜 上作出獨立判斷;
- 於出現潛在利益衝突時擔當領導角色;
- 於獲邀請時加入審核委員會、薪酬委員會及 提名委員會;及
- 觀察本集團於達致協定之企業目標及目的方面之表現,並監察表現之呈報。

本公司已接獲各獨立非執行董事之年度書面確認,確認其對本公司之獨立性。本公司認為全體獨立非執行董事均為獨立人士。

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Board Composition and Board Practices (Cont'd)

The Board schedules four meetings a year at approximately quarterly intervals and organises additional meetings as and when required. The Directors can attend meetings in persons or through other means of electronic communication in accordance with the Company's articles of association. Notice of at least fourteen days is given of a regular Board meeting to give all Directors an opportunity to attend. For other Board and committee meetings, reasonable notice time is generally given. During this financial year, the Board held nine meetings, of which four were regular meetings. The following table shows the attendance of individual Directors at the meetings held during the year:

董事會(續)

董事會之組成及董事會常規(續)

董事會每年安排四次會議,大約每季舉行一次或語,大約每季舉行一次或語,內有需要時組織額外會議。董事可親祖軍子組織章程細則所容許之其他電子通訊最立出席會議。本公司將在定期董事會會議前最出通知,讓其有機會自發出通知。於本財政會會議一般都於行五事會議出通知。於本財政年度,董事會共舉行九董事年內出席會議之情況:

Name of Directors 董事姓名 (From 1 May 2016 to 30 April 2017) (二零一六年.	五月一日至一零一十年四月二十日期間)	Attendance/ Number of General Meeting entitled to attend 出席/有權出席 股東大會數目	Attendance/ Number of Board Meetings entitled to attend 出席/有權出席 董事會會議數目
<u> </u>		2010 12211	
Cao Funshun	曹福順	N/A 不適用	1/1
(resigned with effect from 18 July 2016)	(於二零一六年七月十八日起辭任)		
Chan Bing Woon	陳炳煥	1/1	9/9
Chen Chunguo	陳春國	N/A 不適用	3/3
(appointed with effect from 25 January 2017)	(於二零一七年一月二十五日起獲委任)		
Cui Zhanfeng	崔占峰	N/A 不適用	7/7
(appointed with effect from 7 October 2016)	(於二零一六年十月七日起獲委任)		
Deng Shaoping	鄧紹平	0/1	1/1
(retired with effect from 9 September 2016)	(於二零一六年九月九日起退任)		0.40
Lui Tin Nang	呂天能	1/1	9/9
Pang Chung Fai Benny	彭中輝	1/1	9/9
Ray Yip	葉雷 (於二零一七年二月二十三日起獲委任)	N/A 不適用	2/2
(appointed with effect from 23 February 2017) Shao Zhengkang	(だ一令──七十二月二十二日起復安仕) 邵政康	1/1	9/9
Wang Hui	王輝	0/1	7/9
Wang Jianjun	工 <i>件</i> 干建軍	0/1	1/1
(retired with effect from 9 September 2016)	(於二零一六年九月九日起退任)	0/1	17.1
Wong Sai Hung	黄世雄	1/1	8/9
Wong Yiu Kit Ernest	黃耀傑	N/A 不適用	2/2
(appointed with effect from 23 February 2017)	(於二零一七年二月二十三日起獲委任)		_, _
Xiong Chengyu	熊澄宇	N/A 不適用	N/A 不適用
(appointed with effect from 20 March 2017)	(於二零一七年三月二十日起獲委任)		
Yang Zhengguo	楊正國	N/A 不適用	1/1
(resigned with effect from 5 August 2016)	(於二零一六年八月五日起辭任)		



企業管治報告



BOARD OF DIRECTORS (Cont'd)

Board Composition and Board Practices (Cont'd)

Board papers are circulated at least three days (or other agreed period) before the regular Board meetings and/or other Board/ Committees meetings to enable the Directors to make informed decisions on matters to be raised at the Board meetings. In addition, the Company has maintained a procedure for the Directors to seek independent professional advice, in appropriate circumstances, at the Company's expense in discharging their duties to the Company.

The company secretary of the Company (the "Company Secretary") prepares minutes and/or written resolutions and keeps records of matters discussed and decisions resolved at all Board meetings. The Company Secretary also keeps the minutes, which are open for inspection at any reasonable time on reasonable notice by any Director.

Continuing Professional Development

The Company Secretary is responsible for updating the Board on governance and regulatory matters.

Training will be provided to newly appointed director to his/her individual needs. This includes introduction to the Group business activities, their responsibilities and duties, and other regulatory requirements.

The Company will arrange and/or introduce training courses and/or reading materials for Directors to develop and explore their knowledge and skills.

According to the code provision A.6.5 of the CG Code, all Directors should participate in continuous professional development to develop and refresh their knowledge and skills, ensuring that their contribution to the Board remains informed and relevant. During this financial year, all Directors participated in continuous professional development and had provided the Company with records (if any) on their participation. The individual training record of each Director for this financial year is set out below:

董事會(續)

董事會之組成及董事會常規(續)

董事會文件於定期董事會會議,及/或其他董事會/委員會會議舉行前最少三日(或其他協定時間)向董事傳閱,以使董事能就將於董事會會議提出之事宜,作出知情決定。此外,本公司已訂立一套程序,讓董事在合適情況下,於履行其對本公司之職責時,尋求獨立專業意見,開支由本公司支付。

本公司的公司秘書(「公司秘書」)為所有董事會會議上討論之事宜以及議決之決定,編製會議記錄及/或書面決議案並保存有關記錄。公司秘書亦保存會議記錄,並可於任何董事作出合理通知後,在任何合理時間供索閱。

持續專業發展

公司秘書負責向董事會提供有關管治及規管事宜 之最新消息。

本公司將按新委任董事之個人需要給予他/她培訓,當中包括講解本集團業務、彼等之責任及職 責以及其他監管規定。

本公司將為董事安排及/或介紹培訓課程及/或 閱讀資料以發展及提升彼等知識及技能。

根據企業管治守則之守則條文第A.6.5條,所有董事均需參與持續專業發展,以培養及更新彼等之知識及技能,確保彼等對董事會之貢獻及具備相關資訊及切合所需。於本財政年度,所有董事均參與持續專業發展,並已向本公司提供記錄(如有)。各董事於本財政年度的個人培訓記錄載於下文:

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Continuing Professional Development (Cont'd)

Directors and Types of continuous professional development programmes

Cao Funshun (resigned with effect from 18 July 2016) Chan Bing Woon Chen Chunguo (appointed with effect from 25 January 2017) Cui Zhanfeng (appointed with effect from 7 October 2016) Deng Shaoping (retired with effect from 9 September 2016) Lui Tin Nang Pang Chung Fai Benny Ray Yip (appointed with effect from 23 February 2017) Shao Zhengkang Wang Hui Wang Jianiun (retired with effect from 9 September 2016)	N/A A, B, C A, B, C N/A A, B, C A, B, C A, B, C A, B, C A, C C N/A
Wang Hui Wang Jianjun (retired with effect from 9 September 2016) Wong Sai Hung Wong Yiu Kit Ernest (appointed with effect from 23 February 2017) Xiong Chengyu (appointed with effect from 20 March 2017) Yang Zhengguo (resigned with effect from 5 August 2016)	

- A: attending seminars/meetings/forums/conferences/courses/workshops organized by professional bodies or regulatories
- B: reading journals/newsletters/seminar materials/publications/magazines
- C: reading memoranda issued or materials provided by the Company

All information and materials aforesaid relate, but not limited to the latest development of the GEM Listing Rules, other applicable legal and regulatory matters as well as directors' duties and responsibilities.

Directors' and Officers' Liabilities

The Company has arranged for appropriate insurance covering the liabilities of the Directors that may arise out of the corporate activities, which is in compliance with the CG Code. The insurance coverage is reviewed on an annual basis.

Appointment, Election and Re-election

Appointment of new Directors is a matter for consideration by the Nomination Committee. It reviews the profiles of the candidates and makes recommendations to the Board on the appointment, nomination and retirement of the Directors.

董事會(續)

持續專業發展(續)

董事及持續專業發展課程類別

曹福順(於二零一六年七月十八日起辭任)	不適用
陳炳煥	甲、乙、丙
陳春國(於二零一七年一月二十五日起獲委任)	甲、乙、丙
崔占峰(於二零一六年十月七日起獲委任)	乙、丙
鄧紹平(於二零一六年九月九日起退任)	不適用
呂天能	甲、乙、丙
彭中輝	甲、乙、丙
葉雷(於二零一七年二月二十三日起獲委任)	甲、乙、丙
邵政康	甲、丙
王輝	丙
王建軍(於二零一六年九月九日起退任)	不適用
黃世雄	甲、乙、丙
黃耀傑(於二零一七年二月二十三日起獲委任)	甲、乙、丙
熊澄宇(於二零一七年三月二十日起獲委任)	甲、乙、丙
楊正國(於二零一六年八月五日起辭任)	不適用

甲: 參加由專業或監管機構舉辦的研討會/會議/論壇/討論會/課程/研究會

乙: 閱讀期刊/通訊/研討會材料/出版物/雜誌

丙: 閱讀本公司刊發的備忘錄或提供的資料

前述所有信息及資料均有關,但不限於創業板上 市規則、其他適用法律及監管事宜的最新發展, 以及董事的職責和責任等。

董事及高級職員之責任

本公司已安排適當保險,為董事在公司事務中可 能產生之責任提供保障,此做法符合企業管治守 則。投保範圍每年皆進行檢討。

委任、選舉及重選

委任新董事一事,須由提名委員會考慮。提名委員會將審閱候選人之簡歷,並就委任、提名董事及董事退任等事宜向董事會作出建議。



企業管治報告



BOARD OF DIRECTORS (Cont'd)

Appointment, Election and Re-election (Cont'd)

According to the Company's articles of association, one-third of the Directors are required to retire from office at each annual general meeting, provided that every Director shall be subject to retirement by rotation at least once in every three years. The Directors who will retire at the annual general meeting of the Company shall be those appointed by the Board during the year and those who have been the longest in office since their last election or re-election.

Directors' Responsibility for the Financial Statements

The following sets out the responsibilities for the Directors in relation to the quarterly, interim and annual financial statements:

Annual Report and Financial Statements

The Directors acknowledge their responsibility to prepare financial statements for each financial year which gives a true and fair view of the state of affairs of the Group and in presenting the quarterly, interim and annual financial statements, and announcements to Shareholders, the Directors aim to present a balanced and understandable assessment of the Group's position and prospects.

Accounting Policy

The Directors consider that in preparing the financial statements, the Group uses appropriate accounting policies that are consistently applied, and that all applicable accounting standards are followed.

Accounting Records

The Directors are responsible for ensuring that the Group keeps accounting records which disclose with reasonable accuracy the financial position of the Group and which enable the preparation of financial statements in accordance with the Hong Kong Financial Reporting Standards as promulgated by the Hong Kong Institute of Certified Public Accountants.

Safeguarding Assets

The Directors are responsible for taking all reasonable and necessary steps to safeguard the assets of the Group and to prevent or detect fraud and other irregularities.

董事會(續)

委任、選舉及重選(續)

根據本公司之組織章程細則,三分之一董事須於 各股東週年大會退任,而各董事亦須最少每三年 輪席退任一次。於本公司股東週年大會退任之董 事須為董事會年內委任之董事及自最近獲選或重 選以來任職最長之董事。

董事對財務報表之責任

以下載列董事有關季度、中期及年度財務報表之 責任:

年報及財務報表

董事確認其有責任在每個財政年度,編製能真實及公平反映本集團財政狀況之財務報表,而向股東提呈季度、中期及年度財務報表以及公告時,董事希望能向股東呈列其對於本集團狀況及前景的平衡且易於理解的評估。

會計政策

董事認為於編製財務報表時,本集團貫徹應用合適之會計政策,且亦已遵循所有適用之會計準則。

會計記錄

董事須負責確保本集團存置會計記錄,有關記錄 應合理準確地披露本集團之財務狀況,並且可用 於根據香港會計師公會頒佈之香港財務報告準則 而編製之財務報表。

保障資產

董事負責採取所有合理及所需措施,保障本集團之資產,並且預防或發現欺詐及其他違規行為。

企業管治報告



BOARD OF DIRECTORS (Cont'd)

Directors' Responsibility for the Financial Statements (Cont'd)

Going Concern

The Directors, having made appropriate enquiries, consider that the Group has adequate resources to continue in operational existence for the foreseeable future and that, for this reason, it is appropriate to adopt the going concern basis in preparing the financial statements.

CHAIRMAN AND CFO

Under code provision A.2.1 of the CG Code, the role of the Chairman and the CEO should be separated and should not be performed by the same individual. The division of responsibilities between the Chairman and CEO should be clearly established and set out in writing.

During the year, the roles of the Chairman and the CEO were segregated and performed by different individuals.

On 7 October 2016, Mr. Wong Sai Hung was re-designated from the Chairman to Vice-chairman and Professor Cui Zhanfeng was appointed to serve as the Chairman.

On 23 February 2017, Dr. Shao Zhengkang has ceased to serve as the CEO and Mr. Chen Chunguo was appointed to serve as the CEO.

The segregation of duties ensures a clear distinction of responsibilities between the Chairman and the CEO which allows a balance of power between the Board and the management of the Group, and ensures their independence and accountability. There is no financial, business, family or other material/relevant relationship between the Chairman and the CEO.

Either Mr. Wong Sai Hung or Professor Cui Zhanfeng, as the Chairman during this financial year, has taken overall responsibility for providing leadership for the Board. They ensure that:

- the Board functions effectively, and that all key and appropriate issues are properly briefed and discussed by the Board in a timely manner;
- the responsibilities for drawing up the agenda for each Board meeting and, where appropriate, taking into account any matters proposed by each Director for inclusion in the agenda;
- good corporate governance practices and procedures are established and encourages all Directors to make full and active participation to the affairs of the Group; and
- the Board acts in the best interests of the Group.

董事會(續)

董事對財務報表之責任(續)

持續經營

董事經作出適當查詢後,認為本集團有充足資源,在可預見將來持續經營,且基於此理由,採納持續經營基準編製財務報表乃屬適當。

主席及行政總裁

根據企業管治守則守則條文第A.2.1條,主席與 行政總裁的角色應有區分,並不應由一人同時兼 任。主席與行政總裁之職責分工應清楚界定並以 書面列載。

年內,主席及行政總裁職能已作劃分及分別由不 同人士出任。

於二零一六年十月七日,黃世雄先生由主席調任 為副主席,崔占峰教授獲委任為主席。

於二零一七年二月二十三日, 邵政康博士不再擔任行政總裁, 陳春國先生獲委任為行政總裁。

職能劃分可確保主席及行政總裁能各司其職,制 衡董事會與本集團管理層之間之權力,並且確保 其獨立性及問責性。主席與行政總裁之間並無財 務、業務、家族或其他重大/有關關係。

於本財政年度內,黃世雄先生或崔占峰教授,作為主席整體負責領導董事會。彼等確保:

- 董事會有效運作,而且董事會已及時獲妥為 告知並討論所有主要及適當事務;
- 編製各董事會會議之議程之責任,並且在適 當情況下,將各董事建議之任何事宜,納入 議程內;
- 已制定良好企業管治常規及程序,並鼓勵所有董事全面及積極參與本集團事務;及
- 董事會以本集團之最佳利益行事。



企業管治報告



CHAIRMAN AND CEO (Cont'd)

Either Dr. Shao Zhengkang or Mr. Chen Chunguo as the CEO during this financial year, was responsible for the day-to-day management of the business of the Group, attends to formulation and successful implementation of policies, and assumes full accountability to the Board for all operations of the Group.

Mr. Chen possesses extensive experience in investment, M&A and corporate management. He has given valuable experience and contribution to the Group. Working with the management team of each core business division, he ensures the smooth operations and development of the Group. He maintains a continuing dialogue with the Chairman and all Directors to keep them fully informed of all major business development and issues.

NON-EXECUTIVE DIRECTORS

Under code provision A.4.1 of the CG Code, non-executive directors should be appointed for a specific term and are subject to re-election. All non-executive Directors (including Independent non-executive Directors) of the Company are appointed for a term of two years and they are required to retire by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company.

COMPANY SECRETARY AND COMPLIANCE OFFICER

The Company Secretary is responsible to the Board for ensuring that Board procedures are followed and that the Board is fully briefed on all legislative, regulatory and corporate governance development and accounts for such when making decisions. The compliance officer is directly responsible for advising on and assisting the Board in implementing procedures to ensure the Company complies with the GEM Listing Rules and other relevant Laws and regulations applicable to the Company.

According to Rule 5.15 of the GEM Listing Rules, in each financial year an issuer's company secretary must take no less than 15 hours of relevant professional training. During this financial year, the Company Secretary has complied with the rule by taking more than 15 hours of relevant training courses and seminars.

主席及行政總裁(續)

於本財政年度內,邵政康博士或陳春國先生作為 行政總裁負責本集團日常業務管理,專注於制定 及成功落實政策,並就本集團一切業務對董事會 負責。

陳先生於投資、併購及企業管理方面擁有豐富經驗。彼為本集團帶來寶貴的經驗和貢獻。彼與各核心業務分部之管理隊伍合作,確保本集團營運及發展暢順。彼持續與主席及所有董事溝通,讓彼等能全面掌握所有主要業務發展及事宜。

非執行董事

根據守則條文第A.4.1條,非執行董事之委任應有 指定任期,並須接受重選。本公司之全體非執行 董事(包括獨立非執行董事)按兩年之年期獲委任 且須根據本公司組織章程細則於本公司股東週年 大會上輪席退任及膺撰連任。

公司秘書及監察主任

公司秘書須向董事會負責,確保已妥善依從董事會程序,而且董事會已全面獲悉所有法律、監管規定及企業管治之發展,同時確保董事會在作出決定時已考慮有關事宜。監察主任直接負責執行確保公司符合創業板上市規則及適合於公司的其他有關法行及現例的程序而向董事會提供意見及協助。

根據創業板上市規則第5.15條,於每個財政年度 發行人的公司秘書須參加不少於15小時的相關專 業培訓。在本財政年度,公司秘書已遵守規則, 參與超過15個小時的相關培訓課程和研討會。

企業管治報告



NOMINATION COMMITTEE

According to code provision A.5.1 of the CG Code, the Company has to set up a nomination committee with a majority of the members thereof being independent non-executive directors. The Nomination Committee has been established since 22 July 2005 with written terms of reference which was revised on 16 March 2016 in compliance with code provision A.5.2 of the CG code.

During this financial year, following the nomination of Mr. Wong Sai Hung, Dr. Shao Zhengkang, Mr. Chen Chunguo, Dr. Ray Yip and Mr. Wong Yiu Kit Ernest on 23 February 2017 as the members of the Nomination Committee on, the total members of the Nomination Committee are nine and majority are independent non-executive Directors.

Mr. Lui Tin Nang has served as chairman of the Nomination Committee. The Nomination Committee is scheduled to meet at least once a year. The guorum shall be any two members.

The terms of reference of the Nomination Committee has been posted on the websites of the Stock Exchange and the Company. The principal functions of the Nomination Committee include:

- to make recommendations to the Board on all new appointments or re-appointments of Directors, the establishment of a succession plan for Directors, in particular the Chairman and the CEO and the composition of the Board;
- to identify and nominate qualified individuals, subject to the approval of the Board, to be additional Directors or to fill vacancy in the Board as and when they arise;
- to assess the effectiveness of the Board as a whole and the contribution by each Director to the Board;
- to review the Board structure, size, composition (including the skills, knowledge and experience) and diversity as well as the independent element of the Board on an annual basis and make recommendations on any proposed changes to the Board to complement the Company's corporate strategy;
- to develop the criteria for selection of Directors; and
- to assess the independence of independent non-executive Directors.

The chairman of the Nomination Committee will report to the Board on its proceedings and recommendations after each meeting.

提名委員會

根據企業管治守則之守則條文第A.5.1條,本公司 已設立提名委員會,而其大多數成員為獨立非執 行董事。提名委員會自二零零五年七月二十二日 成立,其職權範圍根據企業管治守則之守則條文 第A.5.2條已於二零一六年三月十六日作出修訂。

於本財政年度內,繼黃世雄先生、邵政康博士、 陳春國先生、葉雷博士及黃耀傑先生於二零一七 年二月二十三日獲提名為提名委員會成員後,提 名委員會成員總數為九名,且大多數成員為獨立 非執行董事。

呂天能先生一直擔任提名委員會主席。提名委員 會預定每年最少舉行一次會議。法定人數為任兩 名成員。

提名委員會之職權範圍刊載於聯交所及本公司網站。提名委員會之主要職責包括:

- 就所有新委任或再委任董事、制定董事更替計劃(尤其主席及行政總裁)以及董事會之組成而向董事會作出推薦建議;
- 物色及提名合資格人士,在獲董事會批准下,出任新增董事或在有需要時填補董事會空缺;
- 評估董事會整體之效能,以及各董事對董事 會之貢獻;
- 每年檢討董事會架構、規模、組成(包括技能、知識及經驗)及多元化,以及董事會之獨立性,並就任何擬作出之變動向董事會提出推薦建議以配合本公司企業策略;
- 制定甄選董事之準則;及
- 評估獨立非執行董事之獨立性。

提名委員會之主席將於每次會議後,向董事會報告委員會之進程及推薦建議。



个業管治報告



NOMINATION COMMITTEE (Cont'd)

During this financial year, six meetings of the Nomination Committee were held to review and recommend the structure, size, composition and diversity of the Board. Altogether the members of the Board bring a wide range of knowledge and experience to the Board, which contributes to the effective direction of the Company. The following table shows the attendance of the members of Nomination Committee at the meetings of the Nomination Committee held during the year:

提名委員會(續)

於本財政年度,提名委員會曾舉行六次會議,藉 以檢討董事會架構、規模、組成及多元化並提供 建議。另外各董事會成員為董事會帶來廣泛的知 識和經驗, 這有助於本公司的有效領導。下表載 列提名委員會之成員年內出席提名委員會會議之 情況:

> Attendance/ Number of **Meetings** entitled to attend 出席/有權出席

Name of Nomination Committee Members 提名委員會成員姓名

(From 1 May 2016 to 30 April 2017) (二零一六年五月一日至二零一十年四月三十日期間)

會議數目

Chan Bing Woon Chen Chunguo Lui Tin Nang	(appointed with effect from 23 February 2017) (chairman of the Committee)	呂天能	(於二零一七年二月二十三日起獲委任) (本委員會主席)	6/6 2/2 6/6
Pang Chung Fai Benny Ray Yip Shao Zhengkang	(appointed with effect from 23 February 2017) (appointed with effect from 23 February 2017)		(於二零一七年二月二十三日起獲委任) (於二零一七年二月二十三日起獲委任)	6/6 2/2 2/2
Wang Hui Wong Sai Hung Wong Yiu Kit Ernest	(appointed with effect from 23 February 2017) (appointed with effect from 23 February 2017)		(於二零一七年二月二十三日起獲委任) (於二零一七年二月二十三日起獲委任)	5/6 2/2 2/2

REMUNERATION COMMITTEE

According to Rule 5.34 of the GEM Listing Rules, the Company has to set up a remuneration committee with a majority of the members thereof being independent non-executive directors. The Remuneration Committee has been established since 22 July 2005 with written terms of reference which was revised on 16 March 2016 in compliance with code provision B.1.2 of the CG code.

During this financial year, following the nomination of Mr. Wong Sai Hung, Dr. Shao Zhengkang, Mr. Chen Chunguo, Dr. Ray Yip and Mr. Wong Yiu Kit Ernest on 23 February 2017 as the members of the Remuneration Committee, the total members of the Remuneration Committee are nine.

Mr. Pang Chung Fai, Benny has served as chairman of the Remuneration Committee. The Remuneration Committee is scheduled to meet at least once a year. The guorum shall be any two members.

薪酬委員會

根據創業板上市規則第5.34條,本公司須設立薪 酬委員會,而其大多數成員為獨立非執行董事。 薪酬委員會自二零零五年七月二十二日成立,其 職權範圍根據企業管治守則守則條文第B.1.2條已 於二零一六年三月十六日作出修訂。

於本財政年度內,繼黃世雄先生、邵政康博士、 陳春國先生、葉雷博士及黃耀傑先生於二零一七 年二月二十三日獲提名為薪酬委員會成員後,薪 酬委員會的成員總數為九名。

彭中輝先生一直擔任薪酬委員會主席。薪酬委員 會預定每年最少舉行一次會議。法定人數為任兩 名成員。

企業管治報告



REMUNERATION COMMITTEE (Cont'd)

The terms of reference of the Remuneration Committee has been posted on the websites of the Stock Exchange and the Company. The principal functions of the Remuneration Committee include:

- to review and approve the management's remuneration proposals with reference to the board's corporate goals and objectives.
- to recommend a fair and transparent framework of executive remuneration for the Board and senior management of the Company, including share option scheme, based on the skill, knowledge, involvement in the Company's affairs and by reference to the Company's performance and profitability, as well as remuneration benchmark in the industry and the prevailing market conditions;
- to make recommendations to the Board on the remuneration packages of individual executive Directors and senior management, including benefits-in-kind, pension rights, and compensation payments, including any compensation payable for loss or termination of their office or appointment;
- to make recommendations to the Board on the remuneration of the non-executive Directors.

No Directors can determine their own remuneration package. The chairman of the Remuneration Committee will report to the Board on its proceedings and recommendations after each meeting. In developing remuneration policies and making recommendation as to the remuneration of the Directors and senior management, the Remuneration Committee takes into account of the corporate goals and objectives of the Group as well as the performance of those individual Directors and senior management.

The remuneration package of Directors and senior management includes the following:

(a) Basic salary

The basic salary (inclusive of statutory employer contributions to Provident Fund) of each executive Director/senior management is recommended by the Remuneration Committee, taking into account the performance of the individual, the inflation price index and information from independent sources on the rates of salary for similar jobs in a selected group of comparable organisations.

薪酬委員會(續)

薪酬委員會之職權範圍已刊載於聯交所及本公司 網站。薪酬委員會之主要職責包括:

- 參考董事會之企業方針及目標,檢討及批准 管理層薪酬建議。
- 根據行政人員之技能、知識、對本公司事務 之參與程度並參考本公司之表現及盈利能 力,以及業界之薪酬基準及當時市況,為董 事會及本公司高級管理人員推薦一套公平及 具透明度之行政人員薪酬制度(包括購股權 計劃);
- 就個別執行董事及高級管理層之薪酬待遇 (包括實物利益、退休金權利及賠償金,包 括喪失或終止彼等職務或委任之任何應付賠 償)向董事會提供建議;
- 就非執行董事之薪酬向董事會提供建議。

董事概不得釐定彼等本身之酬金組合。薪酬委員會之主席於每次舉行會議後,將向董事會報告有關之進程及推薦意見。在制定薪酬政策及就董事與高級管理層之薪酬提供推薦建議方面,薪酬委員會會考慮本集團之企業方針及目標,以及該等個別董事與高級管理層之表現。

董事及高級管理人員之酬金組合包括下列各項:

(a) 基本薪金

各執行董事/高級管理人員之基本薪金(包括向公積金作出之法定僱主供款),由薪酬委員會經考慮個人表現、通脹物價指數及經選定可資比較機構組別類似職位之薪金(來自獨立資料來源)之資料而作出推薦建議。

企業管治報告



REMUNERATION COMMITTEE (Cont'd)

(b) Fees

Fees paid/payable to the executive Directors are determined by the Board after considering the individual's relative performance against the comparable organisations. The fees paid/payable to the non-executive Directors take into account factors such as effort and time spent, and responsibilities of these Directors.

(c) Bonus scheme

The Group operates a bonus scheme for all employees, including the executive Directors and senior management. The criteria for the scheme is the level of profit achieved from certain aspects of the Group's business activities against targets, together with an assessment of corporate and individual's performance during the year. Bonuses payable to the executive Directors/senior management are reviewed by the Remuneration Committee and approved by the Board to ensure alignment of their interests with those of Shareholders.

(d) Benefits in kind

Other customary benefits (such as private medical cover) are made available as appropriate.

(e) Share options scheme

The Group operates a share option scheme for participants, including Directors, senior management, employees, suppliers and customers. The terms of the scheme are set out in note 33 to the financial statements. The movement of share options under the share option scheme adopted by the Company on 14 September 2011 during the year ended 30 April 2017 is set out on pages 122 to 131 of this annual report.

Directors' emoluments comprise payments to the Directors by the Company in connection with the management of the affairs of the Company. The amounts paid to each Director for the year ended 30 April 2017 are set out in note 9 to the financial statements.

薪酬委員會(續)

(b) 袍金

已付/應付執行董事之袍金,由董事會經考 慮個人表現,並比對可資比較機構之袍金後 釐定。已付/應付非執行董事之袍金,經考 慮該等董事之工作量及所花費時間及職責而 釐定。

(c) 花紅計劃

本集團就所有員工(包括執行董事及高級管理人員)設立花紅計劃。該計劃之準則是本集團若干範疇業務所達致之盈利水平與目標之比較,以及企業及個人年內之表現評估。 薪酬委員會將檢討應付執行董事/高級管理人員之花紅,並由董事會批准,以確保符合股東整體利益。

(d) 實物利益

其他一般福利(例如私人醫療保障)將於適當時候提供。

(e) 購股權計劃

本集團為參與者,包括董事、高級管理人員、僱員、供應商及客戶設立購股權計劃。計劃之條款載於財務報表附註33。本公司於二零一一年九月十四日所採納之購股權計劃於截至二零一七年四月三十日止年度之購股權變動載於本年報第122頁至第131頁。

董事酬金包括本公司向董事支付有關管理本公司 事務之酬金。截至二零一七年四月三十日止年度 向各董事支付之金額載於財務報表附註9。

企業管治報告



REMUNERATION COMMITTEE (Cont'd)

During this financial year, seven meetings of the Remuneration Committee were held to review the remuneration package of the Board and the senior management. The following table shows the attendance of the members of Remuneration Committee at the meetings of the Remuneration Committee held during the year:

薪酬委員會(續)

於本財政年度,薪酬委員會曾舉行七次會議,藉 以檢討董事會及高級管理層之薪酬組合。下表載 列薪酬委員會之成員年內出席薪酬委員會會議之 情況:

> Attendance/ **Number of** Meetings entitled to attend 出席/有權出席

Name of Remuneration Committee Members 薪酬委員會成員姓名

(From 1 May 2016 to 30 April 2017) (二零一六年五月一日至二零一七年四月三十日期間)

會議數目

Chan Bing Woon		陳炳煥	7/7
Chen Chunguo	(appointed with effect from 23 February 2017)	陳春國 (於二零一七年二月二十三日起獲委任)	2/2
Lui Tin Nang		呂天能	7/7
Pang Chung Fai Benny	(chairman of the Committee)	彭中輝 (本委員會主席)	7/7
Ray Yip	(appointed with effect from 23 February 2017)	葉雷 (於二零一七年二月二十三日起獲委任)	2/2
Shao Zhengkang	(appointed with effect from 23 February 2017)	邵政康(於二零一七年二月二十三日起獲委任)	2/2
Wang Hui		王輝	6/7
Wong Sai Hung	(appointed with effect from 23 February 2017)	黃世雄 (於二零一七年二月二十三日起獲委任)	2/2
Wong Yiu Kit Ernest	(appointed with effect from 23 February 2017)	黃耀傑 (於二零一七年二月二十三日起獲委任)	2/2

AUDIT COMMITTEE

According to Rule 5.28 of the GEM Listing Rules, the Company has to establish an audit committee comprising of at least three members who must be non-executive directors only, and the majority thereof must be independent non-executive directors, at least one of whom must have appropriate professional qualifications, or accounting or related financial management expertise. The Audit Committee has been established since 4 July 2001 with written terms of reference which was revised on 16 March 2016 in compliance with the code provision C.3.3 and C.3.7 of the CG Code.

During this financial year, following the nomination of Professor Cui Zhanfeng, Dr. Ray Yip and Mr. Wong Yiu Kit Ernest on 23 February 2017 and Professor Xiong Chengyu on 20 March 2017 as the members of the Audit Committee, the total members of the Audit Committee are eight and majority are independent non-executive Directors.

Mr. Lui Tin Nang has served as chairman of the Audit Committee. The quorum shall be any two members.

審核委員會

根據創業板上市規則第5.28條,本公司須設立審 核委員會,其中最少三名成員須為非執行董事, 而審核委員會大部份成員必須為獨立非執行董 事,其中最少一名必須具備適當專業資格或會計 或相關財務管理專業知識。審核委員會自二零零 一年七月四日成立,其職權範圍根據企業管治守 則守則條文第C.3.3條及第C.3.7條已於二零一六 年三月十六日作出修訂。

於本財政年度內,繼崔占峰教授、葉雷博士及黃 耀傑先生於二零一七年二月二十三日及熊澄宇教 授於二零一七年三月二十日獲提名為審核委員會 成員後,審核委員會的成員總數為八名,且大多 數成員為獨立非執行董事。

呂天能先生一直擔任審核委員會主席。法定人數 應為任何兩名成員。

企業管治報告



AUDIT COMMITTEE (Cont'd)

The terms of reference of the Audit Committee has been posted on the websites of the Stock Exchange and the Company. The principal functions of the Audit Committee include:

- to consider and recommend the appointment, re-appointment and removal of external auditors:
- to approve the remuneration and terms of engagement of external auditors, any questions of resignation or dismissal of external auditors;
- to review and monitor external auditors' independence and objectivity and the effectiveness of the audit process in accordance with applicable standards;
- to discuss with external auditors the nature and scope of the audit and reporting obligations before the audit commences;
- to develop and implement policy on engaging an external auditors to supply non-audit services and to make recommendations on any measures for improvements to be taken;
- to review the quarterly, interim and annual financial statements and the quarterly, interim and annual reports before submission to the Board, focusing particularly on:
 - (i) any changes in accounting policies and practices;
 - (ii) major judgmental areas;
 - (iii) significant adjustments resulting from audit;
 - (iv) the going concern assumptions and any qualifications;
 - (v) compliance with accounting principles and standards; and
 - (vi) compliance with the GEM Listing Rules and legal requirements in relation to financial reporting;

審核委員會(續)

審核委員會之職權範圍載於聯交所及本公司網站。審核委員會之主要職能包括:

- 考慮及推薦委任、續聘及罷免外聘核數師;
- 批准外聘核數師之酬金及聘用條款,以及有關外聘核數師之辭任或罷免問題;
- 檢討及監察外聘核數師之獨立性及客觀性, 以及根據適用標準進行審核程序之有效性;
- 在開始審核前,與外聘核數師討論審核之性 質及範疇,以及呈報之責任;
- 制定及落實聘用外聘核數師提供非審核服務 之政策,並就將採取之任何改善措施作出推 薦建議;
- 檢討季度、中期及年度財務報表,以及季度、中期及年度報告,再提交董事會,當中 尤其關注:
 - (i) 會計政策及常規之任何變動;
 - (ii) 主要涉及判斷之範疇;
 - (iii) 因審核而作出之重大調整;
 - (iv) 持續經營假設以及任何保留意見;
 - (v) 遵守會計原則及準則;及
 - (vi) 遵守與財務呈報有關之創業板上市規 則及法律規定;

企業管治報告



AUDIT COMMITTEE (Cont'd)

- to review the Group's financial controls, internal control and risk management systems and ensure that the management has performed its duty to have an effective internal control system;
- to consider major investigations findings on risk management and internal control matters as delegated by the Board or on its own initiative and management's response;
- to review the external auditors' management letter, any
 material queries raised by the auditors to management about
 accounting records, financial accounts or systems of control
 and management's response and to ensure that the Board will
 provide a timely response to the issues raised; and
- to review the Group's financial and accounting policies and practices.

The Audit Committee has explicit authority to investigate into any matter under the scope of its duties and the authority to obtain independent professional advice. It is given full access to and assistance from the management and reasonable resources to discharge its duties properly.

During the financial year, the Audit Committee has met once with the external auditor without the presence of the management.

The Group's results for the three months ended 31 July 2016, six months ended 31 October 2016, nine months ended 31 January 2017 and audited consolidated financial statements for the year ended 30 April 2017 have been reviewed by the Audit Committee.

審核委員會(續)

- 檢討本集團之財務監控、內部監控及風險管理制度,並確保管理層已履行其職責,維繫 有效之內部監控制度;
- 考慮因受董事會授權或自發對風險管理及內 部監控事宜進行調查所獲得的任何重大調查 發現及管理層的回應;
- 審閱外聘核數師致管理層函件、核數師就會計記錄、財務賬目或監控制度而對管理層提出的任何重大問題,以及管理層的回應,並且確保董事會及時回應所提出的問題;及
- 檢討本集團之財務及會計政策與慣例。

審核委員會具明確權力,調查其職責範圍內之任何事宜,並且有權獲取獨立專業意見。委員會可全面接觸管理層及獲得協助,並且獲取合理資源以妥為履行其職責。

於本財政年度,審核委員會在沒有任何管理層在場之情況下,已與外聘核數師會面一次。

審核委員會已審閱本集團截至二零一六年七月 三十一日止三個月、截至二零一六年十月三十一 日止六個月、截至二零一七年一月三十一日止九 個月之業績以及截至二零一七年四月三十日止年 度之經審核綜合財務報表。



CORPORATE GOVERNANCE REPORT 个業管治報告



AUDIT COMMITTEE (Cont'd)

During the financial year, five meetings of the Audit Committee were held to review and supervise the financial reporting process and internal control of the Group. The following table shows the attendance of the members of Audit Committee at the meetings of the Audit Committee held during the year:

審核委員會(續)

於本財政年度,審核委員會共舉行五次會議,以 檢討及監察本集團之財務呈報程序及內部監控。 下表載列審核委員會成員年內出席審核委員會會 議之情況:

> Attendance/ Number of Meetings entitled to attend 出席/有權出席 會議數目

Name of Audit Committee Members 審核委員會成員姓名

Chan Bing Woon

Pang Chung Fai Benny

Cui Zhanfeng

Lui Tin Nana

(From 1 May 2016 to 30 April 2017) (二零一六年五月一日至二零一七年四月三十日期間)

(chairman of the Committee)

(appointed with effect from 23 February 2017)

5/5 崔占峰 (於二零一十年二月二十三日起獲委任) 1/1 呂天能 (本委員會主席) 5/5 5/5 (於二零一七年二月二十三日起獲委任) 1/1

Ray Yip (appointed with effect from 23 February 2017) 葉雷 干輝 5/5 Wang Hui 黃耀傑 (於二零一十年二月二十三日起獲委任) Wong Yiu Kit Ernest (appointed with effect from 23 February 2017) 1/1

陳炳煥

彭中輝

Xiong Chengyu (appointed with effect from 20 March 2017) 熊滑宇 (於二零一十年二月二十日起獲委任) 1/1

Full minutes of the Audit Committee are kept by the Company Secretary. Minutes are drafted and finalised in sufficient details and are circulated to all members of the Audit Committee, as the case may be, for their comments and records within reasonable time after the conclusion of the meetings.

審核委員會之完整會議記錄由公司秘書保存。會 議記錄之初稿及定稿內容詳盡並於會議結束後之 合理時間內,向審核委員會所有成員傳閱(視情 况而定),以供其提供意見及作記錄。

AUDITOR'S REMUNERATION

An amount of HK\$790,000 (2016: HK\$720,000) was charged to the Group for the year ended 30 April 2017 for the auditing services provided by BDO Limited, the existing auditor of the Company who was appointed on 13 December 2010. There was no non-audit service provided by BDO Limited during the year.

核數師酬金

於截至二零一七年四月三十日止年度,本集團已 就香港立信德豪會計師事務所有限公司(本公司 之現任核數師,於二零一零年十二月十三日獲委 任) 提供之審核服務支付790,000港元(二零一六 年:720,000港元)。香港立信德豪會計師事務所 有限公司於年內並無提供非審核服務。

企業管治報告



CORPORATE GOVERNANCE FUNCTION

According to code provision D.3 of the CG code, the Board is responsible for performing the corporate governance duties of the Company in accordance with the written terms of reference adopted by the Board on 15 March 2012. The Board shall have the following duties and responsibilities for performing the corporate governance duties of the Company:

- to develop and review the Company's policies and practices on corporate governance and make recommendations;
- to review and monitor the training and continuous professional development of Directors and senior management;
- to review and monitor the Company's policies and practices on compliance with legal and regulatory requirements;
- to develop, review and monitor the code of conduct and compliance manual (if any) applicable to employees and Directors; and
- to review the Company's compliance with the code provisions and disclosure in the corporate governance report in the annual report of the Company.

During this financial year, the Board has performed the above corporate governance functions through discussion in the Board meeting and by reviewing the Company's policies and practices from time to time in accordance with the legal and regulatory requirements.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board has the overall responsibilities for maintaining a sound and effective internal control system of the Group. The Group's internal control system includes policies and procedures and limits of authority governing the authority level and business processes. It is designed to help achieve business objectives, to safeguard assets against unauthorized use or disposition, to maintain proper accounting records for the provision of reliable financial information and to ensure compliance with relevant legislations and regulations. The system is intended to manage rather than to eliminate or eradicate risks.

企業管治職能

根據企業管治守則之守則條文第D.3條,董事會 須根據董事會於二零一二年三月十五日採納的書 面職權範圍負責履行本公司之企業管治職責。董 事會於履行本公司之企業管治職責方面擁有以下 職責及責任:

- 制定及審閱本公司企業管治政策及常規並提出意見;
- 審閱及監察董事及高級管理層的培訓及持續專業發展;
- 審閱及監察本公司在遵守法律及監管規定方面的政策及常規;
- 制定、審閱及監察僱員及董事的操守準則及 合規手冊(如有);及
- 審閱本公司遵守守則條文的情況及在本公司 年報中企業管治報告的披露。

於本財政年度,董事會透過於董事會會議討論及 根據法律和監管規定不時審閱本公司的政策及常 規,履行上述企業管治職能。

風險管理和內部控制

董事會有整體責任,維持健全有效集團內部控制系統。集團的內部控制系統包括一連串管理制度及明確授權的管理架構,以幫助集團達成業務目標、防範資產在未經授權下使用或處置、保持合適的會計記錄以提供可靠的財務信息、並確保遵守有關法律和法規。內部控制系統旨在管理風險,而不是消除或完全根除風險。

CORPORATE GOVERNANCE REPORT 企業管治報告



RISK MANAGEMENT AND INTERNAL CONTROL (Cont'd)

Risk Management Process

With the support from internal control adviser ("the Adviser"), the Group has performed risk management procedures including risk identifications, risk assessments, risk prioritization as well as risk owner appointment. Management's inputs on risk exposures were obtained through risk identification questionnaires. Identified risks have been further assessed and evaluated by the Management across the business lines. The risks have been evaluated in terms of their impacts and the likelihood of their occurrences. As part of the evaluation process, the risks have been prioritized based on the evaluation results. Follow up action on key identified risks are being taken by the management.

Risk governance structure

The Group has established an enterprise risk management structure in line with the "Three Lines of Defense" model that defines the three layers of roles and responsibilities of oversight, risk monitoring and review as well as risk and control ownership.

The Group's operating units are the first line of defense. They are responsible for the day-to-day risk management and control procedures. The second line of defense is led by the Group's Management who are responsible for the design, implementation and monitoring over the Group's risk exposure. The third line of defense comprises the Audit Committee and the Group' outsourced internal auditor. The Third line of defense is responsible for the independent assessment of the effectiveness of our risk management and internal control systems. The external auditor of the Group further complements the third line of defense by independently auditing material internal controls over the Group's financial reporting processes and reports on material control weaknesses to the Audit Committee on a regular basis.

Internal Control

The Board has engaged the Adviser to conduct internal control review over the key business operations of the Group for the year ended 30 April 2017. The scope of the review includes key business subsidiaries and the scope of review has been determined and approved by the Board. Findings and areas for improvement have been communicated to the Management. The Board and the Audit Committee are of the view there are no material internal control defects during the course of review.

風險管理和內部控制(續)

風險管理程序

在內部控制顧問(「顧問」)的支持下,集團已進行了一系列的風險管理程序,包括風險識別,風險評估及排序和風險負責人的任命。管理層通過問卷調查,識別業務範圍的風險。各業務範圍的管理層根據已識別的風險的影響及發生的可能性作進一步評估。風險會根據評估結果進行排序。管理層將對已識別的風險採取後續行動。

風險管治結構

集團已按照「三道防線」的模式建立了企業風險管理架構,該模式定義了監督、風險監測和審查、 風險和控制所有權的三個角色和職責。

集團的業務部門是第一道防線,負責日常的風險管理和控制過程。第二道防線由集團管理層領導,負責風險管理系統的設計、實施和監測。第三道防線由審計委員會和集團外包的內部控制系統與 組成,負責對集團的風險管理和內部控制系統報 行獨立評估。集團的外部審計人員對集團財務報 告過程中的內部控制也會進行獨立審計,進一步 補充了第三道防線、並定期向審計委員會報告重 大控制弱項。

內部控制

董事會已委聘顧問,對集團截至二零一七年四月三十日的內部控制制度進行年度審查。審查的範圍包括各個關鍵子公司及經過董事會確定和核准,調查結果和改進領域已通報公司管理層。董事會和審計委員會均認為在審查過程中無重大內部控制缺陷。

企業管治報告



CODES AND POLICIES

Securities Dealing Code

The Company has adopted a code of conduct regarding Directors' securities transactions as set out in the GEM Listing Rules as the required standard for securities transactions by the Directors. Having made specific enquiry of all Directors, each of the Directors, has confirmed that they have fully complied with the required standards of dealings regarding securities transaction by the Directors as set out on the GEM Listing Rules throughout the year ended 30 April 2017.

Code of Ethics

The Company adopts a Code of Ethics that applies to the Company's principal executive officer and senior financial officers in the conduct and practice of financial management and lays down the key principles that they shall follow and advocate, which include honest and ethical conduct; full, fair, accurate, timely and understandable disclosure; compliance with the GEM Listing Rules and accounting standards and regulations; prompt internal reporting; and accountability for adherence to the code. The Code of Ethics is also intended to promote the ethical standards of all the employees, officers and Directors in the workplace, and advocate high standards of professional conduct and work performance.

INVESTOR RELATIONS AND SHAREHOLDERS' RIGHT

The Company values communication with Shareholders and investors. The Company uses two-way communication channels to account to Shareholders and investors for the performance of the Company. Enquiries and suggestions from Shareholders or investors are welcomed, and enquiries from Shareholders or investors may be put to the Board through the following channels to the Company Secretary:

- 1. By mail to the Company's head office at 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong;
- 2. By telephone at telephone number (852) 3966 8388;
- 3. By fax at fax number (852) 2802 0026; or
- 4. By email at info@crmi.hk

守則及政策

證券交易守則

本公司已採納創業板上市規則所載董事進行証券 交易之操作守則作為董事進行証券交易之規定標 準。經向全體董事作出特別垂詢後,各董事已確 認彼等於截至二零一七年四月三十日止年度內, 已全面遵守載於創業板上市規則董事進行證券交 易之買賣規定標準。

道德操守

本公司採納適用於本公司最高行政人員及高級財務主管在進行財務管理方面之道德操守,並記制定被等須遵守及奉行之主要原則,其中包括誠及道德操守;披露資料全面、公平、準確、及道德操守創業板上市規則及會計準則及則之責任。道德操守機提升所有僱員、高級職員及董事於工作場所的道德水平,並且推廣高水平之專業操守及工作表現。

投資者關係及股東權利

本公司重視與股東及投資者之溝通。本公司使用 雙向溝通渠道向股東及投資者匯報本公司之表 現。歡迎股東或投資者提出查詢及建議,股東或 投資者可透過以下渠道向公司秘書查詢並提交董 事會:

- 郵寄至本公司總辦事處,地址為香港灣仔告 士打道108號光大中心10樓;
- 2. 致電(852) 3966 8388;
- 3. 傳真至(852) 2802 0026;或
- 4. 電郵至info@crmi.hk

CORPORATE GOVERNANCE REPORT 企業管治報告



INVESTOR RELATIONS AND SHAREHOLDERS' RIGHT (Cont'd)

The Company uses a number of formal communication channels to account to Shareholders and investors for the performance of the Company. These include (i) the publication of quarterly, interim and annual reports; (ii) the annual general meeting or extraordinary general meeting providing a forum for Shareholders to raise comments and exchanging views with the Board; (iii) updated and key information of the Group available on the websites of the Stock Exchange and the Company; (iv) the Company's website offering communication channel between the Company and its Shareholders and investors; and (v) the Company's share registrars in Hong Kong serving the Shareholders in respect of all share registration matters.

The Company aims to provide its Shareholders and investors with high standards of disclosure and financial transparency. The Board is committed to providing clear and detailed information of the Group and on a timely and regular basis to Shareholders through the publication and/or dispatching of quarterly, interim and annual reports, circular, notices, and other announcements.

The Company strives to take into consideration its Shareholders' views and inputs, and address Shareholders' concerns. Shareholders are encouraged to attend the annual general meeting for which at least 20 clear business days' notice will be given. The Chairman as well as chairmen of the Audit Committee, the Nomination Committee and the Remuneration Committee, or in their absence, the Directors are available to answer Shareholders' questions on the Group's businesses at the meeting. To comply with code provision E.1.2 of the CG Code, the management will ensure the external auditor to attend the annual general meeting to answer questions about the conduct of the audit, the preparation and content of the auditor's report, the accounting policies and auditor independence. All Shareholders have statutory rights to call for extraordinary general meetings and put forward agenda items for consideration by Shareholders.

投資者關係及股東權利(續)

本公司利用多個正式通訊渠道向股東及投資者報告本公司之表現。此等渠道包括(i)刊發季度、中期及年度報告:(ii)舉行股東週年大會或股東特別大會,提供予股東提出意見以及與董事會交流觀點的平台:(iii)於聯交所及本公司網站登載本集團之最新重要資訊:(iv)本公司網站作為本公司與其股東及投資者溝通之渠道:及(v)本公司之香港股份過戶登記處為股東處理所有股份登記事宜。

本公司旨在為其股東及投資者作出高標準披露及 財務透明度。董事會致力透過刊發及/或寄發季 度、中期及年度報告、通函、通告及其他公告, 定期向股東提供清晰、詳盡及即時之本集團資料。

本公司力求採納其股東之意見及建議,並回應股東關注之事宜。本公司亦鼓勵股東出席股東出席股東大會,通告會於大會舉行前最少足20個營業計學。主席以及審核委員會、提名委員會及薪酬可會主席(或倘彼等未能出席大會則為董事)可守會上解答股東有關本集團業務之提問。為遵守則之守則條文第E.1.2條,管理層亦會審核工作、核數師報告之編製及內容、會計政策工作、核數師報告之編製及內容、會計政策以及核數師的獨立性等問題。全體股東享有法慮。利召開股東特別大會,並提呈議程供股東考慮。

CORPORATE GOVERNANCE REPORT 企業管治報告



INVESTOR RELATIONS AND SHAREHOLDERS' RIGHT (Cont'd)

According to the Company's articles of association, general meetings shall be convened on the written requisition of any two or more Shareholders deposited at the principal office of the Company in Hong Kong or, in the event the Company ceases to have such a principal office, the registered office specifying the objects of the meeting and signed by the requisitionists, provided that such requisitionists held as at the date of deposit of the requisition not less than one-tenth of the paid up capital of the Company which carries the right of voting at general meetings of the Company. General meetings may also be convened on the written requisition of any one member of the Company which is a recognised clearing house (or its nominee(s)) deposited at the principal office of the Company in Hong Kong or, in the event the Company ceases to have such a principal office, the registered office specifying the objects of the meeting and signed by the requisitionist, provided that such requisitionist held as at the date of deposit of the requisition not less than one-tenth of the paid up capital of the Company which carries the right of voting at general meetings of the Company. The poll will be conducted by the share registrar of the Company and the results of the poll are published on the Stock Exchange's and the Company's websites.

If a Shareholder wishes to propose a person (the "Candidate") for election as a Director at a general meeting, he/she shall deposit a written notice (the "Notice") at the Company's head office in Hong Kong at 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong. The Notice (i) must include the personal information of the Candidate as required by Rule 17.50(2) of the GEM Listing Rules and his/her contact details; and (ii) must be signed by the Shareholder concerned including the information/documents to verify the identity of the Shareholder and signed by the Candidate indicating his/her willingness to be elected and consent of publication of his/her personal data. The period for lodgement of the Notice shall commence no earlier than the day after the dispatch of the notice of the general meeting appointed for such election and end no later than 7 days prior to the date of such meeting. In order to ensure the Shareholders have sufficient time to receive and consider the proposal of election of the Candidate as a Director without adjourning the general meeting, Shareholders are urged to submit and lodge the Notice as soon as practicable, say at least 15 business days prior to the date of the general meeting appointed for such election.

The Board has established a shareholders communication policy on 15 March 2012 and will review it on a regular basis to ensure its effectiveness to comply with the code provision E.1.4 of the CG code.

In order to promote effective communication, the Company also maintains a website (www.crmi.hk) which includes the latest information relating to the Group and its businesses.

投資者關係及股東權利(續)

根據本公司組織章程細則,股東大會可應任何兩 名或以上股東的書面要求而召開,有關要求須送 達本公司於香港的主要辦事處(或倘本公司不再 設置上述主要辦事處,則為註冊辦事處),當中列 明大會的主要商議事項並由請求人簽署,惟該等 請求人於送達要求之日須持有本公司附帶於本公 司股東大會投票權的不少於十分之一繳足股本。 股東大會亦可應本公司任何一名股東(為一間認 可結算所(或其代名人))的書面要求而召開,有 關要求須送達本公司於香港的主要辦事處(或倘 本公司不再設置上述主要辦事處,則為註冊辦事 處),當中列明大會的主要商議事項並由請求人 簽署,惟該請求人於送達要求之日須持有本公司 附帶於股東大會投票權的不少於十分之一繳足股 本。投票將由本公司股份過戶登記處處理,且投 票結果會於聯交所及本公司網站登載。

倘股東擬提名個別人士(「候選人」)於股東擬提名個別人士(「候選人」)於股東通知(「經選人」)於股東通知(「經選人」)於股東通知, (() 經過期, () 經過期, (() 經過期, (() 經過期, () 經過期, (() 經過期, () 經過期, (() 經過期, (() 經過期, () 經過期, (() 經過期, () 經過期, (() 經過期, () 經過期, (() 經過期, () 經期, () 經過期, () 經期, () 經過期, () 經期, (

董事會已於二零一二年三月十五日設立股東通訊 政策,並將定期檢討以確保其有效遵守企業管治 守則之守則條文第E.1.4條。

為了有效增進溝通,本公司亦設立網站 (www.crmi.hk),披露有關本集團及其業務之最新 資料。



環境、社會及管治報告



China Regenerative Medicine International Limited ("CRMI") (Stock Code: 8158) and its subsidiaries (hereinafter "the Group") are pleased to present the Environmental, Social and Governance ("ESG") Report (the "ESG Report") for the year ended 30 April 2017 and express the commitment of the Group to sustainability. This is the first ESG Report of the Group which discloses the management, policies, performance, targets and feedbacks of the business of the Group in providing services in the People's Republic of China (the "PRC") and Hong Kong in relation to sustainable development. The Group would like to take this opportunity to present ESG performance to all investors and stakeholders, and put forward the commitments and contributions on social responsibility.

Report Compilation Basis

This ESG Report is prepared in accordance with the ESG Reporting Guide enclosed in Appendix 20 of the Rules Governing the Listing of Securities on Growth Enterprise Market published by the Stock Exchange of Hong Kong Limited to fulfil all general disclosure requirements.

For details of the Group's financial performance and corporate governance issues, please refer to the previous sections of the annual report of which this ESG Report forms part.

Source of Data

The data and case studies reported in this ESG Report are prepared based on our internal statistics, internal policy documents and other internal records. The Group hereby confirms that no false or misleading statements are made in this ESG Report.

This ESG Report contains forward-looking statements that are based on several assumptions and expectations at the time of its publication. Those assumptions and expectations are deemed to be reliable after internal reviewing process. The statements consist of known and unknown risks and uncertainties, which implies that actual results may differ from the expectations, forecasts and conclusions made herein.

關於本報告

中國再生醫學國際有限公司(「中國再生醫學」)(股份代號:8158)及其附屬公司(以下統稱「本集團」)於然提呈截至二零一七年四月三十日止年度之環境、社會及管治(「環境、社會及管治(「環境、社會及管治報告」)並展現本集團對可持續發展的承擔。這是本集團的首份環境、社會及管治報告,其披露本集團於中華人民共惠國(「中國」)及香港提供服務時有關可持續發展的業務管理、政策、表現、目標及反饋。本集、社會及管治表現,並就社會責任作出承諾及貢獻。

報告編製基準

本環境、社會及管治報告乃根據香港聯合交易所有限公司頒佈的創業板證券上市規則附錄二十所載環境、社會及管治報告指引編製,以符合所有一般披露規定。

有關本集團財務表現及企業管治事宜之詳情,請 參閱本環境、社會及管治報告構成其一部份之年 報之前述章節。

數據來源

本環境、社會及管治報告的數據和案例乃基於內部統計數據、內部政策文件及其他內部記錄編製。本集團謹此確認本環境、社會及管治報告並無作出任何虛假或具誤導性的陳述。

本環境、社會及管治報告包含前瞻性陳述,有關陳述乃基於本報告發佈之時的若干假設及預期。該等假設及預期須於進行內部審閱程序後,方會被視為可靠。有關陳述包括已知及未知風險及不確定性因素,意味著實際結果可能與本報告所作預期、預測及結論有所不同。



環境、社會及管治報告



OUR VALUE

The Group currently focuses on four major business segments, namely tissue engineering, cell, cosmetic and others and medical equipment. 'ActivSkin', the only tissue-engineered skin developed in the PRC that contains living cells, engraved a leading position in tissue engineering and regenerative medicine industry. Patients whom applied the ActivSkin can shorten healing time for burns and scalds, and relieve pain. 'Acornea', the world's first bio-engineered cornea which completed its clinical trials and obtained China Food and Drug Administration ("CFDA") approval for commercialization, helps elevate the Group as well as the nation to the world stage of regenerative medicine research.

Other tissue engineering products of CRMI include: Calcined Bovine Bone — "Gegreen", Acellular Anal Fistula Repair Stroma — "Asiunin", Cell Sheet-Autologous Chondrocyte Implantation — "CS-ACI", Guided Tissue Regeneration Biological Membrane — "Megreen". With sophisticated technology and know-how on live cell culture, CRMI has launched a series of bioactive cosmetics called "AMYbio"that aims to enter the anti-aging, beauty and healthcare industry. Also, CRMI has collaborated with Mila D'Opiz Group in Switzerland to research, develop and production of famous biomedical skincare products "Ascara" and responsible for its overall business in the PRC.

我們的價值

本集團目前專注於組織工程、細胞、化妝品及其他以及醫療設備四個主要業務板塊。其中,中中國唯一具有活細胞的組織工程皮膚「安體膚」,導定了本集團在組織工程及再生醫學領域的領導地位。安體膚主要用於縮短燒燙傷患者的康復間,並減輕患者的痛苦。生物工程角膜「艾欣瞳」是全球首個完成臨床試驗並獲得國家食品藥工程角膜,使本集團及中國在再生醫學研究領域走在世界前沿。

中國再生醫學的其他組織工程產品包括:天然煆燒骨修復材料「骼瑞」、脱細胞肛瘺修復基質「瑞栓寧」、自體軟骨細胞膜片移植技術「瑞骨術」、引導組織再生生物膜「膜瑞」等。利用集團在活細胞領域的成熟技術及專業知識,中國再生醫學推出生物醫學活性美容化妝品一「艾美雅」,進軍抗衰老、美容保健行業。此外,中國再生醫學已與瑞士Mila D'Opiz集團合作研發生產著名生物護膚產品「阿卡蘭」,並負責在中國的整體業務。

環境、社會及管治報告



我們的價值(續)

To become a global leading force in medical innovation 探究人類生命科學新領域、引領全球醫學革新

To become China's one of the pioneers in tissue engineering and biomedical industry 成為中國的組織工程和生物醫藥產業先驅之一

Strive to enhance health and improve quality of life 致力改善和促進人類的生活和健康素質

To lead a new era into the construction of human's organs and tissues from tissue engineering development 引領組織工程發展 於人體器官和組織構造 邁向新紀元

To develop cuttingedge medical products and technologies with a focus on innovation in regeneration medicine 鑽研優質醫療產品與 技術,專注於再生醫學 的治療創新

A value-creating business — this is what the Group aim to be. The Group achieves this goal by leveraging the biological science research competence to create a positive impact to the world. The research of the Group contributes the society by catalyzing bio-medical research and development. The services make biological sciences research more efficient by shortening the time required for biotechnology research procedures. Since the Group is brave in taking innovative steps, it has contributed to breakthroughs in medical and biological science research over the years — thus living out the value.

成為一家創造價值的公司,是本集團鋭意追求的目標。本集團致力憑藉在生物科學研究領域的能力,為世界創造積極的影響。本集團的研究不斷推動生物醫藥研發的發展,為社會作出貢獻。我們的服務可有效縮短生物技術研究程序所需的時間,提高生物科學研究效率。多年來,憑藉勇於創新的精神,本集團成功實現多項醫療及生物科學研究突破,充分彰顯企業價值。





環境、社會及管治報告



OUR VALUE (Cont'd)

The Group's Corporate Social Responsibility Model

The ESG Report provides detailed explanations with regard to the Group's corporate social responsibility model, shown in below, on different aspects, including stakeholder communication, employee welfare, health and safety, environmental protection, fair operation, social contribution and maintaining sustainability.

我們的價值(續)

本集團的企業社會責任模式

環境、社會及管治報告詳細介紹了本集團下列企 業社會責任模式,包括持份者溝通、僱員福利、 健康與安全、環境保護、公平營運、社會貢獻及 維持可持續發展等方面。



環境、社會及管治報告



OUR VALUE (Cont'd)

Our Group's Corporate Social Responsibility Model (Cont'd)

The Group has conducted a comprehensive materiality assessment with regard to the Group's corporate social responsibility model to identify issues that reflect significant economic, environmental and social impacts of the business, and the issues that matter most to stakeholders. Based on the results of the assessment, the Group has identified the following 17 material areas for inclusion in this report:

我們的價值(續)

本集團的企業社會責任模式(續)

本集團已就本集團的企業社會責任模式進行全面的重要性評估以識別反映業務於經濟、環境及社會方面之重大影響事項及對持份者而言屬最為重要之事項。根據評估結果,本集團已識別以下17個重要範疇以供載入本報告:

1	Bribery and corruption 賄賂及貪污	2	Contribution to local economic development 對地方經濟發展的貢獻
3	Corporate governance 企業管治	4	Data privacy and security 資料私隱與安全
5	Diversity and equal opportunities 多元化及平等機會	6	Energy conservation 節能
7	Greenhouse gas emissions 溫室氣體排放	8	Intellectual property 知識產權
9	Occupational health and safety 職業健康與安全	10	Spirit of the contracts 合約精神
11	Stakeholder engagement 持份者參與	12	Supply chain management and product responsibility 供應鏈管理及產品責任
13	Support in community development/Community care 支持社區發展/社區關懷	14	Team Profile 團隊情況
15	Training and education 培訓及教育	16	Use of resources 資源使用
17	Waste management 廢物管理		

For detail of contribution to local economic development and corporate governance, please refer to the previous sections of the annual report.

有關對地方經濟發展的貢獻及企業管治之詳情, 請參閱年報之前述章節。



環境、社會及管治報告



STAKEHOLDER ENGAGEMENT AND MATERIALITY

The Group understands that the long-term success is due to the commitment to the sustainability of businesses and the diligent and innovative employees who deliver quality services to the clients and business partners and make worthwhile contributions to several stakeholders of the Group.

The Group has consolidated and identified seven different groups of stakeholders that are related to its main business. These stakeholders include business partners, community, customers, employees, government, media and shareholders/investors.

The Group regards stakeholder's opinions as a key to the long term success and sustainable development. The Group will increase the involvement of stakeholders via constructive conversation in order to achieve long-term prosperity.

持份者的參與及重要性

本集團明白長期的成功需依靠業務的可持續發展 及勤奮創新、向客戶及商業夥伴提供優質服務及 對本集團之若干持份者作出有價值的貢獻的僱員。

本集團已綜合及識別涉及其主要業務的七個不同 持份者分組。該等持份者包括商業夥伴、社區、 客戶、僱員、政府、媒體及股東/投資者。

本集團認為持份者的意見乃是長期成功及可持續 發展的關鍵。本集團將透過建設性對話增加持份 者的參與,以實現長期繁榮發展。

Stakeholder 持份者	Communication Channels 溝通渠道
Business Partners 商業夥伴	1.Company news updates 公司新聞更新
	2.Email, facsimile and phone contacts 電郵、傳真及電話聯絡方式
	3.Visits and regular meetings 到訪及例會
Community 社區	1.Company website 公司網站
	2.ESG Report 環境、社會及管治報告
	3.Proactive visits 主動訪問
	4. Sponsorship of public welfare activities 贊助公益活動



環境、社會及管治報告



STAKEHOLDER ENGAGEMENT AND MATERIALITY (Cont'd)

持份者的參與及重要性(續)

Stakeholders 持份者	Communication Channels 溝通渠道
Customers 客戶	1.Company news updates 公司新聞更新
	2.Conference 會議
	3.Customer Service Hotline 客戶服務熱線
	4.Email, facsimile and phone contacts 電郵、傳真及電話聯絡方式
Employees 僱員	1.E-mail 電郵
	2.Internal website 內部網站
	3.Regular meetings 例會
Government 政府	1.Cooperate with the government and regulatory authorities on compliance inspections 配合政府及監管機構的合規檢查
	2.Conference 會議
	3.Email, facsimile and phone contacts 電郵、傳真及電話聯絡方式
Media 媒體	1.Company website 公司網站
	2.Press releases 新聞發佈
Shareholders/Investors 股東/投資者	1.Annual General Meeting 股東週年大會
	2.Company news updates 公司新聞更新
	3.Email, facsimile and phone contacts 電郵、傳真及電話聯絡方式
	4.HKEx Website: announcements, notices, annual reports, etc. 香港交易所網站:公告、通告、年報等
	5.Press releases 新聞發佈



環境、社會及管治報告



ENVIRONMENTAL ASPECTS

The Group recognizes the importance of good environmental stewardship and is committed to protect and conserve the environment. The Group hopes that the concept of environmental sustainability lies in all aspects of daily operation.

The Group strives to balance quality, price and environmental impact when consuming resources and materials. The Group is closely monitoring the energy consumption and water consumption, and impressing employees on the rationale and importance of environmentally friendly choices.

As principal operation is based in the PRC, the Group is principally subject to the PRC environmental laws and regulations such as 中華人民共和國環境保護法 (Environmental Protection Law of the PRC*),中華人民共和國水污染防治法 (Law on the Prevention and Control of Water Pollution of the PRC*), and 中華人民共和國大氣污染防治法 (Law on the Prevention and Control of Atmospheric Pollution of the PRC*). The senior management team are delegated to perform the maintenance of the Group's sustainability. The representatives of each operation management team, actively manages business in an environmentally and socially responsible manner. The Group will review the key processes and identify possible aspects underlying the operation of such department annually. The senior management team will also discuss on any significant aspects identified, and design measures accordingly. These measures will be documented for reference to ensure effective implementation.

環境層面

本集團明白到良好的環境管理的重要性,並致力 保護環境。本集團希望環境可持續發展的理念貫 徹於日常營運的各個層面。

在消耗資源及材料的同時,本集團致力於維持質量、價格及環境影響的平衡。本集團密切監控能源消耗及耗水量,並向員工強調選擇環保方式的理由及重要性。

由於本集團主要在中國營運,故本集團主要遵守中國環境法律及法規,例如中華人民共和國環境法律及法規,例如中華人民共和國東國大氣污染防治法。高級管理層團隊獲占民共和國大氣污染防治法。高級管理層團隊獲指派維護本集團的可持續發展。各經營管理團隊之代表積極地以環保及對社會負責之方式管理理形的營運可能涉及的層面。高級管理層團隊亦將就所識別的任何重大層面進行討論及制定相應措施。該等措施將存檔作參考以確保有效實施。



環境、社會及管治報告



ENVIRONMENTAL ASPECTS (Cont'd)

The Group's ultimate goal is to minimize the adverse impact of businesses on the environment. The efforts being made throughout the year can be concluded as follows:

環境層面(續)

本集團的最終目標是將業務對環境的不利影響降 至最低。本集團於本年度所作的工作總結如下:

Practice 常規

- Avoiding generating waste that polluted the environment 避免產生污染環境的廢料
- 2 Compliance with all relevant laws, regulations, rules and requirements of environmental protection 遵守所有環境保護相關的法律、法規、規章及要求
- 3 Creation of an environment for sustainable development 創造可持續發展的環境
- Provision of training for employees on the protection of the environment 為員工提供有關保護環境的培訓
- Reduction in the consumption of various resources including raw materials and fuel 減少各種資源的消耗,包括原材料及燃料
- 6 Reduction in the generation of waste, recycling and reusing as much as possible of the waste 減少廢料產生,並盡可能對廢料進行回收和循環再用
- 7 Using environmentally friendly materials as well as design, technology and raw materials capable of conserving energy and reducing waste
 - 在設計、技術與原材料的使用上,盡量採用環保材料、可節約能源和減少廢料
- Vigorous promotion and implementation of the recyclable economy, minimizing and avoiding negative effects to the environment due to the Group's development
 - 大力推進和實施循環經濟,減少和避免因本集團的發展對環境造成的負面影響



環境、社會及管治報告



ENVIRONMENTAL ASPECTS (Cont'd)

Use of Resources

The Group understands that an excellent resource management system can improve the efficiency of utilization of resources. Resources consumed in the daily business operation are mainly electricity, water and paper. The Group has monitored the use of resource, specified the duties and authority of relevant employees, and avoided resource wastage. Measures aimed at controlling the use of the electricity and fuel in air-conditioning, lighting, machinery and vehicles, as well as water consumption in its operations and daily usage by the Group's staff are put in place. For example, the Group arranges air-conditioning and light zoning in offices to minimize unnecessary energy wastage. After the work is done, all electric equipment must be turned off. In addition, the Group arranges for the equipment and vehicles to undergo regular maintenance in order to improve the performance of equipment and to dispose high energy consumption equipment as part of the efforts to conserve resources at source.

Currently, water resources supply comes from the government via its domestic water supply. The Group is strengthening the management of water usage and the inspection of water conservation. The Group has adopted internal guidelines and provides staff education to promote water conservation, as well as routinely inspects and upkeeps water supply facilities, to reduce water wastage. Rectifications would be implemented whenever a water leakage is found.

Management of Wastes

The Group has taken several measures to deal with wastes. The Group strictly complies with local regulations to ensure safe treatment, transportation, storage, use, recycle or reuse and disposal for them. The Group also conforms to industry practices in order to reduce wastes. The main emissions of the operation include wastes, polluted water and exhaust gas. The Group intends to minimize environmental impacts associated with wastes generated from the operations.

環境層面(續)

資源使用

當前,水資源供應乃由政府當地供水部門提供。 本集團正加強用水管理,並檢查節約用水。本集 團已採納內部指引及對員工進行教育以促進節 約用水以及定期檢查及維護供水設施以減少水浪 費。如發現漏水情況,將會進行整頓。

廢物管理

本集團已採取多項措施處理廢物。本集團嚴格遵守當地法規,以確保安全處理、運輸、儲存、使用、回收或再利用及處置材料。本集團亦遵循業界常規以減少廢物。本集團營運的主要排放物包括廢物、污水及廢氣。本集團致力減輕營運產生廢物的相關環境影響。



環境、社會及管治報告



ENVIRONMENTAL ASPECTS (Cont'd)

Management of Wastes (Cont'd)

In this regard, the Group promotes the "3-R" concept which aims at minimizing, to the extent practicable, the amount of wastes produced during the course of the Group's business operations. The term "3-R" represents:

環境層面(續)

廢物管理(續)

本集團已就此方面推行「3-R」理念,旨在於切實可行的情況下減少本集團在業務經營過程中所產生的廢棄物數量。「3-R」指:

	Concept 理念	Practice 實踐
a)	Reduction 減廢	Reducing the volume of daily wastes generated to the extent practicable, by using alternative materials, processes and procedures 透過使用替代材料、流程及程序於切實可行的情況下減少產生日常廢棄物的數量
b)	Reuse 循環再用	Reusing wastes generated and returning unused materials 循環再用產生的廢棄物及歸還未使用的材料
c)	Recycling 循環再造	Converting waste materials into usable materials or extracting useful substances from them, such as recycling packaging material and paper 將廢料轉換為可用材料或自其中提取有用物質,例如循環再造包裝材料及紙張

Emission of Greenhouse Gases

In the global trend of emission reduction, the Group not only complies with local regulations, but also conforms to industry practices in order to reduce the emission of greenhouse gases. Greenhouse gases by the Group are principally emitted from transport vehicles commissioned. In addition to the direct and indirect gas emissions, the use of electricity by the Group is also indirectly attributable to production of greenhouse gases, most notably carbon dioxide, in the electricity generation process. With reference to the kilowatt-hour power generation to carbon dioxide emission ratio general adopted in the PRC, approximately 2,010 tonnes of carbon dioxide were attributable to the Group's electricity usage in daily operation during the year ended 30 April 2017.

溫室氣體排放

面對全球減排的大趨勢,本集團除遵守當地法規外,亦遵循業界常規以減少溫室氣體排放。本集團的溫室氣體主要排放自在用的運輸車輛。除直接及間接氣體排放外,本集團的用電亦間接產生溫室氣體,最為顯著的是發電過程中產生的二氧化碳。參照中國常用的千瓦時發電量對二氧化碳排放量比率,本集團於截至二零一七年四月三十日止年度之日常營運用電產生約2,010噸二氧化碳。



環境、社會及管治報告



ENVIRONMENTAL ASPECTS (Cont'd)

Emission of Greenhouse Gases (Cont'd)

During the period, the Group did not receive any complaints, fines, sanctions in respect of any environmental protection issues or breaches of environmental regulations, and had not experienced any material environmental incidents arising from daily activities. During the year, no material administrative sanctions or penalties were imposed upon the Group for the violation of environmental laws or regulations which had an adverse impact on the operations.

SOCIAL ASPECTS

Labor Standards

The Group has set up a comprehensive set of human resource policies stipulating rules on recruitment, compensation, training, welfare, promotion guidelines and dismissal. In order to safeguard benefits for the employees, the Group abides by 中華人民共和國勞動法 (Labor Law of the PRC#), 中華人民共和國勞動合同法 (Labor Contract Law of the PRC#), the Employment Ordinance of Hong Kong and employment laws applicable to relevant jurisdictions where operations are located. Labor contracts or employment contracts are entered into between the Group and the employees. Moreover, the Group regularly monitors information related to employment to prevent non-compliance with labor laws and regulations.

As the Group strictly adheres to the 中華人民共和國未成年人保護法 (Protection of Minors Law of the PRC*), the Employment of Children Regulations of Hong Kong and other laws and regulations in all aspects, the Group does not permit forced labor or employ child labor under any circumstances.

Diversity and Equal Opportunities

In order to increase efficiency in hiring and to ensure consistency and compliance in the recruitment and selection process, as well as to promote a fair opportunities to each candidates, the Group has detailed recruitment policies in place. An objective and carefully documented recruitment process ensure that any discrimination risks are minimized and give us the best possible chance of identifying the right candidate. Regardless of nationality, gender, age, race, religious belief or disability, etc, candidates with relevant professional qualifications and working experience receive equal consideration for employment.

環境層面(續)

溫室氣體排放(續)

於本期間,本集團並無接獲有關任何環保問題或違反環保法規的任何投訴、罰款及制裁,亦無遭致因日常活動產生的任何重大環境事故。於本年度,本集團並無就違反環境法律或法規而遭致重大行政制裁或處罰而對營運產生不利影響。

社會層面

勞工準則

本集團已就僱傭、薪酬、培訓、福利、晉升指引及解僱設立一套全面的人力資源政策規定。為保障僱員福利,本集團遵守中華人民共和國勞動 法、中華人民共和國勞動合同法、香港僱傭條例及營運所在地司法機構的適用僱傭法律。勞動合同或僱傭合同乃由本集團與僱員訂立。此外,本集團定期監察僱傭相關資訊以避免不符合勞動法律及法規事宜。

本集團於各個方面均嚴格遵守中華人民共和國未成年人保護法、香港僱用兒童規例及其他法律及 法規,在任何情況下本集團均不允許強迫勞工或 聘請童工。

多元化及平等機會

為了提高招聘僱員的效率,並確保招聘及甄選過程中的一致性及合規性,以及為每位候選人提供公平的機會,本集團已確立詳細的招聘政策。 客觀且小心記錄的招聘程序確保降低任何歧視風險,並為我們物色合適候選人提供最佳機會。不論國籍、性別、年齡、種族、宗教信仰或殘障等,具備相關專業資格及工作經驗的求職者在招聘過程中均享有平等對待。

[#] for identification only



環境、社會及管治報告




Team Profile

The Group recruits talents in a fair and equitable manner through social media such as online platforms and newspaper advertisements. Across the Group's diversified business portfolio, as of 30 April 2017, the Group had a workforce of 542 in a number of locations in the PRC and Hong Kong. The composition of staffs was as follows:

社會層面(續)

團隊情況

本集團利用線上平台及報章廣告等社會媒體公平公正地招募人才。在本集團多元化的業務組合中,本集團截至二零一七年四月三十日已在中國及香港聘有542名員工。員工組成如下:



Categorized by employee's gender, female employees accounted for approximately 56% and male employees accounted for the remaining 44%. The Group has adopted equal employment opportunity policies and treats all our employees equally, implying that their employment, jobs allocation, remuneration and promotion.

按僱員性別分類,女性僱員佔約56%,而男性僱員佔餘下44%。本集團採納平等就業機會政策及公平對待全體僱員,體現在彼等的僱用、工作分配、薪酬及晉升方面。




環境、社會及管治報告

SOCIAL ASPECTS (Cont'd)

社會層面(續)


Team Profile (Cont'd)

團隊情況(續)



As for employee distribution by age, aged 20 to 30 accounted for approximately 42%, aged 31 to 40 accounted for approximately 40%, aged 41 to 50 accounted for approximately 12%, aged 51 to 60 accounted for approximately 5% and aged above 60 accounted for approximately 1%.

按僱員年齡分類,20至30歲佔約42%,31至40 歲佔約40%,41至50歲佔約12%,51至60歲佔 約5%及60歲以上佔約1%。



環境、社會及管治報告



Team Profile (Cont'd)

Employees in different fields are the Group's precious assets. Categorized by education level, employees with Ph.D background accounted for approximately 2% of the total number of employees; employees with Master degree accounted for approximately 12%; employees with Bachelor degree accounted for approximately 40%; employees with diploma accounted for approximately 30%; and others accounted for the remaining 16%.

Health and Safety

Safe, effective and cozy workplace is essential to support the Group's precious asset, employees. In addition to the international labor standards and laws, the Group has created internal guidelines and systems specific to industry to make sure employees would discharge their duties effectively. The Group insists that the injuries and diseases can be prevented effectively by identifying safety risks of various job positions.

Employees Development and Training

The Group recognizes the importance of empowerment through development and training in the Group. Equipping employees with the appropriate knowledge not simply benefits the long term development of the Group, but the society as a whole.

社會層面(續)

團隊情況(續)


各個領域的僱員是本集團的寶貴資產。按教育水平分類,擁有博士學歷的僱員佔僱員總數的約2%;擁有碩士學位的僱員佔約12%;擁有學士學位的僱員佔約40%;擁有畢業文憑的僱員佔約30%;而其他僱員佔餘下16%。

健康及安全

安全、有效及舒適的工作環境對於支持本集團的 實貴資產,僱員至關重要。除國際勞工準則及法 律外,本集團已制定專門針對本行業的內部指引 及制度,以確保僱員能有效地履行職責。本集團 強調要有效避免工傷及職業病的發生,必先識別 不同工作崗位的安全風險。

僱員發展和培訓

本集團深明僱員發展與培訓對本集團之重要性, 提升僱員適當的知識,不但有利於本集團的長遠 發展,對整個社會亦有莫大裨益。





環境、社會及管治報告



SOCIAL ASPECTS (Cont'd)

Employees Development and Training (Cont'd)

Understanding that employees are a vital factor for success in the competitive industry and promotion of innovation, during the year the Group continued to provide a wide range of training opportunities. The total number of training hours provided by the Group was approximately 1,270 hours. The comprehensive training and development opportunities include, but not limited to the followings:

社會層面(續)

僱員發展和培訓(續)

僱員是競爭性行業取得成功和促進創新之關鍵因素,有見及此,本集團於本年內持續提供一連串廣泛的培訓機會。本集團提供培訓的總時數約為1,270小時。綜合培訓和發展機會包括但不限於以下各項:

Development and training 發展和培訓	Target 對象	Summary of Training 培訓概要
Induction Training 新員工入職培訓	New employees 新僱員	Introduction of the Group's vision, mission, culture, organizational structure, rules and regulations as well as trainings on operational standards, job specifications, work procedures and customer service etiquette for each department of the Group 本集團之願景、使命、文化、組織架構、規則及規例介紹以及本集團各部門的操作準則、工作説明、工作流程和客戶服務禮儀培訓
Measures for Implementation of Work Safety in Production 安全生產管理規程	Manufacturing departments 製造部門	Internal training on work safety in the daily operation 日常營運的工作安全的內部培訓
Reinforcement Class for Managerial Representatives in Medical Equipment Business 醫療器械企業管理者代表提 高班	Quality control department 質控部	Comprehensive training specific to the quality control team on building effective coaching techniques; mastering problem analysis and decision making; strengthening interpersonal skills; and recognizing team success with enthusiasm 專門針對質控團隊設立有效輔導技能培訓;掌控問題分析及決策培訓;增強人際交往技巧;及熱情表彰團隊成功的相關管理技巧的綜合培訓
Measures for the Supervision and Administration of Medical Devices 醫療器械經營監督管理辦法	Related departments 生產流程相關部門	Training on the measures deliberated and adopted at the executive meeting of the CFDA 對藥監總局常務會議審議通過的措施進行相關培訓



環境、社會及管治報告



SOCIAL ASPECTS (Cont'd)

社會層面(續)

Employees Development and Training (Cont'd)

僱員發展和培訓(續)

Development and training 發展和培訓	Target 對象	Summary of Training 培訓概要
Director's Induction Training 董事入職訓練	Directors 董事	Specific induction training for directors 董事具體入職培訓
Training on Emotional Management 情緒管理課程	Employees 僱員	Training is provided to ensure the mental health of employees 提供培訓,以確保僱員心理健康
Training on Detection Technology, Detection Measures and Contract Research Organization's ("CRO") Service Process Management 檢測技術、檢測手段及 委託研究機構服務流程 管理	Production technology department 生產技術部	Sessions regarding the detection technologies and CRO service process 有關檢測技術及委託研究機構服務流程的研討會
Fire Safety Training 消防安全基礎知識培訓	All employees 全體僱員	Training on fire prevention and fire escape 預防火災及消防逃生培訓

Through comprehensive, diversified and systematic development mechanism, the Group broadens the international perspectives of the employees, deepens their professional knowledge, strengthens corporate vision and brings out creative ideas to the ever-changing environment.

透過全面、多元化及系統化的發展機制,本集團 拓闊僱員的國際視野、深化其專業知識、強化企 業願景及針對瞬息萬變的環境提出創見。



環境、社會及管治報告



SOCIAL ASPECTS (Cont'd)

Supply Chain Management

Suppliers are the Group's long-term business partners. Stability, safety and effectivity of product quality is directly influenced by the selection of suppliers. To effectively manage the supply chain, the Group has developed a comprehensive system for assessing new and existing suppliers. The Group has further regulated the operational procedures of evaluation and approval for main suppliers, and clarified the suppliers' qualification, selection principle, quality evaluation methods, evaluation standard, and approval procedure for main supplier. The Group requires suppliers to comply with local laws and regulations in all aspects. Most of the supplies of the Group are procured from the PRC. The PRC government has strict laws and regulations governing social and environmental risks.

Anti-corruption

To ensure honest, loyal behaviors and ethical conduct among employees, the Group has adopted code of ethics and applicable requirement of the relevant anti-corruption laws and regulations, so as to enable employees' conducts and behavior to be monitored throughout daily operations. The Group performs annual self-evaluation to look at the implementation of code of ethics and relevant laws and regulations, the objective of which is to ensure the thoroughness and consistency in actual operations and management practices, with a view to balancing and safeguarding interests of the stakeholders and establishing long-term partnerships. The Group also engaged independent auditors to carry out external audits and internal control reviews on the Group, aiming at preventing corruptive behaviors within the Group through internal supervision and external audits.

During the period, the Group was not aware of any material non-compliance with any relevant standards, rules, codes and regulations. There were no complaints of corruption against the Group or any of the Group's employees during the year.

Product Responsibility

The Group strives for products and services excellence across all the business activities. To protect the samples from contamination in the laboratory, the Group has devised procedures for operations in the laboratory. The Group also requires the laboratory technicians to wear protection suits and to regularly clean and disinfect the laboratory equipment, in order to maintain workplace hygiene and prevent the cross-contamination of the products.

社會層面(續)

供應鏈管理

供應商是本集團的長期業務合作夥伴。供應商的甄選直接影響產品質量的穩定性、安全性及有全性。為有效管理供應鏈,本集團已建立一套學型的評估系統去評估新進及現有供應商。本集團已開於一個大學的評估系統去評估新進及現有供應商的評估系統去評估新進及現有供應商的平準時間,明確對主要供應商的供應。本集團要求供應商在各個方面遵傳不可以表達。本集團用品大部份是從中國政府制定有嚴格的社會及環境風險監管法律法規。

反貪污

為確保僱員的誠實、忠誠行為及道德操守,本集團已採納道德守則以及相關反貪污法律及法規的適用規定,以使僱員的行為及態度於整個日常營運中均受到監察。本集團進行年度自我評估以管運中均受到監察。本集團進行年度自我評估的營權保實際營運及管理慣例得到完全一致的履行,從而平衡及保障持份者的利益及建立長期夥伴關係。本集團亦聘用獨立核數師以對本集團進行外部審核及內部監控檢討,藉以透過內部監督及外部審核,防止本集團內出現貪污行為。

於本期間內,本集團並不知悉有任何重大未遵守 有關標準、規則、守則及規例的情況。於年內概 無針對本集團或本集團任何僱員有關貪污的投訴。

產品責任

在業務經營中,本集團不斷在產品及服務上精益 求精。為避免實驗室樣本受污染,本集團就實驗 室運作制定程序。本集團亦規定實驗室技術人員 穿著防護服及定期清潔消毒實驗室設備,以維持 工作場所衛生及防止產品交叉污染。



環境、社會及管治報告



Product Responsibility (Cont'd)

Apart from the hygiene control in laboratory, the Group also understands the importance of an accurate testing result. Thus, the Group has developed policies in relation to the management and maintenance of laboratory equipment, especially the calibration of laboratory equipment. Our equipment is calibrated externally by professionals and internally when necessary to ensure its accuracy. Qualified personnel is assigned to each equipment for the daily management and maintenance, to make sure equipment that we are using is in good condition. Damaged equipments will not be used until they are fixed by the suppliers.

Also, listening to customers about their experiences with products and services is the key to the Group's success. The Group constantly interacts with customers by reviewing their enquiries and feedback so that performance can be tracked regularly. Also, the Group is dedicated to provide after-sale maintenance and operational technical supporting services to customers. Training is provided to employees in offering comprehensive services to customers.

Intellectual Property and Confidential Information

The Group has stringent measures in place to protect operational and customer data privacy. A systematic approach is implemented internally to ensure that only designated employees have access to sensitive and confidential information. No confirmed cases of data leakage were identified during the year.

The Community

With the market's focus on corporate behavior, the short-sighted behavior of maximizing financial returns to shareholders is no longer the management goal of business. The Group stays proactive in fulfilling the responsibilities as a corporate citizen of the community, promote the application of the regenerative medicine products and related healthcare services, and to further raise the awareness of public health. The group will continue its effort in promoting and applying our profession in regenerative medicine products and related healthcare services. The Group believes that employees are the core value makers in the society. The Group will continue to pool the strengths and commit itself in increasing community participation, balance of interests of stakeholders and strives to build a corporate-community relationship that promotes harmony, security and prosperity.



產品責任(續)

除控制實驗室的衛生狀況外,本集團亦了解到準確測試結果的重要性。因此,本集團已制定有關政策,管理及維護實驗室設備(特別是實驗室設備校準工作)。我們的設備由專業人士進行外部校準工作,有需要時本集團內部人員亦會做校準工作,確保設備的準確度。合資格人員獲指派對各項設備進行日常管理及維護,確保我們使用的設備保持良好狀況。損壞的設備需由供應商修理後方可使用。

聆聽客戶對產品及服務的體驗是本集團成功的關鍵。本集團透過檢討客戶查詢及反饋與客戶保持互動,定期追蹤表現。本集團亦悉心為客戶提供售後維護及營運技術支援服務,並對僱員進行培訓,務求為客戶提供全面的服務。

知識產權及保密資料

本集團已制定有嚴格的措施保護營運數據及客戶 資料的私隱。集團內部有系統地執行有關措施, 確保僅指定僱員可取閱敏感及保密資料。本年內 並無發現經證實的數據洩露事件。

社區

隨著市場對企業行為的關注,追求最大財務績效以回饋股東此一短視行為已經不是業務管理的目標。本集團積極履行作為一家企業公民於社區的責任,致力推廣應用再生醫學產品及相關健康服務,並進一步提升大眾健康意識。我們將繼續失力推廣及應用於再生醫學產品及相關健康服務的專業技能。本集團相信員工是為社會創造價值的核心力量。本集團將繼續集眾人力量,增加社區參與,平衡持份者的利益,致力構建推動和諧、安全及繁榮的企業與社區關係。



環境、社會及管治報告

ď	

Aspect 層面	Description 描述	Details 詳情
Aspect A1: Emissions 層面 A1: 排放物	General Disclosure 一般披露 Information on: 有關廢氣及溫室氣體排放、向水及土地排污、有害及無害廢棄物的產生等的: (a) the policies; and 政策;及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規 relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste. 的資料。	For more details, please refer to pages 104 to 108. 有關更多詳情·請參閱第104至108頁。
Aspect A2: Use of Resources 層面 A2: 資源使用	General Disclosure 一般披露 Policies on the efficient use of resources, including energy, water and other raw materials 有效使用資源(包括能源、水及其他原材料)的政策。	For more details, please refer to pages 104 to 106. 有關更多詳情·請參閱第104至106頁。
Aspect A3: The Environment and Natural Resources 層面 A3: 環境及天然資源	General disclosure 一般披露 Policies on minimizing the issuer's significant impact on the environment and natural resources. 減低發行人對環境及天然資源造成重大影響的政策。	For more details, please refer to pages 104 to 108. 有關更多詳情,請參閱第104至108頁。

環境、社會及管治報告



Aspect 層面	Description 描述	Details 詳情
Aspect B1: Employment 層面 B1: 僱傭	General Disclosure 一般披露 Information on: 有關以下各項的資料: (a) the policies; and 政策;及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規	For more details, please refer to page 108. 有關更多詳情,請參閱第108頁。
Aspect B2: Health and Safety 層面 B2: 健康與安全	General Disclosure 一般披露 Information on: 有關以下各項的資料: (a) the policies; and 政策;及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規	For more details, please refer to pages 108 and 111. 有關更多詳情,請參閱第108及111頁。
Aspect B3: Development and Training 層面 B3: 發展及培訓	General disclosure 一般披露 Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. 有關提升僱員履行工作職責的知識及技能的政策。描述培訓活動。	For more details, please refer to pages 111 to 113. 有關更多詳情,請參閱第111至113頁。



環境、社會及管治報告

Aspect 層面	Description 描述	Details 詳情
Aspect B4: Labor Standards 層面 B4: 勞工準則	General disclosure 一般披露 Information on: 有關防止童工或強制勞工的: (a) the policies; and 政策;及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規 relating to preventing child and forced labor. 的資料。	For more details, please refer to pages 108 and 110. 有關更多詳情,請參閱第108及110頁。
Aspect B5: Supply Chain Management 層面 B5: 供應鏈管理	General Disclosure 一般披露 Policies on managing environmental and social risks of the supply chain. 有關管理供應鏈的環境及社會風險的政 策。	For more details, please refer to page 114. 有關更多詳情,請參閱第114頁。
Aspect B6: Product Responsibility 層面 B6: 產品責任	General Disclosure 一般披露 Information on: 有關所提供產品和服務的健康與安全、廣告、標籤及私隱事宜以及補救方法的: (a) the policies; and 政策;及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規 relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	For more details, please refer to pages 114 to 115. 有關更多詳情,請參閱第114至115頁。



的資料。

環境、社會及管治報告



Aspect 層面	Description 描述	Details 詳情
Aspect B7: Anti-corruption 層面 B7: 反貪污	General Disclosure 一般披露 Information on: 有關防止賄賂、勒索、欺詐及洗黑錢的: (a) the policies; and 政策:及 (b) compliance with relevant laws and regulations that have a significant impact on the issuer 遵守對發行人有重大影響的相關法律及法規 relating to bribery, extortion, fraud and money laundering.	For more details, please refer to page 114. 有關更多詳情,請參閱第114頁。
Aspect B8: Community Investment 層面B8: 社區投資	General Disclosure 一般披露 Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests. 有關以社區參與來了解發行人營運所在社區需要和確保其業務活動會考慮社區利益的政策。	For more details, please refer to page 115. 有關更多詳情,請參閱第115頁。

董事會報告





The Directors present to the Shareholders the Company's annual report and audited consolidated financial statements for the year ended 30 April 2017.

董事謹此向股東提呈本公司截至二零一七年四月 三十日止年度之年報及經審核綜合財務報表。

PRINCIPAL ACTIVITIES

The Company is an investment holding company. The principal activities of its subsidiaries are engaged in the R&D of bio-medical and healthcare products, and medical techniques; the provision of the production and sales of tissue engineering products and its related by-products; as well as sales and distribution of medical products and equipment.

主要業務

本公司乃一間投資控股公司,其附屬公司之主要 業務為從事生物醫學和醫療保健產品及醫療技術 之研發;提供組織工程產品及其相關副產品的生 產及銷售;以及銷售及分銷醫療產品及設備。

RESULTS AND DIVIDENDS

Results of the Group for the year ended 30 April 2017 are set out in the consolidated statement of profit or loss and other comprehensive income on page 152.

The Directors do not recommend the payment of a final dividend.

業績及股息

本集團截至二零一七年四月三十日止年度之業績 載於第152頁之綜合損益及其他全面收入表內。

董事並不建議派發末期股息。

FINANCIAL SUMMARY

A summary of the results and the assets and liabilities of the Group for the past five financial years is set out on page 248.

財務摘要

本集團過去五個財政年度之業績以及資產與負債 摘要載於第248頁。

SHARE CAPITAL

Details of movements in the share capital of the Company during the year are set out in note 28 to the financial statements.

股本

本公司股本於年內之變動詳情載於財務報表附註 28內。

RESERVES

The Company's reserves available for distribution to Shareholders as at 30 April 2017 amounted to approximately HK\$2,263,445,000 (2016: HK\$2,444,449,000).

Details of movements in the reserves of the Group and the Company during the year are set out in the consolidated statement of changes in equity on page 154 and note 30 to the financial statements, respectively.

儲備

於二零一七年四月三十日,本公司可供分派予股東之儲備約為2,263,445,000港元(二零一六年:2,444,449,000港元)。

本集團及本公司於年內之儲備變動詳情,分別載 於第154頁之綜合權益變動表及財務報表附註30。

PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Group during the year are set out in note 14 to the financial statements.

物業、廠房及設備

本集團於年內有關物業、廠房及設備之變動詳情 載於財務報表附註14內。



董事會報告



DIRECTORS

The Directors during the year and up to the date of this report are:

Executive Directors

Wong Sai Hung (Vice-chairman) Shao Zhengkang

Chen Chunquo (appointed with effect from (Chief Executive Officer) 25 January 2017)

Non-Executive Directors

Cui Zhanfeng (Chairman) (appointed with effect from

7 October 2016)

(appointed with effect from Ray Yip

23 February 2017)

(appointed with effect from Xiong Chengyu

20 March 2017)

Wang Hui (re-designated from independent

non-executive Director to

non-executive Director with effect

from 1 June 2017) (retired with effect from

9 September 2016)

Cao Fushun (resigned with effect from

18 July 2016)

Yang Zhengguo (resigned with effect from

5 August 2016)

Wang Jianjun (retired with effect from

9 September 2016)

Independent Non-Executive Directors

Lui Tin Nang Pang Chung Fai Benny

Deng Shaoping

Chan Bing Woon

Wong Yiu Kit Ernest (appointed with effect from 23 February 2017)

In accordance with article 116 of the Company's articles of association, Mr. Lui Tin Nang and Mr. Pang Chung Fai Benny shall retire from office by rotation at the forthcoming annual general meeting and, being eligible, offer themselves for re-election.

In accordance with article 99 of the Company's articles of association, Professor Cui Zhanfeng, Mr. Chen Chunguo, Dr. Ray Yip, Mr. Wong Yiu Kit Ernest, Professor Xiong Chengyu and Mr. Wang Hui shall hold office until the forthcoming annual general meeting and, being eligible, offer themselves for re-election.

董事

於年內及截至本報告日期止之董事如下:

執行董事

黃世雄

(副主席) 邵政康

陳春國 (於二零一七年一月二十五日起

(行政總裁) 獲委任)

非執行董事

崔占峰(主席) (於二零一六年十月七日起

獲委任)

葉雷 (於二零一七年二月二十三日起

獲委任)

熊澄宇 (於二零一七年三月二十日起

獲委任)

干輝 (於二零一七年六月一日起

由獨立非執行董事調任為

非執行董事)

鄧紹平 (於二零一六年九月九日起

退任)

曹福順 (於二零一六年七月十八日起

辭仟)

楊正國 (於二零一六年八月五日起

辭任)

(於二零一六年九月九日起 王建軍

退任)

獨立非執行董事

呂天能 彭中輝

陳炳煥

(於二零一七年二月二十三日起 黃耀傑

獲委任)

根據本公司組織章程細則第116條,呂天能先生 及彭中輝先生須於應屆股東週年大會上輪值告 退,惟符合資格並願意膺選連任。

根據本公司組織章程細則第99條,崔占峰教授、 陳春國先生、葉雷博士、黃耀傑先生、熊澄宇教 授及王輝先生須留任至應屆股東週年大會,惟符 合資格並願意膺選連任。

董事會報告



DIRECTORS' AND CHIEF EXECUTIVES' BIOGRAPHIES

Biographical details of the Directors and chief executives of the Company are set out on pages 63 to 72 of this annual report.

DIRECTORS' SERVICE CONTRACTS

Each of the executive Directors, non-executive Directors and independent non-executive Directors has signed an appointment letter with the Company for a term of two years commencing from the date of appointment. After the expiry of the appointment letter(s), the Director(s) shall agree to continue to hold office as a Director, subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. In the event that the Director(s) is successfully re-elected at the conclusion of the annual general meeting of the Company, the Director(s) shall enter into a supplemental letter with the Company for continuation of his/her appointment for a term of two years.

None of the Directors who are proposed for re-election at the forthcoming annual general meeting has a service contract with the Company which is not determinable by the Company within one year without payment of compensation, other than statutory compensation.

DIRECTORS' INTERESTS IN CONTRACTS

Save as those set out in note 35 to the financial statements and under heading "CONNECTED TRANSACTIONS" in this report, none of the Directors had a significant beneficial interest, either directly or indirectly, in any contract of significance to the business of the Group to which the Company or any of its subsidiaries was a party during the year.

SHARE OPTIONS

Share Option Scheme

The share option scheme (the "Share Option Scheme") was adopted on 14 September 2011 for the primary purpose of providing incentives to directors and eligible employees of the Company.

董事及最高行政人員簡介

董事及本公司最高行政人員之簡介詳情載於本年報第63至第72頁。

董事之服務合約

每一位執行董事、非執行董事及獨立非執行董事 已與本公司訂立聘任函,自委任日起計任期兩 年。聘任函屆滿之後,董事可同意繼續留任為董 事,惟須根據本公司之章程細則於本公司之股東 週年大會上輪席退任及膺選連任。於本公司股東 週年大會完結時,倘若董事膺選連任成功,董事 將與本公司訂立補充函,延續其任期兩年。

擬於應屆股東週年大會上膺選連任之董事概無與本公司訂立於一年內不可由本公司無償(法定賠償除外)終止之服務合約。

董事之合約權益

除財務報表附註35及本報告「關連交易」一節所載者外,概無董事直接或間接地於本公司或其任何附屬公司於年內所訂立且與本集團業務有關連之任何重大合約中擁有重大實益利益。

購股權

購股權計劃

於二零一一年九月十四日,本公司採納購股權計劃(「購股權計劃」),主要目的為向本公司董事及合資格僱員提供獎勵。



董事會報告



SHARE OPTIONS (Cont'd)

Share Option Scheme (Cont'd)

The movement of share options under the share option scheme adopted by the Company on 14 September 2011 during the year ended 30 April 2017 was as below:

購股權(續)

購股權計劃(續)

於截至二零一七年四月三十日止年度,本公司於 二零一一年九月十四日採納之購股權計劃項下之 購股權變動如下:

Movement of Share Ontions during the year ended 30 April 2017

								g the year ended 日止年度之購股權變		0.1-1
Eligible persons	Date of grant	Exercise price (HK\$)	Vesting schedule and exercise period of the Share Options	Exercisable portion of the Share Options granted	Outstanding as at 30 April 2016 於	Granted	Exercised	Reclassified	Lapsed	Outstanding as at 30 April 2017 於
合資格人士	授出日期	行使價 (港元)	購股權之 歸屬時間表及 可行使期間	已授出購股權之 可行使部份	二零一六年 四月三十日 尚未行使	已授出	已行使	已重新分類	已失效	二零一七年 四月三十日 尚未行使
Directors 董事	16/9/2015 二零一五年 九月十六日	0.45	16 September 2016 to 15 September 2017 (both days inclusive) (the "1st Period") 二零一六年九月十六日至 二零一七年九月十五日 (包括首尾兩日) (「第一個期間」)	Up to 20% ("1st Options") 最多20% (「第一份購股權」)	73,720,000*1	NIL (E	NL 無	(1,620,000)	(35,090,000)	37,010,000
			16 September 2017 to 15 September 2018 (both days inclusive) (the "2nd Period") 二零一七年九月十六日至二零一八年九月十五日(包括首尾兩日)(「第二個期間」)	Up to 20% ("2nd Options") (together with any 1st Options which have not been exercised during the 1st Period) 最多 20% (「第二份購股權」) (連同於第一個期間尚未行使之任何第一份購股權)						
		16 September 2018 to 15 September 2019 (both days inclusive) (the "3rd Period") 二零一八年九月十六日至 二零一九年九月十五日 (包括首尾兩日) (「第三個期間」) (「第三個期間」) 「第三個期間」) 「第三個期間」) 「第三個期間」) 「第三個期間」)								
			16 September 2019 to 15 September 2020 (both days inclusive) (the "4th Period") 二零一九年九月十六日至 二零二零年九月十五日 (包括首尾兩日) (「第四個期間」)	Up to 20% ("4th Options") (together with any 1st, 2nd and 3rd Options which have not been exercised during the 1st Period, 2nd Period and 3rd Period) 最多 20% (「第四份購股權」) (連同於第一個期間、第二個期間及第三個期間、	d					

尚未行使之任何第一份、 第二份及第三份購股權)







SHARE OPTIONS (Cont'd)

購股權(續)

Share Option Scheme (Cont'd)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 20)17
裁不一要――七年四日二十日上年度う膳野姫線動	

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
					於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

16 September 2020 to 15 September 2025 (both days inclusive) (the "5th Period") 二零二零年九月十六日至 二零二五年九月十五日 (包括首尾兩日) (「第五個期間」)

Up to 20% ("5th Options") (together with any 1st, 2nd, 3rd and 4th Options which have not been exercised during the 1st Period, 2nd Period. 3rd Period and 4th Period) 最多20%(「第五份購股權」) (連同於第一個期間

第二個期間、第三個期間及 第四個期間尚未行使 之任何第一份、第二份 第三份及第四份購股權)

9/9/2016 0.291 9 September 2017 to 二零一六年 8 September 2018 九月九日 (both days inclusive) (the "First Period") 二零一七年九月九日至 二零一八年九月八日 (包括首尾兩日) (「第一個期間」)

Up to 20% ("First Options") 最多20%(「第一份購股權」)

56,200,000 NIL

4,000,000 NIL

NIL

60,200,000

9 September 2018 to 8 September 2019 (both days inclusive) (the "Second Period") 二零一八年九月九日至 二零一九年九月八日 (包括首尾兩日) (「第二個期間」)

Up to 20% ("Second Options") (together with any First Options which have not been exercised during the First Period) 最多20%(「第二份購股權」) (連同於第一個期間尚未行使 之任何第一份購股權)

9 September 2019 to 8 September 2020 (both days inclusive) (the "Third Period") 二零一九年九月九日至 二零二零年九月八日 (包括首尾兩日) (「第三個期間」)

Up to 20% ("Third Options") (together with any First and Second Options which have not been exercised during the First Period and Second Period) 最多20%(「第三份購股權」) (連同於第一個期間及 第二個期間尚未行使之任何

第一份及第二份購股權)

董事會報告



SHARE OPTIONS (Cont'd)

購股權(續)

Share Option Scheme (Cont'd)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017 截至二零一七年四月三十日止年度之購股權變動

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
					於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

9 September 2020 to 8 September 2021 (both days inclusive) (the "Fourth Period") 二零二零年九月九日至 二零二一年九月八日 (包括首尾兩日) (「第四個期間」) Up to 20% ("Fourth Options") (together with any First, Second and Third Options which have not been exercised during the First Period, Second Period and Third Period) 最多20%(「第四份講股權」)(建同於第一個期間、第二個期間及第三個期間尚未行使之任何第一份、第二份及第三份購股權)

9 September 2021 to 8 September 2025 (both days inclusive) (the "Fifth Period") 二零二一年九月九日至 二零二五年九月八日 (包括首尾兩日) (「第五個期間」) Up to 20% ("Fifth Options") (together with any First, Second, Third and Fourth Options which have not been exercised during the First Period, Second Period, Third Period and Fourth Period) 最多 20% (「第五份講股權」)(連同於第一個期間、第三個期間入第二個期間入第二個期間入第三個則可以第二份、第三份及

第四份購股權)

Up to 30% ("A Options")

最多30%(「A類購股權」)

25/1/2017*2 0.3025 二零一七年 一月二十五日*2 1 August 2019 to 31 July 2020 (both days inclusive) (the "A Period") 二零一九年八月一日至 二零二零年七月三十一日 (包括首尾兩日) (「A期間」)

1 August 2020 to 31 July 2021 (together with any A Options") (both days inclusive) (the "B Period") に零二一年七月三十一日(包括首尾兩日)(「B期間」) (使同於A期間尚未行使之任何A類購股権)

0 500,000,000 NIL NIL NIL 500,000,000







SHARE OPTIONS (Cont'd)

購股權(續)

NIL

無

NIL

1,620,000

(79,000,000)

99,560,000

Share Option Scheme (Cont'd)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017
裁ぶニ愛――――――――――――――――――――――――――――――――――――

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
					於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

Up to the remaining 24 January 2027 (both days inclusive) (the "C Period") 二零二一年八月一日至 二零二七年一月二十四日 (包括首尾兩日)(「C期間」)

1 August 2021 to

balance of the options granted (together with any A and B Options which have not been exercised during the A Period and B Period)

最多為已授出購股權之結餘 (連同於A期間及 B期間尚未行使之 任何A類及B類購股權)

Others 16/9/2015 二零一五年 九月十六日 其他

For Grantees other than new employees who have joined the Company for less than 12 months or are yet to

commence work with the Company on the relevant date of

grant (as the case may be):-

就於相關授出日期之承授人(除加入本公司少於十二個月或 仍未開始於本公司任職之新僱員外)而言(視情況而定):一

1st Options 第一份購股權 1st Period 第一個期間

2nd Period 第二個期間 2nd Options (together with any 1st Options which have not been exercised during the 1st Period) 第二份購股權(連同

於第一個期間尚未行使之 任何第一份購股權)

3rd Period 第三個期間 3rd Options (together with any 1st and 2nd Options which have not been exercised during the 1st Period and

2nd Period) 第三份購股權(連同於第一個 期間及第二個期間尚未 行使之任何第一份及 第二份購股權)

董事會報告



SHARE OPTIONS (Cont'd)

Share Option Scheme (Cont'd)

購股權(續)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017 截至二零一七年四月三十日止年度之購股權變動

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
			•	•	於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

5th Period
第五個期間
with any 1st, 2nd, 3rd and
4th Options which have
not been exercised during
the 1st Period, 2nd Period,
3rd Period and 4th Period)
第五份講股權(連同於第一個
期間、第三個期間、第三個期間及
任何事份、第三份、
第三份及第四份講股權)

For Grantees who are new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be):— 就於相關授出日期之承授人(為加入本公司少於十二個月或 仍未開始於本公司任職之新僱員)而言(視情況而定):—

16 March 2017 to 15 March 2018 (both days inclusive) (the "Period 1") 二零一七年三月十六日至 二零一八年三月十五日 (包括首尾兩日) (「期間1」)

16 March 2018 to 15 March 2019 (together with any Options 2") (together with any Options 1 which have not been exercised during the Period 1) 显象一九年三月十五日 (包括首尾兩日) (博同於期間 1 尚未行使之任何購股權 1)







SHARE OPTIONS (Cont'd)

購股權(續)

Share Option Scheme (Cont'd)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017 截至二零一七年四月三十日止年度之購股權變動

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
					於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

16 March 2019 to 15 March 2020 (both days inclusive) (the "Period 3") 二零一九年三月十六日至 二零二零年三月十五日 (包括首尾兩日) (「期間3」) Up to 20% ("Options 3")
(together with any Options 1 and 2 which have not been exercised during the Periods 1 and 2)
最多20% (「購股權3」)(連同期間1及2尚未行使之任何購股權1及2)

16 March 2020 to 15 March 2021 (both days inclusive) (the "Period 4") 二零二零年三月十六日至 二零二一年三月十五日 (包括首尾兩日)

(「期間4」)

Up to 20% ("Options 4") (together with any Options 1, 2 and 3 which have not been exercised during the Periods 1, 2 and 3) 最多 20% (「購股權4」)(建同於期間1、2 及3)尚未行使之任何購股權1、2 及3)

16 March 2021 to 15 September 2025 (both days inclusive) 二零二一年三月十六日至 二零二五年九月十五日 (包括首尾兩日) Up to 20% (together with any Options 1, 2, 3 and 4 which have not been exercised during the Periods 1, 2, 3 and 4) 最多20% (連同於 期間1, 2、3及4尚未行使之任何購股權1, 2、3及4)

0 171,130,000

NIL

(4,000,000)

(28, 100, 000)

139,030,000

9/9/2016 二零一六年 九月九日 0.291

For Grantees other than new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be):—
就於相關授出日期之承授人(除加入本公司少於十二個月或
仍未開始於本公司任職之新僱員外)而言(視情況而定):—

the First Period the First Options 第一個期間 第一份購股權

the Second Period 第二個期間 the Second Options (together with any First Options which have not been exercised during the First Period) 第二份購股權 (連同於第一個 期間尚未行使之 任何第一份購股權)

128

董事會報告



SHARE OPTIONS (Cont'd)

Share Option Scheme (Cont'd)

購股權(續)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017

截至二零一七年四月三十日止年度之購股權變動

Eligible	Date of	Exercise price	Vesting schedule and exercise period	Exercisable portion of the Share Options	Outstanding as at 30 April					Outstanding as at 30 April
persons	grant	(HK\$)	of the Share Options	granted	2016 於	Granted	Exercised	Reclassified	Lapsed	2017
		行使價	購股權之 歸屬時間表及	已授出購股權之	二零一六年 四月三十日					二零一七年四月三十日
合資格人士	授出日期	(港元)	可行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

the Fourth Period 第四個期間 the Fourth Options (together with any First, Second and Third Options which have not been exercised during the First Period, Second Period and Third Period) 第四份購股權 (連同於第一個期間入第三個期間內未行使之任何第一份、第三份及第三份請股權)

the Fifth Period 第五個期間 the Fifth Options (together with any First, Second, Third and Fourth Options which have not been exercised during the First Period, Second Period, Third Period and Fourth Period) 第五份購股權 (連同於第一個期間、第三個期間、第三個期間及定之 任何及第四份 對







SHARE OPTIONS (Cont'd)

購股權(續)

Share Option Scheme (Cont'd)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017 截至二零一七年四月三十日止年度之購股權變動

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
					於					於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

For Grantees who are new employees who have joined the Company for less than 12 months or are yet to commence work with the Company on the relevant date of grant (as the case may be):— 就於相關授出日期之承授人(為加入本公司少於十二個月或 仍末開始於本公司任職之新權員)而言(視情況而定):—

9 March 2018 to 8 March 2019 (both days inclusive) (the "I Period")

(the "I Period") 二零一八年三月九日至 二零一九年三月八日 (包括首尾兩日)

__令一ルキニガハ『 (包括首尾兩日) (「期間I」)

8 March 2020 (both days inclusive) (the "II Period")
二零一九年三月九日至
二零二零年三月八日(包括首尾兩日)

9 March 2020 to 8 March 2021 (both days inclusive) (the "III Period") 二零二零年三月九日至 二零二一年三月八日

9 March 2021 to 8 March 2022 (both days inclusive) (the "IV Period") 二零二一年三月九日至 二零二二年三月八日

> (包括首尾兩日) (「期間IV」)

> (包括首尾兩日)

(「期間Ⅲ」)

Up to 20% ("Options I") 最多20% (「購股權I」)

Up to 20% ("Options II")
(together with any Options I
which have not been
exercised during the
I Period)

最多20%(「購股權II」)(連同於期間I尚未行使之任何購股權I)

Up to 20% ("Options III") (together with any Options I and II which have not been exercised during the I and II Periods) 最多 20% (「購股權III」)(連同於期間I及II尚未行使之任何購股權I及II)

Up to 20% ("Options IV") (together with any Options I, II and III which have not been exercised during the I, II and III Periods) 最多 20% (「購股權 IV」) (連同於期間、IJ及III 间未行使之任何購股權 I、II及III)



董事會報告



SHARE OPTIONS (Cont'd)

Share Option Scheme (Cont'd)

購股權(續)

購股權計劃(續)

Movement of Share Options during the year ended 30 April 2017 截至二零一七年四月三十日止年度之購股權變動

					Outstanding					Outstanding
		Exercise	Vesting schedule	Exercisable portion	as at					as at
Eligible	Date of	price	and exercise period	of the Share Options	30 April					30 April
persons	grant	(HK\$)	of the Share Options	granted	2016	Granted	Exercised	Reclassified	Lapsed	2017
•	_		•	-	於				-	於
			購股權之		二零一六年					二零一七年
		行使價	歸屬時間表及	已授出購股權之	四月三十日					四月三十日
合資格人士	授出日期	(港元)	行使期間	可行使部份	尚未行使	已授出	已行使	已重新分類	已失效	尚未行使

9 March 2022 to 8 September 2025 (both days inclusive) 二零二二年三月九日至 二零二五年九月八日 (包括首尾兩日) Up to 20% (together with any Options I, II, III and IV which have not been exercised during the I, III, IIII and IV Periods) 最多20% (連同於 期間I、III、III及IV尚未行使之

任何購股權Ⅰ、Ⅱ、Ⅲ及Ⅳ)

- The outstanding share options as at 30 April 2016 and as at 1 May 2016 were 73,720,000 and 50,750,000 respectively. The difference is due to the reclassification arising from the changes of the roles in directorship.
- References are made to the announcements of the Company dated 25 January 2017, 20 March 2017 and the circular dated 26 June 2017 in relation to the conditional grant of Share Options to Mr. Chen Chunguo to subscribe for up to an aggregate of 500,000,000 ordinary shares. On 17 July 2017, the Shareholders excluding Mr. Chen and his associates (the "Independent Shareholders") has approved the resolution at the extraordinary general meeting (the "EGM"), please refer to the announcement dated 17 July 2017 for details.
- The outstanding share options as at 30 April 2016 and as at 1 May 2016 were 176,940,000 and 182,410,000 respectively. The difference is due to the reclassification arising from the changes of the roles in directorship and other function.

Share Options of placing agreement

On 5 March 2015, pursuant to a placing agreement dated 10 November 2014 between the Company and a placing agent, 495,000,000 share options with exercise price of HK\$0.25 per share and exercisable period from 5 September 2015 to 4 September 2016 were issued to All Favour and independent parties. The share options had been lapsed on 13 September 2016.

Save as disclosed above, no further share options were granted, outstanding, lapsed, cancelled or exercised for the year ended 30 April 2017.

- 11 於二零一六年四月三十日及二零一六年五月一日之尚未行使購股權分別為73,720,000份及50,750,000份。差額乃由於董事角色變動引致的重新分類。
- 2 茲提述本公司日期為二零一七年一月二十五日、 二零一七年三月二十日之公告及日期為二零一七 年六月二十六日之通函,內容有關向陳春國先生 有條件授出可認購合共最多500,000,000股普通 股之購股權。於二零一七年七月十七日,股東 (不包括陳先生及其聯繫人)(「獨立股東」)已於 股東特別大會(「股東特別大會」)上批准該決議 案,詳情請參閱日期為二零一七年七月十七日之 公告。
- "3 於二零一六年四月三十日及二零一六年五月一日之尚未行使購股權分別為176,940,000份及 182,410,000份。差額乃由於董事角色及其他職 能變動引致的重新分類。

購股權配售協議

於二零一五年三月五日,根據日期為二零一四年十一月十日本公司與配售代理之間的配售協議,向全輝及獨立人士發行495,000,000份購股權,行使價為每股0.25港元及可行使期間為二零一五年九月五日至二零一六年九月四日。購股權已於二零一六年九月十三日失效。

除上文所披露者外,截至二零一七年四月三十日 止年度,概無其他購股權已授出、尚未行使、失 效、註銷或已行使。

董事會報告



DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 April 2017, the following Directors and chief executives of the Company had or were deemed to have interest or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules related to securities transactions by the Directors to be notified to the Company and the Stock Exchange:

Long Positions

Interests in the shares and underlying shares of the Company

董事及最高行政人員於股份及相關股份之權益及淡倉

於二零一七年四月三十日,下列董事及本公司最高行政人員於本公司及其相聯法團(定義見香港法例第571章證券及期貨條例(「證券及期貨條例」)第XV部)之股份、相關股份或債券中,擁有或被視作擁有(i)根據證券及期貨條例第XV部7及8分部須知會本公司及聯交所之權益或淡倉(包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉);或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉;或(iii)根據創業板上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所之權益或淡倉:

好倉

於本公司股份及相關股份之權益

Aggregate long

Approximate

Capacity	Aggregate long position in the shares and underlying shares 於股份及相關股份	Approximate percentage of the issued share capital 佔已發行股本
身份	之好倉總計	概約百分比
Interests held jointly with another person 與其他人士共同持有的權益	30,000,000	0.17%
Beneficial owner 實益擁有人	31,560,000	0.18%
Beneficial owner 實益擁有人	35,530,000	0.20%
Beneficial owner 實益擁有人	500,000,000	2.84%
Beneficial owner 實益擁有人	78,630,000	0.45%
Beneficial owner 實益擁有人	4,500,000	0.03%
Beneficial owner 實益擁有人	4,410,000	0.03%
Beneficial owner 實益擁有人	4,230,000	0.02%
	身份 Interests held jointly with another person 與其他人士共同持有的權益 Beneficial owner 實益擁有人 Beneficial owner	Capacity 身份 Interests held jointly with another person 與其他人士共同持有的權益 Beneficial owner 實益擁有人 Beneficial owner



董事會報告



DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES (Cont'd)

Notes:

 Mr. Wong Sai Hung ("Mr. Wong") is an executive Director and the Vicechairman. Mr. Wong's interests are held jointly with his spouse. By virtue of the SFO, Mr. Wong and his spouse are deemed to be interested in 30,000,000 shares of the Company.

On 16 September 2015, Mr. Wong was granted 7,560,000 share options (the "Share Options") by the Company under the share option scheme of the Company adopted on 14 September 2011 (the "Share Option Scheme") entitling him to subscribe for 7,560,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, Mr. Wong was granted 24,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 24,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Wong on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Wong shall hold the 31,560,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Wong and his spouse, together with their deemed interest in the shares held jointly, shall be deemed to be interested in an aggregate of 61,560,000 shares of the Company as at 30 April 2017.

 Dr. Shao Zhengkang ("Dr. Shao") is an executive Director. Dr. Shao personally holds 500,000 shares of the Company.

On 16 September 2015, he was granted 12,030,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 12,030,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, he was granted 23,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 23,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Dr. Shao on 16 September 2015 and 9 September 2016 have been exercised in full, Dr. Shao shall hold an aggregate of 35,030,000 shares of the Company as beneficial owner.

By virtue of the SFO, Dr. Shao shall be deemed to be interested in an aggregate of 35,530,000 shares of the Company as at 30 April 2017.

董事及最高行政人員於股份及相關股份之權益及淡倉(續)

附註:

 黃世雄先生(「黃先生」)為執行董事兼副主席。 黃先生的權益乃與其配偶共同持有。根據證券及 期貨條例,黃先生及其配偶被視為於30,000,000 股本公司股份中擁有權益。

於二零一五年九月十六日,黃先生獲本公司根據 於二零一一年九月十四日採納之本公司購股權 計劃(「購股權計劃」)授予7,560,000份購股權 (「購股權」),賦予其權利可按每股0.45港元之 行使價認購7,560,000股本公司股份,惟須遵守 購股權計劃之條款及條件。

於二零一六年九月九日,黃先生獲本公司根據購股權計劃授予24,000,000份購股權,賦予其權利可按每股0.291港元之行使價認購24,000,000股本公司股份,惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月 九日授予黃先生之購股權獲悉數行使,黃先生將 作為實益擁有人持有31,560,000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,黃先生及其配偶,連同彼等被視為於共同持有之股份中擁有之權益應被視為於合共61,560,000股本公司股份中擁有權益。

 邵政康博士(「邵博士」)為執行董事。邵博士個 人持有500,000股本公司股份。

於二零一五年九月十六日,彼獲本公司根據購股權計劃授予12,030,000份購股權,賦予其權利可按每股0.45港元之行使價認購12,030,000股本公司股份,惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日,彼獲本公司根據購股權計劃授予23,000,000份購股權,賦予其權利可按每股0.291港元之行使價認購23,000,000股本公司股份,惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月 九日授予邵博士的購股權獲悉數行使,邵博士將 作為實益擁有人持有合共35,030,000股本公司股 份。

根據證券及期貨條例,於二零一七年四月三十日,邵博士應被視為於合共35,530,000股本公司股份中擁有權益。

董事會報告



DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES (Cont'd)

Notes: (Cont'd)

3. Mr. Chen Chunguo ("Mr. Chen") is an executive Director with effect from 25 January 2017 and the CEO with effect from 23 February 2017.

On 25 January 2017, he was conditionally granted 500,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for up to an aggregate of 500,000,000 shares of the Company at the exercise price of HK\$0.3025 per share, subject to the terms and conditions of the Share Option Scheme. On 17 July 2017, the Independent Shareholders has approved the resolution at the EGM.

Assuming the Share Options granted to Mr. Chen on 25 January 2017 have been exercised in full, Mr. Chen shall hold an aggregate of 500,000,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Chen shall be deemed to be interested in 500,000,000 shares of the Company as at 30 April 2017.

4. Professor Cui Zhanfeng ("Prof. Cui") is a non-executive Director and the Chairman with effect from 7 October 2016. Prof. Cui personally holds 65,000,000 shares of the Company.

On 16 September 2015, he was granted 9,630,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 9,630,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, he was granted 4,000,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 4,000,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Prof. Cui on 16 September 2015 and 9 September 2016 have been exercised in full, Prof. Cui shall hold an aggregate of 13,630,000 shares of the Company as beneficial owner.

By virtue of the SFO, Prof. Cui shall be deemed to be interested in an aggregate of 78,630,000 shares of the Company as at 30 April 2017.

董事及最高行政人員於股份及相關股份之權益及淡倉(續)

附註:(續)

3. 陳春國先生(「陳先生」)自二零一七年一月 二十五日起為執行董事及自二零一七年二月 二十三日起為行政總裁。

於二零一七年一月二十五日,彼獲本公司根據購股權計劃有條件授予500,000,000份購股權,賦予其權利可按每股0.3025港元之行使價認購合共最多500,000,000股本公司股份,惟須遵守購股權計劃之條款及條件。於二零一七年七月十七日,獨立股東已於股東特別大會上批准該決議案。

假設於二零一七年一月二十五日授予陳先生的購 股權獲悉數行使,陳先生將作為實益擁有人持有 合共500.000.000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,陳先生應被視為於500,000,000股本公司股份中擁有權益。

 自二零一六年十月七日起,崔占峰教授(「崔教授」)為非執行董事及主席。崔教授個人持有 65,000,000股本公司股份。

於二零一五年九月十六日,彼獲本公司根據購股權計劃授予9,630,000份購股權,賦予其權利可按每股0.45港元之行使價認購9,630,000股本公司股份,惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日,彼獲本公司根據購股權計劃授予4,000,000份購股權,賦予其權利可按每股0.291港元之行使價認購4,000,000股本公司股份,惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月 九日授予崔教授的購股權獲悉數行使,崔教授將 作為實益擁有人持有合共13,630,000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,崔教授應被視為於合共78,630,000股本公司股份中擁有權益。



董事會報告



DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES (Cont'd)

Notes: (Cont'd)

On 16 September 2015, Mr. Wang Hui ("Mr. Wang") is a non-executive Directors (who was re-designated from independent non-executive Director with effect from 1 June 2017), was granted 1,750,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 1,750,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, Mr. Wang, was granted 2,100,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 2,100,000 shares of the Company at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Wang on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Wang shall hold 3,850,000 shares of the Company as beneficial owners.

By virtue of the SFO, Mr. Wang shall be deemed to be interested in 3,850,000 shares of the Company as at 30 April 2017.

6. On 16 September 2015, Mr. Lui Tin Nang ("Mr. Lui"), Mr. Pang Chung Fai Benny ("Mr. Pang") and Mr. Chan Bing Woon ("Mr. Chan") are the independent non-executive Directors, were granted 2,100,000, 2,010,000 and 1,930,000 Share Options respectively by the Company under the Share Option Scheme entitling each of them to subscribe for 2,100,000, 2,010,000 and 1,930,000 shares of the Company respectively at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme.

On 9 September 2016, Mr. Lui, Mr. Pang and Mr. Chan, were granted 2,400,000, 2,400,000 and 2,300,000 Share Options respectively by the Company under the Share Option Scheme entitling each of them to subscribe for 2,400,000, 2,400,000 and 2,300,000 shares of the Company respectively at the exercise price of HK\$0.291 per share, subject to the terms and conditions of the Share Option Scheme.

Assuming the Share Options granted to Mr. Lui, Mr. Pang and Mr. Chan on 16 September 2015 and 9 September 2016 have been exercised in full, Mr. Lui, Mr. Pang and Mr. Chan shall hold 4,500,000, 4,410,000 and 4,230,000 shares of the Company respectively as beneficial owners.

By virtue of the SFO, Mr. Lui, Mr. Pang and Mr. Chan shall be deemed to be interested in 4,500,000, 4,410,000 and 4,230,000 shares of the Company respectively as at 30 April 2017.

董事及最高行政人員於股份及相關股份之權益及淡倉(續)

附註:(續)

5. 於二零一五年九月十六日,非執行董事王輝先生 (「王先生」,其於二零一七年六月一日起調任為 獨立非執行董事)獲本公司根據購股權計劃授予 1,750,000份購股權,賦予其權利可按每股0.45 港元之行使價認購1,750,000股本公司股份,惟 須遵守購股權計劃之條款及條件。

於二零一六年九月九日,王先生獲本公司根據購股權計劃授予2,100,000份購股權,賦予其權利可按每股0.291港元之行使價認購2,100,000股本公司股份,惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月 九日授予王先生的購股權獲悉數行使,王先生將 作為實益擁有人持有3.850,000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,王先生被視為於3,850,000股本公司股份中擁有權益。

6. 於二零一五年九月十六日,獨立非執行董事呂天能先生(「呂先生」)、彭中輝先生(「彭先生」)、及陳炳煥先生(「陳先生」)分別獲本公司根據購股權計劃授予2,100,000份、2,010,000份及1,930,000份購股權,賦予彼等各自權利分別可按每股0.45港元之行使價認購2,100,000股、2,010,000股及1,930,000股本公司股份,惟須遵守購股權計劃之條款及條件。

於二零一六年九月九日,呂先生、彭先生及陳先生分別獲本公司根據購股權計劃授予2,400,000份、2,400,000份及2,300,000份購股權,賦予彼等各自權利可分別按每股0.291港元之行使價認購2,400,000股、2,400,000股及2,300,000股本公司股份,惟須遵守購股權計劃之條款及條件。

假設於二零一五年九月十六日及二零一六年九月 九日授予呂先生、彭先生及陳先生的購股權獲悉 數行使,呂先生、彭先生及陳先生分別將作為 實益擁有人持有4,500,000股、4,410,000股及 4,230,000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,呂先生、彭先生及陳先生將被視為分別於4,500,000股、4,410,000股及4,230,000股本公司股份中擁有權益。

董事會報告



DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES (Cont'd)

Save as disclosed above, as at 30 April 2017, none of the Directors nor the chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) (i) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO); or (ii) which were required, pursuant to Section 352 of the SFO, to be entered in the register referred to therein; or (iii) which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules relating to securities transactions by Directors to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES

So far as known to the Directors, as at 30 April 2017, the following parties (not being the Directors or chief executives of the Company) had, or were deemed to have, interests or short positions in the shares, underlying shares or debentures of the Company (i) which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or (ii) which were required, pursuant to Section 336 of the SFO, to be entered in the register referred to therein:

董事及最高行政人員於股份及相關股份之權益及淡倉(續)

除上文所披露者外,於二零一七年四月三十日,概無董事或本公司最高行政人員於本公司及其相聯法團(定義見證券及期貨條例第XV部)之股份、相關股份或債券中擁有或被視作擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所之權益或淡倉(包括彼等根據證券及期貨條例有關條文被當作或視作擁有之權益或淡倉);或(ii)根據證券及期貨條例第352條須記入該條所述登記冊之權益或淡倉;或(iii)根據創業板上市規則第5.46至5.67條有關董事進行證券交易之規定須知會本公司及聯交所的權益或淡倉。

主要股東及其他人士於股份及相關股份之權益

據董事所知,於二零一七年四月三十日,下列人士(非董事或本公司最高行政人員)於本公司股份、相關股份或債券中,擁有或被視作擁有(i)根據證券及期貨條例第XV部第2及3分部之條文須向本公司及聯交所披露之權益或淡倉;或(ii)根據證券及期貨條例第336條須記入該條所述登記冊內之權益或淡倉:

董事會報告



SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES (Cont'd)

主要股東及其他人士於股份及相關股份之權益(續)

Long positions

好倉

Interests in the shares and underlying shares of the Company

於本公司股份及相關股份之權益

		Aggregate long position in the shares and	Approximate percentage of the issued
Name of Shareholders	Capacity	underlying shares 於股份及相關股份	share capital 佔已發行股本
股東姓名/名稱	身份		概約百分比
All Favour (Note 7) 全輝 (附註7)	Beneficial owner 實益擁有人	3,708,100,319	21.09 %
Hu Yonggang (Note 7) 胡永剛 (附註7)	Held by controlled corporation 由受控法團持有	3,708,100,319	21.09%
Dai Yumin (Note 7) 戴昱敏 (附註7)	Held by controlled corporation 由受控法團持有	3,708,100,319	21.09%
	Beneficial owner 實益擁有人	510,880,000	2.91%
China Orient Asset Management Corporation (Note 8) 中國東方資產管理公司 (附註8)	Held by controlled corporation 由受控法團持有	1,685,320,319	9.58%
China Orient Alternative Investment Fund (Note 8) (附註8)	Held by controlled corporation 由受控法團持有	1,301,320,319	7.40%
China Orient Alternative Investment Fund Management Limited (Note 9) (附註9)	Investment manager 投資經理	1,301,320,319	7.40%

董事會報告



SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES (Cont'd)

好倉 (續)

份之權益(續)

Long positions (Cont'd)

於本公司股份及相關股份之權益(續)

主要股東及其他人士於股份及相關股

Interests in the shares and underlying shares of the Company (Cont'd)

		Aggregate long position in the shares and	Approximate percentage of the issued
Name of Shareholders	Capacity	underlying shares 於股份及相關股份	share capital 佔已發行股本
股東姓名/名稱	身份	之好倉總計	概約百分比
Kwan Man Cheuk (Note 10) 關文焯 (附註10)	Held by controlled corporation 由受控法團持有	1,184,565,000	6.74%
	Beneficial owner 實益擁有人	66,890,000	0.38%
Contech Bio-Med Ltd. (Note 10) 康泰生物醫學有限公司 (附註10)	Beneficial owner 實益擁有人	1,184,565,000	6.74%
China Dragon Asia Champion Fund Series SPC (Note 11) (附註11)	Investment manager 投資經理	1,094,929,300	6.23%

Notes:

7. All Favour Holdings Limited ("All Favour") is beneficially owned as to (i) 40% by Nat-Ace Wood Industry Ltd. ("Nat-Ace Wood Industry") and 20% by Honour Top Holdings Limited which are both ultimately wholly owned by Mr. Dai Yumin ("Mr. Dai"), and (ii) 40% by Mr. Hu Yonggang ("Mr. Hu"). On 5 March 2015, the Company granted to All Favour an option ("Option") which carries a right to subscribe for up to 360,000,000 new shares of the Company at the initial exercise price of HK\$0.25 per share (subject to adjustment) upon exercise of such Option by All Favour. The Option had been lapsed with effect from 13 September 2016. Moreover, All Favour has been the beneficial owner of 3,708,100,319 shares of the Company. By virtue of the SFO, Mr. Dai, Mr. Hu and Nat-Ace Wood Industry are deemed to be interested in 3,708,100,319 shares of the Company in which All Favour is interested as of 30 April 2017.

附註:

7. 全輝控股有限公司(「全輝」)由(i)邦強木業有限公司(「邦強木業」)實益擁有40%及Honour Top Holdings Limited實益擁有20%,而彼等均由前執行董事戴昱敏先生(「戴先生」)最終全資擁有;及(i)胡永剛先生(「胡先生」)實益擁有40%。於二零一五年三月五日,本公司向全輝授出購股權(「購股權」),該購股權將附帶權利於全輝行使相關購股權時按初步行使價每股股份0.25港元(可予調整)認購最多360,000,000股本公司新股份。購股權已自二零一六年九月十三日起失效。此外,全輝為3,708,100,319股本公司股份之海擁有人。根據證券及期貨條例,截至二零一七年四月三十日,戴先生、胡先生及邦強木業被視為於全輝擁有權益的3,708,100,319股本公司股份中擁有權益。

董事會報告



SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES (Cont'd)

Notes: (Cont'd)

7. (Cont'd)

On 16 September 2015, Mr. Dai was granted 17,500,000 Share Options by the Company under the Share Option Scheme entitling him to subscribe for 17,500,000 shares of the Company at the exercise price of HK\$0.45 per share, subject to the terms and conditions of the Share Option Scheme. Moreover, Mr. Dai personally holds 493,380,000 shares of the Company. Assuming the Share Options granted to Mr. Dai has been exercised in full, Mr. Dai shall hold an aggregate of 510,880,000 shares of the Company as beneficial owner.

By virtue of the SFO, Mr. Dai, together with his deemed interests in All Favour, was deemed to be interested in an aggregate of 4,218,980,319 shares of the Company as at 30 April 2017.

The Company was informed by All Favour that it has pledged its interests in 1,301,320,319 shares of the Company in favour of Optimus Prime Management Ltd.

- 8. Based on Forms 2 both filed on 20 May 2016 by China Orient Asset Management Corporation ("COAMC") and China Orient Alternative Investments Fund ("COAIF"), Optimus Prime Management Ltd. ("Optimus") has a security interest in 1,301,320,319 shares of the Company and China Orient Asset Management (International) Holding Limited ("COAMI") has an interest in 384,000,000 shares of the Company. Optimus is wholly owned by COAIF. COAIF is owned as to 45% by COAMI. COAMI is owned as to (i) 50% by Wise Leader Assets Ltd. ("Wise Leader") which is wholly owned by Dong Yin Development (Holdings) Limited ("Dong Yin"); and (ii) 50% by Dong Yin which is wholly owned by COAMC. By virtue of the SFO, Dong Yin, Wise Leader and COAMC are deemed to be interested in 384,000,000 shares of the Company held by COAMI, and COAIF, COAMI, Dong Yin, Wise Leader and COAMC are deemed to be interested in 1,301,320,319 shares of the Company held by Optimus as security interest.
- 9. Based on Form 2 filed on 20 May 2016 by China Orient Alternative Investment Fund Management Limited ("China Orient Alternative Investment Fund Management"), China Orient Alternative Investment Fund Management holds 1,301,320,319 shares of the Company as an Investment manager.
- Based on Form 2 and Form 1 both filed on 4 May 2017 by Contech Bio-Med Ltd. ("Contech") and Mr. Kwan Man Cheuk ("Mr. Kwan"), Contech is wholly owned by Mr. Kwan. Contech has been the beneficial owner of 1,184,565,000 shares of the Company.

主要股東及其他人士於股份及相關股份之權益(續)

附註:(續)

7. (續)

於二零一五年九月十六日,戴先生獲本公司根據購股權計劃授予17,500,000份購股權,賦予其權利可按行使價每股0.45港元認購17,500,000股本公司股份,惟須遵守購股權計劃之條款及條件。此外,戴先生個人持有493,380,000股本公司股份。假設授予戴先生之購股權獲悉數行使,戴先生將作為實益擁有人持有合共510,880,000股本公司股份。

根據證券及期貨條例,於二零一七年四月三十日,連同彼被視為於全輝擁有之權益,戴先生被視為於合共4,218,980,319股本公司股份中擁有權益。

本公司獲全輝告知,其已將其於1,301,320,319股本公司股份中的權益抵押予Optimus Prime Management Ltd。

- 根據中國東方資產管理公司(「東方資產」) 及China Orient Alternative Investments Fund (「COAIFI) 均於二零一六年五月二十日提交 的 表 格2, Optimus Prime Management Ltd. (「Optimus」)於1,301,320,319股本公司股份 中持有保證權益且中國東方資產管理(國際)控 股有限公司(「東方國際」)於384,000,000股本 公司股份中擁有權益。Optimus由COAIF全資 擁有。COAIF由東方國際擁有45%。東方國際 由(i)Wise Leader Assets Ltd.(「WiseLeader」, 由東銀發展(控股)有限公司(「東銀」)全資擁 有)擁有50%;及(ii)東銀(由東方資產全資擁 有)擁有50%。根據證券及期貨條例,東銀、 Wise Leader及東方資產被視為於東方國際持 有的384.000.000股本公司股份中擁有權益 而COAIF、東方國際、東銀、Wise Leader及 東方資產被視為於Optimus持作保證權益的 1.301.320.319 股本公司股份中擁有權益。
- 9. 根據China Orient Alternative Investment Fund Management Limited (「China Orient Alternative Investment Fund Management」) 提交日期為二零一六年五月二十日的表格2, China Orient Alternative Investment Fund Management 作為投資經理持有1,301,320,319股本公司股份。
- 10. 根據康泰生物醫學有限公司(「康泰」)及關文焯 先生(「關先生」)提交日期為二零一七年五月四 日的表格2及表格1,康泰由關先生全資擁有。康 泰為1,184,565,000股本公司股份之實益擁有人。



董事會報告





SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS IN SHARES AND UNDERLYING SHARES (Cont'd)

Notes: (Cont'd)

10. (Cont'd)

By virtue of the SFO, Mr. Kwan is deemed to be interested in 1,184,565,000 shares of the Company in which Contech is interested as of 30 April 2017.

Mr. Kwan personally holds 66,890,000 shares of the Company. By virtue of the SFO, Mr. Kwan, together with his deemed interests in Contech, is deemed to be interested in an aggregate of 1,251,455,000 shares of the Company as at 30 April 2017.

The Company was informed by Contech that it has pledged its interests in 1,184,565,000 shares of the Company in favour of Mason Resources Finance Limited.

11. Based on Form 2 filed on 23 January 2017 by China Dragon Asia Champion Fund Serise SPC ("China Dragon"), China Dragon holds 1,094,929,300 shares of the Company as an Investment manager.

Save as disclosed above, as at 30 April 2017, the Directors are not aware that there is any other party (other than the Directors and the chief executives of the Company) who had, or was deemed to have, interests or short positions in the shares, underlying shares and debentures of the Company (i) which would fall to be disclosed to the Company and Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO; or (ii) which were required, pursuant to section 336 of the SFO, to be entered in the register referred to therein.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed under the heading "DIRECTORS AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES" in this report, at no time during the year were the rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director or chief executive of the Company or their respective spouse or children under 18 years of age, or were any such rights exercised by them; or was the Company or its subsidiaries a party to any arrangement to enable the Directors to acquire such rights or benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

主要股東及其他人士於股份及相關股份之權益(續)

附註:(續)

10. (續)

根據證券及期貨條例,截至二零一七年四月 三十日,關先生被視為於康泰擁有權益的 1,184,565,000股本公司股份中擁有權益。

關先生個人持有66,890,000股本公司股份。根據證券及期貨條例,於二零一七年四月三十日,連同彼被視為於康泰中擁有之權益,關先生被視作於合共1,251,455,000股本公司股份中擁有權益。

本公司獲康泰告知,其已將其於1,184,565,000 股本公司股份中的權益抵押予茂宸資源財務有限 公司。

11. 根 據China Dragon Asia Champion Fund Serise SPC(「China Dragon」) 提交的日期為二零一七年一月二十三日的表格2, China Dragon作為投資經理持有1,094,929,300股本公司股份。

除上文所披露者外,於二零一七年四月三十日,董事概不知悉任何其他人士(董事及本公司最高行政人員除外)於本公司股份、相關股份及債券中,擁有或被視作擁有(i)根據證券及期貨條例第XV部第2及3分部之條文須向本公司及聯交所披露之權益或淡倉;或(ii)根據證券及期貨條例第336條須記入該條所述登記冊內之權益或淡倉。

董事收購股份或債權證之權利

除本報告「董事及最高行政人員於股份及相關股份之權益及淡倉」一節所披露者外,於年內任何時間,任何董事或本公司最高行政人員或彼等各自之配偶或未滿18歲子女概無獲授可透過收購本公司股份或債權證而獲益之任何權利,彼等亦無行使任何上述權利:本公司或其附屬公司亦無訂立任何安排,使董事可透過收購本公司或任何其他法團之股份或債權證以獲取該等權利或利益。

董事會報告



CONNECTED TRANSACTION

The Company had not entered into any connected transaction during the year which is required to be disclosed under the GEM Listing Rules.

EMOLUMENTS OF DIRECTORS AND CHIEF EXECUTIVES AND FIVE HIGHEST PAID INDIVIDUALS

Details of the emoluments of the Directors and chief executives and the five highest paid individuals of the Group are set out in note 9 to the financial statements.

EMOLUMENT POLICY

A Remuneration Committee is set up for reviewing the Group's emolument policy and structure for all remuneration of the Directors and senior management of the Group, having regard to the Group's operating results, individual performance and comparable market practices.

The Company has adopted a share option scheme as incentive to Directors and eligible employees, details of the scheme are set out in note 33 to the financial statements.

DIRECTORS' INTEREST IN COMPETING BUSINESS

None of the Directors or the substantial shareholders of the Company, or any of their respective close associates (as defined under the GEM Listing Rules) had any interest in a business that competes or may compete with the business of the Group.

MAJOR CUSTOMERS AND SUPPLIERS

Sales to the Group's five largest customers accounted for approximately 87% of the Group's total turnover for the year. In particular, sales to the largest customer of the Group accounted for approximately 46% of the Group's total turnover for the year.

Purchases from the Group's five largest suppliers accounted for approximately 95% of the Group's total purchases for the year. In particular, purchases from the Group's largest supplier accounted for approximately 47% of the Group's total purchases for the year.

None of the Directors of the Company, their close associates (as defined in the GEM Listing Rules) or any Shareholder (which to the knowledge of the Directors of the Company own more than 5% of the Company's issued share capital) had any beneficial interests in the Group's five largest customers or suppliers.

關連交易

本公司於年內概無訂立任何根據創業板上市規則 須予披露的關連交易。

董事及最高行政人員以及五位最高薪 人士之酬金

董事及最高行政人員以及本集團五位最高薪人士 之酬金詳情載於財務報表附註9。

薪酬政策

成立薪酬委員會旨在根據本集團之經營業績、個 人表現及可資比較之市場慣例,檢討本集團之薪 酬政策及本集團全體董事及高級管理層之薪酬架 構。

本公司已採納一項購股權計劃,作為對董事及合資格僱員之獎勵,該計劃之詳情載於財務報表附註33。

董事於競爭性業務之權益

董事或本公司主要股東或彼等各自之任何緊密聯繫人(定義見創業板上市規則)概無在與本集團業務產生競爭或可能產生競爭之業務中擁有任何權益。

主要客戶及供應商

本集團向五大客戶的銷售佔本集團本年度總營業額約87%。就此而言,本集團向最大客戶的銷售 佔本集團本年度的總營業額約46%。

本集團向五大供應商的採購佔本集團本年度總採購額約95%。就此而言,本集團向最大供應商的採購佔本集團本年度的總採購額約47%。

概無本公司董事、其緊密聯繫人(定義見創業板上市規則)或任何股東(就本公司董事所悉,持有本公司已發行股本超過5%之股東)於本集團五大客戶或供應商擁有任何實益權益。

董事會報告



USE OF PROCEEDS

所得款項用途

The following table sets out the revised use and actual use of the net proceeds from the placings as at 30 April 2017:

下表載列截至二零一七年四月三十日止,配售所得款項淨額之經修訂用途及實際用途:

Date of announcement 公告日期	Fund raising activities 集資活動	Revised use of the net proceeds 所得款項淨額之 經修訂用途	Total net proceeds 所得款項淨值總額 (HKD Million) (百萬港元)	Utilised 已動用 (HKD Million) (百萬港元)	Unutilised 未動用 (HKD Million) (百萬港元)
10 November 2014, 6 February 2015 and 5 March 2015 二零一四年十一月十日、二零 一五年二月六日及二零一五年 三月五日	Placing of 3,300,000,000 new shares and grant of share options under specific mandate under the First Placing 於第一次配售項下根據特別授權	(a) Used for existing operations and products development and expansion tissue engineering (a) 用於組織工程之現有營運和產品開發及擴展		73.0	-
	配售3,300,000,000股新股份及授出購股權	(b) Used for broadening R&D coverage, capturing strategic investment opportunities in regenerative medicine and stem cell related industries, and other investments (b) 用於擴展研發覆蓋範圍、把握再生醫及幹細胞相關產業的戰略投資機會和他投資	學	269.0	-
		(c) Settlement of consideration under the Sale and Purchase Agreement (c) 清償買賣協議項下之代價	475.0	475.0	-
		Sub-total 小計	817.0	817.0	_
23 March 2015 and 22 April 2015 二零一五年三月二十三日及二零 一五年四月二十二日	Placing of 977,300,000 new shares under general mandate under the Second Placing 於第二次配售項下根據一般授權配售 977,300,000 股新股份	(a) Used for existing operations and products development and expansic in tissue engineering (a) 用於組織工程之現有營運和產品開發及擴展		64.6	_
		(b) Used for broadening R&D coverage, capturing strategic investment opportunities in regenerative medicir and stem cell related industries, and other investments (b) 用於擴展研發覆蓋範圍、把握再生醫及幹細胞相關產業的戰略投資機會和他投資	學	81.4	_
		(c) Settlement of consideration under th Sale and Purchase Agreement (c) 清償買賣協議項下之代價	e 130.0	130.0	_
		Sub-total 小計	276.0	276.0	-

DIRECTORS' REPORT

董事會報告



USE OF PROCEEDS (Cont'd)

所得款項用途(續)

Date of announcement 公告日期	Fund raising activities 集資活動	所得	rised use of the net proceeds 款項淨額之 訂用途	Total net proceeds 所得款項淨值總額 (HKD Million) (百萬港元)	Utilised 已動用 (HKD Million) (百萬港元)	Unutilised 未動用 (HKD Million) (百萬港元)
10 July 2015 and 30 July 2015 —零一五年七月十日及二零一五 年七月三十日 Placing of 1,150,000,000 new shares under general mandate under the Third Placing 於第三次配售項下根據一般授權 配售 1,150,000,000 股新股份	new shares under	(a) (a)	Money lending operation 放債業務	150.0	120.0	30.0
	Third Placing (b) 三次配售項下根據一般授權 (b)	Medical equipment trading 醫療設備貿易	50.0	50.0	_	
		General working capital 一般營運資金				
			256.0	256.0	_	
			Sub-total 小計	456.0	426.0	30.0
			Total 總計	1,549.0	1,519.0	30.0

PURCHASE, REDEMPTION OR SALE OF LISTED SECURITIES OF THE COMPANY

For the year ended 30 April 2017, the Company repurchased a total of 6,390,000 shares, which were wholly cancelled on 8 September 2016, at an aggregate purchase price of HK\$1,847,425 (excluding commission of HK\$11,120) from the Stock Exchange. Particulars of the repurchases are as follows:—

購買、贖回或出售本公司上市證券

截至二零一七年四月三十日止年度,本公司已於聯交所購回合共6,390,000股股份(已於二零一六年九月八日全部註銷),總收購價為1,847,425港元(不包括佣金11,120港元)。購回之詳情如下:一

		Total number	Price per share or highest price	Lowest	
Repurchase date		of shares	paid 已付每股	price paid	Total paid
			價格或	已付	
購回日期		股份總數	最高價格	最低價格	支付總額
		(HK\$)	(HK\$)	(HK\$)	(HK\$)
		(港元)	(港元)	(港元)	(港元)
26 July 2016	二零一六年七月二十六日	1,000,000	0.295	0.295	295,000
27 July 2016	二零一六年七月二十七日	230,000	0.29	0.29	66,700
28 July 2016	二零一六年七月二十八日	1,130,000	0.29	0.29	327,700
29 July 2016	二零一六年七月二十九日	1,035,000	0.29	0.285	296,975
1 August 2016	二零一六年八月一日	995,000	0.29	0.29	288,550
3 August 2016	二零一六年八月三日	500,000	0.29	0.29	145,000
4 August 2016	二零一六年八月四日	1,000,000	0.285	0.285	285,000
5 August 2016	二零一六年八月五日	500,000	0.285	0.285	142,500

DIRECTORS' REPORT

董事會報告



CORPORATE GOVERNANCE

The Company maintains a high standard of corporate governance practices. Details of the corporate governance practices adopted by the Company are set out in the Corporate Governance Report on pages 73 to 96. The Directors believe the long term financial performance as opposed to short term rewards is a corporate governance objective. The Board would not take undue risks to make short term gains at the expense of long term objectives.

SUFFICIENCY OF PUBLIC FLOAT

Based on information publicly available to the Company and within the knowledge of the Directors as at the date of this annual report, the Company has maintained the prescribed public float under the GEM Listing Rules.

INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from each independent non-executive Director the written confirmation of his independence pursuant to Rule 5.09 of the GEM Listing Rules. The Company considers all of the independent non-executive Directors are independent.

AUDIT COMMITTEE

The Audit Committee has eight members, comprising of all non-executive Directors (including independent non-executive Directors), namely Mr. Lui Tin Nang (the chairman of Audit Committee), Professor Cui Zhanfeng, Dr. Ray Yip, Professor Xiong Chengyu, Mr. Wang Hui, Mr. Pang Chung Fai Benny, Mr. Chan Bing Woon and Mr. Wong Yiu Kit Ernest. The Audit Committee has reviewed the Company's audited consolidated financial statements for the year ended 30 April 2017.

PRE-EMPTIVE RIGHTS

There is no provision for pre-emptive rights under the Company's articles of association, or laws of the Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to existing shareholders of the Company.

企業管治

本公司一直維持高水平之企業管治常規。本公司 所採納之企業管治常規詳情乃載於第73至第96 頁之企業管治報告。董事相信,企業管治目標乃 著眼於長期財務表現而非局限於短期回報。董事 會不會冒不必要之風險,以獲取短期收益而犧牲 遠景規劃。

足夠之公眾持股量

根據本公司所獲之公開資料,以及據董事於本年報日期所知,本公司一直維持創業板上市規則規定之公眾持股量。

獨立非執行董事

本公司已接獲各獨立非執行董事根據創業板上市規則第5.09條就其獨立性發出之書面確認。本公司認為全體獨立非執行董事均為獨立人士。

審核委員會

審核委員會有八位成員,包括所有非執行董事 (包括獨立非執行董事),即呂天能先生(審核委員會主席)、崔占峰教授、葉雷博士、熊澄宇教授、王輝先生、彭中輝先生、陳炳煥先生及黃耀傑先生。審核委員會已審閱截至二零一七年四月三十日止年度之本公司經審核綜合財務報表。

優先購買權

本公司之組織章程細則或開曼群島法例並無載列 優先購買權條文,以規定本公司須按比例基準向 本公司現有股東發售新股份。

DIRECTORS' REPORT

董事會報告



AUDITOR

A resolution will be proposed at the forthcoming annual general meeting of the Company to re-appoint BDO Limited as auditor of the Company.

On behalf of the Board

Wong Sai Hung

Executive Director

Hong Kong, 17 July 2017

核數師

有關續聘香港立信德豪會計師事務所有限公司為 本公司核數師之決議案,將於本公司應屆股東週 年大會上提呈。

代表董事會

黃世雄

執行董事

香港,二零一七年七月十七日

獨立核數師報告





Tel: +852 2218 8288 Fax: +852 2815 2239 www.bdo.com.hk

電話:+852 2218 8288

傳真:+852 2815 2239 www.bdo.com.hk 25th Floor Wing On Centre 111 Connaught Road Central

Hong Kong

香港 干諾道中111號 永安中心25樓

TO THE SHAREHOLDERS OF CHINA REGENERATIVE MEDICINE INTERNATIONAL LIMITED 中國再生醫學國際有限公司

(incorporated in the Cayman Islands with limited liability)

OPINION

We have audited the consolidated financial statements of China Regenerative Medicine International Limited (the "Company") and its subsidiaries (together "the Group") set out on pages 152 to 247, which comprise the consolidated statement of financial position as at 30 April 2017, and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 30 April 2017, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the *Auditor's Responsibilities* for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with HKICPA's Code of Ethics for Professional Accountants (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

致中國再生醫學國際有限公司各股東

(於開曼群島註冊成立之有限公司)

意見

本核數師(以下簡稱「我們」)已審計列載於第 152至247頁的中國再生醫學國際有限公司(「貴 公司」)及其附屬公司(統稱「貴集團」)的綜合財 務報表,此綜合財務報表包括於二零一七年四月 三十日的綜合財務狀況表與截至該日止年度的綜 合損益及其他全面收入表、綜合權益變動表及綜 合現金流量表,以及綜合財務報表附註,包括主 要會計政策概要。

我們認為,綜合財務報表已根據香港會計師公會(「香港會計師公會」)頒佈的香港財務報告準則真實而中肯地反映 貴集團於二零一七年四月三十日的綜合財務狀況及其截至該日止年度的綜合財務表現及綜合現金流量,並已遵照香港公司條例的披露規定妥為擬備。

意見的基礎

我們已根據香港會計師公會頒佈的香港審計準則 (「香港審計準則」) 進行審計。我們在該等準則 下承擔的責任在本報告*核數師就審計綜合財務報 表須承擔的責任*部份作進一步闡述。根據香港會 計師公會頒佈的*專業會計師道德守則*(「守則」), 我們獨立於 貴集團,並已履行該等規定及守則 中的其他道德責任。我們相信,我們所獲得的審 計憑證能充足及適當地為我們的意見提供基礎。



獨立核數師報告



KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Impairment of goodwill, other intangible assets and property, plant and equipment

(Refer to notes 14, 16 and 18 to the consolidated financial statements)

As at 30 April 2017, the carrying amounts of goodwill, other intangible assets and property, plant and equipment are HK\$197 million, HK\$426 million and HK\$220 million respectively. These assets are mainly relating to Aierfu Business, Reshine Business, Weikai Business and AK Business and are assessed annually for impairment. The Group has made losses for current and previous years. These situations increase the risk that the carrying value of these assets may be impaired.

Impairment tests require the estimation of recoverable values of the relevant cash generating units using a discounted cash flow, as detailed in note 16 to the consolidated financial statements.

We have identified such impairment assessment is a key audit matter because of their significance to the consolidated financial statements and it involves a significant degree of judgement made by management which includes:

- Preparing future cash flow forecasts for Aierfu Business,
 Reshine Business, Weikai Business and AK Business; and
- Selecting and applying appropriate growth and discount rates.

The Group engages an independent external valuer to assist the management in assessing the recoverable values.

關鍵審計事項

關鍵審計事項是根據我們的專業判斷,認為對本期綜合財務報表的審計最為重要的事項。這些事項是在我們審計整體財務報表及出具意見時進行處理的。我們不會對這些事項提供單獨的意見。

商譽、其他無形資產及物業、廠房及設備 之減值

(請參閱綜合財務報表附註14、16及18)

於二零一七年四月三十日,有關艾爾膚業務、瑞盛業務、衛凱業務及奧凱業務的商譽、其他無形資產及物業、廠房及設備之賬面金額分別為197,000,000港元、426,000,000港元及220,000,000港元,及每年均進行減值評估。 貴集團於本年度及過往年均錄得虧損。此虧損狀況增加該等資產賬面值可能會出現減值的風險。

減值測試要求使用貼現現金流量估計相關現金產 生單位的可收回金額,如綜合財務報表附註16所 詳述。

我們將減值評估確定為關鍵審計事項,此乃由於 其對綜合財務報表實屬重大及涉及管理層作出之 重大判斷,其中包括:

- 編製艾爾膚業務、瑞盛業務、衛凱業務及奧 凱業務的未來現金流量預測;及
- 一 選擇及採用合適增長率及貼現率。

貴集團亦委聘獨立外聘估值師協助管理層評估可 收回金額。

獨立核數師報告



KEY AUDIT MATTERS (Cont'd)

Our response

Our procedures in relation to the management's impairment assessment included:

- Assessing the accuracy of management's forecast by comparing previous budgets to actual results;
- Assessing the reasonableness of the key assumptions of the forecast based on our knowledge of the industry and evidence provided;
- Assessing the appropriateness of the valuation methodologies;
- Reconciling input data to supporting evidence and checking the mathematical accuracy of the calculation of the valuations; and
- Evaluating the independent external valuer's competence, capabilities and objectivity.

OTHER INFORMATION IN THE ANNUAL REPORT

The directors are responsible for the other information. The other information comprises the annual report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

關鍵審計事項(續)

我們的回應

我們有關管理層減值評估的程序包括:

- 透過比較過往預算與實際業績評估管理層所 作出預測的準確性;
- 基於我們的行業知識及獲提供的憑證,評估 預測之關鍵假設的合理性;
- 一 評估所採用評估方法之合適性;
- 核對輸入數據與支持憑證及檢查計算估值之 計算精確性;及
- 一 評估獨立外聘估值師的才能、能力及客觀性。

年報的其他資料

董事須對其他資料負責。其他資料包括年報,但 不包括綜合財務報表及我們的核數師報告。

我們對綜合財務報表的意見並不涵蓋其他資料, 我們亦不對該等資料發表任何形式的鑒證結論。

結合我們對綜合財務報表的審計,我們的責任是 閱讀上文所識別的其他資料,在此過程中,考慮 其他資料是否與綜合財務報表或我們在審計過程 中所了解的情況存在重大抵觸或者存在重大錯誤 陳述的情況。基於我們已執行的工作,如果我們 認為其他資料存在重大錯誤陳述,我們需要報告 該事實。在這方面,我們沒有任何報告。



獨立核數師報告



DIRECTORS' RESPONSIBILITY FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with Hong Kong Financial Reporting Standards issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The directors are also responsible for overseeing the Group's financial reporting process. The Audit Committee assists the directors in discharging their responsibilities in this regard.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. This report is made solely to you, as a body, in accordance with the terms of our engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

董事就綜合財務報表須承擔的責任

董事須負責根據香港會計師公會頒佈的香港財務報告準則及香港公司條例的披露規定擬備真實而中肯的綜合財務報表,並對其認為為使綜合財務報表的擬備不存在由於欺詐或錯誤而導致的重大錯誤陳述所需的內部控制負責。

在擬備綜合財務報表時,董事負責評估 貴集團 持續經營的能力,並在適用情況下披露與持續經 營有關的事項,以及使用持續經營為會計基礎, 除非董事有意將 貴集團清盤或停止經營,或別 無其他實際的替代方案。

董事亦負責監督 貴集團的財務申報過程。審核 委員會協助董事履行其於此方面的責任。

核數師就審計綜合財務報表須承擔的 責任

我們的目標是對綜合財務報表整體是否不存在由 於欺詐或錯誤而導致的重大錯誤陳述取得合理保 證,並出具包括我們意見的核數師報告。根據我 們的委聘條款,本報告僅向 閣下(作為整體)作 出,除此之外別無其他目的。我們不會就本報告 的內容向任何其他人士負上或承擔任何責任。

合理保證是高水平的保證,但不能保證按照香港審計準則進行的審計,在某一重大錯誤陳述存在時總能發現。錯誤陳述可以由欺詐或錯誤引起,如果合理預期它們單獨或滙總起來可能影響綜合財務報表使用者依賴綜合財務報表所作出的經濟決定,則有關的錯誤陳述可被視作重大。

獨立核數師報告



AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Cont'd)

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

核數師就審計綜合財務報表須承擔的 責任(續)

在根據香港審計準則進行審計的過程中,我們運用了專業判斷,保持了專業懷疑態度。我們亦:

- 識別和評估由於欺詐或錯誤而導致綜合財務報表存在重大錯誤陳述的風險,設計及執行審計程序以應對這些風險,以及獲取充足和適當的審計憑證,作為我們意見的基礎。由於欺詐可能涉及串謀、偽造、蓄意遺漏、虚假陳述,或凌駕於內部控制之上,因此未能發現因欺詐而導致的重大錯誤陳述的風險高於未能發現因錯誤而導致的重大錯誤陳述的風險。
- 了解與審計相關的內部控制,以就此設計適當的審計程序,但目的並非對 貴集團內部控制的有效性發表意見。
- 評價董事所採用會計政策的恰當性及作出會 計估計和相關披露的合理性。
- 對董事採用持續經營會計基礎的恰當性作出 結論。根據所獲取的審計憑證,確定是否 存在與事項或情況有關的重大不確定性,從 而可能導致對 貴集團的持續經營能力產 生重大疑慮。如果我們認為存在重大不確 定性,則有必要在核數師報告中提請使用者 注意綜合財務報表中的相關披露。假若有關 的披露不足,則我們應修訂我們的意見。我 們的結論是基於核數師報告日止所取得的 審計憑證。然而,未來事項或情況可能導 致 貴集團不能持續經營。
- 評價綜合財務報表(包括披露資料)的整體 列報方式、結構和內容,以及綜合財務報表 是否中肯反映相關交易和事項。

獨立核數師報告



AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Cont'd)

 Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

核數師就審計綜合財務報表須承擔的 責任(續)

就 貴集團內實體或業務活動的財務信息獲取充足、適當的審計憑證,以便對綜合財務報表發表意見。我們負責集團審計的方向、監督和執行。我們僅為審計意見承擔責任。

我們與審核委員會溝通了(其中包括)計劃的審計 範圍、時間安排、重大審計發現等事項,包括我 們在審計中識別出內部控制的任何重大缺陷。

我們亦向審核委員會提交聲明,說明我們已符合有關獨立性的相關專業道德要求,並與彼等溝通有可能合理地被認為會影響我們獨立性的所有關係和其他事項,以及在適用的情況下,相關的防範措施。

從與董事溝通的事項中,我們確定哪些事項對本期綜合財務報表的審計最為重要,因而構成關鍵審計事項。我們在核數師報告中描述這些事項,除非法律法規不允許公開披露這些事項,或在極端罕見的情況下,如果合理預期在我們報告中溝通某事項造成的負面後果超過產生的公眾利益,我們決定不應在報告中溝通該事項。

BDO Limited

Certified Public Accountants

Lam Pik Wah

Practising Certificate Number P05325

Hong Kong, 17 July 2017

香港立信德豪會計師事務所有限公司

執業會計師

林碧華

執業證書號碼: P05325

香港,二零一七年七月十七日

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其他全面收入表

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

		Notes 附註	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元 (restated) (經重列)
Revenue Cost of sales	收益 銷售成本	5	356,987 (219,462)	27,751 (9,410)
Gross profit	毛利		137,525	18,341
Other income Selling and distribution expenses Administrative and other expenses Finance costs Fair value gain on contingent consideration receivables	其他收入 銷售及分銷開支 行政及其他開支 財務費用 應收或然代價之 公平值收益	5 7 17	45,144 (66,796) (322,464) (24,426) 20,097	110,981 (33,078) (270,171) (25,827) 8,556
Loss before income tax Income tax credit/(expense)	除所得税前虧損 所得税抵免/(開支)	8 11	(210,920) 11,728	(191,198) (3,326)
Loss for the year	本年度虧損		(199,192)	(194,524)
Other comprehensive income Items that may be reclassified subsequently to profit or loss: Exchange loss on translation of financial statements of foreign operations	其他全面收入 其後可能重新分類至 損益之項目: 換算海外業務財務報表 之滙兑虧損		(37,777)	(23,412)
Total comprehensive income for the year	本年度全面總收入		(236,969)	(217,936)
Loss for the year attributable to: Owners of the Company Non-controlling interests	以下人士應佔本年度虧損: 本公司擁有人 非控股股東權益	:	(184,502) (14,690)	(190,902) (3,622)
			(199,192)	(194,524)
Total comprehensive income for the year attributable to: Owners of the Company Non-controlling interests	以下人士應佔本年度 全面總收入: 本公司擁有人 非控股股東權益		(215,988) (20,981)	(213,085) (4,851)
			(236,969)	(217,936)
Loss per share for loss for the year attributable to owners of the Company — basic (HK cents)	本公司擁有人應佔 本年度虧損之每股虧損 — 基本(港仙)	13	(1.049)	(1.103)
- diluted (HK cents)	— 攤薄 (港仙)		N/A 不適用	N/A 不適用

CONSOLIDATED STATEMENT OF FINANCIAL POSITION 綜合財務狀況表

As at 30 April 2017 於二零一七年四月三十日

		Notes 附註	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
ASSETS AND LIABILITIES	資產及負債			
Non-current assets Property, plant and equipment Land use rights Goodwill Contingent consideration receivables Other intangible assets Deposits for acquisition of property,	非流動資產 物業、廠房及設備 土地使用權 商學 應收或然代價 其他無形資產 購置物業、廠房及設備	14 15 16 17 18	220,114 4,219 196,983 46,259 425,716	172,753 4,584 196,983 28,030 486,500
plant and equipment Pledged bank deposits Available-for-sale financial assets	之按金 已抵押銀行存款 可供出售金融資產	23 19	70,136 794,743 112,928	17,934 — —
			1,871,098	906,784
Current assets Inventories Trade receivables Deposits, prepayments and other receivables	流動資產 存貨 應收貿易賬項 按金、預付款項及	20 21	60,567 39,117	8,967 19,992
Financial assets at fair value through	其他應收賬項 按公平值於損益列賬	21	333,679	105,836
profit or loss Pledged bank deposits Cash and cash equivalents	之金融資產 已抵押銀行存款 現金及現金等值項目	22 23 23	12,036 — 571,732	558,873 1,300,825
			1,017,131	1,994,493
Current liabilities Trade payables Accrued charges and other payables Bank borrowings Current tax liabilities	流動負債 應付貿易賬項 應計費用及其他應付賬項 銀行借款 當期税項負債	24 25 26	38,993 104,689 28,345 4,267	1,570 139,651 542,553 8,997
			176,294	692,771
Net current assets	流動資產淨值		840,837	1,301,722
Total assets less current liabilities	總資產減流動負債		2,711,935	2,208,506
Non-current liabilities Bank borrowings Deferred taxation	非流動負債 銀行借款 遞延税項	26 27	725,632 78,411	90,306
			804,043	90,306
Net assets	資產淨值		1,907,892	2,118,200
EQUITY	權益			
Share capital Reserves	股本 儲備	28	175,858 1,701,179	175,922 1,890,442
Equity attributable to owners	本公司擁有人應佔權益			0.000.00
of the Company Non-controlling interests	非控股股東權益		1,877,037 30,855	2,066,364 51,836
Total equity	總權益		1,907,892	2,118,200

On behalf of the directors

Mr. Wong Sai Hung 黃世雄先生 Director 董事 代表董事

Mr. Chen Chunguo 陳春國先生 Director 董事





CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動表

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



		Attributable to owners of the Company 本公司擁有人應佔				Non- controlling interests 非控股 股東權益	Total 合計				
		Share capital 股本 HK\$'000 千港元 (note 28) (附註28)	Share premium 股份溢價 HK\$*000 千港元	Translation reserve 換算儲備 HK\$'000 千港元	Special reserve 特殊儲備 HK\$'000 千港元		Share option // reserve 購股權儲備 HK\$*000 千港元	Accumulated losses 累計虧損 HK\$*000 千港元	Sub-total 小計 HK\$*000 千港元	HK\$'000 千港元	HK\$'000 千港元
At 1 May 2015	於二零一五年五月一日	164,422	2,754,185	4,436	(200)	(410,463)	24,678	(734,060)	1,802,998	41,217	1,844,215
Loss for the year	本年度虧損	-	-	-	-	-	-	(190,902)	(190,902)	(3,622)	(194,524)
Other comprehensive income Exchange loss on translation of financial statements of foreign operations	其他全面收入 換算海外業務財務報表之滙兑虧損	_	_	(22,183)	_	_	_	-	(22,183)	(1,229)	(23,412)
Total comprehensive income for the year	本年度全面總收入	-	-	(22,183)	-	_	_	(190,902)	(213,085)	(4,851)	(217,936)
Shares issued at premium Issue of share options (note 33) Lapse of share options (note 33) Acquisition of subsidiaries (note 34) Capital contributions from non-controlling interests of subsidiaries Share issue expense	按溢價發行股份 發行購股權(附註33) 已失效購股權(附註33) 收購附屬公司(附註34) 附屬公司之非控股股東注資 股份發行開支	11,500 - - - -	448,500 - - - - - (3,894)	- - - -	- - - -	-	20,345 (80) - -	- - 80 - -	460,000 20,345 — — — — (3,894)	- - 12,173 3,297 -	460,000 20,345 — 12,173 3,297 (3,894)
At 30 April 2016 and 1 May 2016	於二零一六年四月三十日 及二零一六年五月一日	175,922	3,198,791	(17,747)	(200)	(410,463)	44,943	(924,882)	2,066,364	51,836	2,118,200
Loss for the year	本年度虧損	_	-	-	-	_	-	(184,502)	(184,502)	(14,690)	(199,192)
Other comprehensive income Exchange loss on translation of financial statements of foreign operations	其他全面收入 換算海外業務財務報表之滙兑虧損	-	-	(31,486)	-	-	-	_	(31,486)	(6,291)	(37,777)
Total comprehensive income for the year	本年度全面總收入	_	_	(31,486)	-	_	_	(184,502)	(215,988)	(20,981)	(236,969)
Issue of share options (note 33) Lapse of share options (note 33) Shares repurchased and cancelled	發行購股權(附註33) 已失效購股權(附註33) 已購回及註銷股份	- - (64)	- - (1,795)	- - -	- - -	- - -	28,520 (38,789)	28,789 -	28,520 — (1,859)	- - -	28,520 — (1,859)
At 30 April 2017	於二零一七年四月三十日	175,858	3,196,996	(49,233)	(200)	(410,463)	34,674	(1,070,595)	1,877,037	30,855	1,907,892

The special reserve represents the difference between the nominal value of the shares of the acquired subsidiaries and the nominal value of the Company's shares issued for their acquisition at the time of the Group's reorganisation in 2001.

特殊儲備指本集團於二零零一年重組時,被收購 附屬公司股份面值與本公司就收購該等附屬公司 而予以發行之本公司股份面值之差額。

The other reserve represents the difference between the fair value of consideration paid to increase the shareholding in a subsidiary, Shaanxi Aierfu Activtissue Engineering Company Limited ("Shaanxi Aierfu"), and the amount of adjustment to non-controlling interests during the years ended 30 April 2011, 2013 and 2014.

其他儲備指於截至二零一一年、二零一三年及二零一四年四月三十日止年度就增加於一間附屬公司,陝西艾爾膚組織工程有限公司(「陝西艾爾膚」),之股權所付代價之公平值與非控股股東權益調整金額之差額。

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量表

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

			2017 二零一七年	2016 二零一六年
	N	lotes	—————————————————————————————————————	—◆一八牛 HK\$'000
		附註	千港元	千港元
Ocale flavor from an auction cativities				
Cash flows from operating activities Loss before income tax	經營活動之現金流量 除所得税前虧損		(210,920)	(191,198)
Adjustments for:	經調整:		(210,920)	(191,190)
Amortisation of land use rights	土地使用權攤銷		102	109
Amortisation of other intangible assets	其他無形資產攤銷		40,997	38,565
Depreciation	折舊		14,181	13,218
Interest income	利息收入		(20,128)	(109,562)
Gain on disposals of property plant	出售物業、廠房及設備		(20, 120)	(109,302)
and equipment, net	之收益(淨額)		(48)	(77)
Gain on financial assets at fair value	按公平值於損益列賬		(40)	(11)
through profit or loss	之金融資產之收益		(2,006)	
Fair value gain on contingent consideration	應收或然代價之		(2,000)	_
receivables	公平值收益		(20,097)	(8,556)
Equity-settled share-base payment expenses			(20,097)	(0,550)
Equity-settled share-base payment expenses	· 以惟無品异之放惟 支付費用		28,520	20,345
Interest expenses	利息費用		24,426	25,827
Interest expenses	何心 其		24,420	20,021
Operating loss before working capital	營運資金變動前			
changes	之經營虧損		(144,973)	(211,329)
Increase in inventories	存貨增加		(51,600)	(4,000)
Increase in trade receivables	應收貿易賬項增加		(19,125)	(19,327)
(Increase)/Decrease in deposits,	按金、預付款項及其他		(10,120)	(10,021)
prepayments and other receivables	應收賬項(增加)/減少		(237,278)	61,737
Increase in trade payables	應付貿易賬項增加		37,423	635
(Decrease)/Increase in accrued charges	應計費用及其他應付賬項		01,120	000
and other payables	(減少)/增加		(34,962)	74,269
Increase in financial assets at fair value	按公平值於損益列賬		(0.,002)	,200
through profit or loss	之金融資產增加		(10,030)	_
	/		(10,000)	
Cash used in operations	經營業務耗用之現金		(460,545)	(98,015)
Income taxes paid	已付所得税		(348)	(1,102)
·			()	(, - = /
Net cash used in operating activities	經營活動耗用現金淨額		(460,893)	(99,117)



CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量表

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

			2017 二零一七年	2016 二零一六年
		Notes 附註	HK\$'000 千港元	HK\$'000 千港元
Cash flows from investing activities	投資活動之現金流量			
Interest received	已收利息		29,563	92,679
Increase in pledged deposits	已抵押存款增加		(235,870)	(536,251)
Increase in deposits for acquisition	購置物業、廠房及設備			
of property, plant and equipment	按金增加		(52,202)	(17,934)
Purchase of property, plant and equipment	購置物業、廠房及設備	14	(70,947)	(16,348)
Purchase of other intangible assets	購置其他無形資產	18	(2,576)	(4,021)
Purchases of available-for-sale financial assets	購置可供出售金融資產		(112,928)	_
Acquisition of subsidiaries,	收購附屬公司,			
net of cash acquired	已扣除已收購現金	34	_	(40,284)
Proceeds from disposal of property,	出售物業、廠房及設備		007	470
plant and equipment	所得款項		227	172
Net cash used in investing activities	投資活動耗用現金淨額		(444,733)	(521,987)
	司次过载之中人次目			
Cash flows from financing activities	融資活動之現金流量 發行股份及購股權			
Proceeds from issue of shares	發1] 放防及期放權 所得款項			460,000
and share options Share repurchased and cancelled	已購回及註銷股份		(1,859)	460,000
Share issue expenses paid	已付股份發行開支		(1,059)	(3,894)
Proceeds from bank borrowings	銀行借款所得款項		725,632	486,012
Repayments of bank borrowings	償還銀行借款		(514,208)	-
Capital contributions from non-controlling	附屬公司之非控股		(01.,200)	
interests of subsidiaries	股東注資		_	3,297
Interest paid on bank borrowings	已付銀行借款			,
and other payables	及其他應付款項之利息		(24,426)	(25,827)
Net cash from financing activities	融資活動所得現金淨額		185,139	919,588
Net (decrease)/increase in cash	現金及現金等值項目			
and cash equivalents	之(減少)/增加淨額		(720,487)	298,484
and dash equivalents			(120,401)	200,404
Cash and cash equivalents at beginning	年初之現金及			
of the year	現金等值項目		1,300,825	1,008,984
Effect of exchange rate changes	滙率變動對現金及			
on cash and cash equivalents	現金等值項目之影響		(8,606)	(6,643)
Ocale and cook assistants at and	左 士 之 理 众 及			
Cash and cash equivalents at end	年末之現金及			

of the year

現金等值項目

571,732

1,300,825

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



China Regenerative Medicine International Limited (the "Company") was incorporated as an exempted company with limited liability in the Cayman Islands under the Companies Law (Revision 2001) of Cayman Islands on 20 April 2001. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and its principal place of business is 10th Floor, Everbright Centre, 108 Gloucester Road, Wanchai, Hong Kong. The Company's shares are listed on the Growth Enterprise Market (the "GEM") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

The Company is an investment holding company. Details of the activities of its principal subsidiaries are set out in note 36 to the financial statements. The Company and its subsidiaries are collectively referred to as the "Group" hereafter.

The comparative figures of selling and distribution expenses and administrative and other expenses have been reclassified to conform with the current year's presentation.

The financial statements for the year ended 30 April 2017 were approved for issue by the board of directors on 17 July 2017.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2.1 Basis of preparation

The financial statements on pages 152 to 247 have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") which collective term includes all applicable individual Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards and Interpretations issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA"). The financial statements also include the applicable disclosure requirements of the Hong Kong Companies Ordinance and the Rules Governing the Listing of Securities on GEM of the Stock Exchange ("GEM Listing Rules").

1. 一般資料

中國再生醫學國際有限公司(「本公司」) 於二零零一年四月二十日根據開曼群島公司法(二零零一年修訂版)在開曼群島註冊 成立為獲豁免有限公司。其註冊辦事處及 主要營業地點之地址分別為P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands及香港灣仔告士打道108號 光大中心10樓。本公司股份於香港聯合交 易所有限公司(「聯交所」)創業板(「創業 板」)上市。

本公司乃一間投資控股公司,其主要附屬公司之業務詳情載於財務報表附註36。本公司及其附屬公司下文統稱為「本集團」。

銷售及分銷開支以及行政及其他開支之比較 數據已被重新分類以配合本年度之呈報。

截至二零一七年四月三十日止年度之財務報 表已於二零一七年七月十七日獲董事會批准 刊發。

2. 主要會計政策概要

2.1 編製基準

載於第152至247頁之財務報表乃依據香港財務報告準則(「香港財務報告準則」,該統稱包括由香港會計師公會(「香港會計師公會」)頒佈之所有適用個別香港財務報告準則、香港會計準則及詮釋)而編製。財務報表亦包括香港公司條例及聯交所創業板證券上市規則(「創業板上市規則」)之適用披露規定。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.1 Basis of preparation (Cont'd)

The significant accounting policies that have been used in the preparation of these financial statements are summarised below. These policies have been consistently applied to all the years presented unless otherwise stated. The adoption of new or amended HKFRSs and the impacts on the Group's financial statements, if any, are disclosed in note 3.

The financial statements have been prepared on the historical cost basis except for contingent consideration receivable and financial assets at fair value through profit or loss, which are stated at fair value. The measurement bases are fully described in the accounting policies below.

It should be noted that accounting estimates and assumptions are used in preparation of the financial statements. Although these estimates are based on management's best knowledge and judgement of current events and actions, actual results may ultimately differ from those estimates. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 4.

2.2 Business combination and basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. Inter-company transactions and balances between group companies together with unrealised profits are eliminated in full in preparing the consolidated financial statements. Unrealised losses are also eliminated unless the transaction provides evidence of impairment on the asset transferred, in which case the loss is recognised in profit or loss.

2. 主要會計政策概要(續)

2.1 編製基準(續)

用以編製此等財務報表之主要會計政策概述於下文。除另有列明者外,此等政策已貫徹應用於所有呈報年度。採納新訂或經修訂之香港財務報告準則及對本集團財務報表之影響(如有)乃於附註3中披露。

財務報表乃按歷史成本基準編製,惟應收或然代價及按公平值於損益列賬之金融資產以公平值列值。計量基準詳述於下文之會計政策中。

務請註意,編製財務報表時會採用會計估計及假設。儘管此等估計乃基於管理層對現時事件及行動之最深切了解及判斷而作出,惟實際結果最終對會有別於估計之情況。涉及高度判斷或複雜性之範疇或涉及對財務報表有重大影響之假設及估計之範疇披露於附註4。

2.2 業務合併及綜合基準

綜合財務報表包括本公司及其附屬公司之財務報表。集團公司之間內部公司交易及結餘以及未變現之溢利乃於編製綜合財務報表時全部對銷。除非交易顯示所轉讓之資產出現減值,該虧損會於損益中確認,否則未變現虧損亦須對銷。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.2 Business combination and basis of consolidation (Cont'd)

The results of subsidiaries acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the effective dates of acquisition or up to the effective dates of disposal, as appropriate. Where necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by other members of the Group.

Acquisition of subsidiaries or businesses is accounted for using the acquisition method. The cost of an acquisition is measured at the aggregate of the acquisition-date fair value of assets transferred, liabilities incurred and equity interests issued by the Group, as the acquirer. The identifiable assets acquired and liabilities assumed are principally measured at acquisition-date fair value. The Group's previously held equity interest in the acquiree is re-measured at acquisition-date fair value and the resulting gains or losses are recognised in profit or loss. The Group may elect, on a transaction-by-transaction basis, to measure the non-controlling interests that represent present ownership interests in the subsidiary either at fair value or at the proportionate share of the acquiree's identifiable net assets. All other non-controlling interests are measured at fair value unless another measurement basis is required by HKFRSs. Acquisitionrelated costs incurred are expensed unless they are incurred in issuing equity instruments in which case the costs are deducted from equity.

Any contingent consideration to be transferred by the acquirer is recognised at acquisition-date fair value. Subsequent adjustments to consideration are recognised against goodwill only to the extent that they arise from new information obtained within the measurement period (a maximum of 12 months from the acquisition date) about the fair value at the acquisition date. All other subsequent adjustments to contingent consideration classified as an asset or a liability are recognised in profit or loss.

2. 主要會計政策概要(續)

2.2 業務合併及綜合基準(續)

年內收購或出售之附屬公司,其業績由收購生效日期起計或直至出售生效日期止(如適用)列入綜合損益及其他全面收入表內。當需要時,附屬公司之財務報表會被調整,使其會計政策與本集團其他成員公司所採用者一致。

收購附屬公司或業務按收購會計法入 賬。收購成本乃按收購日期所轉讓之 資產、所產生之負債及本集團(作為 收購方)發行之股權之公平值總額計 量。被收購之可識別資產及所承擔負 債主要按收購日期之公平值計量。本 集團先前所持被收購方之股權以收購 日期的公平值重新計量,而所產生之 收益或虧損則於損益中確認。本集團 可按每宗交易選擇按公平值或按應佔 被收購方可識別資產淨值之比例計量 相當於目前於附屬公司擁有權之非控 股股東權益。所有其他非控股股東權 益均按公平值計量,除非香港財務報 告準則要求另一種計量基準,則作別 論。與收購相關的成本在發生時支 銷,除非其在發行權益工具時發生, 在該情況下,有關成本從權益中扣除。

收購方將予轉讓之任何或然代價均按 收購日期的公平值確認。其後代價調 整僅於計算期間(最長為收購日期起 計12個月)內所取得有關於收購日期 的公平值之新資料時,方可於商譽中 確認。分類為資產或負債之或然代價 的所有其他其後調整均於損益中確認。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.2 Business combination and basis of consolidation (Cont'd)

Changes in the Group's interests in subsidiaries that do not result in a loss of control are accounted for as equity transactions. The carrying amounts of the Group's interest and the non-controlling interest are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interest is adjusted and the fair value of the consideration paid or received is recognised directly in equity and attributed to owners of the Company.

When the Group loses control of a subsidiary, the profit or loss on disposal is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interest. Amounts previously recognised in other comprehensive income in relation to the subsidiary are accounted for in the same manner as would be required if the relevant assets or liabilities were disposed of.

Subsequent to acquisition, the carrying amount of non-controlling interests that represent present ownership interests in the subsidiary is the amount of those interests at initial recognition plus such non-controlling interest's share of subsequent changes in equity. Total comprehensive income is attributed to such non-controlling interests even if this results in those non-controlling interests having a deficit balance.

2. 主要會計政策概要(續)

2.2 業務合併及綜合基準(續)

本集團於附屬公司的權益變動(並無導致失去控制權)列作權益交易入 脹。本集團之權益與非控股股東權益 之賬面值均予以調整,以反映其於附屬公司相對權益之變動。非控股股東權益之調整金額與已付或已收代價公平值之間的任何差額均直接於權益中確認,並撥歸予本公司擁有人。

倘本集團失去附屬公司之控制權,出 售之損益乃按下列兩者之差額計算: (i)已收代價之公平值與任何保留權益 之公平值總額,與(ii)該附屬公司之股 產(包括商譽)及負債與任何非控股股 東權益先前之賬面值。先前就該附屬 公司於其他全面收入確認之金額按出 售相關資產或負債所規定之相同方式 入賬。

收購後,相當於目前於附屬公司擁有權之非控股股東權益之賬面值為該等權益於初始確認時之金額加上非控股股東權益應佔權益其後變動之部份。即使會導致非控股股東權益出現虧絀結餘,全面總收入乃歸屬於該等非控股股東權益。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.3 Subsidiaries

A subsidiary is an investee over which the Group is able to exercise control. The Group controls an investee if all three of the following elements are present: power over the investee, exposure, or rights, to variable returns from the investee, and the ability to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control.

In the Company's statement of financial position, investments in subsidiaries are carried at cost less impairment loss, if any. The results of the subsidiaries are accounted for by the Company on the basis of dividends received and receivable.

2.4 Foreign currency translation

The financial statements are presented in Hong Kong dollars ("HK\$"), which is also the functional currency of the Company.

In the individual financial statements of the consolidated entities, foreign currency transactions are translated into the functional currency of the individual entity using the exchange rates prevailing at the dates of the transactions. At the reporting date, monetary assets and liabilities denominated in foreign currencies are translated at the foreign exchange rates ruling at that date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the reporting date retranslation of monetary assets and liabilities are recognised in profit or loss. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

2. 主要會計政策概要(續)

2.3 附屬公司

附屬公司是本集團能夠對其行使控制權之接受投資方。如果符合下列全產。如果符合下列全產。如果符合下列投資方:可對接受投資方行使權力,承自接受投資方之風險或有權及實力,不會接受投資方之可變動回報,與會重用其權力來影響有關可變動時,則會重新時出現變動時,則會重新時代是否擁有控制權。

於本公司之財務狀況表內,於附屬公司之投資按成本減去減值虧損(如有)列賬。本公司將附屬公司業績入賬時以已收和應收股息為基礎。

2.4 外幣換算

本財務報表乃以港元(「港元」)呈列,港元亦為本公司之功能貨幣。





財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.4 Foreign currency translation (Cont'd)

In the consolidated financial statements, all individual financial statements of foreign operations, originally presented in a currency different from the Group's presentation currency, have been converted into HK\$. Assets and liabilities have been translated into HK\$ at the closing rates at the reporting date. Income and expenses have been converted into HK\$ at the exchange rates ruling at the transaction dates, or at the average rate over the reporting period provided that the exchange rates do not fluctuate significantly. Any differences arising from this procedure have been recognised in other comprehensive income and accumulated separately in the translation reserve in equity.

When a foreign operation is sold, such exchange differences are reclassified from equity to profit or loss as part of the gain or loss on sale.

2.5 Property, plant and equipment

Buildings held for own use which are situated on leasehold land, where the fair value of the building could be measured separately from the fair value of the leasehold land at the inception of the lease, and other items of property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and accumulated impairment losses. The cost of an asset comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

主要會計政策概要(續)

2.4 外幣換算(續)

於綜合財務報表中,海外業務所有原 先以不同於本集團呈報貨幣呈列之個 別財務報表,均已折算為港元。資產 及負債均以報告日之收市滙率換算為 港元。收入與開支則按交易當日之滙 率或報告期之平均滙率(倘滙率並無 大幅波動) 折算為港元。該程序產生 之任何差額均已於其他全面收入中確 認及於權益內之換算儲備中分開累計 處理。

於海外業務出售時,該等滙兑差額乃 重新由權益劃分為損益,作為銷售收 益或虧損之一部份。

2.5 物業、廠房及設備

建於租賃土地上之持作自用樓宇,其 公平值可於租賃開始時與租賃土地之 公平值分開計量,其他物業、廠房及 設備項目(在建工程除外)乃按成本減 累計折舊及累計減值虧損列值。資產 成本包括收購價及將資產帶至其運營 狀況及地點作預定用途的任何直接應 佔成本。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.5 Property, plant and equipment (Cont'd)

Depreciation on property, plant and equipment is provided to write off the cost less their residual values over their estimated useful lives, using the straight-line method, at the following rates per annum:

Buildings	over 50 years or the
	terms of the leases,
	whichever is shorter

Leasehold improvement33%Furniture and equipment5%-25%Computer equipment33%Motor vehicles20%-25%

The assets' residual values, depreciation methods and useful lives are reviewed, and adjusted if appropriate, at each reporting date.

The gain or loss arising on retirement or disposal is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in profit or loss.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other costs, such as repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.

2.6 Land use rights

Upfront payments made to acquire land held under an operating lease are stated at costs less accumulated amortisation and any accumulated impairment losses. The determination if an arrangement is or contains a lease and the lease is an operating lease is detailed in note 2.13. Amortisation is calculated on the straight-line method over the term of the lease/right of use except where an alternative basis is more representative of the time pattern of benefits to be derived by the Group from use of the land.

2. 主要會計政策概要(續)

2.5 物業、廠房及設備(續)

物業、廠房及設備乃按下列年利率, 於估計可使用年期內以直線法計提折 舊,以撇減其成本減去其殘值:

樓宇 以五十年或租賃期 (以較短者為準)計算

租賃物業裝修 33% 傢俬及設備 5%-25% 電腦設備 33% 汽車 20%-25%

於各報告日會審閱資產之殘值、減值 方法及可使用年期,並於適當時進行 調整。

報廢或出售產生之收益或虧損會按銷售所得款項與資產賬面值間之差額釐 定,並於損益中確認。

倘與該項目有關之未來經濟利益有可能流入本集團,而項目成本能可靠地計量方會將其後成本列入資產賬面值或確認為獨立資產(如適用)。所有其他成本(如維修及保養)會於產生之財政期間內從損益中扣除。

2.6 土地使用權

收購經營租賃項下所持有土地之預付款項乃按成本減累計攤銷及任何累計減值虧損列賬。釐定一項安排是否屬於或包含租賃以及該租賃是否屬於附註2.13中詳述。攤銷乃於租賃/使用權期間按直線法計算,惟倘有另一種基準更能反映本集團透過使用有關土地可產生收益之時間模式除外。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.7 Goodwill

Goodwill is initially recognised at cost being the excess of the aggregate of consideration transferred and the amount recognised for non-controlling interests over the fair value of identifiable assets, liabilities and contingent liabilities acquired.

Where the fair value of identifiable assets, liabilities and contingent liabilities exceed the fair value of consideration paid, the excess is recognised in profit or loss on the acquisition date, after re-assessment.

Goodwill is measured at cost less accumulated impairment losses. Goodwill is allocated to cash-generating units and is tested annually for impairment (see note 2.17).

On subsequent disposal of a subsidiary, the attributable amount of goodwill capitalised is included in the determination of the amount of gain or loss on disposal.

2.8 Intangible assets (other than goodwill) and research and development activities

Acquired intangible assets are recognised initially at cost. After initial recognition, intangible assets with finite useful lives are carried at cost less accumulated amortisation and any accumulated impairment losses. Amortisation for intangible assets with finite useful lives is provided on straight-line basis over their estimated useful lives. Amortisation commences when the intangible assets are available for use. The following useful lives are applied:

Trademark 15 years
Patents 7-15 years
Capitalised development costs 10 years

2. 主要會計政策概要(續)

2.7 商譽

商譽初步以成本確認,指所轉讓之代 價及確認為非控股股東權益之金額的 總和超出所收購可識別資產、負債及 或有負債公平值之差額。

倘可識別資產、負債及或有負債公平 值超出已付代價之公平值,則有關差 額於重估後於收購日期於損益中確認。

商譽乃按成本減去累計減值虧損後計量。商譽會分配至現金產生單位,並 且每年接受減值檢測(見附註2.17)。

其後出售附屬公司時,釐定出售之收 益或虧損金額時應計入已資本化商譽 之應佔金額。

2.8 無形資產(商譽除外)及研發活動

收購之無形資產初步按成本確認。初步確認後,有限可使用年期之無形資產按成本減累計攤銷及任何累計減值虧損列值。有限可使用年期之無形資產按直線法於其估計可使用年期內攤銷。無形資產一旦可供使用即開始攤銷。有關無形資產適用以下可使用年期:

商標15年專利7-15年資本化之開發成本10年



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.8 Intangible assets (other than goodwill) and research and development activities (Cont'd)

Expenditure on internally developed products is capitalised if it can be demonstrated that:

- It is technically feasible to develop the product for it to be sold;
- Adequate resources are available to complete the development;
- There is an intention to complete and sell the product;
- The Group is able to sell the product;
- Sale of the product will generate future economic benefits; and
- Expenditure on the project can be measured reliably.

Capitalised development costs are amortised over the periods the Group expects to benefit from selling the products developed. The amortisation expense is recognised in profit or loss.

Development expenditure not satisfying the above criteria and expenditure on the research phase of internal projects are recognised in profit or loss as incurred.

2.9 Financial assets

Financial assets are classified into loans and receivables, financial assets at fair value through profit or loss and available-for-sale financial assets. Management determines the classification of its financial assets at initial recognition depending on the purpose for which the financial assets were acquired and where allowed and appropriate, re-evaluates this designation at every reporting date.

2. 主要會計政策概要(續)

2.8 無形資產(商譽除外)及研發活動(續)

內部開發產品的費用於可證明下列情 況下予以資本化:

- 開發產品,以致其可供出售在技術上可行;
- 擁有可供完成開發之充足資源;
- 有完成及銷售該產品之意向;
- 本集團有能力銷售該產品;
- 銷售該產品將產生未來經濟利益;及
- 該項目開支能可靠計量。

資本化之開發成本乃於本集團預期將 從銷售已開發產品獲利之期間攤銷。 攤銷費用於損益中確認。

不符合上述標準之開發費用及內部項 目在研究階段之費用乃於產生時於損 益中確認。

2.9 金融資產

金融資產分為貸款及應收賬項、按公平值於損益列賬之金融資產及可供出售金融資產。購入金融資產時,管理層會依據購入該金融資產之目的,於初步確認時確定其種類,並於許可及適當時在各報告日重新評估有關分類。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.9 Financial assets (Cont'd)

All financial assets are recognised when, and only when, the Group becomes a party to the contractual provisions of the instrument. Regular way purchases and sales of financial assets are recognised on trade date. When financial assets are recognised initially, they are measured at fair value, plus, in the case of investments not at fair value through profit or loss, directly attributable transaction costs.

Derecognition of financial assets occurs when the rights to receive cash flows from the investments expire or are transferred and substantially all of the risks and rewards of ownership have been transferred.

At each reporting date, financial assets are reviewed to assess whether there is objective evidence of impairment. If any such evidence exists, impairment loss is determined and recognised based on the classification of the financial asset.

Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss includes financial assets held for trading and financial assets designated upon initial recognition as at fair value through profit or loss.

Financial assets are classified as held for trading if they are acquired for the purpose of selling in the near term. Derivatives, including separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments or financial guarantee contracts.

Where a contract contains one or more embedded derivatives, the entire hybrid contract may be designated as a financial asset at fair value through profit or loss, except where the embedded derivative does not significant modify the cash flows or it is clear that separation of the embedded derivative is prohibited.

2. 主要會計政策概要(續)

2.9 金融資產(續)

所有金融資產於及僅於本集團參與訂立該工具之合約條文時方予確認。金融資產之一般買賣於交易日期確認。 初步確認金融資產時,會按公平值計量,倘為並非按公平值於損益列賬之投資,則加上直接應佔交易成本。

倘收取投資產生之現金流量之權利失 效或被轉讓,且擁有權之絕大部份風 險及回報已經轉移,即終止確認金融 資產。

於各報告日,金融資產均被檢討以釐 定其是否有任何減值之客觀證據。如 果存在任何有關證據,減值虧損乃按 其金融資產的分類確定和確認。

按公平值於損益列賬之金融資產

按公平值於損益列賬之金融資產包括 持作買賣金融資產以及於初步確認時 指定為按公平值於損益列賬之金融資 產。

倘購買金融資產之目的旨在近期出售,則有關金融資產分類為持作買賣。衍生工具(包括單獨嵌入式衍生工具)亦分類為持作買賣,除非被指定為有效對沖工具或金融擔保合約。

倘一份合約含有一份或以上嵌入式衍生工具,則整份混合合約可指定為按公平值於損益列賬之金融資產,惟嵌入式衍生工具並無導致現金流量出現重大變動,或明確禁止分列嵌入式衍生工具則除外。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.9 Financial assets (Cont'd)

Financial assets at fair value through profit or loss (Cont'd)

Financial assets may be designated at initial recognition as at fair value through profit or loss if the following criteria are met:

- The designation eliminates or significantly reduces the inconsistent treatment that would otherwise arise from measuring the assets or recognising gains or losses on them on a different basis; or
- The assets are part of a group of financial assets which are managed and their performance evaluated on a fair value basis, in accordance with a documented risk management strategy and information about the group of financial assets is provided internally on that basis to the key management personnel; or
- The financial asset contains an embedded derivative that would need to be separately recorded.

Subsequent to initial recognition, the financial assets included in his category are measured at fair value with changes in fair value recognised in profit or loss.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Loans and receivables are subsequently measured at amortised cost using the effective interest method, less any impairment losses. Amortised cost is calculated taking into account any discount or premium on acquisition and includes fees that are an integral part of the effective interest rate and transaction cost.

2. 主要會計政策概要(續)

2.9 金融資產(續)

按公平值於損益列賬之金融資產(續)

倘符合以下條件,則可於初步確認時 將金融資產指定為按公平值於損益列 賬:

- 該分類消除或大幅減少按不同基準計量資產或確認其收益或虧損 所導致之不一致入賬方法;或
- 該等資產為根據明文規定之風險 管理政策按公平值基準管理及評 估表現之金融資產組別一部份; 而有關金融資產組別之資料亦 按此基準對內提供給主要管理人 員;或
- 一 金融資產包括需獨立列賬之嵌入 式衍生工具。

於初步確認後,列入此類別之金融資 產將按公平值計量,其公平值變動在 損益確認。

貸款及應收賬項

貸款及應收賬項為具有固定或可確定付款,但於活躍市場中無報價之非衍生金融資產。貸款及應收賬項隨後以實際利率法計算之攤銷成本(減任何減值虧損)計量。攤銷成本按計及任何收購折讓或溢價後計算,包括屬實際利率及交易成本一部份之費用。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.9 Financial assets (Cont'd)

Available-for-sale financial assets

These assets are non-derivative financial assets that are designated as available-for-sale or are not included in other categories of financial assets. Subsequent to initial recognition, these assets are carried at fair value with changes in fair value recognized in other comprehensive income, except for impairment losses and foreign exchange gains and losses on monetary instruments, which are recognised in profit or loss.

For available-for-sale equity investments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured and derivatives that are linked to and must be settled by delivery of such unquoted equity instruments, they are measured at cost less any identified impairment losses.

Impairment of financial assets

At each reporting date, financial assets other than at fair value through profit or loss are reviewed to determine whether there is any objective evidence of impairment.

Objective evidence of impairment of individual financial assets includes observable data that comes to the attention of the Group about one or more of the following loss events:

- Significant financial difficulty of the debtor;
- A breach of contract, such as a default or delinquency in interest or principal payments;
- Granting concession to a debtor because of debtor's financial difficulty;
- It becoming probable that the debtor will enter bankruptcy or other financial reorganisation; and
- A significant or prolonged decline in the fair value of an investment in an equity instrument below its cost.

2. 主要會計政策概要(續)

2.9 金融資產(續)

可供出售金融資產

該等資產被界定為可供出售或不計入 金融資產其他分類之非衍生金融資 產。經初步確認後,該等資產按公平 值列賬,其公平值變動於其他全面收 入中確認,惟減值虧損及貨幣工具之 滙兑收益及虧損除外。減值虧損及貨 幣工具之滙兑收益及虧損於損益內確 認。

於活躍市場上並無市場報價且其公平 值無法可靠計量之可供出售股本投資 以及與交付相關無報價權益工具掛鈎 及以此結付之衍生工具須按成本減任 何已確認減值虧損後予以計量。

金融資產減值

於各報告日,除按公平值於損益列賬 之金融資產外,金融資產均被檢討以 釐定其是否有任何減值之客觀證據。

個別金融資產之客觀減值證據包括引 致本集團對下列一項或多項虧損事件 關注之可觀察數據:

- 一 債務人面對重大財務困難;
- 一 違反合約,例如未能如期或拖欠 償還利息或本金;
- 因債務人財務困難而向其授予寬免;
- 债務人可能會破產或經歷其他財務重組;及
- 權益工具投資之公平值大幅或長期下跌至低於其成本值。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.9 Financial assets (Cont'd)

Impairment of financial assets (Cont'd)

Loss events in respect of a group of financial assets include observable data indicating that there is a measurable decrease in the estimated future cash flows from the group of financial assets. Such observable data includes but not limited to adverse changes in the payment status of debtors in the group and, national or local economic conditions that correlate with defaults on the assets in the group.

Loans and receivables

If there is objective evidence that an impairment loss on loans and receivables carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The amount of the loss is recognised in profit or loss of the period in which the impairment occurs.

If, in subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed to the extent that it does not result in a carrying amount of the financial asset exceeding what the amortised cost would have been had the impairment not been recognised at the date the impairment is reversed. The amount of the reversal is recognised in profit or loss of the period in which the reversal occurs.

2. 主要會計政策概要(續)

2.9 金融資產(續)

金融資產減值(續)

有關某一組金融資產之虧損事件包括 顯示該組金融資產之估計未來現金流 量出現可計量跌幅之可觀察數據。該 等可觀察數據包括但不限於組別內債 務人之付款狀況,以及與組別內資產 拖欠情況有關之國家或當地經濟狀況 出現不利變動。

貸款及應收賬項

倘有客觀證據表明按攤銷成本入賬之貸款及應收賬項出現減值虧損,則虧損金額按資產之賬面值與估計未來現金流量(不包括未產生之未來信貸虧損)按金融資產之原本實際利率(即初步確認時計算之實際利率)貼現之現值兩者間之差額計算。虧損金額於減值出現期間之損益中確認。

倘若於其後期間減值虧損金額減少, 而有關減幅可客觀地與確認減值後發 生之事件聯繫,則撥回過往確認之減 值虧損,惟於撥回減值當日不得導致 金融資產賬面值超過如無確認減值之 原有攤銷成本。撥回金額於撥回發生 期間在損益內確認。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.9 Financial assets (Cont'd)

Impairment of financial assets (Cont'd)

Available-for-sale financial assets

When a decline in the fair value of an available-forsale financial asset has been recognised in other comprehensive income and accumulated in equity and there is objective evidence that the asset is impaired, an amount is removed from equity and recognised in profit or loss as an impairment loss. That amount is measured as the difference between the asset's acquisition cost (net of any principal repayment and amortisation) and current fair value, less any impairment loss on that asset previously recognised in profit or loss.

Reversals in respect of investment in equity instruments classified as available-for-sale and stated at fair value are not recognised in profit or loss. The subsequent increase in fair value is recognised directly in other comprehensive income. Impairment losses in respect of debt securities are reversed if the subsequent increase in fair value can be objectively related to an event occurring after the impairment loss was recognised. Reversal of impairment losses in such circumstances are recognised in profit or loss.

For financial assets other than financial assets at fair value through profit or loss, available-for-sale financial assets and loan and receivables that are stated at amortised cost, impairment losses are written off against the corresponding assets directly. Where the recovery of trade receivables is considered doubtful but not remote, the impairment losses for doubtful receivables are recorded using an allowance account. When the Group is satisfied that recovery of trade receivables is remote, the amount considered irrecoverable is written off against trade receivables directly and any amounts held in the allowance account in respect of that receivable are reversed. Subsequent recoveries of amounts previously charged to the allowance account are reversed against the allowance account. Other changes in the allowance account and subsequent recoveries of amounts previously written off directly are recognised in profit or loss.

2. 主要會計政策概要(續)

2.9 金融資產(續)

金融資產減值(續)

可供出售金融資產

當可供出售金融資產之公平值減少已於其他全面收入中確認並於權益內累計及有客觀證據表明資產減值時,有關金額乃從權益中剔除並於損益內確認作為減值虧損。該金額按資產收購成本(扣除任何本金償還及攤銷)及當時公平值,減該資產先前於損益內確認之任何減值虧損計量。

分類為可供出售並按公平值列賬之權 益工具投資之撥回,不得於損益中確 認。公平值之隨後增加直接於其他全 面收入中確認。倘公平值之隨後增加 客觀上與減值虧損確認之後發生之事 項有關,則債務證券之減值虧損將 撥回。在此情況,減值虧損之撥回於 損益內確認。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.10 Inventories

Inventories are carried at the lower of cost and net realisable value. Cost is determined using the weighted average method. In the case of work in progress and finished goods, cost also comprises direct materials, direct labour and an appropriate proportion of overheads. Net realisable value is the estimated selling price in the ordinary course of business less the estimated cost of completion and applicable selling expenses.

2.11 Cash and cash equivalents

Cash and cash equivalents include cash at banks and in hand, time deposits with banks within original maturities of three months or less that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

2.12 Financial liabilities

The Group's financial liabilities include trade payables, accrued charges and other payables and bank borrowings.

Financial liabilities are recognised when the Group becomes a party to the contractual provisions of the instrument. All interest related charges are recognised in accordance with the Group's accounting policy for borrowing costs (see note 2.20).

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires.

Where an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amount is recognised in profit or loss.

2. 主要會計政策概要(續)

2.10存貨

存貨按成本及可變現淨值兩者之較低 者列賬。成本按加權平均法釐定。在 製品及製成品之成本亦包括直接材料、直接勞工及按適當比例計算之生 產成本。可變現淨值乃按照日常業務 過程中之估計售價減估計完成成本及 適當銷售開支計算。

2.11 現金及現金等值項目

現金及現金等值項目包括銀行及手頭 現金,以及原到期日為三個月或以下 可隨時轉換為已知數額現金且價值變 動風險較少之銀行定期存款。

2.12 金融負債

本集團之金融負債包括應付貿易賬項、應計費用及其他應付賬項和銀行 借款。

金融負債在本集團成為工具合約條文 一方時確認。所有與利息相關之支出 均根據本集團的會計政策確認為借款 成本(見附註2.20)。

當負債項下之責任獲解除或註銷或屆 滿時,則取消確認金融負債。

倘一項現有金融負債被同一借款人按 基本上不同之條款提供之其他債項取 代,或現有負債條款被重大修改,該 取代或修改會被視作取消確認原有負 債及確認一項新負債,且各賬面值間 之差額會在損益中確認。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.12 Financial liabilities (Cont'd)

Borrowings

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowing using effective interest method.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Other financial liabilities

Other financial liabilities are recognised initially at their fair value and subsequently measured at amortised cost, using the effective interest method.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating interest income or interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts or payments through the expected life of the financial asset or liability, or where appropriate, a shorter period.

2. 主要會計政策概要(續)

2.12 金融負債(續)

借款

借款初步按公平值(扣除已產生的交易成本)確認。借款其後按已攤銷成本列賬,所得款項(扣除交易成本)與贖回價值之間的任何差額於借款期採用實際利率法於損益中確認。

除非本集團有無條件權利將償還負債 的期限延遲至報告日後最少十二個 月,否則借款歸類為流動負債。

其他金融負債

其他金融負債初步按其公平值確認,隨後採用實際利率法按攤銷成本計量。

實際利息法

實際利息法乃就有關期間計算金融資產或金融負債之攤銷成本及分配利息收入或利息開支之方法。實際利率是將估計未來現金收入或付款透過金融資產或金融負債之預期年期或(倘適用)更短期間準確折現之利率。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.13 Leases

An arrangement, comprising a transaction or a series of transactions, is or contains a lease if the Group determines that the arrangement conveys a right to use a specific asset or assets for an agreed period of time in return for a payment or a series of payments. Such a determination is made based on an evaluation of the substance of the arrangement and is regardless of whether the arrangement takes the legal form of a lease.

(i) Classification of assets leased to the Group

Assets that are held by the Group under leases which transfer to the Group substantially all the risks and rewards of ownership are classified as being held under finance leases. Leases which do not transfer substantially all the risks and rewards of ownership to the Group are classified as operating leases, with the following exception:

— land held for own use under an operating lease, the fair value of which cannot be measured separately from the fair value of a building situated thereon, at the inception of the lease, is accounted for as being held under a finance lease, unless the building is also clearly held under an operating lease (see note 2.6). For these purposes, the inception of the lease is the time that the lease was first entered into by the Group, or taken over from the previous lessee.

(ii) Operating lease charges as the lessee

Where the Group has the right to use of assets held under operating leases, payments made under the leases are charged to profit or loss on a straight line basis over the lease terms except where an alternative basis is more representative of the time pattern of benefits to be derived from the leased assets. Lease incentives received are recognised in profit or loss as an integral part of the aggregate net lease payments made. Contingent rental are charged to profit or loss in the accounting period in which they are incurred.

2. 主要會計政策概要(續)

2.13租賃

倘本集團決定於協定時期內將特定資 產使用權出讓以換取一筆或一連串款 項之安排,包括一項交易或一連串交 易之該項安排屬於或包括一項租賃。 該項決定乃基於安排內容之實質評估 而作出,而不論該項安排是否採取租 賃之法律形式。

(i) 租予本集團之資產分類

就本集團根據租賃持有之資產而言,如有關租賃將擁有權之絕大 部份風險及回報轉移至本集團, 則會被分類為根據融資租賃持有 之資產。不會向本集團轉移絕擁 有權之絕大部份風險及回報之租 賃乃分類為經營租賃,惟以下情 況例外:

(ii) 作為承租人之經營租賃支出

如本集團是以經營租賃獲得資產 之使用權,其租賃之支出於。 期間以直線法自損益中扣除。 有另一種基準更能反映其租 產所產生收益之時間模式除外 已收取之租賃獎勵金額已在損益 成部份。或有租金在其產生之會 計期間內自損益中扣除。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.14 Share capital

Ordinary shares are classified as equity. Share capital is determined using the nominal value of shares that have been issued.

Any transaction costs associated with the issuing of shares are deducted from share premium (net of any related income tax benefit) to the extent they are incremental costs directly attributable to the equity transaction.

2.15 Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the sale of goods, the rendering of services and the use by others of the Group's assets yielding interest, net of rebates and discounts. Provided it is probable that the economic benefits will flow to the Group and the revenue and costs, if applicable, can be measured reliably, revenue is recognised as follows:

Sales of goods are recognised upon transfer of significant risks and rewards of ownership to the customer. This is usually taken as the time when the goods are delivered and the customer has accepted the goods.

Interest income is recognised on a time-proportion basis using the effective interest method.

2.16 Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. Government grants relating to costs are deferred and recognised in profit or loss over the period necessary to match them with the costs that they are intended to compensate. Government grants relating to the purchase of property, plant and equipment are included in non-current liabilities as deferred government grants and are recognised in profit or loss on a straight line basis over the expected lives of the related assets.

2. 主要會計政策概要(續)

2.14股本

普通股乃分類為權益。股本乃使用已 發行股份之面值釐定。

任何與發行股份有關之交易成本會自 股份溢價中扣除(減去任何相關所得 税利益),惟以權益交易直接應佔之增 加成本為限。

2.15 收益確認

收益包括銷售貨物、提供服務及他人 使用本集團資產所產生之權益扣除回 佣及折扣之已收或應收代價之公平 值。倘經濟利益將會流入本集團且收 益及成本(如適用)能可靠計量,則收 益按以下基準確認:

銷售貨物乃於擁有權的大部份風險及 回報轉嫁予客戶時予以確認。通常於 貨物交付及客戶接獲貨物時確認。

利息收入以實際利息法按時間比例確認。

2.16 政府補貼

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.17 Impairment of non-financial assets

Goodwill arising on an acquisition of subsidiaries, other intangible assets, property, plant and equipment, land use rights and interests in subsidiaries are subject to impairment testing.

Goodwill is tested for impairment at least annually, irrespective of whether there is any indication that they are impaired. All other assets are tested for impairment whenever there are indications that the asset's carrying amount may not be recoverable.

An impairment loss is recognised as an expense immediately for the amount by which the asset's carrying amount exceeds its recoverable amount. Recoverable amount is the higher of fair value less costs of disposal and value in use.

In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessment of time value of money and the risk specific to the asset.

For the purposes of assessing impairment, where an asset does not generate cash inflows largely independent from those from other assets, the recoverable amount is determined for the smallest group of assets that generate cash inflows independently (i.e. a cashgenerating unit). As a result, some assets are tested individually for impairment and some are tested at cashgenerating unit level. Goodwill in particular is allocated to those cash-generating units that are expected to benefit from synergies of the related business combination and represent the lowest level within the Group at which the goodwill is monitored for internal management purpose.

2. 主要會計政策概要(續)

2.17非金融資產減值

收購附屬公司所產生之商譽、其他無 形資產、物業、廠房及設備、土地使 用權及於附屬公司之權益須進行減值 檢測。

不論是否出現任何減值跡象,商譽須至少每年進行一次減值檢測。所有其 他資產則在出現未必能收回有關資產 賬面值之跡象時進行減值檢測。

減值虧損按資產之賬面值超出其可收 回金額之差額,即時確認為開支。可 收回金額為公平值減銷售成本與使用 價值兩者中之較高者。

評估使用價值時,估計未來現金流量 採用税前折現率折現至其現值,以反 映現時市場對金錢之時間價值及有關 資產特有風險之評估。

就評估減值而言,倘資產產生之現金 流入大致上並不獨立於其他資產。 收回金額則按可獨立產生現金流入 最少資產組合(即現金產生單位) 最少資產組合(即現金產生單位檢測 ,另有部份按現金產生單位檢測 關學分配至該等預期可受惠於相關 關內就內部管理目的而監控商譽 之最小單位。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.17 Impairment of non-financial assets (Cont'd)

Impairment losses recognised for cash-generating units, to which goodwill has been allocated, are credited initially to the carrying amount of goodwill. Any remaining impairment loss is charged pro rata to the other assets in the cash generating unit, except that the carrying value of an asset will not be reduced below its individual fair value less cost to sell, or value in use, if determinable.

An impairment loss on goodwill is not reversed in subsequent periods including impairment losses recognised in an interim period. In respect of other assets, an impairment loss is reversed if there has been a favourable change in the estimates used to determine the asset's recoverable amount and only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss has been recognised.

2.18 Employee benefits

(i) Retirement benefits

The Group operates a defined contribution Mandatory Provident Fund retirement benefits scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance, for those employees who are eligible to participate in the MPF Scheme. Contributions are made based on a percentage of the employees' basic salaries and are charged to profit or loss as they become payable in accordance with the rules of the MPF Scheme. The assets of the MPF Scheme are held separately from those of the Group in an independently administered fund. The Group's employer's contributions vest fully with the employees when contributed into the MPF Scheme.

2. 主要會計政策概要(續)

2.17非金融資產減值(續)

就已分配商譽之現金產生單位確認之 減值虧損,初步計入商譽賬面值。除 資產賬面值將不會調減至低於其個別 公平值減銷售成本或使用價值(如可 釐定)外,任何剩餘減值虧損將按比 例自該現金產生單位之其他資產扣除。

商譽減值虧損(包括中期確認之減值 虧損)不會於其後期間撥回。就其他 資產而言,倘用於釐定資產可收回款 額之估計出現有利變動時,則撥回減 值虧損,惟以資產賬面值不得高於倘 並無確認減值虧損時原應釐定之賬面 值(扣除任何折舊或攤銷)為限。

2.18 僱員福利

(i) 退休福利

本集團遵照強制性公積金計劃條例設立一項定額供款強制性公積金計劃(「強積金別的、對象為合資格參與強積、對象為合資格參與基本安員。供款按僱員基於損與基本方。 強積金計劃之規則應付時資產立時,並由獨立主計劃之規則應付資產之規則應付資產之計劃之規則應付資產之時,並由獨立主計劃之規則應付資產之時,並由獨立主計劃之權主,並由獨立。 基金持有。本集團為強積金本理基金持有。本集團為強時全數歸僱員所有。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.18 Employee benefits (Cont'd)

(i) Retirement benefits (Cont'd)

The employees of the Group's subsidiaries which operate in the Mainland China are required to participate in a central pension scheme operated by the local municipal government. These subsidiaries are required to contribute a percentage of its payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

(ii) Short-term employee benefits

Employee entitlements to annual leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave as a result of services rendered by employees up to the reporting date.

Non-accumulating compensated absences such as sick leave and maternity leave are not recognised until the time of leave.

2.19 Share-based payments

Where share options are awarded to employees and others providing similar services, the fair value of the options at the date of grant is recognised in profit or loss over the vesting period with a corresponding increase in share-based payment reserve within equity. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at the end of each reporting period so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

2. 主要會計政策概要(續)

2.18僱員福利(續)

(i) 退休福利(續)

本集團於中國大陸營運之附屬公司所聘僱員,須參與由地方市政府籌辦之中央退休金計劃。該等附屬公司須撥備薪金成本之某一百分比作為中央退休金計劃供款。有關供款根據中央退休金計劃之規定於應支付時在損益中內扣除。

(ii) 短期僱員福利

僱員有權享有年假,且於僱員支取年假時確認入賬。本集團已為 截至報告日止因僱員提供服務而 享有之年假之估計負債作出撥 備。

非累計賠償缺席(如病假及產假)於僱員支取有關假期時確認入賬。

2.19以股份為基礎之付款

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.19 Share-based payments (Cont'd)

All employee services received in exchange for the grant of any share-based compensation are measured at fair values. These are indirectly determined by reference to the equity instruments awarded. The value is appraised at the grant date and excludes the impact of any non-market vesting conditions.

All share-based compensation is recognised as an expense in profit or loss with a corresponding credit to share-based payment reserve, net of deferred tax where applicable. If vesting periods or other vesting conditions apply, the expense is recognised over the vesting period, based on the best available estimate of the number of share options expected to vest. Non-market vesting conditions are included in assumptions about the number of options that are expected to become exercisable. Estimates are subsequently revised, if there is any indication that the number of share options expected to vest differs from previous estimates. No adjustment to expense recognised in prior periods is made if fewer share options ultimately are exercised than originally vested.

Where the terms and conditions of options are modified before they vest, the increase in fair value of the options, measured immediately before and after the modification, is also recognised in profit or loss over the remaining vesting period.

Where equity instruments are granted to persons other than employees and others providing similar services, the fair value of goods or services received is recognised in profit or loss unless the goods or services qualify for recognition as assets. A corresponding increase in equity is recognised. For cash-settled share based payments, a liability is recognised at the fair value of the goods or services received.

2. 主要會計政策概要(續)

2.19以股份為基礎之付款(續)

以提供任何以股份為基礎之補償而換取之所有僱員服務按公平值計量。此乃參考所授出之權益工具而間接釐定。價值乃於授出日期評估,且並不包括任何非市場歸屬條件之影響。

若購股權歸屬前其條款及條件被修 改,緊接修改前後計量之購股權公平 值增加亦會於餘下歸屬期在損益確認。

凡權益工具授予僱員及其他提供相似服務之人士以外之人士,所收取貨品或服務之公平值於損益確認,除非貨品或服務合資格確認為資產則作別論。權益亦會確認相應增加。至於以現金結算之股份為基礎之付款,負債乃按所收取貨品或服務之公平值確認。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.19 Share-based payments (Cont'd)

At the time when the share options are exercised, the amount previously recognised in share-based payment reserve will be transferred to share premium. When the vested share options are lapsed, forfeited or still not exercised at the expiry date, the amount previously recognised in share-based payment reserve will be transferred to accumulated losses.

2.20 Borrowing costs

Borrowing costs incurred for the acquisition, construction or production of any qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use. A qualifying asset is an asset which necessarily takes a substantial period of time to get ready for its intended use or sale. Other borrowing costs are expensed when incurred.

Borrowing costs are capitalised as part of the cost of a qualified asset when expenditure for the asset is being incurred, borrowing costs are being incurred and activities that are necessary to prepare the asset for its intended use or sale are being undertaken. Capitalisation of borrowing costs ceases when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete.

2.21 Accounting for income taxes

Income tax comprises current tax and deferred tax.

Current income tax assets and/or liabilities comprise those obligations to, or claims from, tax authorities relating to the current or prior reporting period, that are unpaid at the reporting date. They are calculated according to the tax rates and tax laws applicable to the fiscal periods to which they relate, based on the taxable profit for the year. All changes to current tax assets or liabilities are recognised as a component of tax expense in profit or loss.

2. 主要會計政策概要(續)

2.19以股份為基礎之付款(續)

行使購股權時,過往於以股份為基礎之付款儲備確認之金額將轉撥至股份溢價。倘已歸屬之購股權失效、被沒收或於到期時尚未行使,則過往於以股份為基礎之付款儲備確認之金額將轉撥至累計虧損。

2.20 借款成本

借款成本就收購、建造或生產任何合資格資產所產生之借款成本,於完成及準備資產作擬定用途的期間內撥充資本。合資格資產是指必須要一段長時間方可達致擬定用途或出售的資產。其他借款成本於產生時支銷。

在產生資產開支、借款成本及使資產 投入擬定用途或銷售所必須的準備工 作進行期間,借款成本乃撥充資本, 作為合資格資產成本的一部份。在使 合資格資產投入擬定用途或銷售所必 須的絕大部份準備工作完成時,借款 成本便會停止資本化。

2.21 所得税之會計方法

所得税包括當期税項及遞延税項。

當期所得稅資產及/或負債包括本期或以往報告期(且於報告日尚未支付),向稅務當局繳納稅金之責任或來自稅務當局之索償,其乃根據年內應課稅溢利,按有關財政期間之適用稅率及稅法計算。當期稅項資產或負債之一切變動均於損益中確認為稅項開支之一部份。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.21 Accounting for income taxes (Cont'd)

Deferred tax is calculated using the liability method on temporary differences at the reporting date between the carrying amounts of assets and liabilities in the financial statements and their respective tax bases. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are recognised for all deductible temporary differences, tax losses available to be carried forward as well as other unused tax credits, to the extent that it is probable that taxable profit, including existing taxable temporary differences, will be available against which the deductible temporary differences, unused tax losses and unused tax credits can be utilised.

Deferred tax assets and liabilities are not recognised if the temporary difference arises from goodwill or from initial recognition (other than in a business combination) of assets and liabilities in a transaction that affects neither taxable nor accounting profit or loss.

Deferred tax liabilities are recognised for taxable temporary difference arising on investments in subsidiaries, except where the Group is able to control the reversal of the temporary differences and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred tax is calculated, without discounting, at tax rates that are expected to apply in the period the liability is settled or the asset realised, provided they are enacted or substantively enacted at the reporting date.

Changes in deferred tax assets or liabilities are recognised in profit or loss, or in other comprehensive income or directly in equity if they relate to items that are charged or credited to other comprehensive income or directly in equity.

2. 主要會計政策概要(續)

2.21 所得税之會計方法(續)

遞延稅項乃按於資產及負債在報告日 於財務報表之賬面值與其各自之稅稅 之暫時差異以負債法計算。遞延稅稅 負債一般就所有應課稅暫時差異以負債。倘可能出現應課稅溢利(包 有應課稅暫時差異)以動用可未動用 時差異、未動用稅項虧損及末動用稅 務抵免,則就所有可扣減暫時差異稅 務抵免確認遞延稅項資產。

倘因商譽或初步確認(業務合併除外) 某交易之資產及負債產生之暫時差異 對應課税或會計損益無影響,則不確 認遞延税項資產及負債。

於附屬公司之投資產生之應課税暫時 差異會確認遞延税項負債,惟倘本集 團可控制暫時差異之撥回及暫時差異 將不會於可見將來撥回則作別論。

遞延税項乃按預期於負債清償或資產變賣期間適用之税率計算(不作貼現),惟有關税率必須為於報告日已實施或大致上實施之稅率。

遞延稅項資產或負債變動乃於損益中 獲確認,而倘與其他全面收入或直接 扣除自或直接計入權益之項目有關, 則於其他全面收入或直接於權益中確 認。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.21 Accounting for income taxes (Cont'd)

Current tax assets and current tax liabilities are presented in net if, and only if.

- (a) The Group has the legally enforceable right to set off the recognised amounts; and
- (b) intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

The Group presents deferred tax assets and deferred tax liabilities in net if, and only if,

- (a) the entity has a legally enforceable right to set off current tax assets against current tax liabilities; and
- (b) the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on either:
 - (i) the same taxable entity; or
 - (ii) different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

2.22 Segment reporting

The Group identifies operating segments and prepares segment information based on the regular internal financial information reported to the executive directors for their decisions about resources allocation to the Group's business components and for their review of the performance of those components. The business components in the internal financial information reported to the executive directors are determined following the Group's major product and service lines.

2. 主要會計政策概要(續)

2.21 所得税之會計方法(續)

當期税項資產與當期税項負債只會於 以下情況以淨額呈列:

- (a) 本集團依法有強制執行權可以將 已確認金額對銷;及
- (b) 計劃以淨額基準結算或同時實現 資產及結清負債。

本集團只會在以下情況下以淨額呈列 遞延税項資產及遞延税項負債:

- (a) 該實體依法有強制執行權可以將 當期稅項資產與當期稅項負債對 銷;及
- (b) 遞延税項資產與遞延税項負債是 關於同一税務機關就以下任何一 項所徵收的所得税:
 - (i) 同一應課税實體;或
 - (ii) 計劃於各段未來期間(而預期在有關期間內將結清或 收回大額的遞延税項負債 或資產)以淨額基準結算當期稅項負債與資產或同時 變現資產及結清負債的不 同應課稅實體。

2.22分部報告

根據向執行董事呈報以供彼等決定本 集團各業務成分的資源分配及評核該 等成分表現的定期內部財務資料,本 集團確認經營分部及編製分部資料。 向執行董事呈報的內部財務資料內的 業務成分乃依據本集團主要產品及服 務種類確定。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.22 Segment reporting (Cont'd)

The Group has identified the following reportable segments:

Tissue engineering — production and sale of tissue engineering products;

Cell — cell therapy, and medical equipment and other services;

Cosmetic and others — production and sales of cosmetic, healthcare and others products; and

Medical equipment — trading of medical equipment.

The measurement policies the Group uses for reporting segment results under HKFRS 8 are the same as those used in its financial statements prepared under HKFRSs, except that:

- fair value gain on contingent consideration receivables
- finance costs
- income tax
- corporate income and expenses which are not directly attributable to the business activities of any operating segment

are not included in arriving at the operating results of the operating segment.

Segment assets include all assets except contingent consideration receivables, available-for-sale financial assets, financial assets at fair value through profit or loss and corporate assets which are not directly attributable to the business activities of any operating segment are not allocated to a segment, which primarily applies to the Group's headquarter.

2. 主要會計政策概要(續)

2.22分部報告(續)

本集團已確認以下須予呈報分部:

組織工程 一 組織工程產品生產及銷售;

細胞 — 細胞療法,以及醫療設備及其 他服務;

化妝品及其他 — 化妝品、醫療保健及 其他產品的生產及銷售;及

醫療設備 一 買賣醫療設備。

本集團根據香港財務報告準則第8號 就報告分部業績所採用的計量政策, 與根據香港財務報告準則於財務報表 所採用的相同,惟以下所述者除外:

- 應收或然代價之公平值收益
- 一 財務費用
- 一 所得税
- 並非直接歸屬於任何經營分部之 業務活動的企業收入及開支

於計算經營分部的經營業績時並不包括在內。

除未直接歸屬於任何經營分部之業務 活動之應收或然代價、可供出售金融 資產、按公平值於損益列賬之金融資 產及企業資產並不歸類於某一分部 (即其主要為本集團總部所用)外,分 部資產包括所有資產。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.22 Segment reporting (Cont'd)

Segment liabilities exclude corporate liabilities which are not directly attributable to the business activities of any operating segment and are not allocated to a segment. These include deferred tax liabilities and liabilities incurred for financing rather than operating purposes.

2.23 Related parties

- (a) A person or a close member of that person's family is related to the Group if that person:
 - (i) has control or joint control over the Group;
 - (ii) has significant influence over the Group; or
 - (iii) is a member of key management personnel of the Group or the Company's parent.
- (b) An entity is related to the Group if any of the following conditions apply:
 - (i) The entity and the Group are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).
 - (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
 - (iii) Both entities are joint ventures of the same third party.
 - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity.

2. 主要會計政策概要(續)

2.22分部報告(續)

分部負債不包括未直接歸屬於任何經營分部之業務活動且並不歸類於某一分部之企業負債。該等分部負債包括 遞延稅項負債及因融資(而非營運目的)而產生之負債。

2.23 關連人士

- a) 倘屬以下人士,即該人士或該人 士之近親家族成員與本集團有關 連:
 - (i) 控制或共同控制本集團;
 - (ii) 對本集團有重大影響;或
 - (iii) 為本集團或本公司母公司 的主要管理層成員。
- (b) 倘符合下列任何條件,即實體與 本集團有關連:
 - (i) 該實體與本集團屬同一集 團之成員公司(即各母公司、附屬公司及同系附屬 公司彼此間有關連)。
 - (ii) 一間實體為另一實體的聯營公司或合營企業(或另一實體為成員公司之集團旗下成員公司之聯營公司或合營企業)。
 - (iii) 兩間實體均為同一第三方 的合營企業。
 - (iv) 一間實體為第三方實體的 合營企業,而另一實體為 該第三方實體的聯營公司。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

2.23 Related parties (Cont'd)

- (b) (Cont'd)
 - (v) The entity is a post-employment benefit plan for the benefit of the employees of the Group or an entity related to the Group.
 - (vi) The entity is controlled or jointly controlled by a person identified in (a).
 - (vii) A person identified in (a)(i) has significant influence over the entity or is a member of key management personnel of the entity (or of a parent of the entity).
 - (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the Group's parent.

Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity and include:

- (i) that person's children and spouse or domestic partner;
- (ii) children of that person's spouse or domestic partner; and
- (iii) dependents of that person or that person's spouse or domestic partner.

2. 主要會計政策概要(續)

2.23 關連人士(續)

- (b) (續)
 - (v) 實體為本集團或與本集團 有關連之實體就僱員利益 設立的離職福利計劃。
 - (vi) 實體受(a)所識別人士控制 或受共同控制。
 - (vii) 於(a)(i)所識別人士對實體 有重大影響力或屬該實體 (或該實體的母公司)主要 管理層成員。
 - (viii) 向本集團或向本集團母公司提供主要管理層人員服務的實體或集團任何成員公司。

有關人士之近親家族成員為預期於買 賣實體時將影響該人士或受該人士影 響之該等家族成員,包括:

- (i) 該人士之子女及配偶或家庭伴 侶;
- (ii) 該人士配偶或家庭伴侶之子女; B
- (iii) 該人士或其配偶或家庭伴侶之受養人。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



2.24 Provision and contingent liabilities

Provisions are recognised for liabilities of uncertain timing or amount when the Group has a legal or constructive obligation arising as a result of a past event, which it is probable will result in an outflow of economic benefits that can be reliably estimated.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. Possible obligations, the existence of which will only be confirmed by the occurrence or non-occurrence of one or more future events, are also disclosed as contingent liabilities unless the probability of outflow of economic benefits is remote.

3. ADOPTION OF NEW OR AMENDED HKFRSs

During the year, the Group has adopted all the amended HKFRSs which are first effective for the reporting year and relevant to the Group. The adoption of these amended HKFRSs did not result in material changes to the Group's accounting policies.

The following new or amended HKFRSs, potentially relevant to the Group's financial statements, have been issued, but are not yet effective and have not been early adopted by the Group. The Group's current intention is to apply these changes on the date they become effective.

Amendments to HKAS 7 — Statement of Cash Flows

The amendments are effective for accounting periods beginning on or after 1 January 2017. The amendments introduce an additional disclosure that will enable users of financial statements to evaluate changes in liabilities arising from financial activities.

2. 主要會計政策概要(續)

2.24 撥備及或有負債

當本集團因過往事項須承擔法律或推 定責任,而該責任可能導致可可靠估 計的經濟利益流出時,該等未確定時 間或金額之負債則確認為撥備。

當不大可能有經濟利益流出,或未能可靠地估計該金額,則該責任披露為或有負債,除非經濟利益流出之可能性極微則作別論。可能須承擔的責任,(其存在僅由一項或多項未來事項是否發生而確定)亦會披露為或有負債,除非經濟利益流出之可能性極微則作別論。

3. 採納新訂或經修訂香港財務報告 準則

年內,本集團已採納所有於報告年度首次生效並與本集團有關之經修訂香港財務報告準則。採納該等經修訂香港財務報告準則並不會導致本集團會計政策出現重大變動。

以下可能與本集團財務報表有關的新訂或經 修訂香港財務報告準則已經頒佈但尚未生 效,亦沒有獲本集團提前採納。本集團現時 有意於生效時實施該等變動。

香港會計準則第7號之修訂 — 現金 流量表

該項修訂於二零一七年一月一日或之後開始 之會計期間生效。該項修訂引入額外披露以 使財務報表使用者能夠評估財務活動產生之 負債之變動。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

ADOPTION OF NEW OR AMENDED HKFRSs (Cont'd)

Amendments to HKAS 12 - Income Taxes

The amendments are effective for accounting periods beginning on or after 1 January 2017. The amendments relate to the recognition of deferred tax assets and clarify some of the necessary considerations, including how to account for deferred tax assets related to debt instruments measured at fair value.

Amendments to HKFRS 2 — Share-based Payment

The amendments are effective for accounting periods beginning on or after 1 January 2018. The amendments provide a requirement on the accounting for the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations; and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled.

HKFRS 9 (2014) - Financial Instruments

This standard is effective for accounting periods beginning on or after 1 January 2018. HKFRS 9 introduces new requirements for the classification and measurement of financial assets. Debt instruments that are held within a business model whose objective is to hold assets in order to collect contractual cash flows (the business model test) and that have contractual terms that give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding (the contractual cash flow characteristics test) are generally measured at amortised cost. Debt instruments that meet the contractual cash flow characteristics test are measured at fair value through other comprehensive income ("FVTOCI") if the objective of the entity's business model is both to hold and collect the contractual cash flows and to sell the financial assets. Entities may make an irrevocable election at initial recognition to measure equity instruments that are not held for trading at FVTOCI. All other debt and equity instruments are measured at fair value through profit or loss ("FVTPL").

3. 採納新訂或經修訂香港財務報告 準則(續)

香港會計準則第12號之修訂 — 所得 税

該項修訂乃於二零一七年一月一日或之後開始之會計期間生效。該項修訂與遞延税項資產之確認有關,並澄清若干必要考量,包括如何將與按公平值計量的債務工具有關的遞延稅項資產入賬。

香港財務報告準則第2號之修訂 — 以股份為基礎之付款

該項修訂乃於二零一八年一月一日或之後開始之會計期間生效。該項修訂規定歸屬及非歸屬條件對以現金結算以股份為基礎之付款計量的影響的會計處理;預提稅責任具有淨額結算特徵的以股份為基礎之付款交易;以及交易類別由現金結算變更為權益結算之以股份為基礎之付款的條款及條件的修改。

香港財務報告準則第9號(二零一四年)— 金融工具

該項準則於二零一八年一月一日或之後開始 之會計期間生效。香港財務報告準則第9號 引進有關金融資產分類及計量之新規定。以 持有資產收取合約現金流的商業模式持有 (商業模式測試),且合約現金流僅為本金及 未償還本金之利息(合約現金流特徵測試) 的債務工具,一般按攤銷成本計量。倘債務 工具之實體商業模式之目的為同時持有及收 取合約現金流以及出售金融資產,則符合合 約現金流特徵測試,按公平值於其他全面收 入列賬(「按公平值於其他全面收入列賬」) 計量。實體可於初步確認時作出不可撤銷之 選擇,以按公平值於其他全面收入列賬計量 並非持作買賣之權益工具。所有其他債務及 權益工具以按公平值於損益列賬(「按公平 值於損益列賬」)計量。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



HKFRS 9 (2014) — Financial Instruments (Cont'd)

HKFRS 9 includes a new expected loss impairment model for all financial assets not measured at FVTPL replacing the incurred loss model in HKAS 39 and new general hedge accounting requirements to allow entities to better reflect their risk management activities in financial statements.

HKFRS 9 carries forward the recognition, classification and measurement requirements for financial liabilities from HKAS 39, except for financial liabilities designated at FVTPL, where the amount of change in fair value attributable to change in credit risk of the liability is recognised in other comprehensive income unless that would create or enlarge an accounting mismatch. In addition, HKFRS 9 retains the requirements in HKAS 39 for derecognition of financial assets and financial liabilities.

HKFRS 15 — Revenue from Contracts with Customers

This standard is effective for accounting periods beginning on or after 1 January 2018. The new standard establishes a single revenue recognition framework. The core principle of the framework is that an entity should recognise revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. HKFRS 15 supersedes existing revenue recognition guidance including HKAS 18 Revenue, HKAS 11 Construction Contracts and related interpretations.

HKFRS 15 requires the application of a 5 steps approach to revenue recognition:

Step 1: Identify the contract(s) with a customer

Step 2: Identify the performance obligations in the contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to each performance obligation

Step 5: Recognise revenue when each performance obligation is satisfied

3. 採納新訂或經修訂香港財務報告 準則(續)

香港財務報告準則第9號(二零一四年)—金融工具(續)

香港財務報告準則第9號就並非按公平值於 損益列賬計量之所有金融資產納入新的預期 虧損減值模式(取代香港會計準則第39號之 已產生虧損模式),並納入新的一般對沖會 計規定,以使實體於財務報表內更好地反映 其風險管理活動。

香港財務報告準則第9號遵從香港會計準則第39號有關金融負債之確認、分類及計量規定,惟指定按公平值於損益計量之金融負債除外,因負債信貸風險變動引致之公平值變動金額於其他全面收入確認,除非其會產生或擴大會計錯配風險則作別論。此外,香港財務報告準則第9號保留香港會計準則第39號有關終止確認金融資產及金融負債之規定。

香港財務報告準則第15號 — 客戶合 約收益

該準則於二零一八年一月一日或之後開始之會計期間生效。此項新準則確立單一收益確認框架。該框架的核心原則為實體應確認收益以便用金額描述向客戶轉讓承諾之商品或服務,該金額反映該實體預期有權就交換該等商品及服務所收取的代價。香港財務報告準則第15號取代現行收益確認指引(包括香港會計準則第18號收益、香港會計準則第11號建築合約及相關詮釋)。

香港財務報告準則第15號要求以五個步驟確認收益:

步驟 1: 識別與客戶所訂立合約 步驟 2: 識別合約之履約責任

步驟3:釐定交易價格

步驟 4:將交易價格分配至各履約責任

步驟5:於達致各履約責任時確認收益

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

ADOPTION OF NEW OR AMENDED HKFRSs (Cont'd)

HKFRS 15 — Revenue from Contracts with Customers (Cont'd)

HKFRS 15 includes specific guidance on particular revenue related topics that may change the current approach taken under HKFRS. The standard also significantly enhances the qualitative and quantitative disclosures related to revenue.

HKFRS 16 - Leases

HKFRS 16 will be effective for accounting period beginning on 1 January 2019. From the perspective as a lessee, under the existing standard, leases are classified as either finance lease or operating lease, resulting in different accounting treatment. Finance leases are required to be accounted for "On Balance Sheet" (i.e. lease asset and corresponding liabilities are recognised in the statement of financial position); while operating lease is accounted for "Off Balance Sheet" where no asset or liabilities are recognised and the lease expenses are recognised on a straight-line basis along the lease period. Under the new standard, "On Balance Sheet" accounting treatment is required for all leases, except for certain shortterm leases and leases of low-value assets. The statement of financial position will be "inflated" by their rights and obligations relating to their existing operating leases. In addition, the recognition of operating lease expenses will change from the existing straight-line model to a "front-loaded" model as finance lease, i.e. during the initial period of the lease term, the lease expenses (asset depreciation plus interest) under the new standard are higher compared to the operating lease expenses recognised under the existing standard.

From the perspective as a lessor, the accounting stays almost the same. However, the HKICPA has updated the guidance on the definition of a lease, sub-lease, as well as the guidance on the combination and separation of contracts, lessors will also be affected by the new standard.

The Group is not yet in a position to state whether these new pronouncements will result in substantial changes to the Group's accounting policies and financial statements.

3. 採納新訂或經修訂香港財務報告 準則(續)

香港財務報告準則第 15 號 — 客戶合 約收益(續)

香港財務報告準則第15號包含與特定收益 相關議題的特定指引,該等指引或會更改香 港財務報告準則現時應用方法。該準則亦顯 著提升與收益相關的質化與量化披露。

香港財務報告準則第16號 — 租賃

香港財務報告準則第16號將於二零一九年 一月一日開始的會計期間生效。就承租人而 言,根據現有準則,租賃可分為融資租賃或 經營租賃,因而導致不同會計處理方式。融 資租賃須於「資產負債表內」(即租賃資產及 相關負債於財務狀況表內確認)入賬;而經 營租賃須予「資產負債表外」入賬,租賃期 內並無資產或負債予以確認,而租賃開支乃 以直線法基準於租賃期內確認。根據新準 則,所有租賃(若干短期租賃及低值資產租 賃除外)均須按「資產負債表內」的會計處 理方式處理。財務狀況表將按其現有經營租 賃有關的權利及責任將予「上升」。此外, 經營租賃開支的確認將由現有直線法模型變 更為「前收式」模型,乃由於根據新準則的 融資租賃(即於租賃期內的初始期間,租賃 開支(資產折舊加利息))較根據現有準則 確認的經營租賃開支為高。

就出租人而言,會計方法幾乎相同。然而, 香港會計師公會已更新租賃、分租及合併及 分拆租約釋義的指引,出租人亦將受新準則 的影響。

本集團尚未能説明該等新宣告是否會導致本 集團會計政策及財務業績有重大變動。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Impairment of trade and other receivables

The Group's management determines the impairment of trade and other receivables on a regular basis. This estimate is based on the credit history of its customers or debtors and current market conditions. Management reassesses the impairment of trade and other receivables at the reporting date.

Estimated impairment of goodwill, other intangible assets and property, plant and equipment related to cash-generating units

The Group tests annually whether goodwill has suffered any impairment in accordance with the accounting policy stated in note 2.17. The carrying values of other intangible assets and property, plant and equipment are reviewed for impairment when there are any indications that the carrying value of other intangible assets and property, plant and equipment may not be recoverable. The recoverable amounts of cash-generating units have been determined based on value-in-use/fair value less costs of disposal calculations. These calculations require the use of estimates about future cash flows and discount rates.

4. 關鍵會計估計及判斷

本集團根據過往經驗及其他因素,包括對當 前情況相信屬合理的未來事件的預期,持續 就估計及判斷進行評估。

本集團就未來作出估計及假設。所達致的會計估計(按照定義)甚少與有關實際結果一致。具有可引致於下個財政年度對資產及負債賬面值作出重大調整的重大風險的估計及假設論述如下:

貿易及其他應收賬項減值

本集團管理層定期釐定貿易及其他應收賬項 減值。估計乃根據客戶或債務人信貸記錄及 現時市況作出。管理層於報告日對貿易及其 他應收賬項之減值重新評估。

有關現金產生單位之商譽、其他無 形資產以及物業、廠房及設備之估 計減值

本集團根據附註2.17所述會計政策每年測試商譽是否已有所減值。其他無形資產以及物業、廠房及設備之賬面值乃於存在跡象表明其他無形資產以及物業、廠房及設備之賬面值可能無法收回時進行減值評核。現金產生單位的可收回數額已按使用價值/公平值減銷售成本釐定。該等計算法需就未來現金流及折現率作出估計。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (Cont'd)

Estimated impairment of goodwill, other intangible assets and property, plant and equipment related to cash-generating units (Cont'd)

In the process of estimating expected future cash flows, management makes assumptions about future revenues and profits. The assumptions about future revenues are mainly based on the actual financial performance of the Group's revenue from respective cash generating unit for the year, the current market demand of the products in the PRC, the current supply of the similar products in the market, the estimated utilisation of the Group's production capacity and the management's current assessment of the economic outlook. The unit selling price is assumed to remain constant throughout the forecasted period. The assumptions about future profits are mainly based on the available market data of the profit margin ratio of companies engaged in respective cash generating unit in the PRC and global market. As these assumptions relate to future events and circumstances, the actual results may vary and may cause a material adjustment to the carrying amount of goodwill, other intangible assets and property, plant and equipment within the next financial year.

Determining the appropriate discount rate involves estimating the appropriate adjustment for market risk and for asset specific risk factors. The management has taken consideration of risk-free rate (reference to the yield of the long term bond issued in the PRC), the cost of equity and debt of the companies in respective industries and other possible risk factors such as the market capitalisation of the Group in estimating the discount rate. Details of the estimates of the recoverable amounts of cash generating units are disclosed in note 16.

4. 關鍵會計估計及判斷(續)

有關現金產生單位之商譽、其他無 形資產以及物業、廠房及設備之估 計減值(續)

釐定適當折現率涉及對市場風險及資產特定 風險因素之適當調整作出估計。管理層已考 慮無風險率(參考中國已發行長期債券的收 益率)、於相關行業的公司之股本及債務成 本及其他可能風險因素,例如本集團於估計 折現率時的市場資本。現金產生單位的可收 回金額的估計詳情乃於附註16披露。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees/consultants by reference to the fair value of the equity instruments at the date at which they are granted. Estimating fair value for share-based payment transactions requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model including the expected life of the share option, volatility and dividend yield and making assumptions about them. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in note 33.

Contingent consideration receivables

Where the fair value of contingent consideration receivables cannot be derived from active markets, their fair value is determined using valuation techniques including the discounted cash flow model. The inputs to these models are taken from observable markets, where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. The judgments include considerations of inputs such as probability-adjusted profit/loss and marketability discount. Changes in assumptions about these factors could affect the reported fair value of contingent consideration receivables.

Impairment of available-for-sale financial assets

The directors review available-for-sale financial assets at the end of each reporting period to assess whether they are impaired. The Group records impairment charges on available-for-sale financial assets when there has a significant or prolonged decline in the fair value below their costs. The determination of what is significant or prolonged required judgement. In making this judgement, the directors evaluate, among other factors, historical financial performance and financial position of the available-for-sale equity investments.

4. 關鍵會計估計及判斷(續)

以股份為基礎之付款交易

本集團參考僱員/顧問獲授權權益工具當日之公平值估量與彼等進行股權結算交易之成本。估計以股份為基礎之付款交易的公平值須根據授權條款及條件釐定最為適當的估值模型。該估計亦須釐定估值模型最為合適的數據(包括購股權預期年限、波幅及股息包報率)並就此作出假設。用於估計以股份為基礎之付款費用交易的公平值之假設及模型於附註33披露。

應收或然代價

倘應收或然代價之公平值無法從活躍市場得出,其公平值使用估值技術(包括貼現現金流量模型)釐定。在可行的情況下,該等模型的數據根據可觀察市場得出;倘不可行,則須作出一定判斷以設定公平值。該等判斷包括可能性調整溢利/虧損及市場流動折現率等數據之考量。該等因素假設之變化可影響應收或然代價之呈報公平值。

可供出售金融資產減值

董事於各報告期末檢討可供出售金融資產以評估有否出現減值。當可供出售金融資產之公平值大幅或長期跌至低於其成本時,本集團則錄得可供出售金融資產減值支出。釐訂大幅或長期須作出判斷。在作出此項判斷時,董事評估(包括其他因素)可供出售股本投資的歷史財務表現及財務狀況。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

REVENUE AND OTHER INCOME

The Group's turnover represents revenue from its principal activities, measured at the net invoiced value of goods sold, after allowances for returns and trade discounts during the years presented.

Other income recognised during the year is as follows:

5. 收益及其他收入

本集團之營業額指於呈報年度內來自其主要 活動,按扣除退貨及貿易折扣後之已售貨品 發票淨值計算之收益。

本年度內已確認其他收入如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
		丁/仓儿	一 一 一
Bank interest income Fair value gain on financial assets	銀行利息收入 按公平值於損益列賬	12,813	20,532
at fair value through profit or loss Gain on disposals of property,	之金融資產公平值收益 出售物業、廠房及設備之收益	2,006	_
plant and equipment		48	77
Government grant income	政府補貼收入	11,322	768
Interest income on loan receivables Gain on purchase and sale	應收貸款之利息收入 買賣應收債務之收益(附註)	7,315	89,030
of Debt Receivables (note)		10,843	_
Others	其他	797	574
		45,144	110,981

Note: On 1 November 2016, the Group entered into a sale and purchase agreement with independent third parties to acquire the debt receivables and the associated security package of Shenzhen Longzhu Hospital (the "Debt Receivables") for a consideration of RMB520 million. On 22 November 2016, the Group entered into another sale and purchase agreement with another independent third party to dispose the Debt Receivables for a consideration of RMB530 million. Accordingly, a gain on purchase and sale of Debt Receivables of RMB10 million (equivalent to HK\$11 million) was recognised in profit or loss during the year. Details of the disposal were contained in the Company's announcement dated 22 November 2016.

附註:於二零一六年十一月一日,本集團與獨立 第三方訂立了買賣協議以收購深圳龍珠醫院所結欠之應收債務及相關抵押組合(「應收債務」),代價為人民幣520,000,000元。於二零一六年十一月二十二日,本集團與另一獨立第三方訂立了另一份買賣協議以出售應收債務,代價為人民幣530,000,000元。因此,於本年度,於損益確認買賣應收債務之收益人民幣10,000,000元(相當於11,000,000港元)。有關出售事項之詳情載於本公司日期為二零一六年十一月二十二日之公告。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



6. SEGMENT INFORMATION

The executive directors have identified the Group's four business lines as operating segments as further described in note 2.22.

The operating segments are monitored and strategic decisions are made on the basis of adjusted segment operating results.

6. 分部資料

執行董事已確認本集團四條業務線為經營分部(詳情載於附註2.22)。

根據經調整分部經營業績就該等經營分部實施監控及作出策略決策。

		Tissue en 組織	•	Co 細		oth	etic and ners 及其他		equipment 設備	To 合	tal 計
		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元 (Restated) (經重列)	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元 (Restated) (經重列)	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Revenue — From external customers — From intersegment revenue	收益 一來自外界客戶 一來自分部間收益	126,281 2	5,776 –	2,724 —	1,321 –	44,926 187	20,211	183,056 —	443 –	356,987 189	27,751 –
Reportable segment revenue	須予呈報分部收益	126,283	5,776	2,724	1,321	45,113	20,211	183,056	443	357,176	27,751
Reportable segment profit/(loss)	須予呈報分部溢利/(虧損)	538	(69,081)	(50,380)	(19,096)	(10,023)	(3,533)	(1,233)	(385)	(61,098)	(92,095)
Amortisation of land use rights Amortisation of other intangible assets Depreciation Interest income	土地使用權難銷 其他無形資產攤銷 折舊 利息收入	102 33,682 7,758 2,702	109 34,450 8,960 34,217	- 7,315 2,174 78	- 4,115 417 13	- - 633 280	- - 224 1,312	- - 34 17	- - 48 15	102 40,997 10,599 3,077	109 38,565 9,649 35,557
Reportable segment assets	須予呈報分部資產	1,003,750	435,143	320,783	209,171	149,159	59,329	79,725	344,405	1,553,417	1,048,048
Additions to non-current segment assets during the year Reportable segment liabilities	年內非流動分部資產之添置 須予呈報分部負債	3,810 65,380	17,837 102,748	66,214 13,899	998 8,869	3,118 51,726	835 6,743	4 2,680	- 5,046	73,146 133,685	19,670 123,406



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

6. SEGMENT INFORMATION (Cont'd)

6. 分部資料(續)

The totals presented for the Group's operating segments reconcile to the Group's key financial figures as presented in the financial statements as follows:

本集團經營分部列示的總額與本集團於財務 報表列示的關鍵財務數據對賬如下:

		2017	2016
		二零一七年	二零一六年
		HK\$'000 千港元	HK\$'000 千港元
		干疮儿	
Reportable segment revenue	須予呈報分部收益	357,176	27,751
Less: Elimination of intersegment revenue	減:對銷分部間收益	(189)	27,701
Lead. Limination of interesgment revenue	//W 2131/2 HEIG IX III	(100)	
Group revenue	集團收益	356,987	27,751
	(T - 7 - D + D - 0 + D + D - D		<i>(</i>)
Reportable segment loss	須予呈報分部虧損	(61,098)	(92,095)
Unallocated corporate income	未分配企業收入	18,429	74,079
Unallocated corporate expenses	未分配企業開支	(163,922)	(155,911)
Fair value gain on contingent	應收或然代價之公平值收益	00.007	0.550
consideration receivables		20,097	8,556
Finance costs	財務費用	(24,426)	(25,827)
Loss before income tax	除所得税前虧損	(210,920)	(191,198)
	13-77 3 2003 2004	(=10,0=0)	(101,100)
Reportable segment assets	須予呈報分部資產	1,553,417	1,048,048
Available-for-sale financial assets	可供出售金融資產	112,928	_
Financial assets at fair value	按公平值於損益列賬之金融資產	,-	
through profit or loss		12,036	_
Contingent consideration receivables	應收或然代價	46,259	28,030
Cash and cash equivalents	現金及現金等值項目	288,405	1,197,818
Pledged bank deposits	已抵押銀行存款	794,743	558,873
Other corporate assets	其他企業資產	80,441	68,508
Group assets	集團資產	2,888,229	2,901,277
Reportable segment liabilities	須予呈報分部負債	133,685	123,406
Bank borrowings	銀行借款	753,977	542,553
Deferred taxation	遞延税項	78,411	90,306
Other corporate liabilities	其他企業負債	14,264	26,812
	A		
Group liabilities	集團負債	980,337	783,077

Unallocated corporate expenses mainly included staff costs, exchange loss, equity-settled share-based payments, rental and other expenses not directly attributable to the business of any operating segments.

未分配企業開支主要包括非直接由任何經營 分部之業務活動產生的員工成本、滙兑虧 損、以權益結算之股權支付費用、租金及其 他開支。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



6. SEGMENT INFORMATION (Cont'd)

The Group's revenue from external customers and its noncurrent assets other than contingent consideration receivables, available-for-sale financial assets and pledged deposits ("Specified non-current assets") are divided into the following geographical areas:

6. 分部資料(續)

本集團來自外界客戶的收益及其非流動資產 (應收或然代價、可供出售金融資產及已抵 押存款除外)(「特定非流動資產」)按地區 分析如下:

	external c	Revenue from external customers 來自外界客戶的收益		ified nt assets :動資產
	2017	2016	2017	2016
	二零一七年	二零一六年	二零一七年	二零一六年
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
	千港元	千港元	千港元	千港元
Hong Kong 香港	328	_	123,705	2,450
The PRC (domicile) 中國(主體所	E地) 356,659	27,751	793,463	876,304
	356,987	27,751	917,168	878,754

During the year ended 30 April 2017, 46% and 33% of the Group's revenue depended on one customer in medical equipment segment and one customer in tissue engineering segment respectively. As at 30 April 2017, 0% and 18% of the Group's trade receivables were due from these two customers respectively.

During the year ended 30 April 2016, 71% of the Group's revenue depended on one customer in cosmetic and others segment. As at 30 April 2016, 97% of the Group's trade receivables were due from this customer.

截至二零一七年四月三十日止年度,本集團收益的46%及33%分別來自於醫療設備分部之一名客戶及組織工程分部之一名客戶。 於二零一七年四月三十日,本集團應收貿易 賬項的0%及18%分別來自該兩名客戶。

截至二零一六年四月三十日止年度,本集團收益的71%來自於化妝品及其他分部之一名客戶。於二零一六年四月三十日,本集團應收貿易賬項的97%來自該名客戶。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The geographical location of customers is based on the location at which the services were provided or the goods delivered. The geographical location of the specified noncurrent assets is based on (1) the physical location of the assets (for property, plant and equipment and land use rights) and (2) location of operations (for goodwill and other intangible assets). The Company is an investment holding company where the Group has majority of its operation and workforce in the PRC, and therefore, the PRC is considered as the Group's country of domicile for the purpose of the disclosures as required by HKFRS 8 "Operating Segment".

Certain comparative figures in the segment information for the year ended 30 April 2016 have been restated. Previously, executive directors identified tissue engineering, cell and cosmetics and others as separate reportable segments. For the year ended 30 April 2017, the executive directors allocated the results from trading of medical equipment from tissue engineering segment to a new reportable segment, medical equipment, of the Group as a result of the change in information reported internally for the purposes of resources allocation and assessment of business performance. Comparative figures have been reclassified accordingly.

6. 分部資料(續)

客戶所在地點乃根據所提供之服務或交付貨品之地點劃分。特定非流動資產之地點乃根據(1)資產實際所在地(適用於物業、廠房及設備和土地使用權)及(2)經營所在地(適用於商譽及其他無形資產)劃分。本公司為一間投資控股公司,而本集團大多數營運及勞動力均在中國,因此,中國被認為是根據香港財務報告準則第8號「經營分部」規定而披露之本集團之主體所在地。

已重列截至二零一六年四月三十日止年度分部資料之若干比較數據。之前,執行董事將組織工程、細胞、化妝品及其他識別為須予單獨呈報分部。截至二零一七年四月三十日止年度,在為了資源配置及業務表現評估而進行的內部呈報資料變更後,執行董事將百難行的內部呈報資料變更後,執行董事將至實醫療設備之業績由組織工程分部份配至本集團新須予呈報分部,醫療設備。比較數據已相應地重新分類。

7. FINANCE COSTS

7. 財務費用

		2017	2016
		二零一七年	二零一六年
		HK\$'000	HK\$'000
		千港元	千港元
Interest on bank borrowings	銀行借款及其他應付賬項		
and other payables	之利息	24,426	25,827



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

8. LOSS BEFORE INCOME TAX

8. 除所得税前虧損

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Loss before income tax has been arrived at after charging:	除所得税前虧損已扣除 下列各項:		
Amortisation of land use rights Amortisation of other intangible assets, included in administrative expenses Auditor's remuneration Depreciation Equity-settled share-based payments Exchange difference, net Operating lease rentals in respect of office premises Research and development costs	土地使用權攤銷 其他無形資產攤銷 (已包括在行政開支中) 核數師酬金 折舊 以權益結算之股權支付費用 滙兑差額(淨額) 辦公室物業之經營租賃租金 研發成本	102 40,997 1,133 14,181 28,520 18,224 23,169 58,623	109 38,565 1,074 13,218 20,345 21,996 23,968
Less: Capitalisation to other intangible assets	減:資本化至其他無形資產	(2,576) 56,047	(4,021) 58,655
Employee benefit expense (including directors' emoluments (note 9)) (note 10) Less: Employee benefit expenses included in research and development costs	僱員福利開支 (包括董事酬金(附註9)) (附註10) 減:包括在研發成本內 之僱員福利開支	131,746 (5,304)	95,110 (15,421)
		126,442	79,689



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

DIRECTORS' AND CHIEF EXECUTIVES' 9. 董事及最高行政人員酬金 **EMOLUMENTS**

		Fees 袍金 HK\$'000 千港元	Salaries and allowances 薪金及津貼 HK\$'000 千港元	Contribution to defined contribution plans 定額供款 計劃之供款 HK\$*000 千港元	Equity-settled share-based payments 以權益結算之 股權支付費用 HK\$*000 千港元	Total 合計 HK\$'000 千港元
Year ended 30 April 2017 Executive directors Mr. Chen Chunguo (appointed as president on 25 October 2016 and re-designated as chief executive officer on 23 February 2017; appointed as executive director on 25 January 2017) Mr. Wong Sai Hung	截至二零一七年四月三十日止年度 執行董事 陳春國先生 (於二零一六年十月二十五日 獲委任為總裁及 於二零一七年二月二十三日 調任為行政總裁; 於二零一七年一月二十五日 獲委任為執行董事) 黃世雄先生	770 —	1,440	5 18	1,374	775 2,832
Dr. Shao Zhengkang (ceased to be chief executive officer on 23 February 2017)	邵政康博士 (於二零一七年二月二十三日 不再擔任行政總裁)	1,800	150	18	1,317	3,285
Independent non-executive directors	獨立非執行董事					
Mr. Lui Tin Nang Mr. Pang Chung Fai, Benny Mr. Chan Bing Woon Mr. Wang Hui* Mr. Wong Yiu Kit Ernest	呂天能先生 彭中輝先生 陳炳煥先生 王輝先生* 黃羅傑先生	240 240 240 240	- - -	-	137 137 132 120	377 377 372 360
(appointed on 23 February 2017)	(於二零一七年二月二十三日獲委任)	44	-	-	-	44
Non-executive directors Professor Cui Zhanfeng (appointed on 7 October 2016) Dr. Ray Yip	非執行董事 崔占峰教授 (於二零一六年十月七日獲委任) 葉雷博士	682	_	_	645	1,327
(appointed on 23 February 2017)	(於二零一七年二月二十三日獲委任)	110	_	-	_	110
Professor Xiong Chengyu (appointed on 20 March 2017)	熊澄宇教授 (於二零一七年三月二十日獲委任)	70	_	_	_	70
Mr. Yang Zhengguo (resigned on 5 August 2016)	楊正國先生 (於二零一六年八月五日辭任)	316	_	_	_	316
Professor Deng Shaoping (retired on 9 September 2016)	鄧紹平教授 (於二零一六年九月九日退任)	430	_	_	_	430
Mr. Wang Jianjun (retired on 9 September 2016)	王建軍先生 (於二零一六年九月九日退任)	360	_	_	_	360
Mr. Cao Fushun (resigned on 18 July 2016)	曹福順先生 (於二零一六年七月十八日辭任)	258	_	_	_	258
		5,800	1,590	41	3,862	11,293

Mr. Wang Hui was re-designated as non-executive director on 1 June 2017.



王輝先生於二零一七年六月一日調任為非 執行董事。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

9. DIRECTORS' AND CHIEF EXECUTIVES' 9. 董事及最高行政人員酬金(續) **EMOLUMENTS** (Cont'd)

				Contribution		
				to defined	Equity-settled	
			Salaries and	contribution	share-based	
		Fees	allowances	plans 定額供款	payments 以權益結算之	Total
		袍金	薪金及津貼	計劃之供款	股權支付費用	合計
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元
Year ended 30 April 2016	截至二零一六年四月三十日止年度					
Executive directors	執行董事					
Mr. Dai Yumin	戴昱敏先生					
(resigned on 30 April 2016)	(於二零一六年四月三十日辭任)	_	1,440	18	1,441	2,899
Ms. Wang Yurong	王玉榮女士					
(resigned on 30 April 2016)	(於二零一六年四月三十日辭任)	_	1,440	18	1,441	2,899
Mr. Wong Sai Hung	黃世雄先生					
(re-designated as executive	(於二零一六年一月十一日					
director on 11 January 2016)	調任為執行董事)	_	406	6	_	412
Dr. Shao Zhengkang	邵政康博士					
(appointed on 30 April 2016)	(於二零一六年四月三十日獲委任)	_	1	_	_	1
Independent non-executive directors	獨立非執行董事					
Mr. Lui Tin Nang	呂天能先生	210	_	_	173	383
Mr. Pang Chung Fai, Benny	彭中輝先生	210	_	_	166	376
Mr. Chan Bing Woon	陳炳煥先生	210	_	_	159	369
Mr. Wang Hui	王輝先生					
(appointed on 18 June 2015)	(於二零一五年六月十八日獲委任)	194	_	_	144	338
Non-executive directors	非執行董事					
Mr. Wong Sai Hung	黃世雄先生					
(re-designated as executive	(於二零一六年一月十一日					
director on 11 January 2016)	調任為執行董事)	868	_	_	623	1,491
Mr. Yang Zhengguo	楊正國先生	1,200	_	_	519	1,719
Professor Deng Shaoping	鄧紹平教授	1,200	_	_	476	1,676
Mr. Wang Jianjun	王建軍先生	1,200	_	_	476	1,676
Mr. Cao Fushun	曹福順先生	1,200	_	_	454	1,654
Chief Executive Officer	行政總裁					
Dr. Shao Zhengkang	邵政康博士	_	1,310	18	_	1,328
		6,492	4,597	60	6,072	17,221

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

DIRECTORS' AND CHIEF EXECUTIVES' EMOLUMENTS (Cont'd)

There was no arrangement under which a director waived or agreed to waive any remuneration during the year (2016: Nil).

No emoluments were paid by the Group to the directors as an inducement to join or upon joining the Group, or as compensation for loss of office.

Employees' emoluments

The five individuals whose emoluments including share-based payment expenses were the highest in the Group for the year included three (2016: five) directors whose emoluments are reflected in the analysis presented above. The emoluments of the remaining two individual were as follows:

9. 董事及最高行政人員酬金(續)

年內概無董事放棄或同意放棄任何酬金之安 排(二零一六年:無)。

本集團並無向董事支付任何酬金,作為加入 本集團或於加入本集團時之獎勵或離職補 償。

僱昌酬金

本集團年內五名最高薪人士(其酬金包括以股份為基礎之付款開支)包括三名(二零一六年:五名)董事,其酬金反映於上述分析內。餘下兩名人士的酬金如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Salaries and other benefits Retirement benefits scheme contributions Equity-settled share-based payments	薪金及其他福利 退休福利計劃供款 以權益結算之股權支付費用	2,464 30 359	_ _ _
		2,853	_

The emoluments of the highest paid non-director individuals fell within the following band:

非董事的最高薪人士的酬金介乎以下範圍以內:

Number of individual

人數

		2017 二零一七年	2016 二零一六年
Nil to HK\$1,000,000	零至1,000,000港元	1	_
HK\$1,000,001 — HK\$2,000,000	1,000,001港元 — 2,000,000港元	1	_



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



10. EMPLOYEE BENEFIT EXPENSE (INCLUDING 10. 僱員福利開支(包括董事酬金) DIRECTORS' EMOLUMENTS)

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Wages and salaries Equity-settled share-based payments Pension costs — defined contribution plans Other staff benefits	工資及薪金 以權益結算之股權支付費用 退休金成本 — 定額供款計劃 其他員工福利	90,191 24,597 10,377 6,581	66,295 17,205 7,510 4,100
		131,746	95,110

11. INCOME TAX (CREDIT)/EXPENSE

Hong Kong Profits Tax is calculated at 16.5% (2016: 16.5%) of the estimated assessable profit for the year. The PRC enterprise income tax of 25% (2016: 25%) is applicable to the Group's PRC subsidiaries except that Shenzhen AiNear Cornea Engineering Company Limited and Tianjin Weikai Bioeng Ltd are entitled to enjoy the tax benefit as an High and New Tech Enterprise for three years starting from the year ended 31 December 2016. They are subject to preferential income tax rate of 15%. Taxation on overseas profits has been calculated on the estimated assessable profits for the year at the rates of taxation prevailing in the countries in which the Group operates.

11. 所得税(抵免)/開支

香港利得税乃按年內估計應課税溢利的16.5%(二零一六年:16.5%)計算。本集團中國附屬公司適用25%(二零一六年:25%)之中國企業所得税,惟深圳艾尼爾角膜工程有限公司及天津衛凱生物工程有限公司於截至二零一六年十二月三十一日止年度起計三個年度內作為高新技術企業而享有税項優惠,只須按15%之優惠所得税率繳稅。海外利得税乃根據本年度估計應課税溢利按本集團經營所在地之現行税率計算。

		2017	2016
		二零一七年 HK\$'000	二零一六年 HK\$'000
		千港元	千港元
Profits tax — for the current year	利得税 — 本年度		
Hong Kong	香港	_	1,612
The PRC	中國	_	8,487
Over provision in respect of prior years	過往年度超額撥備	(4,382)	_
Deferred taxation (note 27)	遞延税項(附註27)	(7,346)	(6,773)
Income tax (credit)/expense	所得税(抵免)/開支	(11,728)	3,326



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

11. INCOME TAX (CREDIT)/EXPENSE (Cont'd)

Reconciliation between income tax (credit)/expense and accounting loss at applicable tax rates:

11. 所得税 (抵免) / 開支 (續)

按適用税率計算之所得税(抵免)/開支及會計虧損之對賬如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Loss before income tax	除所得税前虧損	(210,920)	(191,198)
Notional tax calculated at the rates applicable to the loss in the tax	按有關税項司法權區之虧損適用 之稅率計算的名義稅項		
jurisdictions concerned	, = , = ,,	(43,294)	(41,685)
Tax effect of expenses not deductible for tax purpose	不可用作扣税之開支的税務影響	43,617	35,972
Tax effect of income not taxable	毋須課税收入的税務影響		00,012
for tax purpose		(5,357)	(1,686)
Tax effect of tax losses not recognised	尚未確認税項虧損的税務影響	3,125	10,725
Utilisation of previously unrecognised	動用過往尚未確認之税項虧損		
tax losses		(5,437)	_
Over provision in respect of prior years	過往年度超額撥備	(4,382)	_
Income tax (credit)/expense	所得税(抵免)/開支	(11,728)	3,326

12. DIVIDENDS

The directors do not recommend the payment of a dividend for the year (2016: Nil).

12. 股息

董事並不建議派付本年度股息(二零一六年:無)。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



13. LOSS PER SHARE

E 13. 每股虧損

The calculation of the basic and diluted loss per share attributable to owners of the Company is based on the following data:

本公司擁有人應佔每股基本及攤薄虧損乃根 據以下數據計算:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Loss for the year attributable to owners of the Company for the purpose of basic loss per share	用以計算每股基本虧損 之本公司擁有人應佔 本年度虧損	(184,502)	(190,902)
		2017 二零一七年 '000 千股	2016 二零一六年 '000 千股
Number of shares	股份數目		
Weighted average number of ordinary shares for the purpose of basic loss per share	用以計算每股基本虧損 之普通股加權平均數	17,587,434	17,309,393

For the years ended 30 April 2017 and 2016, diluted loss per share attributable to owners of the Company was not presented because the impact of the exercise of share options was anti-dilutive.

截至二零一七年及二零一六年四月三十日止年度,由於行使購股權具反攤薄影響,故並無呈列本公司擁有人應佔每股攤薄虧損。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

14. PROPERTY, PLANT AND EQUIPMENT 14. 物業、廠房及設備

Ruikings improvement 操動機能	Total 合計 HK\$'000 千港元 198,527 (23,627) 174,900
横字 祖實物業装修 保格及股傷 電腦股橋 汽車 HKS 000	合計 HK\$'000 千港元 198,527 (23,627)
横字 相貨物業業券 係税 D股機	HK\$'000 千港元 198,527 (23,627)
### At 1 May 2015	千港元 198,527 (23,627)
At 1 May 2015	198,527 (23,627)
Cost 成本	(23,627)
Cost 成本	(23,627)
Recumulated depreciation 累計折舊 (3,708) (3,673) (12,205) (1,308) (2,733) Net book amount 順面淨值 102,977 8,694 61,109 671 1,449 Year ended 30 April 2016 截至二零一六年四月三十日 止年度 Opening net book amount 期初腰面淨值 102,977 8,694 61,109 671 1,449 Exchange differences 運発差額 (4,317) (182) (2,144) (24) (64) Disposal 出售 一 一 (50) (7) (38) Additions 添置 6,483 602 8,643 620 — Acquisitions through business combinations (note 34) Depreciation 折舊 (1,961) (3,773) (6,812) (361) (311) Closing net book amount 期末腰面淨值 103,182 5,417 62,002 1,039 1,113 At 30 April 2016 放二零一六年四月三十日 Cost 成本 108,666 12,777 80,386 2,615 3,171 Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 Opening net book amount 開初腰面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 運発差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 漆置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(23,627)
Net book amount 下下下下四月三十日 上午度	
Year ended 30 April 2016	174,900
世年度	
Opening net book amount 期初帳面淨值 102,977 8,694 61,109 671 1,449 Exchange differences 滙見差額 (4,317) (182) (2,144) (24) (64) Disposal 出售 (50) (7) (38) Additions 添置 6,483 602 8,643 620 - Acquisitions through business combinations (note 34) - 76 1,256 140 77 Depreciation 折舊 (1,961) (3,773) (6,812) (361) (311)	
Exchange differences	
Exchange differences	174,900
Disposal 出售	(6,731)
Additions 添置 6,483 602 8,643 620 — Acquisitions through business	(95)
Acquisitions through business combinations (note 34)	16,348
Combinations (note 34)	
Depreciation 折舊 (1,961) (3,773) (6,812) (361) (311) Closing net book amount 期末賬面淨值 103,182 5,417 62,002 1,039 1,113 At 30 April 2016 於二零一六年四月三十日 Cost 成本 108,666 12,777 80,386 2,615 3,171 Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 上年度 2002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 上年度 2002 1,039 1,113 Exchange differences 運送差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) - (95) - - Additions 添置 - 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681)	1,549
Closing net book amount 期末脹面淨值 103,182 5,417 62,002 1,039 1,113 At 30 April 2016 於二零一六年四月三十日 Cost 成本 108,666 12,777 80,386 2,615 3,171 Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 脹面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 Opening net book amount 期初脹面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(13,218)
At 30 April 2016	(- , -)
Cost 成本 108,666 12,777 80,386 2,615 3,171 Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	172,753
Cost 成本 108,666 12,777 80,386 2,615 3,171 Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 103,182 5,417 62,002 1,039 1,113 Exchange differences 進兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	
Accumulated depreciation 累計折舊 (5,484) (7,360) (18,384) (1,576) (2,058) Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 Opening net book amount 期初賬面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	207,615
Net book amount 賬面淨值 103,182 5,417 62,002 1,039 1,113 Year ended 30 April 2017 截至二零一七年四月三十日 止年度 Opening net book amount 期初賬面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(34,862)
Year ended 30 April 2017 截至二零一七年四月三十日 止年度 Opening net book amount 期初賬面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) - (95) - - Additions 添置 - 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(0 1,002)
止年度 Opening net book amount 期初賬面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) - (95) - - Additions 添置 - 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	172,753
Opening net book amount 期初賬面淨值 103,182 5,417 62,002 1,039 1,113 Exchange differences 滙兑差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) - (95) - - Additions 添置 - 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	
Exchange differences 進光差額 (5,904) (189) (2,976) (99) (58) Disposal 出售 (84) — (95) — — Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	470 750
Disposal 出售 (84) 一 (95) 一 一 Additions 添置 一 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	172,753
Additions 添置 — 47,793 21,202 621 1,331 Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(9,226)
Depreciation 折舊 (2,495) (3,681) (7,074) (407) (524)	(179)
	70,947
	(14,181)
Closing net book amount 期末賬面淨值 94,699 49,340 73,059 1,154 1,862	220,114
At 30 April 2017 於二零一七年四月三十日	
Cost 成本 102,331 60,189 99,497 3,289 4,531	269,837
Accumulated depreciation 累計折舊 (7,632) (10,849) (26,438) (2,135) (2,669)	(49,723)
Net book amount	(-,)

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



As at 30 April 2017 and 2016, all the Group's buildings are situated in the PRC and are held under medium term leases.

As at 30 April 2017, certain of the Group's property, plant and equipment with net carrying amount of HK\$78,027,000 (2016: HK\$84,494,000) were pledged to secure the bank borrowings granted to the Group (note 26).

15. LAND USE RIGHTS

14. 物業、廠房及設備(續)

於二零一七年及二零一六年四月三十日,本 集團所有樓宇均位於中國且以中期租賃形式 持有。

於二零一七年四月三十日,本集團賬面淨值 78,027,000港元(二零一六年:84,494,000 港元)之若干物業、廠房及設備已予抵押, 以為本集團獲授之銀行借款提供擔保(附註 26)。

15. 土地使用權

	2017	2016
	二零一七年	二零一六年
	HK\$'000	HK\$'000
	千港元	千港元_
Opening net carrying amount 期初賬面淨值	4,584	4,898
Exchange differences	(263)	(205)
Amortisation 攤銷	(102)	(109)
Closing net carrying amount 期末賬面淨值	4,219	4,584

The Group's land use rights represent payments to acquire interests in the usage of lands situated in the PRC, which are held under medium-term leases.

As at 30 April 2017 and 2016, the Group's entire land use rights were pledged to secure the bank borrowings granted to the Group (note 26).

16. GOODWILL

The goodwill arose from (1) the acquisition of FD(H) Investments Limited and its subsidiaries ("Aierfu Business"), which are engaged in the production and sales of tissue engineering products, in 2008; (2) the acquisition of Maylion Management Limited and its subsidiary ("Reshine Business"), which is engaged in bio-medical engineering, research and development of regenerative medical products in relation to tissue engineering technology in December 2013; (3) the acquisition of Passion Stream Limited and its subsidiaries ("Weikai Business"), which is engaged in the design and manufacturing of pre-clinical cell and stem cell related equipment, especially in 3D cell culture bio-reactors and their related consumables, as well as provision of CRO services in April 2015; and (4) Frame Sharp Limited and its subsidiaries ("AK Business"), which is principally engaged in providing service and equipment for human cell and cell related clinical applications in August 2015.

本集團之土地使用權指收購位於中國之土地 之使用權益(以中期租賃形式持有)之支付 款項。

於二零一七年及二零一六年四月三十日,本 集團之全部土地使用權已予抵押,以為本集 團獲授之銀行借款提供擔保(附註26)。

16. 商譽



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

16. GOODWILL (Cont'd)

16. 商譽(續)

The net carrying amount of goodwill can be analysed as follows:

商譽之賬面淨值之分析如下:

		Aierfu Business 艾爾膚業務 HK\$'000 千港元	Reshine Business 瑞盛業務 HK\$'000 千港元	Weikai Business 衛凱業務 HK\$'000 千港元	AK Business 奥凱業務 HK\$'000 千港元	Total 合計 HK\$'000 千港元
		.,_,			.,,,,,	
At 1 May 2015	於二零一五年五月一日					
Gross carrying amount	總賬面值	141,310	152,615	96,213	_	390,138
Accumulated impairment	累計減值		(152,615)	(49,442)		(202,057)
Net carrying amount	賬面淨值	141,310		46,771		188,081
Year ended 30 April 2016	截至二零一六年四月三十日 止年度					
Opening net carrying amount	期初賬面淨值	141,310	_	46,771	_	188,081
Business combinations	業務合併					
(note 34)	(附註34)	_	_	_	8,902	8,902
Closing net carrying amount	期末賬面淨值	141,310	_	46,771	8,902	196,983
At 30 April 2016	於二零一六年四月三十日					
Gross carrying amount	終 した	141,310	152,615	96,213	8,902	399,040
Accumulated impairment	累計減值	-	(152,615)	(49,442)	-	(202,057)
'				(, ,		
Net carrying amount	賬面淨值	141,310	_	46,771	8,902	196,983
Year ended 30 April 2017	截至二零一七年四月三十日					
Opening net carrying amount	期初賬面淨值	141,310	_	46,771	8,902	196,983
Closing net carrying amount	期末賬面淨值	141,310	_	46,771	8,902	196,983
At 30 April 2017	於二零一七年四月三十日					
Gross carrying amount	總賬面值	141,310	152,615	96,213	8,902	399,040
Accumulated impairment	累計減值	_	(152,615)	(49,442)		(202,057)
Net carrying amount	賬面淨值	141,310	_	46,771	8,902	196,983

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



For the purpose of impairment testing, goodwill is allocated to four cash generating units, Aierfu Business, Reshine Business, Weikai Business and AK Business.

The recoverable amounts for these cash-generating units have been determined based on value-in-use ("VIU")/fair value less cost of disposal ("FVLCD") calculation using discounted cash flow technique, covering detailed five-year budget plans. Cash flows beyond the five-year period are extrapolated using the estimated growth rates as stated below. The discount rates used for VIU and FVLCD are pre-tax and post-tax respectively and reflect specific risks relating to the relevant cash-generating unit.

The key assumptions used for recoverable amounts are as follows:

16. 商譽(續)

為進行減值檢測,商譽會分配至四個現金產 生單位,艾爾膚業務、瑞盛業務、衛凱業務 及奧凱業務。

該等現金產生單位的可收回金額已根據使用 貼現現金流量法(按詳盡五年預算計劃)計 算之使用價值(「使用價值」)/公平值減出 售成本(「公平值減出售成本」)計算釐定。 五年期以後之現金流量乃按以下所列估計增 長率推算。用於使用價值/公平值減出售成 本的折現率分別為除稅前及除稅後,並反映 相關現金產生單位之特定風險。

可收回金額所使用的主要假設如下:

			Aierfu Business 艾爾膚業務				Business AK Business 業務 奧凱業務		
		2017 二零一七年	2016 二零一六年	2017 二零一七年	2016 二零一六年	2017 二零一七年	2016 二零一六年	2017 二零一七年	2016 二零一六年
Basis	基準	VIU 使用價值	FVLCD 公平值減 出售成本	VIU 使用價值	FVLCD 公平值減 出售成本	FVLCD 公平值減 出售成本	FVLCD 公平值減 出售成本	FVLCD 公平值減 出售成本	FVLCD 公平值減 出售成本
Growth rate Discount rate	增長率 折現率	3% 22%	3% 18%	3% 28%	3% 22%	3% 20%	3% 19%	3% 20%	3% 21%

The key assumptions are those regarding the discount rate, growth rate and budgeted gross margin, which had been determined based on the market comparables and budgeted revenue, which had been determined based on the management's expectation for the market development and the production capacity of relevant cash generating units.

Apart from the considerations described above in determining the recoverable amount of the cash-generating unit, the Group's management is not currently aware of any other probable changes that would necessitate changes in their key assumptions. However, the estimate of recoverable amount of the Group's cash generating units is particularly sensitive to the discount rate applied.

The recoverable amount has been determined by an independent professional valuer, Hong Kong Appraisal Advisory Limited (2016: Roma Appraisal Limited) with the discounted cash flow approach. The recoverable amounts of these cash generating units are classified as level 3 measurement.

主要假設為有關折現率、增長率及預算毛利率,彼等根據市場可比較值及預算收益(其根據管理層對市場的發展和相關現金產生單位的生產能力之預期釐定)釐定。

除上述釐定現金產生單位可收回金額之考慮 因素外,本集團之管理層現時並不知悉任何 其他可能之變化,令其需要修改主要假設。 然而,本集團現金產生單位的可收回金額之 估計對所採用之折現率尤為敏感。

可收回金額乃由獨立專業估值師香港評值國際有限公司(二零一六年:羅馬國際評估有限公司)使用貼現現金流量法釐定。該等現金產生單位的可收回金額被列為第三級計量。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The valuation basis for the recoverable amounts of Aierfu Business and Reshine Business was changed from FVLCD to VIU in view of the stable and increasing revenue generated by these cash generating units during the year and these businesses no longer under development stage. Accordingly, the directors considered that VIU is more appropriate for these cash generating units. There were no other changes to the valuation techniques during the year.

Impairment assessment

As at 30 April 2017 and 2016, the Group carried out a review of the recoverable amount of its cash generating units because the cash generating units of Aierfu Business, Reshine Business, Weikai Business and AK Business had made losses during the year. As the recoverable amounts exceed the carrying amounts of the relevant assets of the cash generating units, the management considered that there is no impairment to be recognised in profit or loss for the year ended 30 April 2016 and 2017.

17. CONTINGENT CONSIDERATION RECEIVABLES

16. 商譽(續)

鑒於艾爾膚業務及瑞盛業務現金產生單位於 年內產生的收益穩定且不斷增加及該等業務 不再處於開發階段,該等現金產生單位可收 回金額的估值基準由公平值減出售成本變更 為使用價值。因此,董事認為使用價值更適 合該等現金產生單位。年內估值方法概無其 他變動。

減值評估

於二零一七及二零一六年四月三十日,因為艾爾膚業務、瑞盛業務、衛凱業務和奧凱業務之現金產生單位於年內錄得虧損,本集團就其現金產生單位的可收回金額進行了評核。由於現金產生單位相關資產的可收回金額超過其賬面值,管理層認為於截至二零一六及二零一七年四月三十日止年度不會於損益中確認減值。

17. 應收或然代價

		2017	2016
		二零一七年	二零一六年
		HK\$'000	HK\$'000
<u> </u>		千港元	千港元
At 1 May	於五月一日	28,030	15,088
Fair value gain	公平值收益	20,097	8,556
Acquisition of subsidiaries (note 34)	收購附屬公司(附註34)	_	5,193
Exchange differences	滙兑差額	(1,868)	(807)
At 30 April	於四月三十日	46,259	28,030

There are profit guarantees for the acquisitions of Weikai Business and AK Business.

For Weikai Business, the former owner guaranteed that total net profit for the years ended 31 December 2015 to 2018 not less than RMB25,000,000, or he will transfer part of the shares of Passion Stream Limited (a 70% indirectly owned subsidiary) held by non-controlling interests to the Group. The adjustment will be settled after the end of the four-year period.

收購衛凱業務及奧凱業務均有溢利保證。

有關衛凱業務,前擁有人保證,截至二零 一五年至二零一八年十二月三十一日止年度 之總溢利淨額將不少於人民幣25,000,000 元,否則其將向本集團轉讓非控股股東權益 所持部份Passion Stream Limited (70%間 接附屬公司) 之股份。有關調整將於四年期 結束後結算。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



For AK Business, the former owner guaranteed that total net profit for the years ended 31 December 2015 to 2018 not less than RMB8,000,000, or he will transfer part of the shares of Frame Sharp Limited (a 70% indirectly owned subsidiary) held by non-controlling interests to the Group. The adjustment will be settled after the end of the four-year period.

The contingent consideration receivables represent the fair value of the profit guarantees in accordance with the share purchase agreements for the acquisition of Weikai Business and AK Business are estimated by independent professional valuers, Hong Kong Appraisal Advisory Limited (2016: Roma Appraisal Limited). As at 30 April 2017 and 2016, the fair value of the contingent consideration receivables were estimated by applying income approach on the estimated profit from Weikai Business and AK Business for the four years ended 31 December 2018 and the estimated fair values of the shares of Passion Stream Limited and Frame Sharp Limited held by non-controlling interests.

The fair value of contingent consideration receivables is a level 3 recurring fair value measurement. Significant unobservable inputs for the valuation approach are as follows:

17. 應收或然代價(續)

有關奧凱業務,前擁有人保證,截至二零一五年至二零一八年十二月三十一日止年度之總溢利淨額將不少於人民幣8,000,000元,否則其將向本集團轉讓非控股股東權益所持部份Frame Sharp Limited (70%間接附屬公司) 之股份。有關調整將於四年期結束後結算。

應收或然代價指根據收購衛凱業務及奧凱業務之股份購買協議的溢利保證之公平值,乃由獨立專業估值師香港評值國際有限公司(二零一六年:羅馬國際評估有限公司)估計。於二零一七年及二零一六年四月三十日,應收或然代價之公平值乃使用收益法根據截至二零一八年十二月三十一日止四個年度衛凱業務及奧凱業務估計溢利以及非控股股東權益所持Passion Stream Limited及Frame Sharp Limited股份之估計公平值而估計得出。

應收或然代價之公平值為第三級經常性公平 值計量。估值法之重大非可觀察數據如下所 示:

			Weikai Business 衛凱業務		iness _{養務}
		2017 二零一七年	2016 二零一六年	2017 二零一七年	2016 二零一六年
Probability-adjusted profit/(loss)	可能性調整溢利/(虧損)	(RMB1,589,000) to RMB1,957,000 介乎 (人民幣 1,589,000元) 至 人民幣 1,957,000 元	(RMB1,039,000) to RMB5,037,000 介乎 (人民幣 1,039,000元)至 人民幣5,037,000元	(RMB6,753,000) to (RMB1,002,000) 介乎 (人民幣 6,753,000元) 至 (人民幣1,002,000元)	(RMB3,731,000) to RMB17,399,000 介乎 (人民幣 3,731,000元) 至 人民幣17,399,000元
Marketability discount on the fair value of shares	股份公平值之市場流動折現率	20.89%	20.89%	20.89%	20.89%

Higher probability-adjusted profit or loss will result in corresponding lower or higher fair values. Higher marketability discount on the fair value of shares of Passion Stream Limited and Frame Sharp Limited will result in corresponding lower fair values.

可能性調整溢利或虧損增加將導致公平值相應減少或增加。Passion Stream Limited及Frame Sharp Limited之股份公平值之市場流動折現率升高將導致公平值相應減少。





財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

17. CONTINGENT CONSIDERATION RECEIVABLES (Cont'd)

As at 30 April 2017 and 2016, it is estimated that with all other variables held constant, the sensitivity analysis of the change in significant unobservable inputs to the fair values of contingent consideration receivables is as follows:

17. 應收或然代價(續)

於二零一七年及二零一六年四月三十日,預 計所有其他變數保持不變,應收或然代價之 公平值根據重大非可觀察數據變化之敏感度 分析如下:

Decrease in fair values of contingent consideration receivables 應收或然代價之公平值減少

Weikai Business 衛凱業務

AK Business 奥凱業務

	2017 二零一七年	2016 二零一六年	2017 二零一七年	2016 二零一六年
Increase in the 可能性調整溢利增加 或可能性調整虧損 profit or decrease in the probability-adjusted loss by 5%	0%	0%	0%	0%
Increase in the marketability 市場流動折現率升高5% discount by 5%	5%	6%	5%	6%

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

18. OTHER INTANGIBLE ASSETS

18. 其他無形資產

			D	evelopment		
		Trademark	Patents	costs	Total	
		商標	專利	發展成本	信合 本	
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	
		千港元	千港元	千港元	千港元	
	<u> </u>					
At 1 May 2015	於二零一五年五月一日					
Cost	成本	79,986	512,329	64,199	656,514	
Accumulated amortisation	累計攤銷及減值虧損					
and impairment losses		(34,686)	(137,839)	_	(172,525)	
Net book amount	賬面淨值	45,300	374,490	64,199	483,989	
Year ended 30 April 2016	截至二零一六年四月三十日止年度					
Opening net book amount	期初賬面淨值	45,300	374,490	64,199	483,989	
Acquisitions through business	通過業務合併所收購(附註34)	40,000	014,400	04,100	400,000	
combinations (note 34)	应是来仍百万万·人将(旧正O+/	_	_	51,180	51,180	
Additions	添置	_	930	3,091	4,021	
Exchange differences	派 <u>虽</u> 滙兑差額		(11,025)	(3,100)	(14,125)	
Amortisation	推出	(5,330)	(33,235)	(0,100)	(38,565)	
Amortisation	# # # # # # # # # # # # # # # # # # #	(5,550)	(33,233)		(30,303)	
Closing net book amount	期末賬面淨值	39,970	331,160	115,370	486,500	
At 30 April 2016	於二零一六年四月三十日					
Cost	成本	79,984	497,839	115,370	693,193	
Accumulated amortisation	累計攤銷及減值虧損					
and impairment losses		(40,014)	(166,679)	_	(206,693)	
Net book amount	賬面淨值	39,970	331,160	115,370	486,500	
Year ended 30 April 2017	截至二零一七年四月三十日止年度					
Opening net book amount	期初賬面淨值	39,970	331,160	115,370	486,500	
Additions	添置	_	_	2,576	2,576	
Exchange differences	滙兑差額	_	(15,556)	(6,807)	(22,363)	
Amortisation	攤銷	(5,330)	(32,223)	(3,444)	(40,997)	
Closing net book amount	期末賬面淨值	34,640	283,381	107,695	425,716	
At 30 April 2017	於二零一七年四月三十日					
Cost	成本	79,984	473,372	111,095	664,451	
Accumulated amortisation	累計攤銷及減值虧損					
and impairment losses		(45,344)	(189,991)	(3,400)	(238,735)	
Net book amount	賬面淨值	34,640	283,381	107,695	425,716	



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

19. AVAILABLE-FOR-SALE FINANCIAL ASSETS

19. 可供出售金融資產

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Non-current, at cost Unlisted equity securities — the PRC	非流動,按成本 非上市股本證券 ─ 中國	112,928	_

Unlisted equity securities are measured at cost less impairment losses as the variability in the range of reasonable fair value estimates is significant and the probabilities of the various estimates within the range cannot be reasonably assessed and used in estimating fair value. The directors of the Company are of the opinion that the fair value cannot be measured reliably.

鑒於合理公平值估計範疇之變動屬重大及於估計公平值時該範疇內各估計的可能性不能合理評估及使用,非上市股本證券按成本減減值虧損計量。本公司董事認為公平值並不能可靠計量。

20. INVENTORIES

20. 存貨

	2017	2016
	二零一七年	二零一六年
	HK\$'000	HK\$'000
	千港元	千港元
Raw materials 原材料	3,716	1,712
Work in progress 在製品	1,728	3,639
Finished goods 製成品	9,310	3,616
Goods in transit 在運品	45,813	
	60,567	8,967


21. TRADE RECEIVABLES, DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

21. 應收貿易賬項、按金、預付款項 及其他應收賬項

		2017 二零一七年	2016 二零一六年
		HK\$'000 千港元	HK\$'000 千港元
		17870	17670
Trade receivables	應收貿易賬項	39,117	19,992
Deposits	按金	14,509	10,370
Prepayments	預付款項	138,518	42,067
Bank interest receivables	應收銀行利息	7,448	16,883
Loan receivables	應收貸款	_	8,421
Other receivables	其他應收賬項	173,204	28,095
		333,679	105,836

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



As at 30 April 2017, ageing analysis of trade receivables based on sales invoice date and net of provisions, is as follows:

21. 應收貿易賬項、按金、預付款項及其他應收賬項(續)

於二零一七年四月三十日,應收貿易賬項按 銷售發票日期及扣除撥備後之賬齡分析如 下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
0-90 days Over 90 days but less than 1 year 1 year or over 1 year	0-90天 超過90天但少於1年 1年或1年以上	12,348 18,590 8,179	13,767 6,105 120
		39,117	19,992

The Group allows an average credit period of 60-180 days (2016: 60-180 days) to its customers.

The carrying amount of trade receivables is considered as reasonable approximation of their fair value. Impairment of trade receivables is established when there is objective evidence that the Group will not be able to collect all amounts due according to the original terms of the receivables. Significant financial difficulties of the debtors and default or delinquency in payments are considered indicators that the trade receivable is impaired. All of the Group's trade receivables have been reviewed for indicators of impairment.

In addition, some of the unimpaired trade receivables are past due as at the reporting date. Ageing analysis of trade receivables not impaired is as follows:

本集團給予其客戶之平均信貸期為60-180 天(二零一六年:60-180天)。

應收貿易賬項之賬面值被視為其公平值之合理約數。當有客觀證據表明本集團將未能夠按應收賬項之原訂條款收回全部欠款時,則會確定應收貿易賬項出現減值。債務人面對重大財務困難,以及未能如期或拖欠還款,均被視為應收貿易賬項出現減值之跡象。本集團所有應收貿易賬項已進行減值跡象審閱。

此外,於報告日,部份並無減值之應收貿易 賬項乃逾期未付。並無減值之應收貿易賬項 之賬齡分析如下:

		2017	2016
		二零一七年	二零一六年
		HK\$'000	HK\$'000
		千港元	千港元
0-90 days	0-90天	8,605	_
Over 90 days past due but less than 1 year	超過90天但少於1年	13,516	66
1 year or over 1 year	1年或1年以上	8,178	120
		30,299	186

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

21. TRADE RECEIVABLES, DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES (Cont'd)

Trade receivables that were past due but not impaired related to customers that had a good track record of credit with the Group. Based on past credit history, management believes that no impairment allowance is necessary in respect of these balances as there has not been a significant change in credit quality and the balances are still considered to be fully recoverable. The Group did not hold any collateral in respect of trade receivables that were past due but not impaired.

As at 30 April 2016, loan receivables represented loan to an independent third party of RMB7,000,000 which was unsecured, interest bearing at 10% per annum and repayable on 31 December 2016. The loan has been fully repaid on 14 September 2016 and no new loan was granted during the year.

22. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

These represented the listed equity securities in Hong Kong and are held for trading purposes. The balances at the reporting dates are stated at fair values which have been determined by reference to the quoted bid prices at the reporting dates.

21. 應收貿易賬項、按金、預付款項及其他應收賬項(續)

逾期但無減值之應收貿易賬項涉及與本集團有良好信貸記錄的客戶。根據過往的信貸記錄,管理層相信,由於信貸質素並無發生重大變動,且該等結餘仍被視為可全數收回,故毋須就該等結餘計提減值撥備。本集團並無就逾期但無減值之應收貿易賬項持有任何抵押品。

於二零一六年四月三十日,應收貸款指向一名獨立第三方貸出無抵押、以年利率10%計息及須於二零一六年十二月三十一日償還的人民幣7,000,000元貸款。該貸款已於二零一六年九月十四日悉數償還且於年內並無授出新貸款。

22. 按公平值於損益列賬之金融資產

該等資產指香港上市股本證券且持作買賣用 途。於報告日之結餘按公平值(經參考報告 日之報價釐定)列賬。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

23. CASH AND CASH EQUIVALENTS/PLEDGED 23. 現金及現金等值項目/已抵押銀 BANK DEPOSITS 行存款

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Cash and bank balances Short-term deposits (note (a))	現金及銀行結餘 短期存款 (附註(a))	571,732 —	867,745 433,080
Cash and cash equivalents	現金及現金等值項目	571,732	1,300,825
Pledged deposits (note (b)) Non-current Current	已抵押存款 (附註(b)) 非流動 流動	794,743 —	_ 558,873
		794,743	558,873

- (a) Short-term bank deposits of the Group as at 30 April 2016 earned interest at the rates of 1.21% per annum. These deposits had maturity of three months and were eligible for immediate cancellation without penalty but any interest for the last deposit period would be forfeited. The directors considered that the fair value of short-term deposits was not materially different from its carrying amount because of the short maturity period on its inception.
- (b) The deposits are pledged to banks to secure bank loans (as detailed in note 26 to the financial statements). These deposits earn interests from 2.10% to 3.68% (2016: 3.30% to 3.68%) per annum. As at 30 April 2017, the pledged deposits are classified as non-current assets as it is pledged to secure non-current bank loans. As at 30 April 2016, the pledged deposits were classified as current assets as it was pledged to secure short-term bank loans.
- (a) 於二零一六年四月三十日,本集團之 短期銀行存款按年利率1.21%計息。 該等存款為期三個月,可於不繳納任 何違約金的情況下即時取消,惟最後 存款期之利息將被沒收。由於短期存 款將於短期內到期,故董事認為其之 公平值與其賬面值差異並不重大。
- (b) 存款已抵押予銀行以作為銀行貸款之擔保(如財務報表附註26中詳述)。該等存款年利率為2.10%至3.68%(二零一六年:3.30%至3.68%)。於二零一七年四月三十日,已抵押存款因抵押作為非即期銀行貸款之擔保而分類為非流動資產。於二零一六年四月三十日,已抵押存款因抵押作為短期銀行貸款之擔保而分類為流動資產。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

23. CASH AND CASH EQUIVALENTS/PLEDGED BANK DEPOSITS (Cont'd)

(c) Included in cash and bank balances, short-term deposits and pledged bank deposits of the Group is HK\$641,938,000 (2016: HK\$552,190,000) of bank balances denominated in Renminbi ("RMB") placed with banks in the PRC. RMB is not a freely convertible currency. Under the Mainland China's Foreign Exchange Control Regulations and Administration of Settlement and Sales and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for foreign currencies through banks that are recognised to conduct foreign exchange business.

23. 現金及現金等值項目/已抵押銀行存款(續)

(c) 本集團之現金及銀行結餘、短期存款及已抵押銀行存款包括存放於中國之銀行並以人民幣(「人民幣」)計值之銀行結餘641,938,000港元(二零一六年:552,190,000港元)。人民幣並非可自由兑換之貨幣。根據中國內地之外滙管理條例及結滙、售滙及付滙管理規定,本集團獲准透過獲授權進行外滙業務之銀行將人民幣兑換為外幣。

24. TRADE PAYABLES

As at 30 April 2017, ageing analysis of trade payables based on invoice date is as follows:

24. 應付貿易賬項

於二零一七年四月三十日,應付貿易賬項按 發票日期之賬齡分析如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
0-30 days	0-30天	37,075	245
31-60 days	31-60天	55	120
Over 60 days but less than 1 year	超過60天但少於1年	1,049	827
1 year or over 1 year	1年或1年以上	814	378
		38,993	1,570

General credit terms granted by suppliers are 30 days to 60 days.

供應商授出之一般信貸期介乎30天至60天。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



25. ACCRUED CHARGES AND OTHER PAYABLES

25. 應計費用及其他應付賬項

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Accrued charges	應計費用	9,306	7,047
Receipt in advance from customers	預收客戶賬項	18,678	58,992
Other payables (note (a))	其他應付賬項(附註(a))	32,815	20,754
Other payables for acquisition	購置樓宇的其他應付賬項		
of buildings (note (c))	(附註(c))	_	6,015
Government subsidies (note (b))	政府補助 (附註(b))	43,890	46,843
		104,689	139,651

- (a) As at 30 April 2017, other payables are unsecured, interest free and repayable on demand except the amount of HK\$434,000 (2016: HK\$444,000), which was interest bearing at 5.5% per annum.
- (b) Government subsidies represent payments granted by the local governments in the PRC in relation to the research and development of tissue engineering and stem cell projects carried out in the PRC. These payments will be recognised as income upon the approval from the local government on the output of the relevant projects.
- (c) As at 30 April 2016, the balance represented payables for acquisition of buildings in the PRC. The amounts were interest bearing at 12% per annum, repayable within one year and secured by the buildings with net carrying amount of HK\$18,686,000. Such amount was fully repaid during the year.

- (a) 於二零一七年四月三十日,其他應付 賬項乃為無抵押、免息及須按要求償 還,惟一筆434,000港元(二零一六 年:444,000港元)之款項按年利率 5.5%計息除外。
- (b) 政府補助指中國當地政府就於中國進 行之組織工程及幹細胞項目研究及開 發授出之款項。該等款項將於當地政 府對相關項目成果作出批准後確認為 收入。
- (c) 於二零一六年四月三十日,結餘指收 購位於中國樓宇的應付賬項。該等款 項以年利率12%計息且須於一年內償 還,由賬面淨值為18,686,000港元之 樓宇作抵押。該款項已於年內悉數償 還。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

26. BANK BORROWINGS

26. 銀行借款

As at 30 April 2017, the Group's bank borrowings are repayable as follows:

於二零一七年四月三十日,本集團之應償還 銀行借款如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Current: Bank loans, secured — repayable within one year (i)	即期: 銀行貸款,有抵押 — 一年內 償還(i)	28,345	542,553
Non-current: Bank loans, secured — repayable over one year but less than five years (ii)	非即期: 銀行貸款,有抵押 — 一年後 但五年內償還(ii)	725,632	_
		753,977	542,553

The interest-bearing bank borrowings are carried at amortised cost.

- (i) As at 30 April 2017, the current bank borrowings represented bank loans with principal amounts of RMB25,000,000 (2016: RMB451,000,000), which are repayable within one year. The bank loans of RMB25,000,000 (2016: RMB30,000,000) are secured by the Group's property, plant and equipment and land use rights with carrying amounts of HK\$78,027,000 (2016: HK\$84,494,000) and HK\$4,219,000 (2016: HK\$4,584,000) respectively. As at 30 April 2016, the remaining bank loan of RMB421,000,000 was secured by the Group's pledged bank deposits with carrying amounts of HK\$558,873,000.
- (ii) As at 30 April 2017, the non-current bank borrowings represented bank loans with principal amounts of RMB640,000,000 (2016: Nil), which are repayable over one year but less than five years. The bank loans of RMB640,000,000 are secured by the Group's pledged bank deposits with carrying amounts of HK\$794,743,000 (2016: Nil).

Interest rate of the bank borrowings was from 4.750% to 6.090% (2016: 4.140% to 6.090%) per annum for the year.

計息銀行借款乃按攤銷成本列賬。

- (i) 於二零一七年四月三十日,即期銀行借款指本金金額為人民幣25,000,000元(二零一六年:人民幣451,000,000元)且須於一年內償還的銀行貸款。人民幣25,000,000元(二零一六年:人民幣30,000,000元)的銀行貸款由本集團賬面值分別為78,027,000港元(二零一六年:84,494,000港元)及4,219,000港元(二零一六年:4,584,000港元)之物業、廠房及設備以及土地使用權作抵押。於二零一六年四月三十日,餘下人民幣421,000,000元的銀行貸款由本集團賬面值為558,873,000港元之已抵押銀行存款作抵押。
- (ii) 於二零一七年四月三十日,非即期銀行借款指須於一年後但五年內償還之賬面值為人民幣640,000,000元(二零一六年:無)之銀行貸款。該筆人民幣640,000,000元之銀行貸款以本集團賬面值為794,743,000港元(二零一六年:無)之已抵押銀行存款作抵押。

本年度銀行借款之年利率為介乎4.750% 至6.090%之間(二零一六年:4.140%至 6.090%)。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



27. DEFERRED TAXATION

Deferred taxation is calculated on temporary differences under the liability method using the rates of taxation prevailing in the countries in which the Group operates.

The movement on deferred tax liabilities is as follows:

27. 遞延税項

遞延税項乃根據負債法以本集團經營所在國家之現行稅率按暫時差額計算。

遞延税項負債之變動如下:

Fair value adjustments arising from other intangible assets 其他無形資產所產生之公平值調整

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
At beginning of the year	年初	90,306	86,626
Fair value adjustments arising from	收購附屬公司所產生		,
acquisition of subsidiaries (note 34) Credited to profit or loss for the year	之公平值調整(附註34) 已計入本年度損益	_	12,796
(note 11)	(附註11)	(7,346)	(6,773)
Exchange differences	滙兑差額	(4,549)	(2,343)
At end of the year	年末	78,411	90,306

As at 30 April 2017, the Group has unused tax losses of HK\$81,992,000 (2016: HK\$130,346,000) available for offset against future profits. No deferred tax asset has been recognised in respect of the tax losses due to the unpredictability of future profit streams. Tax losses will expire after 5 years from the year in which the tax losses were incurred.

於二零一七年四月三十日,本集團有未動用稅項虧損81,992,000港元(二零一六年:130,346,000港元),可用於抵扣未來溢利。由於未來溢利來源的不可預測性,故並無就稅項虧損確認遞延稅項資產。稅項虧損將於其產生當年起計5年後到期。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

28. SHARE CAPITAL

28. 股本

		2017 - 東一上	2017 二零一七年		} ÷年	
		Number	.т	二零一7 Number	/\T	
		of shares 股份數目	Amount 金額 HK\$'000 千港元	of shares 股份數目	Amount 金額 HK\$'000 千港元	
Ordinary shares of HK\$0.01 each	每股面值0.01港元之普通股					
Authorised: At beginning of the year	法定股本: 年初及年末					
and at end of the year		100,000,000,000	1,000,000	100,000,000,000	1,000,000	
Issued and fully paid:	已發行及繳足:	47 500 400 000	475.000	10 110 100 000	104 400	
At beginning of the year Shares issued in placing	年初 按配售安排發行之股份	17,592,180,000	175,922	16,442,180,000	164,422	
arrangement (note (i))	(附註(i))	-	_	1,150,000,000	11,500	
Shares repurchased and cancelled (note (ii))	已購回及註銷之股份 (附註(ii))	(6,390,000)	(64)	-		
At end of the year	年末	17,585,790,000	175,858	17,592,180,000	175,922	

Notes:

- (i) On 30 July 2015, pursuant to a placing agreement dated 10 July 2015 between the Company and a placing agent, the Company issued an aggregate of 1,150,000,000 new ordinary shares of HK\$0.01 each at a price of HK\$0.40 per share to independent parties. Details of the share placement were contained in the Company's announcements dated 10 July 2015 and 30 July 2015
- (ii) On 8 September 2016, the Company cancelled 6,390,000 of its shares in respect of the repurchases made on 26-29 July 2016, 1 August 2016 and 3-5 August 2016. Details of the share cancellation were contained in the Company's announcement dated 8 September 2016.

All these ordinary shares issued by the Company during the years rank pari passu with the then existing ordinary shares in all respects.

附註:

- (i) 於二零一五年七月三十日,根據本公司與配售代理於二零一五年七月十日訂立之配售協議,本公司按每股0.40港元之價格向獨立第三方發行合共1,150,000,000股每股面值0.01港元的新普通股。股份配售之詳情載於本公司日期為二零一五年七月十日及二零一五年七月三十日之公告。
- (ii) 於二零一六年九月八日,本公司註銷 6,390,000股其於二零一六年七月二十六 日至二十九日、二零一六年八月一日及二 零一六年八月三日至五日購回之股份。有 關股份註銷之詳情載於本公司日期為二零 一六年九月八日之公告。

本公司於各年度發行之所有普通股於各方面均與當時之現有普通股享有同等權益。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



29. 控股公司之財務狀況表

AS AT 30 APRIL 2017

於二零一七年四月三十日

		Notes 附註	2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
ASSETS AND LIABILITIES	資產及負債			
Non-current assets Property, plant and equipment Investments in subsidiaries	非流動資產 物業、廠房及設備 於附屬公司之投資		86 200	1,811 200
			286	2,011
Current assets Deposits and prepayments Financial assets at fair value through profit or loss Amounts due from subsidiaries	流動資產 按金及預付款項 按公平值於損益列賬 之金融資產 應收附屬公司款項		16,153 12,036 2,493,180	6,232 _ 2,374,100
Cash and cash equivalents	現金及現金等值項目		69,586	336,015
			2,590,955	2,716,347
Current liabilities Accrued charges and other payables Amounts due to subsidiaries Current tax liabilities	流動負債 應計費用及其他應付賬項 應付附屬公司款項 當期税項負債		7,919 142,693 1,326	7,478 89,183 1,326
			151,938	97,987
Net current assets	流動資產淨值		2,439,017	2,618,360
Net assets	資產淨值		2,439,303	2,620,371
EQUITY	權益			
Share capital Reserves	股本 儲備	28 30	175,858 2,263,445	175,922 2,444,449
Total equity	總權益		2,439,303	2,620,371

On behalf of directors

代表董事

Mr. Wong Sai Hung 黃世雄先生 Director 董事 Mr. Chen Chunguo 陳春國先生 Director 董事





財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

30. RESERVES

30. 儲備

The Company

本公司

		Share premium 股份溢價 HK\$'000 千港元	Share option reserve 購股權儲備 HK\$'000 千港元	Translation reserve 滙兑儲備 HK\$'000 千港元	Accumulated losses 累計虧損 HK\$'000 千港元	Total 合計 HK\$'000 千港元
At 1 May 2015	於二零一五年五月一日	2,754,185	24,678	12	(662,331)	2,116,544
Shares issue expense Exchange gain on translation of financial statements	股份發行開支 換算海外業務財務報表 之滙兑收益	(3,894)	-	-	_	(3,894)
of foreign operations		_	_	1	_	1
Issue of share options	發行購股權	_	20,345	_	_	20,345
Lapse of share options	已失效購股權	_	(80)	_	80	_
Share issued at premium	按溢價發行股份	448,500	_	_	_	448,500
Loss for the year	本年度虧損	_	_		(137,047)	(137,047)
At 30 April 2016 and 1 May 2016	於二零一六年四月三十日 及二零一六年五月一日	3,198,791	44,943	13	(799,298)	2,444,449
Exchange gain on translation of financial statements	換算海外業務財務報表 之滙兑收益					
of foreign operations		_	_	1	_	1
Issue of share options	發行購股權	_	28,520	_	_	28,520
Lapse of share options	已失效購股權	_	(38,789)	_	38,789	_
Share repurchased and cancelled	已購回及註銷股份	(1,795)	_	_	_	(1,795)
Loss for the year	本年度虧損		_	_	(207,730)	(207,730)
At 30 April 2017	於二零一七年四月三十日	3,196,996	34,674	14	(968,239)	2,263,445

In accordance with the Companies Law of the Cayman Islands, the share premium account of the Company is also available for distribution to shareholders provided that the Company is able to pay its debts as they fall due in the ordinary course of business immediately following the date on which any such distribution is proposed to be paid.

根據開曼群島公司法,本公司之股份溢價賬 亦可分派予股東,惟本公司須於緊隨建議派 付任何有關分派日期後,能夠在日常業務過 程中償還到期債務。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



31. OPERATING LEASE COMMITMENTS

As lessee

The Group leases a number of properties under operating leases. The leases run for an initial period of one to five years.

At the reporting date, the total future minimum lease payments under non-cancellable operating leases are as follows:

31. 經營租賃承擔

作為承租方

本集團根據經營租賃租用若干物業。有關租 約初始期為一至五年。

於報告日,根據不可撤銷經營租賃而須支付 之未來最低租金總額如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Within one year In the second to fifth year inclusive Later than five years	一年內 第二至第五年(包括首尾兩年) 五年以上	26,445 44,962 —	13,568 21,596 864
		71,407	36,028

During the year, the Group entered into the framework agreements with independent third parties to establish an ophthalmic clinic and a specialist hospital located in Shenzhen, PRC. According to the terms of the two framework agreements, the Group may have use of each of the two sites for the first eight years following the date the relevant site becomes available for use and the Group is required to share 49% of the audited net profit (after tax) of the specialist hospital with the independent third party during the term of that lease. Thereafter, the Group may elect to continue to rent the sites at a rental to be determined by reference to the then prevailing market rate for the seven years that follow.

於本年度,本集團與獨立第三方訂立框架協議,以於中國深圳成立一間眼科診所及一間專科醫院。根據兩份框架協議之條款,本集團可於有關場所可供使用之日起首個八年內使用該兩個場所,但本集團須於租賃年期內與獨立第三方分享專科醫院49%經審核淨利潤(稅後)。此後,本集團可選擇繼續租賃該等場所,租金將參考七年後的通行市場利率釐定。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

32. CAPITAL AND OTHER COMMITMENTS

32. 資本及其他承擔

As at 30 April 2017, the Group had capital and other commitments as follows:

於二零一七年四月三十日,本集團之資本及 其他承擔如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Capital commitments:	資本承擔:		
Authorised but not contracted for: Purchase of property, plant and equipment Contracted but not provided for:	已授權但未訂約: 購置物業、廠房及設備 已訂約但未撥備:	_	68,780
Purchase of property, plant and equipment	購置物業、廠房及設備	15,038	21,658

The Company signed two sponsorship agreements with the University of Oxford for the research of stem cell therapy and tissue engineering. The Company agreed to provide GBP9.0 million (equivalent to HK\$102.6 million) to the University of Oxford by instalments over the period covered by agreements. Up to 30 April 2017, the Company has paid GBP4.5 million (equivalent to HK\$52.6 million) (2016: GBP2.5 million (equivalent to HK\$28.4 million)) to the University of Oxford.

On 31 March 2017, the Group entered into the commitment letter with independent third parties to subscribe for the interest in a Haitong International Zhong Hua Finance Acquisition Fund I, L.P. ("the Fund"), an exempted limited partnership to be established in the Cayman Islands, and irrevocably undertake to make a capital contribution of US\$75 million (equivalent to HK\$585 million) to the Fund as a limited partner of the Fund, subject to and assumes the satisfaction of the conditions contained in the limited partnership agreement and subscription agreement of the fund and acceptance by the general partner of the fund. Up to 30 April 2017, the Company has not yet made any payment to the fund. On 15 July 2017, the Group entered into the limited partnership agreement and subscription agreement of the fund.

本公司與牛津大學就幹細胞治療及組織工程的研究訂立兩份贊助協議。本公司同意於協議涵蓋期間向牛津大學分期提供9,000,000英鎊(相當於102,600,000港元)。截至二零一七年四月三十日,本公司已向牛津大學支付4,500,000英鎊(相當於52,600,000港元)(二零一六年:2,500,000英鎊(相當於28,400,000港元))。

於二零一七年三月三十一日,本集團與獨立第三方訂立認購Haitong International Zhong Hua Finance Acquisition Fund I, L.P.(「基金」)(為將於開曼群島成立之獲豁免有限責任合夥事業)權益的承擔函,並不可撤銷地承諾作為基金之有限合夥人向為基金之有限合夥協議中所載之條件獲達成以及獲基金之普通合夥人接納後方可作實。截至二零一七年四月三十日,本公司尚未向基金支付任何款項。於二零一七年七月十五日,本集團訂立有限合夥協議及基金認購協議。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



A share option scheme was adopted by the Company pursuant to a resolution passed on 14 September 2011 (the "Scheme"). Under the Scheme, the directors may grant options to (i) any eligible employee (means any employee, whether full time or part time employee, including any executive directors and nonexecutive directors) of the Company, any of its subsidiaries and any invested entity; (ii) any supplier of goods or services to any member of the Group or any invested entity; (iii) any customer of the Group or any invested entity; (iv) any person or entity that provides research, development or technological support or other services to the Group or any invested entity; and (v) any shareholder or any member of the Group or any invested entity or any holder of any securities issued by any member of the Group to any invested entity (collectively known as the "Participants"), to subscribe for shares in the Company. The purpose of the Scheme is to provide incentives or rewards to the Participants thereunder for their contributions to the Group and/or to enable the Group to recruit and retain high-caliber employees and attract human resources that are valuable to the Group and any invested entity. The period of the Scheme shall not be more than ten years from the date of adoption of the Scheme.

33. 購股權

本公司根據一項於二零一一年九月十四日 通過之決議案採納一項購股權計劃(「計 劃」)。根據計劃,董事可向下列人士授出 購股權以認購本公司股份:(i)本公司、其任 何附屬公司及任何所投資實體之任何合資格 僱員(指任何全職或兼職僱員,包括任何執 行董事及非執行董事);(ii)向本集團任何成 員公司或任何所投資實體供應貨品或服務之 任何供應商;(iii)本集團或任何所投資實體 之任何顧客; (iv) 向本集團或任何所投資實 體提供研究、開發或技術支援或其他服務之 任何人士或實體;及(v)本集團或任何成員 公司或任何所投資實體之任何股東或本集團 任何成員公司向任何所投資實體發行之任何 證券之任何持有人(統稱「參與者」)。計劃 之目的乃就有關參與者對本集團所作之貢獻 作出鼓勵或獎勵及/或使本集團得以招攬及 挽留優秀僱員,並吸納對本集團及任何所投 資實體而言寶貴之人力資源。計劃期由採納 計劃日期起計不得超過十年。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The total number of shares in respect of which options may be granted under the Scheme is not permitted to exceed 10% of the shares of the Company in issue at the date of the approval of the Scheme, unless approved by the Company's shareholders. In addition, the maximum number of shares of the Company which may be issued upon exercise of all outstanding options granted under the Scheme is not permitted to exceed 30% of the shares of the Company in issue from time to time. The number of shares in respect of which options may be granted to any individual in any 12-month period is not permitted to exceed 1% of the shares of the Company in issue at any point in time. Options granted to substantial shareholders or independent non-executive directors of the Company, or any of their respective associates in excess of 0.1% of the Company's share capital and with a value in excess of HK\$5 million must be approved by the Company's shareholders.

Options granted must be taken up within a period of 28 days from the date of grant, upon payment of HK\$1 per grant. An option period to be determined by the directors is at their absolute discretion shall not be more than ten years after the date of the grant of the share option ("Option Period"). Options may be exercised in accordance with the terms of the Scheme at any time during the Option Period after the option has been granted. The exercise price should not be less than the highest of (i) the nominal value of the Company's shares; (ii) the closing price of the Company's share on the date of grants, which must be a trading day; or (iii) the average of the closing prices of the Company's shares for the five trading days immediately preceding the date of grant.

All share-based employee compensation will be settled in equity. The Group has no legal or constructive obligation to repurchase or settle the options other than by issuing its shares.

During the year ended 30 April 2017, 227,330,000 options (2016: 254,340,000 options) were granted under the Scheme.

33. 購股權(續)

除非獲得本公司股東批准,根據計劃可予授出之購股權涉及之股份總數不得超過本公司於批准計劃當日已發行股份之10%。此外,因行使根據計劃授出而尚未行使之購股權超可予發行之本公司股份數目上限,不得超過本公司不時已發行股份之30%。於任何12個月期間內可向任何人士授出之購股權已發之股份數目不得超過本公司於任何時間可發之股份之1%。倘向本公司主要股東或獨立之財執行董事或任何彼等各自之聯繫人授出之購股權超過本公司股本之0.1%及價值超過5,000,000港元,則必須獲得本公司股東批准。

所授出之購股權必須於授出日期起28日期間內獲接納,而每次接納購股權時須繳付1港元。購股權期間乃由董事全權酌情釐定,惟不得超過授出購股權日期起計十年(「購股權期間」)。授出購股權後,購股權明間內按照計劃條款隨時予以行使。行使價不得低於以下三者之最高者:(i)本公司股份面值;(ii)本公司股份於授出日期(於領為交易日)之收市價;或(iii)本公司股份於緊接授出日期前五個交易日之平均收市價。

所有以股份支付之僱員酬金將以股本支付。 本集團除發行股份外,概無法律或推定義務 購回或支付購股權。

截至二零一七年四月三十日止年度, 227,330,000份購股權(二零一六年: 254,340,000份購股權)已根據計劃授出。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

33. SHARE OPTION (Cont'd)

33. 購股權(續)

The following tables set out the movement in share options:

下表載列購股權之變動:

		Share option type	Outstanding at 1 May 2016 於二零一六年	Granted during the year	Transfer during the year*	Lapsed during the year	Outstanding at 30 April 2017 於二零一七年
Name or category	參與人士之	唯机排料型	五月一日	左手操山	左孔赫施*	左孔出於	四月三十日
of participant	姓名或類別	購股權類型	尚未行使	年內授出	年內轉讓*	年內失效	尚未行使
Placing of shares	配售股份	2015	495,000,000	-	_	(495,000,000)	-
Directors	<i>董事</i>						
Mr. Wong Sai Hung	黃世雄先生	2016	7,560,000	-	-	-	7,560,000
		2017	_	24,000,000	-	_	24,000,000
Dr. Shao Zhengkang	邵政康博士	2016	12,030,000	-	-	-	12,030,000
		2017	-	23,000,000	_	_	23,000,000
Non-executive directors	非執行董事						
Professor Cui Zhanfeng	崔占峰教授						
(appointed on 7 October 2016)	(於二零一六年十月七日獲委任)	2016	_	_	9,630,000	_	9,630,000
		2017	_	-	4,000,000	-	4,000,000
Professor Deng Shaoping	鄧紹平教授						
(retired on 9 September 2016)	(於二零一六年九月九日退任)	2016	5,780,000	-	-	(5,780,000)	-
Mr. Yang Zhengguo	楊正國先生						
(resigned on 5 August 2016)	(於二零一六年八月五日辭任)	2016	6,300,000	_	-	(6,300,000)	_
Mr. Wang Jianjun	王建軍先生	0010	5 700 000		(5.700.000)		
(retired on 9 September 2016)	(於二零一六年九月九日退任)	2016	5,780,000	_	(5,780,000)	-	-
Mr. Cao Fushun (resigned on 18 July 2016)	曹福順先生 (於二零一六年七月十八日辭任)	2016	5,510,000	_	_	(5,510,000)	_
		2010	0,010,000			(0,0.0,000)	
Independent non-executive directors	獨立非執行董事						
Mr. Lui Tin Nang	呂天能先生	2016	2,100,000	_	_	_	2,100,000
IVII. Lui TIITTVariy	ロ人服ルエ	2010	2,100,000	2,400,000	_	_	2,400,000
Mr. Pang Chung Fai, Benny	彭中輝先生	2016	2,010,000	2,400,000	_	_	2,010,000
Will Fully Chang Full, Donny	※ 「 ドエノロエ	2017	2,010,000	2,400,000	_	_	2,400,000
Mr. Chan Bing Woon	陳炳煥先生	2016	1,930,000		_	_	1,930,000
y		2017	_	2,300,000	_	_	2,300,000
Mr. Wang Hui	王輝先生	2016	1,750,000		_	_	1,750,000
		2017		2,100,000	-	-	2,100,000
Sub-total	小計		50,750,000	56,200,000	7,850,000	(17,590,000)	97,210,000
Employees	[6]						
Employees In aggregate	僱員 合計	2016	162 500 000		650,000	(84,470,000)	78,680,000
iii ayyieyale	□ a l	2016	162,500,000	147,130,000	(7,920,000)	(28,100,000)	111,110,000
O	5 用			, , ,	, , , , , ,	, , , , , , , ,	
Consultants	顧問	0040	07.440.000		/4 500 000	(40,000,000)	00 000 000
In aggregate	合計	2016	37,410,000	04.000.000	(4,500,000)	(12,030,000)	20,880,000
		2017		24,000,000	3,920,000		27,920,000
Total	總計		745,660,000	227,330,000	_	(637,190,000)	335,800,000
						(00.,100,000)	



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



During the year, share options granted to directors, employees and consultants have been reclassified in view of (1) Mr. Wang Jianjun was retired as director of the Company but continued to be employed by the Company during the year; (2) Professor Cui Zhanfeng, consultant of the Company, was appointed as director during the year; and (3) certain employees of the Company were acted as consultants during the year.

For the year ended 30 April 2017, share options lapsed were due to (1) 142,190,000 (2016: 3,680,000) share options issued to directors, employees and consultants who resigned/retired/ceased to provide services to the Group during the year; and (2) 495,000,000 share options issued through placing of shares in 2015 were expired. As a result of the lapse of share options during the year, an amount of HK\$38,789,000 (2016: HK\$80,000) were debited to the share option reserve and credited to accumulated losses.

The fair value of equity-settled share-based payment transactions with consultants is by reference to the fair value of the share options granted, as the directors consider that the share options granted is an extra incentive to the consultants and no specified goods or services to be provided to the Group.

The terms and conditions of the share options that existed at 30 April 2017 and 2016 are as follows:

33. 購股權(續)

* 年內,鑒於(1)王建軍先生已退任本公司董事,惟於年內仍由本公司僱傭;(2)本公司之顧問崔占峰教授已於年內獲委任為董事;及(3)本公司若干僱員於年內擔任顧問,授予董事、僱員及顧問之購股權已予以重新分類。

截至二零一七年四月三十日止年度,購股權失效乃由於(1)向年內辭任/退任/不再為本集團提供服務之董事、僱員及顧問發行之142,190,000份(二零一六年:3,680,000份)購股權:及(2)透過於二零一五年之配售股份發行的495,000,000份購股權已屆滿。由於購股權於年內失效,38,789,000港元(二零一六年:80,000港元)從購股權儲備中扣除並計入累計虧損。

由於董事認為所授出之購股權乃為向顧問作出之額外激勵,及並無將向本集團提供之特定貨品或服務,與顧問進行之以權益結算之股權支付費用交易之公平值乃經參考所授出購股權之公平值釐定。

於二零一七年及二零一六年四月三十日之購 股權條款及條件如下:

		Contractual	Contractual	Number of options 購股權數目		
Date of grant 授出日期	Vesting period 歸屬期	Exercise period 行使期	exercise price 合約行使價	life of options 購股權合約年期	2017 二零一七年	2016 二零一六年
Placing of shares 配售股份						
5 March 2015 二零一五年三月五日	Immediately 立即	5 March 2015 to 4 September 2016 二零一五年三月五日至 二零一六年九月四日	HK\$0.25 0.25港元	1 year 1年	-	495,000,000
Directors and chief executive officer 董事及						
行政總裁 16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2016 二零一五年九月十六日至 二零一六年九月十五日	16 September 2016 to 15 September 2025 二零一六年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	7,402,000	14,984,600
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2017 二零一五年九月十六日至 二零一七年九月十五日	16 September 2017 to 15 September 2025 二零一七年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	7,402,000	14,984,600

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



33. SHARE OPTION (Cont'd)

The terms and conditions of the share options that existed at 30 April 2017 and 2016 are as follows (Cont'd):

33. 購股權(續)

於二零一七年及二零一六年四月三十日之購 股權條款及條件如下(續):

Number of options

			Contractual	Contractual	購股權數目	
Date of grant 授出日期	Vesting period 歸屬期	Exercise period 行使期	exercise price 合約行使價	life of options 購股權合約年期	2017 二零一七年	2016 二零一六年
Directors and chief executive officer (Cont'd) 董事及						
行政總裁(續)	10 Cantambay 001F ta	10 Cantambay 0010 ta	LIIZĒO 45	10	7 400 000	14.004.000
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2018	16 September 2018 to 15 September 2025	HK\$0.45 0.45港元	10 years 10年	7,402,000	14,984,600
_	二零一五年九月十六日至 二零一八年九月十五日	二零一八年九月十六日至 二零二五年九月十五日	0.10/0/0	10		
16 September 2015	16 September 2015 to	16 September 2019 to	HK\$0.45	10 years	7,402,000	14,984,600
二零一五年九月十六日	15 September 2019	15 September 2025	0.45港元	10年		
	二零一五年九月十六日至	二零一九年九月十六日至				
100 1 1 0015	二零一九年九月十五日	二零二五年九月十五日	111/40 45	40		
16 September 2015	16 September 2015 to	16 September 2020 to	HK\$0.45	10 years	7,402,000	14,984,600
二零一五年九月十六日	15 September 2020 二零一五年九月十六日至	15 September 2025 二零二零年九月十六日至	0.45港元	10年		
	―令一五十九月十八日王 二零二零年九月十五日	一令一令十九月十八日王 二零二五年九月十五日				
9 September 2016	9 September 2016 to	9 September 2017 to	HK\$0,291	9 years	12,040,000	_
二零一六年九月九日	8 September 2017	8 September 2025	0.291港元	9年	,,	
	二零一七年九月八日	二零二五年九月八日				
9 September 2016	9 September 2016 to	9 September 2018 to	HK\$0.291	9 years	12,040,000	_
二零一六年九月九日	8 September 2018	8 September 2025	0.291港元	9年		
	二零一六年九月九日至	二零一八年九月九日至				
	二零一八年九月八日	二零二五年九月八日				
9 September 2016	9 September 2016 to	9 September 2019 to	HK\$0.291	9 years	12,040,000	-
二零一六年九月九日	8 September 2019	8 September 2025	0.291港元	9年		
	二零一六年九月九日至 二零一九年九月八日	二零一九年九月九日至 二零二五年九月八日				
9 September 2016	ー令 ルキルカハロ 9 September 2016 to	ー令二五十九万八日 9 September 2020 to	HK\$0.291	9 years	12,040,000	_
二零一六年九月九日	8 September 2020	8 September 2025	0.291港元	9 years 9年	12,040,000	_
— ≤ \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	二零一六年九月九日至	二零二零年九月九日至	0.231/6/6	3 +		
	二零二零年九月八日	二零二五年九月八日				
9 September 2016	9 September 2016 to	9 September 2021 to	HK\$0.291	9 years	12,040,000	_
二零一六年九月九日	8 September 2021	8 September 2025	0.291港元	9年	, ,	
	二零一六年九月九日至	二零二一年九月九日至				
	二零二一年九月八日	二零二五年九月八日				



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

33. SHARE OPTION (Cont'd)

33. 購股權(續)

The terms and conditions of the share options that existed at 30 April 2017 and 2016 are as follows (Cont'd):

於二零一七年及二零一六年四月三十日之購 股權條款及條件如下(續):

			Contractual	Contractual	Number of options 購股權數目	
Date of grant 授出日期	Vesting period 歸屬期	Exercise period 行使期	exercise price 合約行使價	life of options 購股權合約年期	2017 二零一七年	2016 二零一六年
Employees 僱員						
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2016 二零一五年九月十六日至 二零一六年九月十五日	16 September 2016 to 15 September 2025 二零一六年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	15,736,000	27,665,400
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2017 二零一五年九月十六日至 二零一七年九月十五日	16 September 2017 to 15 September 2025 二零一七年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	15,736,000	27,665,400
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2018 二零一五年九月十六日至 二零一八年九月十五日	16 September 2018 to 15 September 2025 二零一八年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	15,736,000	27,665,400
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2019 二零一五年九月十六日至 二零一九年九月十五日	16 September 2019 to 15 September 2025 二零一九年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	15,736,000	27,665,400
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2020 二零一五年九月十六日至 二零二零年九月十五日	16 September 2020 to 15 September 2025 二零二零年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	15,736,000	27,665,400
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2017 二零一六年九月九日至 二零一七年九月八日	9 September 2017 to 8 September 2025 二零一七年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	22,222,000	_
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2018 二零一六年九月九日至 二零一八年九月八日	9 September 2018 to 8 September 2025 二零一八年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	22,222,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2019 二零一六年九月九日至 二零一九年九月八日	9 September 2019 to 8 September 2025 二零一九年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	22,222,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2020 二零一六年九月九日至 二零二零年九月八日	9 September 2020 to 8 September 2025 二零二零年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	22,222,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2021 二零一六年九月九日至 二零二一年九月八日	9 September 2021 to 8 September 2025 二零二一年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	22,222,000	-

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

30 April 2017 and 2016 are as follows (Cont'd):

33. SHARE OPTION (Cont'd)

The terms and conditions of the share options that existed at 於二

33. 購股權(續)

於二零一七年及二零一六年四月三十日之購股權條款及條件如下(續):

Number of ontions

				Number of options 購股權數目		
Date of grant 授出日期	Vesting period 歸屬期	Exercise period 行使期	Contractual exercise price 合約行使價	Contractual life of options 購股權合約年期	2017 二零一七年	2016 二零一六年
Consultants 顧問						
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2016 二零一五年九月十六日至 二零一六年九月十五日	16 September 2016 to 15 September 2025 二零一六年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	4,176,000	7,482,000
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2017 二零一五年九月十六日至 二零一七年九月十五日	16 September 2017 to 15 September 2025 二零一七年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	4,176,000	7,482,000
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2018 二零一五年九月十六日至 二零一八年九月十五日	16 September 2018 to 15 September 2025 二零一八年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	4,176,000	7,482,000
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2019 二零一五年九月十六日至 二零一九年九月十五日	16 September 2019 to 15 September 2025 二零一九年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	4,176,000	7,482,000
16 September 2015 二零一五年九月十六日	16 September 2015 to 15 September 2020 二零一五年九月十六日至 二零二零年九月十五日	16 September 2020 to 15 September 2025 二零二零年九月十六日至 二零二五年九月十五日	HK\$0.45 0.45港元	10 years 10年	4,176,000	7,482,000
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2017 二零一六年九月九日至 二零一七年九月八日	9 September 2017 to 8 September 2025 二零一七年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	5,584,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2018 二零一六年九月九日至 二零一八年九月八日	9 September 2018 to 8 September 2025 二零一八年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	5,584,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2019 二零一六年九月九日至 二零一九年九月八日	9 September 2019 to 8 September 2025 二零一九年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	5,584,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2020 二零一六年九月九日至 二零二零年九月八日	9 September 2020 to 8 September 2025 二零二零年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	5,584,000	-
9 September 2016 二零一六年九月九日	9 September 2016 to 8 September 2021 二零一六年九月九日至 二零二一年九月八日	9 September 2021 to 8 September 2025 二零二一年九月九日至 二零二五年九月八日	HK\$0.291 0.291港元	9 years 9年	5,584,000	_
					335,800,000	745,660,000



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



As at 30 April 2017, the Company had 335,800,000 (2016: 745,660,000) share options outstanding under the Scheme, which represented approximately 2% (2016: 4%) of the Company's shares in issue as at that date. The exercise in full of the remaining share options would, under the present capital structure of the Company, result in the issue of 335,800,000 (2016: 745,660,000) additional ordinary shares of the Company and additional share capital of HK\$3,358,000 (2016: HK\$7,457,000) and share premium of HK\$115,875,000 (2016: HK\$229,090,000) (before issue expenses).

The number and weighted average exercise prices of share options are as follows:

33. 購股權(續)

於二零一七年四月三十日,本公司有335,800,000份(二零一六年:745,660,000份)計劃項下之尚未行使購股權,佔本公司於該日之已發行股份約2%(二零一六年:4%)。於本公司現有資本架構下,悉數行使餘下購股權將導致本公司發行335,800,000股(二零一六年:745,660,000股)額外普通股、產生額外股本3,358,000港元(二零一六年:7,457,000港元)及股份溢價115,875,000港元(二零一六年:229,090,000港元)(未扣除發行開支)。

購股權數目及加權平均行使價如下:

		2017		2016 二零一六年	
		二零一十	⊆年		
		Weighted		Weighted	
		average	Number of	average	Number of
		exercise price	options	exercise price	options
		加權平均行使價	購股權數目	加權平均行使價	購股權數目
		HK\$	'000	HK\$	'000
		港元	千份	港元	千份
Outstanding at beginning of year	年初尚未行使	0.32	745,660	0.25	495,000
Issued during the year	年內發行	0.29	227,330	0.45	254,340
Lapsed during the year	年內失效	0.29	(637,190)	0.45	(3,680)
Outstanding at end of year	年末尚未行使	0.36	335,800	0.32	745,660

As at 30 April 2017, the weighted average remaining contractual life for the outstanding share options is 8.37 years (2016: 3.39 years).

於二零一七年四月三十日,尚未行使購股權的加權平均尚餘合約年期為8.37年(二零一六年:3.39年)。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The weighted average fair value of each option issued during the year was HK\$0.193 (2016: HK\$0.303). The fair value of the share options has been determined based on the Binomial model estimated by an independent professional valuer, Roma Appraisal Limited. As at the date of grant, the fair value of the options issued by the Company during the year was HK\$43,970,000 (2016: HK\$76,995,000). The following significant assumptions were used to derive the fair values:

33. 購股權(續)

年內發行的每份購股權之加權平均公平值為0.193港元(二零一六年:0.303港元)。購股權之公平值由獨立專業估值師羅馬國際評估有限公司根據二項式模型估計釐定。於授出日期,本公司年內發行購股權之公平值為43,970,000港元(二零一六年:76,995,000港元)。公平值乃按以下重大假設得出:

		2017 二零一七年	2016 二零一六年
Underlying stock price (HK\$)	相關股價(港元)	0.29	0.45
Exercise price (HK\$)	行使價(港元)	0.291	0.45
Risk-free rate (%)	無風險利率(%)	0.812	1.702
Annualised dividend yield (%)	年度股息回報率(%)	_	_
Expected volatility of underlying share (%)	相關股份之預期波幅(%)	80.16	76.64
Weighted average remaining contractual life	加權平均尚餘合約年期	8.995	9.998

The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may also not necessarily be the actual outcome. No special features pertinent to the options granted were incorporated into the measurement of fair value.

During the year, share-based payments of HK\$28,520,000 (2016: HK\$20,345,000), which included share-based payment transactions with directors and employees of HK\$24,597,000 (2016: HK\$17,205,000) and with consultants of HK\$3,923,000 (2016: HK\$3,140,000), have been recognised in profit or loss.

預期波幅反映有關假設,即以歷史波幅為未來趨勢的指標,但該未來趨勢亦不一定為實際結果。在計量公平值時並無納入有關已授 出購股權的特殊特點。

年內,以股權支付費用為28,520,000港元(二零一六年:20,345,000港元),其中包括與董事及僱員之以股權支付費用交易24,597,000港元(二零一六年:17,205,000港元)以及與顧問之股權支付費用交易3,923,000港元(二零一六年:3,140,000港元),已於損益中確認。

34. BUSINESS COMBINATIONS

Frame Sharp Limited ("Frame Sharp")

On 14 August 2015, the Group acquired 70% equity interests of Frame Sharp with cash consideration of HK\$42,500,000. Frame Sharp and its subsidiaries ("Frame Sharp Group"), which is principally engaged in providing service and equipment for human cell and stem cell related clinical applications. The acquisition was made with the objective to setup a regional hub that takes care of human cell and stem cell processing businesses in the Huadong Region (Eastern China Region) and to generate synergy through the acquisition.

34. 業務合併

於二零一五年八月十四日,本集團以42,500,000港元之現金代價收購Frame Sharp 70%股權。Frame Sharp 及其附屬公司(「Frame Sharp Group」)主要從事為人體細胞及幹細胞相關臨床應用提供服務及設備之業務。此收購目標為於華東地區(中國東部地區)建立處理人體細胞和幹細胞業務的區域中樞,以及透過收購產生協同效應。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

34. BUSINESS COMBINATIONS (Cont'd)

34. 業務合併(續)

Frame Sharp Limited ("Frame Sharp") (Cont'd)

Frame Sharp Limited (「Frame Sharp」) (續)

Details of fair value of identifiable assets and liabilities acquired were as follows:

購入之可識別資產及負債的公平值詳情如下:

		HK\$'000 千港元
Property, plant and equipment (note 14)	物業、廠房及設備(附註14)	1,549
Other intangible assets (note 18)	其他無形資產(附註18)	51,180
Deposits, prepayments and other receivables	按金、預付款項及其他應收賬項	69
Cash and cash equivalents	現金及現金等值項目	2.216
Trade payables	應付貿易賬項	(172)
Accrued charges and other payables	應計費用及其他應付賬項	(1,468)
Deferred tax liabilities recognised	公平值調整後確認的	(1,100)
upon fair value adjustments (note 27)	遞延税項負債(附註27)	(12,796)
Net assets	資產淨值	40,578
Non-controlling interests	非控股股東權益	(12,173)
Net identified assets acquired	購入之可識別資產淨值	28,405
Goodwill on acquisition (note 16)	收購商譽(附註16)	8,902
Total consideration	總代價	37,307
Satisfied by:	由下列各項支付:	
Cash	現金	42,500
Contingent consideration receivable (note 17)	應收或然代價(附註17)	(5,193)
Total purchase consideration	總購買代價	37,307
An analysis of the net inflow of cash and cash e respect of the acquisition of the subsidiaries was as	· ·	見金及現金等值項目流
		HK\$'000 千港元
Cash and cash equivalents acquired	購入之現金及現金等值項目	2,216
Cash and cash equivalents paid	已付現金及現金等值項目	(42,500)
Net outflow of cash and cash equivalents	現金及現金等值項目流出淨額	(40,284)

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



Frame Sharp Limited ("Frame Sharp") (Cont'd)

Since the acquisition date to 30 April 2016, Frame Sharp Group had contributed HK\$55,000 and HK\$3,318,000 to Group's revenue and loss. If the acquisition had occurred on 1 May 2015, Group revenue and loss for the year ended 30 April 2016 would have been HK\$27,751,000 and HK\$195,701,000 respectively. This pro forma information was for illustrative purpose only and was not necessarily an indication of revenue and results of operations of the group that actually would have been achieved had the acquisition been completed on 1 May 2015, nor was it intended to be a projection of future performance.

The goodwill arose from the acquisition of Frame Sharp Group mainly represented (1) significant future prospect and the business value of Frame Sharp Group and (2) synergy effect of the newly acquired business with the existing tissue engineering business.

35. RELATED PARTY TRANSACTIONS

Compensation of key management personnel

The key management personnel of the Group are the directors, chief executives and chief financial officer of the Company. The remuneration of the key management personnel is determined by the remuneration committee having regard to the performance of individuals and market trends. The remuneration of a member of the key management (excluding directors and chief executives) as follows:

34. 業務合併(續)

Frame Sharp Limited (「Frame Sharp」) (續)

自收購日起至二零一六年四月三十日,Frame Sharp Group已為本集團之收益及虧損貢獻55,000港元及3,318,000港元。若收購於二零一五年五月一日發生,本集團截至二零一六年四月三十日止年度之收益及虧損應分別為27,751,000港元及195,701,000港元。此備考資料僅供説明用途,並不表示此為若收購於二零一五年五月一日完成本集團實際會實現的收益及經營業績,亦並非對未來業績的預測。

收購Frame Sharp Group產生之商譽主要為(1) Frame Sharp Group的重大未來前景及商業價值及(2)新收購業務與現有組織工程業務的協同效應。

35. 關連交易

主要管理人員酬金

本集團之主要管理人員即本公司董事,最高 行政人員及首席財務官。主要管理人員之酬 金乃由薪酬委員會根據個別人士之表現及市 場趨勢釐定。一名主要管理人員(不包括董 事及最高行政人員)之酬金範圍如下:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Salaries and other benefits Retirement benefits scheme contributions Equity-settled share-based payments	薪金及其他福利 退休福利計劃供款 以權益結算之股權支付費用	2,409 20 359	970 10 367
		2,788	1,347



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

35. RELATED PARTY TRANSACTIONS (Cont'd)

Compensation of key management personnel (Cont'd)

The emoluments of the key management (excluding directors and chief executives) fell within the following band:

35. 關連交易(續)

主要管理人員酬金(續)

主要管理人員(不包括董事及最高行政人員)的酬金介乎以下範圍:

Number of individual 人數

		2017 二零一七年	2016 二零一六年
Nil to HK\$1,000,000 HK\$1,000,001 — HK\$2,000,000	零至1,000,000港元 1,000,001港元	1	-
	至2,000,000港元	1	1

Details of the remuneration paid to the directors and chief executives are set out in note 9 to the financial statements.

Save as elsewhere in the financial statements and above, there was no other related party transaction during the years ended 30 April 2016 and 2017.

支付予董事及最高行政人員之酬金詳情載於財務報表附註9。

除財務報表內之其他部份及以上所披露者 外,於截至二零一六年及二零一七年四月 三十日14年度概無其他關連交易。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



36. SUBSIDIARIES

36. 附屬公司

Particulars of principal subsidiaries of the Company as at 30 April 2017 are as follows:

於二零一七年四月三十日,本公司之主要附屬公司詳情如下:

Name of company	Place of incorporation/ registration 註冊成立/	Issued ordinary capital/paid up capital 已發行普通股	Percentage of ownership interests held by the Company 本公司持有		Principal activities and place of operations	
公司名稱	註冊地點	股本/繳足資本	擁有權 Directly 直接	權益比例 Indirectly 間接	主要業務及營業地點	
China Bio-Med Regeneration Technology Limited 中國生物醫學再生科技有限公司	British Virgin Islands 英屬處女群島	US\$20,000 20,000美元	100%	-	Investment holding, Hong Kong 投資控股,香港	
China Regenerative Medicine Tissue Engineering Limited (Previously known as Million Profit Group Limited) 中國再生醫學組織工程有限公司 (前稱兆鑫集團有限公司)	British Virgin Islands 英屬處女群島	US\$1 1美元	_	100%	Investment holding, Hong Kong 投資控股,香港	
FD(H) Investments Limited	British Virgin Islands 英屬處女群島	US\$100 100美元	-	100%	Investment holding, Hong Kong 投資控股,香港	
Shaanxi Aierfu 陝西艾爾虜	The PRC 中國	RMB250,000,000 (2016: RMB206,900,000) 人民幣250,000,000元 (二零一六年: 人民幣206,900,000元)	-	100%	Production and sales of tissue engineering skin related products, the PRC 生產及銷售組織工程 皮膚相關產品,中國	
Shaanxi Aimiya Bio-Technology Company Limited 陝西艾美雅生物科技有限公司	The PRC 中國	RMB2,000,000 人民幣2,000,000元	-	100%	Research and development, the PRC 研究及開發·中國	
Shaanxi AiBosin Bio-Engineering Company Limited 陝西艾博生生物工程有限公司	The PRC 中國	RMB2,000,000 人民幣2,000,000元	-	100%	Research and development, the PRC 研究及開發·中國	
Shaanxi AiNear Cornea Engineering Company Limited 陝西艾尼爾角膜工程有限公司	The PRC 中國	RMB3,800,000 人民幣3,800,000元	-	100%	Research and development, the PRC 研究及開發,中國	



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

36. SUBSIDIARIES (Cont'd)

36. 附屬公司(續)

Name of company 公司名稱	Place of incorporation/ registration 註冊成立/ 註冊地點	Issued ordinary capital/paid up capital 已發行普通股 股本/繳足資本	Percentage of ownership interests held by the Company 本公司持有 擁有權權益比例		Principal activities and place of operations	
			Directly 直接	Indirectly 間接		
Shenzhen AiNear Cornea Engineering Company Limited 深圳艾尼爾角膜工程有限公司	The PRC 中國	RMB3,800,000 人民幣3,800,000元	-	100%	Production and sales of bio-engineered cornea, the PRC 生產及銷售生物工程角膜, 中國	
Zhongsheng Medical Equipment Trading Company Limited 中生醫療器械銷售有限公司	The PRC 中國	RMB60,000,000 人民幣60,000,000元	-	100%	Sales and distribution, the PRC 銷售及分銷・中國	
Shaanxi Reshine Biotech Co. Ltd. 陝西瑞盛生物科技有限公司	The PRC 中國	RMB117,000,000 (2016: RMB87,000,000) 人民幣117,000,000元 (二零一六年: 人民幣87,000,000元)	-	100%	Research and development, the PRC 研究及開發,中國	
Shanghai Hesidi Cosmetics Company Limited 上海赫絲蒂化妝品有限公司	The PRC 中國	RMB50,000,000 人民幣50,000,000元	-	51%	Sales and distribution, the PRC 銷售及分銷・中國	
Shenzhen Hesidi Bio-Technology Company Limited 深圳赫絲蒂生物科技有限公司	The PRC 中國	RMB5,000,000 人民幣5,000,000元	-	51%	Sales and distribution, the PRC 銷售及分銷,中國	
China Bio-Med Technology Limited 中生醫學科技有限公司	The PRC 中國	RMB50,000,000 人民幣50,000,000元	-	100%	Research and development, the PRC 研究及開發,中國	
HK International Regenerative Centre Limited (Previously known as Revital Healthcare Biotech Limited) 香港國際再生醫學中心有限公司 (前稱長青健康生物有限公司)	Hong Kong 香港	HK\$100 100港元	-	80%	Healthcare business, Hong Kong 醫療保健業務,香港	
China Regenerative Medicine Limited 中國再生醫學有限公司	Hong Kong 香港	HK\$1 1港元	-	100%	Investment holding, Hong Kong 投資控股,香港	

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



36. SUBSIDIARIES (Cont'd)

36. 附屬公司(續)

Name of company 公司名稱	Place of incorporation/ capital/paid up registration capital 主冊成立/ 已發行普通股 註冊地點 股本/繳足資本		Percentage of ownership interests held by the Company 本公司持有 擁有權權益比例 Directly Indirectly 直接 問控		Principal activities and place of operations 主要業務及營業地點	
			直接	間接		
BioCell Technology Limited (Previously known as China Stem Cell Clinical Applications Centre Limited) 百奥生物科技有限公司 (前稱中國幹細胞臨床 應用中心有限公司)	Hong Kong 香港	HK\$1 1港元	_	100%	Cell operation, Hong Kong 細胞業務,香港	
Tianjin Weikai Bioeng Limited 天津衛凱生物工程有限公司	The PRC 中國	RMB10,400,000 人民幣10,400,000元	-	70%*	Sales and distribution, the PRC 銷售及分銷・中國	
AK (Suzhou) Biomedical Ltd 奥凱 (蘇州) 生物技術咨詢服務有限公司	The PRC 中國	RMB1,470,600 人民幣1,470,600元	-	70%*	Sales and distribution, the PRC 銷售及分銷,中國	

Note:

The above table lists the subsidiaries of the Group which, in the opinion of the directors, principally affected the results of the Group for the year or formed a substantial portion of the net assets of the Group at the end of the year. To give details of other subsidiaries would, in the opinion of the directors, result in particulars of excessive length.

All subsidiaries are limited liability companies.

None of the subsidiaries had any debt securities subsisting at the end of the year or at any time during the year.

Amounts due from/(to) subsidiaries are unsecured, interest-free and repayable on demand.

附註:

上表列出董事認為主要影響本集團本年度業績或 組成本集團年末資產淨值主要部份之附屬公司。 董事認為,列出其他附屬公司之詳情會令篇幅過 於冗長。

所有附屬公司均為有限責任公司。

於年終或於年內任何時間,概無附屬公司擁有任 何債務證券。

應收/(應付)附屬公司款項為無抵押、免息及須按要求償還。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

36. SUBSIDIARIES (Cont'd)

Note: (Cont'd)

The Group does not have any equity interest in Tianjin Weikai Bioeng Limited ("Tianjin Weikai") and AK (Suzhou) Biomedical Ltd ("AK Suzhou"). However, the Group has entered into the contractual arrangements with Tianjin Weikai and AK Suzhou and its equity holders, which enable the Group to (1) exercise effective financial and operational control over Tianiin Weikai and AK Suzhou; (2) exercise equity holders' voting rights of Tianjin Weikai and AK Suzhou; (3) receive substantially all of the economic interest returns generated by Tianjin Weikai and AK Suzhou in consideration for the management services provided by the Group; (4) obtain an irrevocable and exclusive right with an initial period of 10 years to purchase the entire equity interest in Tianjin Weikai and AK Suzhou from the respective equity holders. The right automatically renews upon expiry until the Group specifies a renewal term; an (5) obtain a pledge over the entire equity interest of Tianjin Weikai and AK Suzhou from its respective equity holders as collateral security for all the payments due to the Group and to secure performance of Tianjin Weikai's and AK Suzhou's obligations under the above contractual arrangements. Accordingly, the Group has rights to variable returns from its involvement with Tianjin Weikai and AK Suzhou and has the ability to affect those returns through its power over Tianjin Weikai and AK Suzhou and is considered to control Tianiin Weikai and AK Suzhou. Consequently, the Group regards Tianjin Weikai and AK Suzhou as the indirect subsidiaries under HKFRSs.

36. 附屬公司(續)

附註:(續)

本集團並無持有天津衛凱生物工程有限公 司(「天津衛凱」)及奧凱(蘇州)生物技術 有限公司(「奧凱(蘇州)」)的任何股權。 然而,本集團與天津衛凱及奧凱(蘇州)及 其權益持有人訂立合約協議,使本集團能 夠(1)行使對天津衛凱及奧凱(蘇州)的實 際財務及營運控制權;(2)行使天津衛凱及 奥凱 (蘇州) 權益持有人的投票權; (3) 收取 天津衛凱及奧凱(蘇州)產生絕大部份經濟 利益回報,作為本集團提供的管理服務的 代價:(4)獲得從各權益持有人購買天津衛 凱及奧凱(蘇州)全部股權的不可撤銷及獨 家權利,初始年期為十年。相關權利於屆 滿時自動續期,惟本集團指定續訂年限者 則除外;及(5)獲得各權益持有人對天津衛 凱及奧凱(蘇州)全部股權的質押,作為應 付本集團的所有款項的抵押物並擔保天津 衛凱及奧凱(蘇州)履行上述合約安排項下 的責任。因此,本集團有權通過參與天津 衛凱及奧凱(蘇州)的業務而享受可變回報 且有能力透過其對天津衛凱及奧凱(蘇州) 的控制權影響該等回報,並被視為控制天 津衛凱及奧凱(蘇州)。因此,根據香港財 務報告準則,本集團視天津衛凱及奧凱(蘇 州)為間接附屬公司。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The following table shows the carrying amounts and fair value of the Group's financial assets and liabilities:

37. 金融資產及金融負債分類概要

下表載列本集團的金融資產及負債之賬面值和公平值:

		2017 二零一七年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元
Financial assets	金融資產		
Non-current assets Available-for-sale financial assets	非流動資產 可供出售金融資產	112,928	_
Financial assets at fair value through profit or loss: Contingent consideration receivables	按公平值於損益列賬 之金融資產: 應收或然代價	46,259	28,030
Loans and receivables: Pledged bank deposits	貸款及應收賬項: 已抵押銀行存款	794,743	_
Current assets Financial assets at fair value through profit or loss	流動資產 按公平值於損益列賬 之金融資產	12,036	_
Loans and receivables: Trade receivables Deposits and other receivables Pledged bank deposits Cash and cash equivalents	貸款及應收賬項: 應收貿易賬項 按金及其他應收賬項 已抵押銀行存款 現金及現金等值項目	39,117 195,161 — 571,732	19,992 63,769 558,873 1,300,825
Cash and sach equivalente	· · · · · · · · · · · · · · · · · · ·	1,771,976	1,971,489
Financial liabilities	金融負債		
Financial liabilities measured at amortised costs:	以攤銷成本計量之金融負債:		
Current liabilities Trade payables Accrued charges and other payables Bank borrowings	流動負債 應付貿易賬項 應計費用及其他應付賬項 銀行借款	38,993 42,121 28,345	1,570 33,816 542,553
Non-current liabilities Bank borrowings	非流動負債 銀行借款	725,632	_
		835,091	577,939



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

37. SUMMARY OF FINANCIAL ASSETS AND FINANCIAL LIABILITIES BY CATEGORY (Cont'd)

The following table provides an analysis of financial instruments carried at fair value by level of fair value hierarchy:

- Level 1: quoted prices (unadjusted) in active markets for identical assets and liabilities:
- Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy within which the financial asset or liability is categorised in its entirety is based on the lowest level of input that is significant to the fair value measurement.

The financial assets measured at fair value in the consolidated statement of financial position are grouped into the fair value hierarchy as follows:

37. 金融資產及金融負債分類概要 (續)

下表提供以公平值列賬的金融工具之公平值 架構分析:

- 第一級:相同的資產及負債於活躍市場的報價(未經調整);
- 第二級:有關資產或負債除第一級報 價以外,直接(即價格)或間接(即由 價格得出)可觀察輸入數據;及
- 第三級:有關資產或負債並非依據可 觀察市場數據的輸入數據(非可觀察 輸入數據)。

金融資產或負債於公平值架構內之分類全取 決於對公平值計量屬重要的輸入數據之最低 級別。

於綜合財務狀況表以公平值計量之金融資 產,其歸入之公平值架構如下:

		Level 1 第一級 HK\$'000 千港元	Level 2 第二級 HK\$'000 千港元	Level 3 第三級 HK\$'000 千港元	Total 合計 HK\$'000 千港元
At 30 April 2017	於二零一七年四月三十日				
Contingent consideration receivables	應收或然代價	_	_	46,259	46,259
Listed equity securities	持作買賣上市股本證券			•	ŕ
held for trading		12,036	_	_	12,036
		12,036	_	46,259	58,295
At 30 April 2016 Contingent consideration	於二零一六年四月三十日 應收或然代價				
receivable				28,030	28,030

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The listed equity securities are denominated in Hong Kong dollars. Fair values have been determined by reference to their quoted bid prices at the reporting date.

The details of the valuation of the fair value of contingent consideration receivable are disclosed in note 17.

There have been no significant transfers between levels in the reporting period.

The methods and valuation techniques used for the purpose of measuring fair value are unchanged compared to the previous reporting periods.

38. FINANCIAL RISK MANAGEMENT

The Group is exposed to financial risks through its use of financial instruments in its ordinary course of operations and in its investment activities. The financial risks include market risk (including currency risk, interest risk and other price risk), credit risk and liquidity risk.

The Group has a written risk management policy in place in relation to credit risk associated with loan receivables. The board of directors meets periodically to analyse and formulate strategies to manage and monitor the Group's exposure to a variety of risks associated with financial instruments which arise from the Group's operating and investing activities. Generally, the Group employs conservative strategies regarding its risk management to ensure appropriate measures are implemented on a timely and effective manner. The risks associated with these financial instruments and the policies on how these risks are mitigated are described as follows:

(a) Foreign currency risk

The Group has exposure to foreign currency risk as certain of its assets are denominated in RMB. The Group currently does not have a foreign currency hedging policy in respect of other foreign currency transactions, assets and liabilities. The Group will monitor its foreign currency exposure closely and will consider hedging significant foreign currency exposure should the need arise.

37. 金融資產及金融負債分類概要 (續)

上市股本證券以港元計值。公平值乃參考彼 等於報告日所報的買入價釐定。

應收或然代價公平值之估值詳情披露於附註 17。

於報告期間,架構間並無重要轉移。

比對過往報告期間,用於計量公平值的方法 及估值技術並無變動。

38. 財務風險管理

本集團因於日常業務過程中及其投資活動中 使用金融工具而承擔財務風險。財務風險包 括市場風險(包括貨幣風險、利率風險及其 他價格風險)、信貸風險及流動資金風險。

本集團制訂與應收貸款有關的信貸風險之書面風險管理政策。董事會定期召開會議進行分析並制定策略,以管理及監控本集團所承受有關本集團經營及投資業務產生之金融工具之不同風險。一般而言,本集團對風險管理採用審慎策略,以確保能及時有效採取適當措施。與該等金融工具相關之風險及如何減少此等風險之政策載述如下:

(a) 外滙風險

由於本集團若干資產乃以人民幣計值,故本集團面臨外滙風險。本集團目前並無有關其他外幣交易、資產及負債之外滙對沖政策。本集團將密切監控其外滙風險並於有需要時考慮對沖重大外滙風險。

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

38. FINANCIAL RISK MANAGEMENT (Cont'd)

(a) Foreign currency risk (Cont'd)

As at 30 April 2017, if the RMB had weakened/strengthened 5% (2016: 5%) against HK\$ with all other variables held constant, the Group's loss for the year and accumulated losses would have been HK\$1,302,000 (2016: HK\$27,944,000) higher/lower, arising mainly as a result of the foreign exchange loss/gain on pledged bank deposits denominated in RMB.

(b) Interest rate risk

Financial assets and liabilities at variable interest rates expose the Group to cash flow interest rate risk and those at fixed rates expose the Group to fair value interest rate risk. The Group monitors the interest rate risk exposure on a continuous basis and adjusts the portfolio of financial assets and liabilities when necessary. A reasonable change in interest rate in the next twelve months is assessed to result in immaterial change in the Group's loss for the year and accumulated losses. Changes in interest rates have no impact on the Group's other components of equity.

(c) Credit risk

The carrying amounts of these financial assets presented in the Group's statement of financial position are net of impairment losses, if any. The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. The default risk of the industry and country in which customers operate also has an influence on credit risk but to a lesser extent. At the end of reporting period, the Group has a certain concentration of credit risk as 26% (2016: 97%) of the total trade receivables was due from the Group's largest debtor within the cosmetic and others segment.

The Group has deposited its cash with various banks. The credit risk on cash and bank balances is limited because most of the Group's bank deposits are deposited with major banks in Hong Kong and the PRC.

38. 財務風險管理(續)

(a) 外滙風險(續)

於二零一七年四月三十日,倘人民幣 兑港元貶值/升值5%(二零一六年: 5%)而所有其他變量保持不變,本集 團之本年度虧損及累計虧損將增加/ 減少1,302,000港元(二零一六年: 27,944,000港元),乃主要由於以人 民幣計值之已抵押銀行存款的外滙虧 損/收益所致。

(b) 利率風險

(c) 信貸風險

本集團之財務狀況表內呈列金融資產的賬面值已扣除減值虧損(如有)。本集團之信貸風險主要受各客戶之行情況影響。客戶經營所在之行業約國家之違約風險亦對信貸風險產生影響,惟程度較低。於報告期末,由於應收貿易賬項總額之26%(二零一六年:97%)來自本集團化妝品及其有若可能分部的最大債務人,故本集團具有若干集中信貸風險。

本集團於多家銀行存放現金。由於本 集團之銀行存款大部份存放於香港及 中國之主要銀行,故現金及銀行結餘 之信貸風險有限。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



(d) Fair value

The directors of the Company consider the fair values of the Group's current financial assets and liabilities are not materially different from their carrying amounts because of the immediate or short-term maturity of these financial instruments. The fair value of non-current financial assets was not disclosed because the carrying amount is not materially different from its fair value.

(e) Liquidity risk

The Group's policy is to regularly monitor its liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and longer term. The Group has net current assets of HK\$840,837,000 (2016: HK\$1,301,722,000) and net assets of HK\$1,907,892,000 (2016: HK\$2,118,200,000) as at 30 April 2017. In the opinion of the directors, the Group's exposure to liquidity risk is limited.

38. 財務風險管理(續)

(d) 公平值

本公司董事認為由於本集團之該等金融工具屬即將或於短期內到期,故流動金融資產及負債之公平值與其賬面值之差異並不重大。由於非流動金融資產的公平值與其賬面值差異並不重大,故並未作出披露。

(e) 流動資金風險

本集團之政策乃定期監控其流動資金需要,確保維持充裕現金儲備,應付短期及長期之流動資金需求。於二零一七年四月三十日,本集團流動資產淨值為840,837,000港元(二零一六年:1,301,722,000港元),資產淨值為1,907,892,000港元(二零一六年:2,118,200,000港元)。董事認為,本集團的流動資金風險是有限的。



財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度

38. FINANCIAL RISK MANAGEMENT (Cont'd)

(e) Liquidity risk (Cont'd)

The following table details the remaining contractual maturities at each of the reporting dates of the Group's non-derivative financial liabilities, which are based on contractual undiscounted cash flows (including interest payment computed using contractual rates or, if floating, based on current rates at the reporting date) and the earliest date the Group may be required to pay:

38. 財務風險管理(續)

(e) 流動資金風險(續)

下表詳列本集團非衍生金融負債於各報告日之剩餘合約期,該表乃根據訂約未貼現現金流量(包括按訂約利率或(若為浮息)根據報告日之當期利率計算之利息支出)及本集團可能須付款之最早日期編製:

		Carrying amount 賬面值 HK\$'000	Total contractual undiscounted cash flow 訂約未貼現 現金流量總額 HK\$'000	Within 1 year or on demand 於1年內 或應要求 HK\$'000	More than 1 year but less than 5 years 超過1年但 少於5年 HK\$'000
		千港元	千港元	千港元	千港元
As at 30 April 2017 Trade payables Accrued charges	於二零一七年四月三十日 應付貿易賬項 應計費用及其他應付賬項	38,993	38,993	38,993	-
and other payables		42,121	42,121	42,121	_
Bank borrowings	銀行借款	753,977	840,800	28,719	812,081
		835,091	921,914	109,833	812,081
As at 30 April 2016	於二零一六年四月三十日	4.570	4.570	4.570	
Trade payables Accrued charges	應付貿易賬項 應計費用及其他應付賬項	1,570	1,570	1,570	_
and other payables		33,816	34,538	34,538	_
Bank borrowings	銀行借款	542,553	544,153	544,153	
		577,939	580,261	580,261	_

財務報表附註

For the year ended 30 April 2017 截至二零一七年四月三十日止年度



The Group's objectives when managing capital are:

- To safeguard the Group's ability to continue as a going concern, so that it continues to provide returns for shareholders and benefits for other stakeholders;
- To support the Group's stability and growth; and
- To provide capital for the purpose of strengthening the Group's risk management capability.

The Group actively and regularly reviews and manages its capital structure to ensure optimal capital structure and shareholder returns, taking into consideration the future capital requirements of the Group and capital efficiency, prevailing and projected profitability, projected operating cash flows, projected capital expenditures and projected strategic investment opportunities. The Group has not adopted any formal dividend policy.

Management regards total equity as capital, for capital management purpose. The amount of capital as at 30 April 2016 and 2017 amounted to approximately HK\$2,118,200,000 and HK\$1,907,892,000 respectively, which the management considers as optimal having considered the projected capital expenditures and the projected strategic investment opportunities.

39. 資本管理政策及程序

本集團管理資本之目標為:

- 保持本集團持續經營之能力,繼續為 股東帶來回報及為其他持份者帶來利 益;
- 維持本集團之穩定及增長;及
- 提供資金以加強本集團之風險管理能力。

本集團積極定期檢討及管理其資本架構,確保具備最佳資本架構及提供最佳股東回報,並考慮本集團未來資金需要及資本效率、現時及預測盈利能力、預測經營現金流量、預測資本開支及預測策略性投資機會。本集團目前並無採取任何正式股息政策。

管理層視總權益為資本管理之資本。於二零一六年及二零一七年四月三十日,資本金額分別約為2,118,200,000港元及1,907,892,000港元,其中管理層已考慮到預期之資本開支及預測策略性投資機會,並認為處於最佳資本狀況。

FINANCIAL SUMMARY





RESULTS

業績

Financial year ended 30 April 截至四月三十日止財政年度

		2013	2014	2015	2016	2017
		二零一三年 HK\$'000	二零一四年 HK\$'000	二零一五年 HK\$'000	二零一六年 HK\$'000	二零一七年 HK\$'000
		千港元	千港元	千港元	千港元	千港元
		(restated)	(restated)	(restated)	(restated)	1 7670
		(經重列)	(經重列)	(經重列)	(經重列)	
Revenue	收益	1,377	510	2,817	27,751	356,987
Cost of services provided/	已提供服務之成本/					ŕ
Cost of sales	銷售成本	(1,615)	(352)	(1,431)	(9,410)	(219,462)
Gross profit/(loss)	毛利/(毛損)	(238)	158	1,386	18,341	137,525
Other income	其他收入	6,788	5,662	2,101	110,981	45,144
Selling and distribution expenses	銷售及分銷開支	(804)	(2,912)	(8,226)	(33,078)	(66,796)
Administrative and other expenses	行政及其他開支	(73,426)	(133,967)	(162,899)	(270,171)	(322,464)
Finance costs	財務費用	(1,694)	(2,532)	(3,058)	(25,827)	(24,426)
Fair value gain on contingent	應收或然代價之公平值收益	,	,	(, ,	, , ,	, ,
consideration receivables		_	_	_	8,556	20,097
Impairment of goodwill	商譽減值	_	(141,657)	(60,400)	_	_
Impairment of other intangible assets	其他無形資產減值		_	(41,432)	_	_
Loss before income tax	除所得税前虧損	(69,374)	(275,248)	(272,528)	(191,198)	(210,920)
Income tax (expense)/credit	所得税 (開支) /抵免	1,890	3,951	17,136	(3,326)	11,728
Loss for the year	本年度虧損	(67,484)	(271,297)	(255,392)	(194,524)	(199,192)
Attributable to:	下列應佔:					
Owners of the Company	本公司擁有人	(61,320)	(263,442)	(250,098)	(190,902)	(184,502)
Non-controlling interests	非控股股東權益	(6,164)	(7,855)	(5,294)	(3,622)	(14,690)
Loss for the year	本年度虧損	(67,484)	(271,297)	(255,392)	(194,524)	(199,192)

As at 30 April 於四月三十日

		2013 二零一三年 HK\$'000 千港元	2014 二零一四年 HK\$'000 千港元	2015 二零一五年 HK\$'000 千港元	2016 二零一六年 HK\$'000 千港元	2017 二零一七年 HK\$'000 千港元
Total assets Total liabilities	總資產 總負債	753,185 (122,267)	961,342 (181,292)	2,054,815 (210,600)	2,901,277 (783,077)	2,888,229 (980,337)
Shareholders' funds	股東資金	630,918	780,050	1,844,215	2,118,200	1,907,892

Notes:

附註:

The financial summary does not form part of the financial statements.

財務摘要並非組成財務報表之部份。



China Regenerative Medicine International Limited 中國再生醫學國際有限公司

www.crmi.hk